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Resumen 
  
 
 
 
Hoy en día ha habido un notable aumento del número de pacientes polimedicados 
que reciben simultáneamente varios fármacos para el tratamiento de una o varias 
enfermedades. Esta situación proporciona el escenario ideal para la prescripción de 
combinaciones de fármacos que no han sido estudiadas previamente en ensayos clínicos, 
y puede dar lugar a un aumento de interacciones farmacológicas (DDIs por sus siglas en 
inglés). Las interacciones entre fármacos son un tipo de reacción adversa que supone no 
sólo un riesgo para los pacientes, sino también una importante causa de aumento del 
gasto sanitario. Por lo tanto, su detección temprana es crucial en la práctica clínica. En la 
actualidad existen diversos recursos y bases de datos que pueden ayudar a los 
profesionales sanitarios en la detección de posibles interacciones farmacológicas. Sin 
embargo, la calidad de su información varía considerablemente de unos a otros, y la 
consistencia de sus contenidos es limitada. Además, la actualización de estos recursos es 
difícil debido al aumento que ha experimentado la literatura farmacológica en los últimos 
años. De hecho, mucha información sobre DDIs se encuentra dispersa en artículos, 
revistas científicas, libros o informes técnicos, lo que ha hecho que la mayoría de los 
profesionales sanitarios se hayan visto abrumados al intentar mantenerse actualizados en 
el dominio de las interacciones farmacológicas. 
La ingeniería informática puede representar un papel fundamental en este campo 
permitiendo la identificación, explicación y predicción de DDIs, ya que puede ayudar a 
recopilar, analizar y manipular grandes cantidades de datos biológicos y farmacológicos. 
En concreto, las técnicas del procesamiento del lenguaje natural (PLN) pueden ayudar a 
recuperar y extraer información sobre DDIs de textos farmacológicos, ayudando a los 
investigadores y profesionales sanitarios en la complicada tarea de buscar esta 
información en diversas fuentes. Sin embargo, el desarrollo de estos métodos depende de 
la disponibilidad de recursos específicos que proporcionen el conocimiento del dominio, 
como bases de datos, vocabularios terminológicos, corpora u ontologías, entre otros, que 
son necesarios para desarrollar las tareas de extracción de información (EI). 
En el marco de esta tesis hemos desarrollado dos recursos semánticos en el dominio 
de las interacciones farmacológicas que suponen una importante contribución a la 
investigación y al desarrollo de sistemas de EI sobre DDIs. En primer lugar hemos 
revisado y analizado los corpora y ontologías existentes relevantes para el dominio y, en 
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base a sus potenciales y limitaciones, hemos desarrollado el corpus DDI y la ontología 
para interacciones farmacológicas DINTO. El corpus DDI ha demostrado cumplir con las 
características de un estándar de oro de gran calidad, así como su utilidad para el 
entrenamiento y evaluación de distintos sistemas en la tarea de extracción de información 
SemEval-2013 DDIExtraction Task. Por su parte, DINTO ha sido utilizada y evaluada en 
dos aplicaciones diferentes. En primer lugar, hemos demostrado que esta ontología puede 
ser utilizada para inferir interacciones entre fármacos y los mecanismos por los que 
ocurren. En segundo lugar, hemos obtenido una primera prueba de concepto de la 
contribución de DINTO al área del PLN al proporcionar el conocimiento del dominio 
necesario para ser explotado por un prototipo de un sistema de EI. En vista de estos 
resultados, creemos que estos dos recursos semánticos pueden estimular la investigación 
en el desarrollo de métodos computaciones para la detección temprana de DDIs. 
Este trabajo ha sido financiado parcialmente por el Gobierno Regional de Madrid a 
través de la red de investigación MA2VICMR [S2009/TIC-1542], por el Ministerio de 
Educación Español, a través del proyecto MULTIMEDICA [TIN2010-20644-C03-01], y 
por el Séptimo Programa Macro de la Comisión Europea a través del proyecto 
TrendMiner [FP7-ICT287863]. 
 
 
 
Palabras clave: Corpus, Ontología, Representación del Conocimiento, 
Farmacovigilancia, Interacción Farmacológica, Procesamiento del Lenguaje Natural, 
Extracción de Información, Inferencia. 
 
 v 
 
Abstract 
 
 
 
 
Nowadays, with the increasing use of several drugs for the treatment of one or more 
different diseases (polytherapy) in large populations, the risk for drugs combinations that 
have not been studied in pre-authorization clinical trials has increased. This provides a 
favourable setting for the occurrence of drug-drug interactions (DDIs), a common 
adverse drug reaction (ADR) representing an important risk to patients safety, and an 
increase in healthcare costs. Their early detection is, therefore, a main concern in the 
clinical setting. Although there are different databases supporting healthcare 
professionals in the detection of DDIs, the quality of these databases is very uneven, and 
the consistency of their content is limited. Furthermore, these databases do not scale well 
to the large and growing number of pharmacovigilance literature in recent years. In 
addition, large amounts of current and valuable information are hidden in published 
articles, scientific journals, books, and technical reports. Thus, the large number of DDI 
information sources has overwhelmed most healthcare professionals because it is not 
possible to remain up to date on everything published about DDIs. 
Computational methods can play a key role in the identification, explanation, and 
prediction of DDIs on a large scale, since they can be used to collect, analyze and 
manipulate large amounts of biological and pharmacological data. Natural language 
processing (NLP) techniques can be used to retrieve and extract DDI information from 
pharmacological texts, supporting researchers and healthcare professionals on the 
challenging task of searching DDI information among different and heterogeneous 
sources. However, these methods rely on the availability of specific resources providing 
the domain knowledge, such as databases, terminological vocabularies, corpora, 
ontologies, and so forth, which are necessary to address the Information Extraction (IE) 
tasks. 
In this thesis, we have developed two semantic resources for the DDI domain that 
make an important contribution to the research and development of IE systems for DDIs. 
We have reviewed and analyzed the existing corpora and ontologies relevant to this 
domain, based on their strengths and weaknesses, we have developed the DDI corpus and 
the ontology for drug-drug interactions (named DINTO). The DDI corpus has proven to 
fulfil the characteristics of a high-quality gold-standard, and has demonstrated its 
usefulness as a benchmark for the training and testing of different IE systems in the 
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SemEval-2013 DDIExtraction shared task. Meanwhile, DINTO has been used and 
evaluated in two different applications. Firstly, it has been proven that the knowledge 
represented in the ontology can be used to infer DDIs and their different mechanisms. 
Secondly, we have provided a proof-of-concept of the contribution of DINTO to NLP, by 
providing the domain knowledge to be exploited by an IE pilot prototype. From these 
results, we believe that these two semantic resources will encourage further research into 
the application of computational methods to the early detection of DDIs. 
This work has been partially supported by the Regional Government of Madrid 
under the Research Network MA2VICMR [S2009/TIC-1542], by the Spanish Ministry of 
Education under the project MULTIMEDICA [TIN2010-20644-C03-01] and by the 
European Commission Seventh Framework Programme under TrendMiner project [FP7-
ICT287863]. 
 
Keywords: Corpus, Ontology, Knowledge Representation, Pharmacovigilance, Drug-
drug interaction, Natural Language Processing, Information Extraction, Inference.   
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Chapter 1 
Introduction 
1.1 Motivation 
Recent technological developments and advances in the field of biomedicine have 
brought an increasing knowledge of molecular and cellular physiology, genomics, 
proteomics, and pharmacology. This has led to the generation of large amounts of 
experimental and computational biomedical data along with new discoveries, which are 
generally described, in the first instance, in research biomedical publications. Only 
considering the bibliographic database MEDLINE, the number of published research 
articles is increasing between 10,000 and 20,000 articles per week (NLM, 2014). The 
process of reviewing all the literature related to a biomedical or pharmacological subject 
is very time-consuming. Natural Language Processing (NLP) techniques can provide an 
interesting way to reduce the time spent by healthcare professionals and scientific 
researches on reviewing biomedical literature, as well as a promising approach for new 
knowledge discovery (Mack & Hehenbergerb, 2002).  
Recently, one of the areas that have attracted a great deal of attention by the NLP 
research community is pharmacovigilance. Pharmacovigilance is formally defined by the 
World Health Organization (WHO) as the science and activities relating to the detection, 
assessment, understanding, and prevention of adverse effects (AEs) or any other drug-
related problem (WHO, 2002). A type of common and important adverse drug reaction 
(ADR), having a significant impact on patient safety and healthcare costs, is drug-drug 
interactions (DDIs) (Aronson, 2007; Jankel, McMillan, & Martin, 1994; Pirmohamed et 
al., 2004). A DDI is the process that occurs when one drug affects the levels or effects of 
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another drug in the body. Although there is a large quantity of pharmacological databases 
and semi-structured resources - such as DrugBank (Wishart et al., 2006), Stockley 
(Baxter, 2013),  and Drug Interactions Facts (Tatro, 2010), among others - to assist 
healthcare professionals in the prevention of DDIs, the quality of these databases is very 
uneven and the consistency of their content is limited, so it is very difficult to assign a 
real clinical significance to each interaction (Paczynski, Alexander, Chinchilli, & 
Kruszewski, 2012; Rodríguez-Terol et al., 2009). On the other hand, despite the 
availability of these databases, a large proportion of the most current and valuable 
information on DDIs is unstructured, written in natural language and hidden in published 
articles. A simple search for the term “drug-drug interactions” in the web search engine 
Google Scholar® increased from 63,500 results in January 2014 to 73,400 results in 
December 2014, and, at the time of this writing, 139,984 documents are indexed in the 
online library MEDLINE with the Medical Subject Headings (MeSH) term “drug 
interaction”.  
Computational methods can play a key role in the identification, explanation, and 
prediction of DDIs on a large scale, since they can be used to collect, analyze, and 
manipulate large amounts of biological and pharmacological data (Percha & Altman, 
2013). On the one hand, several recent NLP systems have shown promising results in 
extracting DDIs from biomedical literature (Chowdhury & Lavelli, 2013b; Segura-
Bedmar, Martínez, & de Pablo-Sánchez, 2011b; Segura-Bedmar, Martínez, & Herrero-
Zazo, 2013; Segura-Bedmar, 2010; Thomas, Neves, Rocktäschel, & Leser, 2013). The 
major bottleneck for advancing in this area is, however, that these systems rely on 
specific resources providing the domain knowledge (databases, terminological 
vocabularies, corpora, ontologies, etc.) necessary to address the Information Extraction 
(IE) tasks. Although there is a wealth of linguistic resources for NLP in the biomedical 
domain, including terminologies and corpora, most of them are too broad to support the 
development of IE approaches applied to pharmacovigilance.  
Furthermore, the same problem is encountered in the development of other 
computational tools to assist in pharmacovigilance, such as clinical decision support 
systems (CDSS) or signal detection systems for the early detection of ADRs and DDIs. 
These methods rely on the availability of computable representations of the general 
domain knowledge that can be understood and exploited by information systems (Olivié, 
2007). Ontologies can be powerful tools representing pharmacovigilance knowledge and, 
specifically, the DDI domain. They can be used to integrate, in a common and 
harmonised framework, information from different resources, and can be exploited by 
reasoning engines systems to infer new knowledge, such as, as we describe in this thesis, 
the inference of DDIs. However, ontologies developed so far in this domain do not 
provide a comprehensive representation of the DDI domain, since they focus on shallow 
and partial representations of the domain. 
1.2 Context 
The occurrence of ADRs is one of the main concerns in the clinical setting, and 
DDIs are known to be a risk factor for their development (Ganeva, Gancheva, Troeva, 
Kiriyak, & Hristakieva, 2013). For example, in a study involving more than two thousand 
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patients, it was observed that 1.4% of hospitalized patients in medical wards experienced 
potentially preventable adverse drug events (ADE), 11.7% of them due to DDIs (Otero-
López et al., 2006). Although not all exposures to combinations of potentially interacting 
drugs lead to the occurrence of an adverse clinical manifestation, DDIs have been 
described to be the fifth cause involved in ADRs (Vargas et al., 1997). A prospective 
study in patients admitted to an internal medicine service showed that the 43% of the 
studied patients was exposed at least to one potential DDI, of which a 14% showed a 
relationship with an ADR (Ibáñez, Alcalá, García, & Puche, 2008). It was observed too, 
as in similar studies (Ganeva et al., 2013; Klarin, 2007; Obreli Neto et al., 2012), that the 
number of interactions did relate to the number of prescriptions. 
Nowadays, with the increasing use of several drugs for the treatment of one or more 
different diseases (polytherapy) in large populations, the risk for drug combinations that 
have not been studied in pre-authorization clinical trials has increased (Back & Else, 
2013). Moreover, it has been shown that genetic factors can lead to differences in a 
drug’s effect between individuals (Martiny & Miteva, 2013). Therefore, the consequence 
of a DDI can differ from one patient to another. In this scenario, it is vital to increase the 
efforts devoted to the prediction and prevention of DDIs (Huang et al., 2008).  
With this deeper knowledge about DDIs and their related factors, there is an 
increase in the publication of new aspects of known DDIs and in the discovery of new 
DDIs, too. Therefore, DDI information resources should be updated continuously in order 
to reflect all this new information. As mentioned before, currently known DDIs are 
described in different sources, such as compendia, databases, or approved-drug 
information, such as the Summary of Product Characteristics (SPC) or Package Insert 
(PI). However, deficiencies and inconsistencies between different DDI information 
resources have been reported by different authors (Aronson, 2004; Barillot, Sarrut, & 
Doreau, 1997; Bergk, Haefeli, Gasse, Brenner, & Martin-Facklam, 2005; Hansten, Horn, 
& Hazlet, 2001; Nikolić & Ilić, 2013; Paczynski et al., 2012). Thus, the development of 
automatic methods for collecting, maintaining, and interpreting the information about 
drugs is crucial to achieve a real improvement in the early detection of DDIs. 
The computer science research community has worked, on the recent years, in 
different approaches regarding ADRs and DDIs. On the one hand, prediction of unknown 
DDIs is a very attractive subject. There have been approaches based on ontologies and 
taxonomies (Arikuma et al., 2008; Cami, Manzi, Arnold, & Reis, 2013) in conjunction 
with statistical comparison of similar characteristics (Vilar et al., 2012). Digital 
workbenches for the quantitative prediction of DDIs (Bonnabry, Sievering, Leemann, & 
Dayer, 1999), computational inference methods (Gottlieb, Stein, Oron, Ruppin, & 
Sharan, 2012), or database analysis (Ito, Brown, & Houston, 2004; van Puijenbroek, 
Egberts, Heerdink, & Leufkens, 2000) are other strategies in this domain. Data signalling 
for the early detection of DDIs has been studied, too (Tatonetti, Fernald, & Altman, 2011; 
Thakrar, Grundschober, & Doessegger, 2007), and adverse events reporting systems have 
been used for data mining of DDIs (Harpaz et al. 2010; Iyer et al. 2013).  
On the other hand, NLP has become a very active research area. Several research 
groups have developed different systems for the extraction of ADRs from a diverse set of 
resources, such as FDA drug labels or PIs (Bisgin, Liu, Fang, Xu, & Tong, 2011; Boyce, 
Gardner, & Harkema, 2012), electronic health records (EHR) and clinical notes (Lependu 
et al., 2013), scientific literature (Karnik, Subhadarshini, Wang, Rocha, & Li, 2011), or 
social network websites (Nikfarjam & Gonzalez, 2011). Information retrieval (IR) of 
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DDI-related research articles has been studied, too (Duda, Aliferis, Miller, Statnikov, & 
Johnson, 2005). Segura-Bedmar (2010) carried out the deepest study on the research field 
of NLP applied to the DDI domain, leading to several relevant achievements, such as the 
study of anaphora resolution for DDI extraction (Segura-Bedmar, Crespo, de Pablo-
Sánchez, & Martínez, 2010) or the study of different IE techniques for the extraction of 
DDI relations (Segura-Bedmar, Martínez, & de Pablo-Sánchez, 2011a, 2011b, 2010). 
Moreover, one of the main contributions of this work was the development of the 
DrugDDI corpus, a gold-standard used in the first edition of the DDIExtraction 2011 
challenge task (Segura-Bedmar, Martínez, & Sánchez-Cisneros, 2011). It was the first 
evaluation task designed to provide a framework for comparing different approaches to 
extracting DDIs from texts, and encouraged the research in this domain (Chowdhury & 
Lavelli, 2013a; Karnik et al., 2011).  
As demonstrated by the interest raised by the DDIExtraction 2011 challenge, the 
development of NLP systems for the DDI domain relies heavily on manually annotated 
corpora for training and testing purposes (Bada et al., 2012). Similarly, the development 
of other pharmacovigilance supporting systems relies on resources providing the 
knowledge of the domain, such as ontologies (Cimiano, Unger, & McCrae, 2014; 
Wimalasuriya, 2010). However, there is a lack of these specific and appropriate resources 
for the DDI domain. 
In summary, the availability of proper resources providing a deep knowledge of the 
pharmacological domain is necessary for the encouragement and support of computer 
science research groups working in pharmacovigilance.  The combination of computer 
science techniques and pharmacological domain knowledge becomes essential for the 
development of new systems and techniques for the prediction and early detection of 
DDIs in pharmacovigilance. For this purpose, we intend to provide, within the framework 
of this thesis, two semantic resources necessary for the progress of this research field. 
The first one is a manually annotated corpus for training and evaluation of IE systems, 
and the second one is an ontology that will be validated and proven useful in two 
application domains: NLP of pharmacological text and inference of DDI knowledge. 
1.3 Objectives 
The objective of this thesis is twofold: (1) contributing to the improvement on the 
early detection of DDIs from scientific literature through the development of two 
different resources, an annotated corpus and a comprehensive ontology, which will 
enable the development, training, and evaluation of automatic NLP systems for 
pharmacological texts in the field of DDIs, and (2) the application of such ontology to 
infer new knowledge, in particular, new DDIs that could not have been reported in 
biomedical publications.  
Concerning the first objective, most NLP techniques heavily rely on annotated 
corpora to learn models that can be used to extract information from raw text. Annotated 
corpora are valuable resources as they provide a gold-standard data for the reproducible 
automatic training and evaluation of machine learning-based NLP techniques (van 
Mulligen et al., 2012). Most recent research has focused on biological entities and their 
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relationships (such as gene and protein interactions), mainly because of the availability of 
annotated corpora in the biological domain. However, the extraction of relations in the 
pharmacological domain, such as DDIs, requires a corpus created and annotated 
specifically for these purpose. Unfortunately, to date the number of corpora annotated 
with DDIs is very small (see Chapter 2 for a review of corpora annotated with 
pharmacological substances and DDIs). Moreover, they have been annotated considering 
a unique type of DDIs: pharmacokinetic DDIs (PK DDIs), excluding the annotation of 
pharmacodynamic DDIs (PD DDIs). These two types of DDIs relate to the type of 
mechanism preceding them. A pharmacokinetic (PK) mechanism occurs when the 
concentration of one drug is altered by another one (e.g., ciprofloxacin increases the 
blood levels of duloxetine by impairing its elimination from the body). A 
pharmacodynamic (PD) mechanism leads to an alteration on the effect of one drug 
without a variation of its levels in the body (e.g., concomitant use of two different drugs, 
such as alcohol and sedative pills, with a depressive effect in the central nervous system, 
can produce the potentiation of their effects and increase related symptoms, such as 
somnolence). This kind of PD mechanism is often described in the biomedical literature. 
However, there is no corpus annotated with PD DDIs. Therefore, the creation of a new 
annotated corpus including all possible types of DDIs is necessary for the development of 
NLP systems suitable for the comprehensive extraction of DDI information. Therefore, 
one of the main goals of this thesis is the creation of a large corpus annotated specifically 
for its final application in DDI extraction and including both types of DDIs: PK and PD 
DDIs. 
On the other hand, ontologies and controlled vocabularies have been commonly 
used in NLP techniques applied to pharmacology. The main application of ontologies has 
been to support the construction of conceptual dictionaries or lists of terms for different 
pharmacological semantic categories (Segura-Bedmar et al., 2013). The integration of 
different ontologies to this purpose has proven to be useful for the Named Entity 
Recognition (NER) task (Grego & Couto, 2013; Lamurias, Grego, & Couto, 2013). 
However, different common issues, such as ambiguity, polysemy, synonymy, and 
spelling variations, cannot be addressed through the application of these dictionary-based 
methods. On the other hand, several works have applied lexical Relation Extraction (RE) 
to ontology learning and population (Poesio, Barbu, Giuliano, & Romano, 2008). 
However, using ontologies for RE has not been sufficiently studied.  Despite this, 
ontologies, through the formal representation of relationships between different concepts, 
can be exploited in NLP techniques for both, NER and RE tasks, since they provide a 
contextual framework and semantic knowledge base. Therefore, there has been an 
increasing interest in bringing together traditional approaches on NLP and recent 
developments in the Sematic Web and ontological engineering fields (Cimiano et al., 
2014), the application of ontologies to IE and IR (Hassanpour, O’Connor, & Das, 2011; 
Müller, Kenny, & Sternberg, 2004; Wimalasuriya, 2010; Zhang, Hoffmann, & Weld, 
2012), or the use of ontologies to normalize relations extracted by NLP techniques 
(Coulet et al., 2011; Percha & Altman, 2012). Application of ontologies to the extraction 
of DDIs is limited, however, by the lack of appropriate resources (a review of related 
knowledge resources for DDIs is provided in Chapter 5). The main challenge is that 
DDIs can be described in many different ways in text. For example, these three sentences 
describe the same DDI, providing different information about it: 
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« The effects of duloxetine, including serotonergic syndrome, are increased by 
ciprofloxacin. » (i) 
« Ciprofloxacin decreases the metabolism of duloxetine by inhibiting the enzyme 
CYP 2D6. » (ii) 
« Treatment with ciprofloxacin is contraindicated in patients taking duloxetine. » (iii) 
As this example shows, a DDI relationship is not simple: sentence (i) describes the 
consequence of the DDI; sentence (ii) explains how the DDI occurs; sentence (iii) 
provides a recommendation to avoid the DDI. No existing ontology represents all these 
different types of relationships between two interacting drugs. Moreover, related 
concepts, such as ‘metabolism’ (a pharmacokinetic process), ‘CYP 2D6’ (a metabolic 
enzyme), or ‘serotonergic syndrome’ (an adverse effect), are not collected in a specific 
ontology for the recognition of DDI-related concepts. Therefore, one on the main 
contribution of this thesis is the development of a specific and appropriate ontology that 
systematically organizes all DDI-related information, necessary to provide a knowledge 
base to be integrated in NLP systems devoted to IE in pharmacovigilance.  
In addition to this, such a comprehensive ontology might be useful for the 
development of other tools supporting pharmacovigilance-related activities. Therefore, 
the second main objective of this thesis is the application of the ontology to the inference 
of new knowledge and, in particular, to the inference of DDIs and their mechanisms. 
These inference capabilities might represent the first step in the development of further 
CDSS or signal detection systems, providing new approaches for the detection of DDIs.  
The specific objectives to be achieved in this thesis are: 
Objective 1 To study the annotated corpora relevant to the DDI domain. 
Objective 2 To create the DDI corpus, a manually annotated corpus that will be a 
benchmark for IE of DDIs. Specifically, the following topics will be 
addressed: 
 a. annotation of pharmacological substances at different levels 
of granularity. 
 b. annotation of different types of DDIs. 
 c. annotation of different types of documents. 
 d. creation of annotation guidelines. 
 e. measurement of inter-annotator agreement (IAA) to assess 
the quality of the corpus. 
Objective 3 To validate the DDI corpus as gold-standard for training and 
evaluation of NLP systems devoted to the NER and RE tasks in the 
DDI domain. 
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Objective 4 To study the different linguistic phenomena in text describing DDIs. 
Objective 5 To study the main semantic resources in the pharmacological 
domain. 
Objective 6 To analyse and compare current modeling approaches in the DDI 
domain. 
Objective 7 To create an ontology for the representation of all DDI-related 
knowledge, including formal representation of: 
 a. different types of DDIs, including all possible mechanisms. 
 b. possible effects or consequences of DDIs. 
 c. different recommendations for avoiding a DDI. 
Objective 8 To evaluate the ontology in different tasks: 
 a. prediction or inference of DDIs. 
 b. information extraction of DDIs from text. 
1.4 Document structure 
The layout of this thesis is split into two main parts. The first one focuses on the 
creation of the DDI corpus.  
Chapter 2 reviews and compares the different corpora relevant in the DDI domain, 
including those annotated with pharmacological substances and those annotated with 
DDIs, too. 
Chapter 3 describes the construction of the new DDI corpus, including the 
collection process, the pre-processing stage, and the annotation process. The main issues 
encountered during this annotation process are also described and exemplified in this 
chapter.  Quantitative features of the DDI corpus are provided, and the corpus is 
compared to the corpora reviewed in Chapter 2. 
Chapter 4 provides a detailed description of the evaluation of the DDI corpus. 
Firstly, results of the IAA are provided and discussed. Secondly, we describe the 
SemEval-2013 DDIExtraction shared task, where the DDI corpus is used as a gold-
standard for training and evaluation of different IE systems. Their results are described in 
this chapter, along to an error analysis of the results of the DDI extraction systems, which 
allows for the identification of further improvements in the DDI corpus. 
The second part of this thesis describes the creation of an ontology for drug-drug 
interactions: DINTO. 
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Chapter 5 reviews existing semantic resources in the pharmacological domain 
covering relevant aspects related to DDIs. These include terminological resources for 
chemical and pharmacological substances, adverse drug reactions (ADRs), and DDI-
related aspects.  
Chapter 6 reviews the state of the art on current modeling efforts that have dealt 
with the representation of some aspect of DDIs. Their different conceptualizations are 
analysed, represented in a common representation framework, and compared to identify 
strengths and weaknesses of current conceptual models in the DDI domain. 
Chapter 7 describes the construction of DINTO and the different development 
activities. The final ontology is described in detail, too, and a summary of the available 
files is provided at the end of this chapter. 
Chapter 8 introduces ontology evaluation and describes the strategy followed to 
evaluate DINTO, which combines technical and application-based evaluations. In 
particular, in this chapter the ontology is technically evaluated in its form and content to 
assess its consistency and expressivity, and to detect possible errors. 
In Chapter 9, the ontology is evaluated in an application scenario for the inference 
of DDIs and their mechanisms. Firstly, we review the related work on computational 
inference of DDIs. Then, we describe three different experiments designed and conducted 
to evaluate, in a comprehensive way, the inference capabilities of DINTO. 
Chapter 10 describes the evaluation of DINTO in a different application scenario. 
To this purpose, we provide a proof-of-concept of the contribution of DINTO to different 
NLP tasks, by providing the domain knowledge to be exploited by an IE pilot prototype.  
Finally, Chapter 11 highlights the main conclusions of this thesis, discusses the 
achievement of the proposed objectives, the dissemination and publication of our work, 
and highlights the future work on both the DDI corpus and DINTO as directions for 
further related research. 
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Chapter 2 
Corpora in the pharmacological 
domain 
The first main contribution of this thesis is the development of an annotated corpus 
for drugs and their interactions, which will be a benchmark to train and test DDI 
extraction systems. Gold-standard annotated corpora are necessary resources when 
building and evaluating NLP systems, since they provide correct annotations for both the 
training and evaluation of automatic systems.  
A gold-standard corpus in NLP has been defined as a collection of texts manually 
annotated with the instances and/or relationships relevant to the specific tasks by one or 
more annotators (Deleger et al., 2012; Klein, Riazanov, Hindle, & Baker, 2014; Neves & 
Leser, 2014; Neves, 2014; Wissler, Almashraee, Monett, & Paschke, 2014). However, a 
quality gold-standard requires not only manual annotation, but its subsequent checking 
and correction (Baker, Hardie, & McEnery, 2006). Although it is not possible to avoid 
the introduction of errors in almost any manual task, incorrect annotations in the training 
corpus are propagated to the final system (Wissler et al., 2014). Therefore, the number of 
mistakes should be reduced to their minimum level. The most common way to ensure 
quality of the annotations is the analysis of the inter-annotator agreement (IAA) - a 
measure of the degree of concordance between the annotations made by different 
annotators (Cohen, 1960) -,  and the creation of annotation guidelines - the document 
describing in detail the annotation process and the concepts to be annotated (Klein et al., 
2014).   
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In addition to these characteristics,  to be useful to the NLP community, a gold-
standard should be rich in information and include large variety of documents and 
annotated instances that represent the diversity of document types and instances of 
interest for a specific task (Deleger et al., 2014). Finally, a wide acceptance and use by 
the NLP community converts a corpus into a de facto gold-standard, such as the GENIA 
corpus (Kim, Ohta, Tateisi, & Tsujii, 2003), which has been described to have the highest 
usage rate among several corpus designed for biomedical NLP (Cohen, Ogren, Fox, & 
Hunter, 2005). 
Therefore, from the analysis provided above, we can conclude that the characteristics 
of a gold-standard must be: 
1. Manual annotation. 
2. High quality, ensured by: 
a. the measurement of the IAA, 
b. the creation of annotation guidelines. 
3. Usefulness, by providing: 
a. rich information, 
b. diversity of document types and annotated instances, 
c. large number of documents and annotations. 
4. Wide acceptance and use by the NLP community. 
In this chapter, we analyse existing corpora annotated with entities and relationships 
relevant to the DDI domain. Table 2.1 summarizes all the mentioned corpora, with a 
brief description of their main purpose, and Figure 2.1 shows the timeline of 
pharmacological corpora annotated with pharmacological entities and DDIs. 
 
Figure 2.1. Timeline of pharmacological corpora included in this review 
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Corpora Description 
BioText 
(Rosario & 
Hearst, 2004) 
BioText is a corpus created for the evaluation of relation extraction of 
treatment-disease relationships. 
ITI TXM 
(Alex et al., 
2008) 
The Tissue Expressions and Protein–Protein Interactions (ITI TXM) corpus 
was created in the framework of the TXM project for development of tools for 
assisting in the curation of biomedical research papers. It was annotated with a 
broad range of biomedical entities and relationships between them. 
CLEF 
(Roberts et al., 
2009) 
The Clinical E-Science Framework (CLEF) corpus was developed within the 
CLEF project to support extracting information from clinical patient reports. 
BioCaster 
(Doan et al., 
2009) 
BioCaster is a manually annotated corpus created for the evaluation of a 
system aimed to detect outbreak diseases. 
DrugDDI 
(Segura-
Bedmar, 
2010) 
The DrugDDI corpus was created and used in the DDIExtraction 2011 
challenge to promote research and provide a common framework for 
comparing the latest advances in information extraction techniques applied to 
the extraction of DDIs from biomedical texts. 
ADE 
(Gurulingappa 
et al., 2012) 
The Adverse Drug Effects (ADE) corpus was created to support the 
development and validation of methods for the automatic extraction of drug-
related adverse effects from medical case reports.  
PK DDI 
(Boyce et al., 
2012) 
The PK DDI corpus was created for the development of automated methods 
for identifying PK DDIs from drug package inserts. 
Rubrichi 
(Rubrichi & 
Quaglini, 
2012) 
These authors created a small in-house annotated corpus for the automatic 
extraction of drug information conveyed in the Summary of Product 
Characteristics. 
EU-ADR (van 
Mulligen et 
al., 2012) 
The Exploring and Understanding Adverse Drug Reactions (EU-ADR) corpus 
was developed as part of the EU-ADR project. It contains annotations of 
multiple entities (drugs, diseases, and targets) and relationships between them. 
PK (Wu et al., 
2013) 
The PK corpus was created to cover the domain of pharmacokinetic studies, 
including in vivo and in vitro PK DDI studies. 
CHEMDNER 
(Krallinger et 
al., 2013) 
The CHEMDNER corpus was created for the “Chemical compound and drug 
name recognition” task of the BioCreative IV Challenge and Workshop, which 
goal was to promote the implementation of systems to detect mentions of 
chemical compounds and drugs, in particular those chemical entity mentions 
that can subsequently be linked to a chemical structure.  
Table 2.1. Summary of corpora annotated with pharmacological substances and corpora 
annotated with DDIs. 
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The identification of drug names is a preliminary and crucial step in many text 
mining tasks such as the detection of the outbreak of diseases (Doan et al., 2009), the 
extraction of medication-related information (Deléger, Grouin, & Zweigenbaum, 2010), 
the detection of adverse-drug events (Warrer, Hansen, Juhl-Jensen, & Aagaard, 2012), or 
the extraction of relationships such as drug-disease (Xu & Wang, 2013), drug-gene 
interactions (Sutton, Wojtulewicz, Mehta, & Gonzalez, 2012), or drug-drug interactions 
(Segura-Bedmar, Martínez, & de Pablo-Sánchez, 2011b), among many others. In fact, 
several corpora have been built for these purposes in recent years (Figure 2.1). Here, we 
review the main corpora annotated with drug entities (Section 2.1), giving a special focus 
on those corpora that also contain DDIs (Section 2.2). Then, in Section 2.3, we examine 
these resources with respect to the previously described characteristics of a gold-standard 
corpus. Finally, main conclusions are discussed in Section 2.4. 
2.1 Corpora annotated with drug entities 
Annotation of drug entities differs between corpora, especially from those created 
some years ago and the more recent ones. Since each corpus has been developed for a 
specific task, the definition of a drug entity varies significantly from corpus to corpus.  
Thus, in CLEF (Roberts et al., 2009) and BioText (Rosario & Hearst, 2004) 
corpora drug names and therapeutic devices or interventions were annotated with the 
same entity type. Other corpora, such as ADE (Gurulingappa et al., 2012), EU-ADR (van 
Mulligen et al., 2012), or ITI TXM (Alex et al., 2008), used a single entity type to 
annotate both drugs and chemicals, while the BioCaster corpus (Doan et al., 2009) 
distinguished between substances for the treatment of diseases and chemicals not 
intended for therapeutic purposes.  
In contrast, corpora such as PK DDI (Boyce et al., 2012) or that developed by 
Rubrichi & Quaglini (Rubrichi & Quaglini, 2012) proposed a more fine-grained 
classification of pharmacological substances. The annotation schema of the PK DDI 
corpus described three entity types to annotate pharmacological substances: ACTIVE 
INGREDIENT, DRUG PRODUCT and METABOLITE. Similarly, Rubrichi & 
Quaglini, proposed three different entity types: ACTIVE DRUG INGREDIENT, DRUG 
and DRUG CLASS. Similarly, the CHEMDNER corpus distinguished between eight 
subtypes of chemical named entities, the TRIVIAL type being the closest to drug 
mentions.  
Finally, in the DrugDDI corpus (Segura-Bedmar, 2010), drugs were automatically 
recognized on the basis of drug-related Unified Medical Language System (UMLS) 
semantic types using the MetaMap Transfer tool (MMTx) (Aronson, 2001) and annotated 
as a unique entity DRUG. In a similar way, drug names and metabolites were assigned 
the same type DRUG in the PK corpus (Wu et al., 2013).  
This diversity in the annotation of pharmacological substances among different 
corpora shows that there is not a consensus between annotators about which definition 
should be used for the drug entity, mainly because it is application dependent. 
 13 
 
2.2 Corpora annotated with DDIs 
To the best of our knowledge, only three works have addressed the annotation of 
DDIs: the DrugDDI corpus, the PK DDI corpus and the PK corpus. The first corpus 
annotated with pharmacological substances and DDIs was the DrugDDI corpus. It was 
developed in the framework of Dr. Segura-Bedmar’s PhD thesis: ‘Application of 
information extraction techniques to pharmacological domain’ (Segura-Bedmar, 2010). 
The objective of this work was the development and evaluation of IE techniques in 
biomedical documents, particularly for automatic detection of DDIs from unstructured 
text. The DrugDDI corpus was created and used in the DDIExtraction 2011 challenge 
(Segura-Bedmar, Martínez, & Sánchez-Cisneros, 2011). The goal of this task was to 
promote research and provide a common framework for comparing the latest advances in 
IE techniques applied to the extraction of DDIs from biomedical texts. This work was a 
starting point for research on such problems and has received much interest in the 
community of text mining, which is demonstrated by the number of papers that have 
appeared later and attempting to address the same problem. This work is the onset of this 
thesis, and can be considered as a preliminary version of the DDI corpus.  
The DrugDDI corpus consisted of 579 documents describing drug interactions that 
were taken from the DrugBank database (Wishart et al., 2006).  A total of 3,160 DDIs 
were manually annotated as relationships between two interacting drugs at a sentence 
level.  However, this version presented important limitations. Firstly, drug names were 
automatically annotated without any manual intervention in the process. Secondly, no 
annotation guidelines were produced. Thirdly, the annotation was carried out by a single 
annotator, without pharmacological background. Finally, the quality of the corpus was 
not evaluated in terms of the IAA. 
Another corpus created for the development of automated methods for identifying 
DDIs from texts is the PK DDI corpus (Boyce et al., 2012). It is a manually annotated 
corpus made up of FDA-approved drug package inserts (PIs), annotated with 592 DDIs. 
These documents were annotated only for a specific type of DDIs, PK DDIs. They were 
annotated as POSITIVES (if they asserted the existence of the DDI) or NEGATIVES (if 
the sentence denied the occurrence of the DDI) and as QUANTITATIVE (when the 
statement contained quantitative data) or QUALITATIVE (otherwise). 
The last annotated corpus for DDIs is the PK corpus (Wu et al., 2013), which also 
focused on the annotation of PK DDIs. However, it consisted of MEDLINE abstracts that 
were manually annotated with a total of 1,333 DDIs. In this corpus, sentences describing 
DDIs were classified regarding their level of certainty, which could be mainly classified 
as types DDI, AMBIGUOUS DDI or NON-DDI. 
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2.3 Analysis of corpora features 
2.3.1 Type of annotation procedure 
As mentioned before, the first characteristic defining a gold-standard corpus is the 
type of annotation procedure: manual, automatic, semi-automatic or hybrid (Neves, 
2014). In this section, we describe the different ways to create annotated corpora, and 
compare the processes adopted by the studied corpora. 
Manual annotation is performed by annotators from scratch based on a pre-
established annotation schema. Well-designed annotation processes, such as that in the 
annotation of the ADE corpus (Gurulingappa et al., 2012), establish a training period for 
annotators. During this period, they study a small set of texts from the corpus and 
contribute to the creation of a comprehensive annotation schema, adapted to the 
information and peculiarities that will be found in the text (Herrero-Zazo, Segura-
Bedmar, & Martínez, 2013).  However, it is a very time consuming task, and there might 
be a high number of missing annotations or other sources of error due to the human 
factor. The participation of several annotators in the annotation process contributes 
significantly to avoid these issues. 
Corpus Entity annotation DDI annotation 
Annotation 
guidelines 
IAA 
BioText Manual -   
ITI TXM Manual - *  
CLEF Manual -   
BioCaster Manual - *  
DrugDDI Automatic Manual   
ADE Manual - *  
PK DDI Semi-automatic Manual   
Rubrichi Manual -   
EU-ADR Automatic - *  
PK Automatic Manual *  
CHEMDNER Manual -   
Table 2.2. Annotation procedure, availability of annotation guidelines, and evaluation 
based on the IAA (* is used when authors mentioned the creation of specific annotation 
guidelines, but these are not available). 
In contrast, automatic annotation of biomedical corpora relies on programs or tools 
that recognize and annotate biomedical terms by mapping them with pre-established 
vocabularies or dictionaries. The UMLS MetaMap Transfer tool (MMTx) (Aronson, 
2001) is a highly configurable program to map biomedical text to the UMLS 
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Metathesaurus1. Moreover, MMTx enables the syntactic and semantic analysis of the 
documents by performing sentence splitting, tokenization, POS-tagging, shallow 
syntactic parsing, and linking of phrases with UMLS concepts. Those corpora completely 
derived from automated methods and never manually validated by experts are referred to 
as silver-standard corpora (Neves, 2014). Automatic annotation reduces the time required 
by the annotation process and those problems associated with the manual annotation. 
However, the quality of the annotation relies strongly on the characteristics of the 
vocabulary or dictionary used by the annotation tool. Therefore, problems such as 
incorrect annotation of ambiguous terms or missing annotation of spelling variations, 
abbreviations, or synonyms, are frequent. In fact,  previous works have shown that the 
recognition of pharmacological substances cannot be performed properly by current 
automatic IE systems without human intervention (Jagannathan et al., 2009). 
A common variant to manual annotation is semi-automatic approaches combining 
both manual and automatic annotation. First, documents are pre-annotated with an 
automatic tool, and then annotators review and annotate these pre-annotated documents. 
With this method, time consumed in the annotation process is reduced, as well as the 
number of missing annotations associated to manual annotation. If the reviewing process 
includes not only the validation of the automatic annotations, but is accompanied by a 
carefully reading of the text to identify missing ones, then this method provides the same 
quality that manual annotation. 
Finally, some corpora combine automatic annotation for entities and manual 
annotation for relationships. They are known as hybrid corpora (Neves, 2014).The most 
important limitation of these resources is that they cannot be considered as gold-standards 
for the NER task, and that the quality of the annotation of relationships relies on the 
number of missing and incorrectly annotated entities. 
Most corpora were manually annotated with pharmacological substances (CLEF, 
BioText, BioCaster, ITI-TXM, ADE, CHEMDNER or Rubrichi and Quaglini’s 
corpora), while automatic annotation was the method used in the EU-ADR, PK and 
DrugDDI corpora. Only the PK DDI corpus was annotated semi-automatically for 
pharmacological entities using a dictionary from the database DrugBank, and later 
manually reviewed. In contrast, all the DDI relationships were manually annotated 
(Table 2.2). 
The type of annotations determines the suitability of the corpora for different IE 
tasks. On the one hand, corpora manually annotated with chemical entities could be 
suitable for chemical NER (ITI-TXM, BioCaster, ADE, or CHEMDNER), while those 
annotated specifically with pharmacological entities, such as BioCaster, PK DDI, 
Rubrichi & Quaglini or CHEMDNER, could be useful for drug NER. In addition to 
this, corpora with different annotation types for drug entities, such as the PK DDI or 
Rubrichi & Quaglini’s corpora, could be suitable for drug named entity classification, 
too. However, as we explain in next sections, other aspects such as the quality and 
number of annotations should be considered when selecting a corpus for NER. 
On the other hand, from the three resources annotated with DDIs, only the PK DDI 
and the PK corpus could be used in both DDI extraction and classification tasks. The 
former one only classified relationships as positives or negatives and as qualitative or 
                                                 
1 http://www.nlm.nih.gov/pubs/factsheets/umlsmeta.html 
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quantitative, while the latter one classified PK DDIs based on the level of certainty 
expressed in the sentence. These resources could be useful, therefore, for the 
development of systems training modality recognition (Aramaki et al., 2009). However, 
they are not suitable for classification of relationships based on DDI-related aspects, such 
as those describing the mechanism of a DDI or those describing the effect.  
2.3.2 Corpora quality: annotation guidelines and IAA 
Annotation guidelines are the documents defining the annotation task and the 
annotation conventions (Bird, Klein, & Loper, 2009). The extent and detail of these 
documents are related to the quality of the annotation process and the agreement between 
annotators. Moreover, the usefulness of the corpora depends on the quality of the 
annotation guidelines (Dipper, Götze, & Skopeteas, 2004). Therefore, it is necessary that 
the annotation guidelines be accessible to the final user of the corpus (Leech, 1993; 
Pustejovsky & Stubbs, 2012) and that these documents fulfil requirements such as 
explicitness and completeness (Dipper et al., 2004). However, some biomedical 
annotated corpora do not provide annotation guidelines or linguistic aspects are not 
described with sufficient level of detail (Lu, Bada, Ogren, Cohen, & Hunter, 2006). For 
example, the CLEF corpus was annotated based on exhaustive and well defined 
annotation guidelines. However, since the aim of this project was not the annotation of 
drugs, descriptions regarding their annotation are not detailed enough. In contrast, the PK 
DDI corpus’ annotation guidelines are available to the research community and provide 
instruction for the annotation of drugs and PK DDIs. They include definitions, examples, 
and specific instructions regarding annotation aspects and use of the annotation tool. 
Although definitions and examples for all those entities describing drugs in their 
annotation schema are provided, drug names term variants are not explicitly described. 
Regarding DDIs annotation rules, however, explicit and clear instructions are provided 
(Table 2.2). 
As mentioned before, most common way to ensure quality of the annotations is the 
analysis of the inter-annotator agreement (IAA), a measure of the degree of concordance 
between the annotations made by different annotators (C. Müller & Strube, 2006). It is 
commonly measured in terms of the standard Kappa statistic (Cohen, 1960), which takes 
into account that a certain degree of agreement between annotators can also be ascribed 
to chance. IAA enables the assessment of the quality and consistency of the corpus and 
the annotation guidelines, as well as the complexity of the annotation task. 
The measurement of the IAA requires that more than one annotator annotates the 
same texts in the corpus. This is another important factor in the quality of the annotation 
process. Strategies of multi-annotation, in which all documents are annotated by more 
than one annotator, have been proposed as the best way to avoid problems related to 
manual annotation (Jagannathan et al., 2009; Wilbur, Rzhetsky, & Shatkay, 2006). 
However, only some corpora provided IAA scores (Table 2.2). These included the 
CLEF, ITI-TXM, EU-ADR, ADE, PK, and PK DDI corpora. In general, the 
consistency in the annotation of drug entities was high (greater than 75%), while IAA 
scores reported for the PK DDI corpus (around 60%) suggested that annotation of DDIs 
is a more complex task than simply the identification of drug names. 
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2.3.3 Type of documents 
Pharmacological information can be found in different texts, such as research 
articles, manually curated databases, patent documents, patient clinical records, clinical 
notes, and so forth. Manual annotation of these texts should be carried out by domain 
experts capable of understanding the information described on them. However, not all 
corpora are equally complex. Complexity varies depending on several facts, such as the 
source of the documents (e.g., manual curated databases or primary scientific literature), 
the type of study described in the text (e.g., clinical study or in vitro study), and content-
related and linguistic aspects, such as the use of technical vocabulary, complex sentences, 
and so forth. The level of complexity of texts determines which annotators should be 
selected for the annotation task (e.g., a pharmacovigilance expert or a life science 
bachelor student), the length of training for annotators, and the explicit rules that should 
be described in the annotation guidelines. In summary, the complexity of the texts 
influences the manual annotation process and the subsequent IAA results. Similarly, the 
precision and recall obtained by automatic IE systems trained and tested in a corpus 
might vary considerably with the purpose and style of the texts used to train and/or test 
them (Jessop, Adams, Willighagen, Hawizy, & Murray-Rust, 2011).  
Regarding the type of document, almost all of the aforementioned corpora were 
made up of MEDLINE abstracts (BioText, ADE, EU-ADR, PK and CHEMDNER), 
while full articles were used only in the ITI TXM corpora. Both the PK DDI corpus and 
that developed by Rubrichi & Quaglini consisted of texts taken from PIs, which are one 
of the most important sources of information for healthcare professionals and patients on 
the use of medicines. The DrugDDI corpus is the only corpus consisting of DrugBank 
documents (Table 2.3). 
Corpus Type of document Size Sentences Drugs DDIs 
BioText MEDLINE abstracts np np np - 
ITI TXM Full articles 400 np 18,000 - 
CLEF Patient records 150 np 197 - 
BioCaster Internet news 1,000 articles np 1,022 - 
DrugDDI DrugBank documents 579 5,806 23,190 3,160 
ADE MEDLINE abstracts np 4,272 5,063 - 
PK DDI Package Inserts 68 np 3,896 592 
Rubrichi Package Inserts 100 sections np np - 
EU-ADR MEDLINE abstracts 300 np 1,753 - 
PK MEDLINE abstracts 428 5,026 np 1,333 
CHEMDNER MEDLINE abstracts 10,000 np 84,355 - 
Table 2.3. Comparison of size, type of documents, and number of annotations for corpora 
annotated with drugs or chemicals and DDIs (we use np for those figures not provided by 
the authors). 
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2.3.4 Size and number of annotations 
The size of corpora consisting of clinical texts is very small. For example, the 
CLEF corpus consisted of 150 patient records, which were annotated only with 197 
drugs. Conversely, the ITI-TXM corpus were made up of 455 full text research articles 
and were annotated with almost 18,000 drug compounds. Usually, the size of the 
different corpora of MEDLINE abstracts never exceeded 500 abstracts, until the recent 
development of the CHEMDNER corpus, which included 10,000 abstracts annotated 
with 84,355 entities. Meanwhile, the EU-ADR corpus contained 300 MEDLINE 
abstracts annotated with 1,753 drugs, and the ADE corpus consisted of 4,272 sentences 
annotated with a total of 5,063 drugs. The size of the PK corpus was 428 MEDLINE 
abstracts divided into 5,026 sentences. In contrast, the DrugDDI corpus was made up of 
5,806 sentences from 579 DrugBank documents. However, the latter contained 3,160 
DDIs while the former 1,333. Meanwhile, in the PK DDI corpus, consisting of 208 
multi-sentence sections from 64 PIs, which were annotated with a total of 3,986 drugs, 
the number of annotated DDIs was 592. A review of these metrics is shown in Table 2.3. 
2.4 Discussion and conclusions 
In this chapter, we have reviewed the primary corpora annotated with drugs, paying 
special attention to those annotated with DDIs. One of the purposes of this thesis is to 
create a corpus that can provide a benchmark framework for the automatic extraction of 
DDIs to cope with some of the limitations of the existing ones. 
First, differences in the annotation of pharmacological substances among different 
corpora have been observed. The main reason is that each corpus has been developed for 
a specific task, leading to disparate definitions of the drug concept, which is annotated at 
different levels of detail. A preliminary analysis of texts describing DDIs showed that a 
DDI might be described between different types of drugs, such as generic drugs, brand 
drugs, groups of drugs or other substances not approved for human use (e.g., toxins or 
abused substances). References to different types of drugs are used in texts because they 
provide important information that can be used and interpreted by domain experts. For 
example, a healthcare professional knows that a DDI described for the drug paracetamol 
must be extrapolated to the brand drugs Gelocatil® and Efferalgan®, since they contain 
paracetamol as their active substance. He or she can infer, as well, that a document 
describing those different interactions for the drug product Gelocatil® would probably 
have been written by the manufacturer of this specific drug product. Moreover, a domain 
expert infers from a DDI described to occur between duloxetine and the group of drugs 
CYP450 inhibitors that the mechanism of the DDI is a reduction in the metabolism of 
duloxetine. In spite of this, none of the aforementioned corpora provided annotations for 
all these different types of drugs. One of our goals is, therefore, to create a corpus 
including specific annotations for all these different entity types. 
Regarding DDI-annotated corpora, only three resources have been identified. The 
DrugDDI corpus proved to be useful as a training and evaluation resource in the 
DDIExtraction 2011 challenge. Moreover, its size and the number of annotated drugs and 
DDIs were higher than for the other related corpora. However, some aspects such as the 
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automatic annotation of drugs, the lack of annotation guidelines, or the evaluation 
through the IAA were shortcomings of this version to be a gold-standard. Other corpora, 
such as the PK corpus and the PK DDI corpus provided different types of annotated texts 
to those included in the DrugDDI corpus. However, they had a small size and only PK 
DDIs were annotated, thus excluding the equally important PD DDIs. 
In general, we have observed that different corpora vary on the type of documents, 
size, and number of annotations. None of them addressed, however, the task of annotating 
different types of documents and studying their influence on training and testing machine 
learning systems. Moreover, none of the DDI-annotated corpora was annotated with 
different type of DDI information, such as effect, mechanism, or recommendation. 
We try to overcome all these issues in this thesis. An important contribution of our 
work is to provide the first annotated corpus with PK and PD DDIs, and with a fine-
grained annotation schema for pharmacological substances. In addition, our goal is that 
the corpus has a bigger size than those related corpora and provides different styles of 
texts, thus enabling training and development of NLP systems devoted to DDI extraction 
in different text sources. Finally, in order to assess the quality and consistence of the 
corpus, annotation guidelines should be created and the IAA should be measured. 
To conclude this chapter, we provide a list of the specific limitations that will be 
addressed in this thesis. 
1. There are significant differences in the annotation of drugs names among 
different corpora, since no existing work has focused on the study and 
annotation of drug classification and nomenclature variations, such as 
synonyms, abbreviations, acronyms, and so forth. For example, the same 
concept ‘Nonsteroidal Anti-inflammatory drug’ can be expressed as well as 
‘Nonsteroidal Anti-inflammatory drugs’, ‘Nonsteroidal Anti-inflammatory 
agents’ or ‘NSAID’, among others. However, corpora annotated with 
pharmacological substances have not included these, or similar, aspects in the 
annotation. 
2. Corpora annotated with pharmacological substances do not provide detailed 
guidelines with the different definitions of these substances and the 
annotation conventions or rules. 
3. The study and identification of the issues affecting the manual annotation of 
pharmacological texts can be useful to anticipate the problems that will be 
encountered by NLP systems, since there is a relationship between the 
complexity of the manual annotation and the performance of automatic 
systems. However, there is not existing work studying the aspects influencing 
the annotation of pharmacological substances.   
4. There is a lack of gold-standard corpora for the extraction of DDIs. Available 
corpora have been annotated only with a type of DDIs, PK DDIs. However, 
there are not corpora annotated with PD DDIs. 
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5. A DDI can be described in multiple ways regarding its mechanism, effect, or 
recommendation (see Section 1.3 for an example). These aspects are crucial 
for the appropriate management of DDIs in the clinical setting (Bergk et al., 
2005; Tatro, 2010) and, all together, provide the whole picture of a specific 
DDI. However, different sources of DDI information have been reported to 
have a lack of some of them (Bergk et al., 2005), leading to differences 
among different types of documents. In spite of this, there is not one 
annotated corpus classifying the type of information provided to describe 
each DDI. 
6. Each of the existing DDI corpora consists of homogeneous documents 
(DrugBank documents, PIs, or MEDLINE abstracts). However, none of them 
includes different types of documents in the same corpus. This approach is 
interesting for the study of the influence of different texts in the annotation 
process and the performance of evaluated NLP systems. 
7. As we explain in Section 1.3, DDIs are described in text in very different 
ways and there are multiple patterns used to describe a DDI relationship. 
Therefore, the number of annotations of a DDI corpus must be large enough 
to cover most of them in a comprehensive way. In addition to this, corpora 
are usually divided into two sets: one for training and one for testing 
purposes. In order to be useful for the development and evaluation of IE 
systems, both of them must contain a representative sample of these different 
annotated patterns. However, the limited size and number of annotations in 
the existing corpora annotated with DDIs might compromise their use as 
gold-standards for NLP purposes. 
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Chapter 3 
The DDI corpus 
As we have shown in the previous chapter, there is no existing corpus that can be 
considered a gold-standard for pharmacological substances and DDIs. The lack of an 
appropriate resource becomes a bottleneck to apply NLP techniques to the extraction of 
DDIs. To overcome this problem, we have developed a new corpus: the DDI corpus. This 
chapter describes its construction and annotation processes (Section 3.1, Section 3.2 and 
Section 3.3). The main annotation issues identified during the annotation of the corpus 
are described in Section 3.4. Then, we outline the main characteristics of the corpus in 
terms of the frequency of entities and relationships in Section 3.5. Finally, in Section 3.6 
we compare the DDI corpus with previous corpora for DDIs reviewed in our related 
work, and highlight the main conclusions in Section 3.7. 
3.1 Collecting the corpus 
As mentioned before (Section 2.2), the origin of this thesis is the DrugDDI corpus 
(Segura-Bedmar, 2010), an antecedent version of the new DDI corpus that was used in 
the DDIExtraction 2011 challenge (Segura-Bedmar, Martínez, & Sánchez-Cisneros, 
2011). The DrugDDI corpus consisted of 579 documents describing DDIs taken from the 
DrugBank database. To improve the quality and usefulness of the corpus, we have added 
213 DrugBank new texts, and a second type of documents: abstracts from the MEDLINE 
database. We refer to the first subset of the corpus as the DDI-DrugBank dataset, while 
the latter one is referred to as the DDI-MEDLINE dataset. 
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3.1.1 The DDI-DrugBank dataset 
The initial source of unstructured textual information on DDIs is the DrugBank 
database2. It is a free online resource created and maintained by the Wishart Research 
Group at University of Alberta (Canada), which contains information on a large number 
of pharmacological substances including small molecule drugs, biotech drugs, 
nutraceuticals, and experimental drugs. This database provides information oriented to 
biochemists and biologists regarding the nomenclature, structure, and physical properties 
of drugs and their drug targets. DrugBank also offers clinical information such as 
pharmacology, metabolism, and indications. Since its first release in 2006, it has become 
a very popular resource and has been widely used in several contexts, including drug 
repositioning (Pérez-Nueno, Karaboga, Souchet, & Ritchie, 2014), drug target discovery 
(Liu et al., 2014), and drug interaction prediction (Cheng & Zhao, 2014), among many 
other applications.  
For each drug, DrugBank contains more than 100 data fields including drug 
synonyms, brand names, chemical formula and structure, drug categories, corresponding 
codes for the ATC and AHFS drug codes systems, mechanism of action, indication, 
dosage forms, and toxicity. In addition to this, DrugBank offers drug interaction 
information, which is manually curated by the DrugBank team. DDI information has 
changed along the different releases of the database. The version used in the creation of 
the corpus (DrugBank 2.1 (Wishart et al., 2008)) provides a detailed description of DDIs 
in unstructured text. Since this information has been manually curated, texts focus 
completely on the description of DDIs and use a language similar to that used in PIs (see 
example in Section 3.6). In contrast, most recent versions of DrugBank provide a semi-
structured but briefer description of the DDIs. Figure 3.1 and Figure 3.2 show the 
description of the DDIs for the drug heparin in both versions DrugBank 2.1 and 
DrugBank 4.1, respectively. 
 
Figure 3.1. Description of the DDIs for the drug heparin in DrugBank version 
2.1 (from (Segura-Bedmar, 2010)) 
 
                                                 
2 http://www.drugbank.ca/ 
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Figure 3.2. Description of the DDIs for the drug heparin in DrugBank version 4.1 
The DDI-DrugBank dataset includes a total of 792 documents from DrugBank 2.1. 
From them, 579 made up the DrugDDI corpus, while the remaining 213 have been 
included in this new version. We use the Kapow’s free RoboMaker screen-scraper3 to 
download the interaction documents, which are then analysed by the UMLS MMTx 
(Section 3.2). 
3.1.2 The DDI-MEDLINE dataset 
The MEDLINE database is a free, publicly available service of the National Library 
of Medicine (NLM)4. It is a primary repository for biomedical peer-reviewed journal 
articles, which has become a valuable resource to the health care professionals and 
biomedical research community. These abstracts provide an appropriate type of text for 
training and testing of NLP systems, since they represent the scientific literature where 
new pharmacological discoveries are described. Therefore, mining these types of 
documents has a great interest for the biomedical community (Kim, Ohta, & Tsujii, 
2008). In contrast to DrugBank, MEDLINE texts are usually written in a very scientific 
language, and the main topic of the scientific texts would not necessarily be on DDIs.  
Document selection for the DDI-MEDLINE corpus has been carried out against 
PubMed5, the search engine for the MEDLINE database. An initial set of documents is 
selected from PubMed using a query with ‘‘drug interactions’’ as MeSH term. This query 
return 116,919 citations (published between 1975 and 2011) of which 233 documents are 
randomly selected for annotation. Documents without an abstract section are discarded. 
                                                 
3 http://openkapow.com/ 
4 http://www.nlm.nih.gov/ 
5 http://www.ncbi.nlm.nih.gov/pubmed 
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3.2 Processing the corpus 
The aim of this activity is processing the documents to generate a corpus in 
Extensible Markup Language (XML) format and annotated with shallow syntactic and 
semantic information. The latter one refers to an initial annotation of drug entities in the 
corpus, which will be subsequently reviewed during the manual annotation. This semi-
automatic approach assists annotators during the annotation process, reducing the task 
duration and the number of missing entities (Fort & Sagot, 2010). Here, we review the 
main NER tools available for processing of biomedical text, and describe the processes 
used to analyse the texts conforming the DDI corpus. 
3.2.1 Review of the main NER tools for biomedical text 
In order to choose the best option for our task, we make a detailed review of the 
main tools for NER task in the biomedical domain. Although current efforts, such as the 
CHEMDNER task at the Fourth BioCreative challenge (Krallinger et al., 2013), have 
encourage research into the development of chemical NER systems, the number of freely 
available tools in the past years was small. Indeed, to the best of our knowledge, only five 
tools were available when we started the annotation of the DDI corpus. They are 
summarized in Table 3.1 and described below. In order to provide an updated description 
of available tools for chemical NER, we also include the recently developed CheNER 
tool. 
In this review, we have observed that one of the most important differences among 
chemical NER tools is the type of named chemical entities that they recognize. Chemical 
named entities can be divided into two main groups: systematic and common names. 
Systematic nomenclatures use a set of rules to generate systematic names for chemical 
compounds, being the most frequently used worldwide the IUPAC (International Union 
of Pure and Applied Chemistry) nomenclature (McNaught & Wilkinson, 1997). Authors 
specialized in chemical NER assert that IUPAC names are usually complex multiword 
terms including punctuation marks, sequences of numbers separated by commas, and so 
forth (e.g., N-(4-hydroxyphenyl)acetamide) calling for a classification-based tool, 
whereas common names follow hardly any rule (e.g., acetaminophen) and are best 
captured by an exhaustive dictionary (Rocktäschel, Weidlich, & Leser, 2012; Usié, 
Alves, Solsona, Vázquez, & Valencia, 2014).  
Therefore, dictionary-based approaches are used to identify drug names, 
abbreviations, trivial names, molecular formulas, and family names, whereas machine 
learning techniques are applied for NER of IUPAC chemical entities. In our case, the 
DDI corpus focuses on the former type of entities, being less common those mentions to 
IUPAC-like entities. 
To the best of our knowledge, the first freely available chemical NER tool was the 
Open-Source Chemistry Analysis Routines (OSCAR), whose latest version is 
OSCAR4 (Jessop et al., 2011). It is a system for the recognition of chemical entities, 
which has been developed since 2002. It offers different methods to recognize chemical 
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entities, including dictionary-based approaches, predetermined regular-expression, or 
machine learning in the form of a Maximum Entropy Markov Model (MEMM). 
Tool Purpose Method 
Syntactic 
analysis 
OSCAR NER in chemistry 
publications 
MEMMs  
Jochem Identification of small 
molecules and drugs in text 
Dictionary-based approach 
combining information 
from different sources 
 
ChemSpot Identification of chemical 
mentions in natural 
language texts, including 
trivial names, drugs, 
abbreviations, molecular 
formulas, and IUPAC 
entities 
CRF for IUPAC named 
recognition 
Dictionary-based approach 
for drug named recognition 
(ChemIDPlus) 
 
MetaMap To provide access to the 
concepts in the UMLS 
Metathesaurus from 
biomedical text 
UMLS mapping  
DrugNER Identification and 
classification of drug 
named entities 
MetaMap + INN rule-based 
system 
 
(MetaMap) 
CheNER Recognition of IUPAC 
chemical names 
Machine learning based on 
CRF 
 
Table 3.1. Comparison of text processing tools 
Although not a NER tool, the Joint Chemical Dictionary (Jochem) should be 
mentioned in this review. It is a dictionary for the identification of small molecules and 
drugs in text, which combines data extracted and from different resources: UMLS, 
MeSH, ChEBI, DrugBank, KEGG, HMDB, and ChemIDplus. Hettne et al. (2009) used 
the dictionary and their concept recognition software Peregrine (Schuemie, 2007) 
combined with disambiguation rules to extract chemical entities from SCAI (Kolárik, 
Klinger, Friedrich, Hofmann-Apitius, & Fluck, 2008), a corpus annotated with chemical 
entities, and compared the performance for each individual dictionary alone and for 
Jochem. Although results obtained with the combined resource outperformed those 
obtained for individual resources, the performance of a dictionary based on ChemIDplus 
alone was comparable to the performance of the combined dictionary. 
ChemSpot is a hybrid system combining Conditional Random Fields (CRF) for 
IUPAC named recognition, and a dictionary built from ChemIDplus for drug names 
(Rocktäschel et al., 2012). The ChemSpot dictionary-matching component uses the 
previously mentioned ChemIDplus dictionary processed by Hettne et al., (2009). 
However, ChemSpot includes a different post-processing architecture based on the 
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LINNAEUS software (Gerner, Nenadic, & Bergman, 2010) and match expansion instead 
of the dictionary-matching software Peregrine.  
A well-known and very popular tool that has been broadly used for NER task in the 
biomedical domain is the MetaMap Transfer tool (MMTx) (Aronson & Lang, 2010). 
This is a NLP engine created and maintained by the NLM that maps free text to 
biomedical concepts in the UMLS Metathesaurus (Bodenreider, 2004). In addition to this, 
MMTx performs lexical and syntactic analysis of the text, including tokenization and 
sentence boundary, acronym/abbreviation identification, part-of-speech tagging or lexical 
lookup of input words, which are the pre-processing steps that must be performed prior to 
any named recognition step (Eltyeb & Salim, 2014).  
In an attempt to increase the performance of MMTx for drug named entity 
recognition, Segura-Bedmar et al. (2008) developed DrugNER, a drug name recognition 
and classification system that combines the information obtained by the MMTx program 
and a set of nomenclature rules recommended by the WHO International Nonproprietary 
Names (WHOINN) Program (WHO, 2006).  
Finally, to the best of our knowledge the most recently developed chemical NER 
tool is CheNER, a machine learning application based on CRFs, which has been created 
and trained for the recognition of IUPAC chemical entities in text. The authors reported 
that CheNER performed better than OSCAR4 and ChemSpot in identifying IUPAC 
names. However, results for non-IUPAC names were lower.  
While CheNER has been created specifically for IUPAC named recognition, 
OSCAR does not differentiate between entity types. However, Hette et al. (2009) and 
Rocktäschel et al. (2012) showed in two different studies that a dictionary-based system 
employing Jochem, and another one based on the dictionary-component of ChemSpot 
alone, respectivelly, outperformed OSCAR for chemical NER on the SCAI corpus. On 
the other hand, the performance of the combined dictionary Jochem was comparable to 
those obtained by the ChemIDplus dictionary alone, while being the latter one 
substantially smaller. In addition to this, ChemSpot, which uses as dictionary the same 
ChemIDplus dictionary, obtained better results than the Jochem-based system. This 
ChemIDplus dictionary was created from concepts extracted from the NLM ChemIDplus 
database6. In contrast, MMTx relies on a rich and updated terminological resource, the 
UMLS Metathesaurus, which covers not only drugs, but chemical names, too. 
UMLS is a set of resources developed by the NLM, whose main objective is to 
assist in the developing of natural language technology for biomedical texts. UMLS has 
three major knowledge sources: the Metathesaurus, the Semantic Network and the 
Specialist Lexicon. The Metathesaurus is a large vocabulary containing concepts, concept 
names, and other attributes from more than 100 terminologies, classifications, and 
thesauri. These include MeSH (Lipscomb, 2000), RxNorm (Nelson, Zeng, Kilbourne, 
Powell, & Moore, 2011), SNOMED CT (Stearns, Price, Spackman, & Wang, 2001), and 
the ATC classification system (WHO, n.d.), among many others. All concepts in the 
Metathesaurus are assigned to at least one semantic type from the UMLS Semantic 
Network, providing a consistent categorization of all concepts represented in the UMLS 
Metathesaurus. The Semantic Network contains 135 semantic types such as 
‘Pharmaceutical substance’, ‘Amino Acid, Peptide, or Protein’, ‘Disease or Syndrome’ or 
                                                 
6 http://chem.sis.nlm.nih.gov/chemidplus/ 
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‘Gene or Genome’. Therefore, in addition to drugs and chemical entities, UMLS includes 
other concepts related to the DDI domains, such as diseases, signs and symptoms, 
proteins, and so forth. MMTx is highly configurable and allows the selection of the 
vocabularies or data models, including selection by sematic types, to be used. This is an 
interesting characteristic for our project, since it would enable a further annotation of 
relevant concepts (such as ADRs or proteins) in future work. Finally, the Specialist 
Lexicon is a biomedical lexicon with syntactic, morphological, and orthographic 
information. 
Another advantage of MMTx over other tools is that it performs shallow syntactic 
analysis, such as sentence splitting. Moreover, at least one enhanced release is launched 
every year, and has been widely used for text mining applications in the biomedical 
domain (Bashyam, Divita, Bennet, Browne, & Taira, 2007; Meystre & Haug, 2006; Yip, 
Mete, Topaloglu, & Kockara, 2010). 
For all these reasons, we have selected MMTx as our text processing tool for the 
syntactic and semantic analyses of the documents in the corpus.  
3.2.2 Analysing the texts 
This section focuses on the description of the processes used to analyse the texts. 
The main processes perform by MMTx are represented in Figure 3.3. 
 
Figure 3.3. MMTx processes 
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During the syntactic analysis, the first activity consists in tokenization, sentence 
boundary determination, and acronym/abbreviation (AA) identification. Then, during the 
part-of-speech (POS) tagging, phrases in each sentence are identified and classified. The 
different types of phrases that can be assigned by MMTx are shown in Table 3.2. In case 
the type could not be determined, the phrase is annotated with the label UNK, which 
indicates that the corresponding type is “unknown”.  
Type of phrase Examples 
Noun phrase (NP) Drug Interactions, the cytochrome P450 3A4 enzyme system 
Prepositional phrase (PP) with drugs, of azole antimycotics, of orally administered 
Verbal phrase (VP) administered, inhibit, decrease 
Adjectival phrase (ADJ) hypersensitive 
Adverbial phrase (ADV) concurrently, no, to significantly 
Conjunctions (CONJ) and, or, since 
Table 3.2. Types of phrases identified by MMTx 
As shown in Figure 3.4, MMTx annotates each phrase with its type, the number of 
tokens, the text, and an identifier in the XML document. The next process is a lexical 
lookup of input words in the SPECIALIST lexicon (McCray, Aronson, Browne, & 
Rindflesch, 1993), and the assignment of the POS tags to the tokens. In case that a token 
has several tags in the lexicon, MMTx uses the Xerox part-of-speech tagger (Cutting, 
Kupiec, Pedersen, & Sibun, 1992) to select the correct one. The final syntactic analysis 
consists of a shallow parse in which phrases and their lexical heads are identified by the 
SPECIALIST minimal commitment parser (Mccray, Srinivasan, & Browne, 1994). In 
this way, each token is annotated with its POS tag, its word, and a boolean value 
indicating if it is the head of the phrase (ISHEAD). In addition, the starting and ending 
offsets of each token within the text are stored in the attributes start and end, respectively. 
These character offsets allow mapping from the annotation to the raw text easily. 
Once the shallow syntactic parsing has been performed, MMTx looks for the 
phrases in the UMLS Metathesaurus. For each phrase, a set of variants is generated using 
the SPECIALIST lexicon and linguistic techniques. The set of variants consists of the 
text of the phrase and its acronyms, abbreviations, synonyms, and derivational, 
inflectional, and spelling variants. MMTx looks these variants up in the Metathesaurus 
and retrieves those concepts containing at least one of them, which are considered 
candidates. Each candidate is evaluated against the text of the phrase using several 
linguistic metrics to determine its similarity. Finally, those concepts with a highest 
similarity are selected as the final mapping. For each concept in the final mapping set, 
MMTx provides the concept unique identifier (CUI), the concept name, and the semantic 
types.  
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Figure 3.4. Example of a document processed by MMTx 
Finally, the output of MMTx is transformed into XML format, which follows the 
Document Type Defintion (DTD) shown in Figure 3.5.  
 
Figure 3.5. DTD for the XML files in the DDI corpus 
 30 
 
As shown in the Figure above, the root element is the <document> element with the 
following attribute: 
- id: an unique id that is composed by the name of the corpus (DDI-DrugBank 
or DDI-MEDLINE) and an identifier beginning with “d” and followed by a 
number. 
The next element is the <sentence> element. Each one of them has the following 
attributes: 
- id: a unique id which is composed by the name of the corpus (DDI-DrugBank 
or DDI-MEDLINE), the id of the document (d505), and an id beginning with 
“s” and followed by the index of the sentence (the index of the first sentence 
should be 0). 
- text: contains the text of the sentence. 
Within the <sentence> element, there are the following elements: <entity> and 
<ddi>. Elements of type <entity> correspond to all annotated pharmacological 
substances, while elements of type <ddi> correspond to all annotated drug-drug 
interactions. Each <entity> element has the following attributes: 
- id: a unique id that is composed by the name of the corpus (DDI-DrugBank or 
DDI-MEDLINE) , the id of the document (d505), the id of the sentence, and 
an id beginning with “e” and followed by the index of the entity in the 
sentence (the first entity of the sentence should have the index 0). 
- charOffsets: contains the start and end positions, separated by a dash, of the 
mention in the sentence. When the mention is as discontinuous name, it will 
contain the start and end positions of all parts of the mention separated by 
semicolon. 
- text: stores the text in the mention. 
- type: stores the type of the pharmacological substance (drug, brand, group 
or drug_n)7. 
Similarly, each <ddi> element has the following attributes: 
- id: a unique id that is composed by the name of the corpus (DDI-DrugBank or 
DDI-MEDLINE), the id of the document (d505), the id of the sentence, and 
an id beginning with “d” and followed by the index of the ddi in the sentence 
(the first ddi of the sentence should have the index 0). 
- e1: stores the id of the first interacting entity. 
- e2: stores the id of the second interacting entity. 
- type: stores the type of the drug-drug interaction (advice, effect, 
mechanism, int)7. 
The XML format provides maximum flexibility for the use of the DDI corpus. In 
addition, the corpus is distributed in a standoff annotation format that involves storing 
annotation and text separately (Leech, 1993). An advantage of the standoff annotation 
format is that the original texts can be immediately retrieved without need of recovering 
                                                 
7 These types are described in Section 3.1.1. 
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it from the annotations. Furthermore, this format preserves useful information about the 
structure of the texts. 
3.3 Annotating the corpus 
As we have described in the previous section, we carry out an automatic pre-
annotation of drug entities with MMTx. This tool allows for the recognition of a variety 
of biomedical entities occurring in texts, which correspond to different semantic types of 
the UMLS Metathesaurus. In prior work the UMLS Semantic Network was reviewed, 
and those semantic types including drugs were selected (Segura-Bedmar, 2010). 
However, automatic annotation leads to certain issues, such as incorrect annotation of 
ambiguous terms or missing entities. Therefore, the annotation process for the DDI 
corpus includes a manual review of the texts and their automatic annotations, plus the 
manual annotation of DDI relationships. All the decisions made during the annotation 
process, as well as the description of the annotation process and the annotated entities and 
relations, are documented in form of annotation guidelines (Cohen et al., 2005). 
3.3.1 Annotation guidelines 
Annotation guidelines are the documents defining the annotation task and the 
annotation conventions (Bird et al., 2009). Their extent and detail are related to the 
quality of the annotation process, and the final agreement between annotators (Corbett, 
Batchelor, House, & Teufel, 2007). Moreover, the usefulness of the corpora has been 
defined to be dependent on the quality of the annotation guidelines, which should fulfil 
requirements such as explicitness and completeness (Dipper et al., 2004). Since they 
provide a detailed description of the annotations and, thus, of the corpus itself, it is 
important to make them available along with the annotated corpora (Leech, 1993; 
Pustejovsky & Stubbs, 2012). Therefore, the annotation guidelines for the DDI corpus are 
publicly available and can be downloaded from http://www.cs.york.ac.uk/SemEval-
2013/task9/data/uploads/annotation_guidelines_ddi_corpus.pdf. 
These annotation guidelines provide clear and accurate definitions for all those 
relevant entities and relationships described in the annotation schema (Figure 3.6). This 
document also contains the rules and conventions on how the annotation task should be 
carried out as well as providing examples clarifying their use. 
As shown in Figure 3.6, four entity types are proposed to annotate pharmacological 
substances: drug, brand, group and drug_n.  
 drug: The drug type is used to annotate human medicines known by a 
generic name (e.g., ciprofloxacin, acetaminophen). 
 brand: Drugs described by a trade or brand name are annotated as brand 
entities (e.g., Adacip®, Gelocatil®). A drug medication frequently has several 
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brand names since different companies can market it. The use of a brand-name 
drug instead of its generic name might be related to a higher risk of ADEs 
(Hochman, Hochman, Bor, & McCormick, 2008; Steinman, Chren, & 
Landefeld, 2007). The use of either generic or brand names depends on the 
drug information source. Thus, while generic names are used in medical and 
pharmacological textbooks and scientific medical journals, brand names are to 
be used in drug product labels (SPCs and PIs).  
 group: Since the descriptions of DDIs involving groups of drugs are very 
common in texts, we decide to include the group type to annotate groups of 
drugs (e.g., quinolones, NSAIDs). Extrapolation of drug interactions involving 
a specific compound to interactions involving its group is a common 
procedure in some DDI information sources. However some authors have 
established that this procedure is wrong because this generalization is not true 
for all drugs (Aronson, 2004; Bergk et al., 2005). 
 drug_n: The last entity type refers to active substances not approved for 
human use, such as, and among others, toxins or pesticides (e.g., picrotoxin, 
MPTP). This type is included because interactions between drugs and 
substances not approved for human use are frequently reported in MEDLINE 
documents. 
 
Figure 3.6. Annotation schema in the DDI corpus 
 
 
 
 
33 
 
Concerning the relationships, four different types of DDI relationships are 
proposed: 
 mechanism:  This type is used to annotate DDIs that are described by their 
PK mechanism (e.g., Grepafloxacin may inhibit the metabolism of 
theobromine). 
 effect: This type is used to annotate DDIs describing an effect (e.g., In 
uninfected volunteers, 46% developed rash while receiving SUSTIVA and 
clarithromycin) or a PD mechanism (e.g., Chlorthalidone may potentiate the 
action of other antihypertensive drugs). 
 advice: This type is used when a recommendation or advice regarding a DDI 
is given (e.g., UROXATRAL should not be used in combination with other 
alpha-blockers). 
 int: This type is used when a DDI appears in the text without providing any 
additional information (e.g., The interaction of omeprazole and ketoconazole 
has been established). 
Figure 3.7 and Figure 3.8 show sentences describing DDIs. In Figure 3.7, the first 
sentence describes two interactions: effect and mechanism, and the last one also 
describe a DDI of effect type. In Figure 3.8, DDIs of effect type are described 
between fenfluramine and a group of drugs, antihypertensive drugs, as well as with some 
of its members (guanethidine, methyldopa, reserpine). The last sentence gives an advice 
to avoid a DDI. 
 
Figure 3.7. Examples of DDIs: effect and mechanism types (from the stav text 
annotation visualizer8 (Stenetorp & Topi, 2011)) 
 
Figure 3.8. Examples of DDIs: effect and advice types (from the stav text annotation 
visualiser8 (Stenetorp & Topi, 2011)) 
The proposed classification of DDIs is consistent with the information requirements 
established by pharmacology experts for an appropriate management of DDIs in the 
                                                 
8 http://http://corpora.informatik.hu-berlin.de/ 
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clinical setting (Aronson, 2004; Bergk et al., 2005). For this purpose, healthcare 
professionals should be provided with information on how the interaction occurs 
(mechanism), what consequences can be expected (effect) and how it can be managed to 
avoid or reduce the associated risk (advice).  
Furthermore, this classification is useful to reflect the type of information provided 
from different sources. Thus, drug product labels provide little advice on how to 
minimize the risk of an interaction, whereas PK descriptions are very common in these 
documents (Bergk et al., 2005). On the other hand, DDI compendia (such as Stockley’s 
Drug Interactions (Baxter, 2013) or Drug Interaction Facts (Tatro, 2010)) also contain 
considerable information on advice regarding drug interactions. 
Although the principal aim of the annotation task is annotation at the semantic 
level, linguistic phenomena usually arise during the annotation process. The reason is that 
grammar and meaning are intertwined and, therefore, most annotation efforts should 
combine the two (Simpson & Demner-Fushman, 2012). Therefore, quality annotated 
corpora should be annotated taking into account both semantic and grammatical aspects. 
During the annotation of the DDI corpus, we have identified linguistic phenomena that 
complicate the manual annotation of drug named entities, and different syntactic 
phenomena that should be considered during the annotation of DDIs. We provide a 
detailed description of them in Section 3.4. 
3.3.2 Annotation process 
This section describes the process followed in the annotation of drugs and their 
interactions in the DDI corpus. Four people participate in this activity: two expert 
pharmacists with a substantial background in pharmacovigilance and two text miners 
involved in the creation of the DrugDDI corpus. The process is divided in the following 
steps: training, manual annotation, IAA measurement and harmonization. Figure 3.9 
shows a representation of these phases, which are described in detail below. 
 
Figure 3.9. Annotation process 
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As mentioned before, the annotation process relies on annotation guidelines, which 
are created in an iterative process. In the training stage, the first annotator studies and 
annotates a set of 30 documents from DrugBank and 10 MEDLINE abstracts. During this 
annotation, a previously defined annotation schema and initial annotation guidelines are 
discussed between the pharmacist and the two text mining experts, until the creation of a 
defined schema and annotation guidelines, whose main points have been presented in the 
previous sections. 
The first annotator marks up then the whole corpus, while the second one annotates 
a total of 1600 randomly selected sentences from the DDI-DrugBank dataset and 400 
ones from the DDI-MEDLINE dataset. Since the documents are pre-annotated with 
pharmacological substance entities by the MMTx tool and labelled with drug type, the 
annotators have to review manually these labels, adding missing entities, removing 
erroneous ones, and modifying spans or type of entities when necessary. All mentions of 
pharmacological substances are annotated, even those that are not involved in a DDI. 
Finally, DDIs are manually annotated at a sentence level. During this process, one of the 
text miners assists annotators in technical aspects, such as the use of the annotation tool. 
Afterward, the double annotation is used to measure the IAA to assess the consistency 
and quality of the corpus. 
An important aspect in the creation of a gold-standard corpus is the selection of the 
annotation tool that will support the manual annotation. Neves & Leser (2014) provided a 
recent and detailed review of annotation tools for the biomedical literature, which 
involved almost 30 tools, of which 13 were selected and compared using predefined 
criteria and hands-on experiences whenever possible. Therefore, a new review of these 
tools is out of the scope of this thesis, and we refer the interested reader to this 
publication for more details about available annotation tools. 
From their review, the authors concluded that there is no single tool supporting all 
use cases with equal robustness, and that their suitability for an annotation project 
depends on their individual pros and cons and the characteristics of the annotation task 
(Neves & Leser, 2014). In our case, there are two main requirements influencing the 
selection of the annotation tool. Firstly, the DDI corpus is built from a preliminary corpus 
for the DDIExtraction 2011 task, rather than raw texts, which already contained drug and 
DDI annotations. Therefore, we required a tool supporting the adequate integration of 
pre-annotations in XML format. Secondly, the annotation process of the DDI corpus 
needs an annotation tool ensuring the annotation of relationships in an easy and effective 
manner. Although three annotation tools support the first requirement (Bionotate (Cano, 
Monaghan, Blanco, Wall, & Peshkin, 2009), WordFreak (Morton & LaCivita, 2003), and 
XConc (Kim et al., 2003)), none of them fulfil both conditions.  
For these reasons, we select the open-source XML editor XML Notepad, published 
by Microsoft® (CodePlex, 2014). XML Notepad provides a simple intuitive user 
interface for browsing and editing large XML documents, and has real time XML schema 
validation. Moreover, the editor features incremental search in both tree and text views, 
drag/drop support, IntelliSense, find/replace with regular expressions and XPath 
expressions, and support for XInclude. 
Finally, during the harmonization process the text mining experts check and review 
those sentences containing disagreements between the two annotators, and classify them 
according to the main reason for discrepancy (e.g., missed entity annotation, partial 
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matching, different entity type assigned, missed DDI annotation, different DDI type 
assigned). These cases are studied and discussed between the two annotators and the two 
text mining experts, who help to achieve consensus on the final corpus. Changes in the 
corpus are made accordingly to the consensus-driven decisions. In the same way, the 
annotation guidelines are modified to include new rules and examples. 
3.4 Annotation issues in pharmacological 
texts 
In this section, we review the main sources of annotation problems that affect in 
general the manual annotation process, the linguistic phenomena that complicate the 
manual annotation of drug named entities, and the different syntactic phenomena that 
should be considered during the annotation of DDIs. 
3.4.1 Main sources of annotation problems 
In this section, we describe the main sources of annotation problems identified 
during the annotation process of the DDI corpus. These issues have been addressed in the 
framework of a pharmacological corpus. However, due to their general nature, they could 
be extrapolated to domains others than pharmacology, such as medicine or chemistry. 
 Tokenization problems 
Corpus texts need to be segmented into words and sentences through tokenization 
before any further processing can be done. Different tokenizers have been developed for 
this purpose (He & Kayaalp, 2006). However, pharmacological texts, and specifically 
chemical and drug names, are a source of ambiguous numbers, punctuation marks, and 
parentheses (e.g., ‘N-methyl-D-aspartic acid’, ‘R,3-hydroxybutan-2-one’, or ‘(+)-
aplysinillin’). These ambiguous characters can lead to erroneous sentence splitting and 
word tokenization. 
 Complexity of drug named entities 
Drug NER seems to be a relatively simple task, since the number of possible drug 
names is smaller compared to those of other biomedical entities, such as genes or 
proteins. Moreover, there are different controlled vocabularies and lists of drugs 
collecting them, (e.g., RxNorm (Nelson et al., 2011) or the ATC classification system 
(WHO, n.d.)). However, current automatic information extraction systems are not able to 
properly extract drug names from biomedical texts without human intervention 
(Jagannathan et al., 2009). This finding highlights that drug names are complex named 
entities. There are different characteristics of drug names contributing to this complexity. 
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First, the same drug can have different generic and several trade names in different 
countries. For example, the drug ‘paracetamol’ is named ‘acetaminophen’ in the USA. 
Some of its branded names include Acephen® (in the USA), Efferalgan® (in Spain) or 
Ultralief® (in the UK).  Moreover, drug names can have different abbreviations or 
synonyms. In addition, some drugs are approved in some countries, while they are not in 
others. Therefore, there is not a comprehensive list of drugs collecting all drug names 
approved in the world as well as all their synonyms. For example, RxNorm provides 
normalized names for clinical drugs approved in the USA, linking them to different 
synonyms, such as branded names. On the other hand, the ATC classification system 
refers to each pharmacological substance by one official name only, excluding possible 
synonyms. In addition to this, another important barrier to the maintenance of an updated 
controlled list is that new discovered drugs are continuously approved for sale. 
Secondly, in pharmacological texts the mention of terms describing a group of 
drugs is frequent. These are complex terms, since they are usually represented by nested 
multi-word terms including protein names, numbers, abbreviations, or adjectives, as well 
as punctuation marks such as parentheses or hyphens (Kolárik, Hofmann-Apitius, 
Zimmermann, & Fluck, 2007). Moreover, group of drugs names are terms with multiple 
possible variants that usually are not collected in a comprehensive way in a controlled 
vocabulary or database. For example, the group of drugs ‘Beta Blocking Agents’ (term 
used in the ATC classification system) can be described as well as ‘Adrenergic beta-
Antagonists’, ‘beta-Adrenergic Receptor Blockaders’ (terms collected in the MeSH 
thesaurus) or, simply as ‘β-blockers’, among many others (Paolillo et al., 2013). 
 Complexity of biomedical texts 
Manual annotation of biomedical texts should be carried out by domain experts 
capable of understanding the information described in the corpus. However, not all 
corpora are equally complex. Complexity varies depending on several facts, such as the 
source of the documents (e.g., manually curated databases or primary scientific 
literature), the type of study described in the text (e.g., clinical study or in vitro study) as 
well as content-related and linguistic aspects, such as the use of technical vocabulary, 
complex sentences, and so forth. The level of complexity of text will determine which 
annotators should be selected for the annotation task (e.g., a pharmacovigilance expert or 
a life science bachelor student), the length of training for annotators, and the explicit rules 
that should be described in the annotation guidelines. 
 Lack of standard or reference works in the specific domain 
A set of standard rules for manual annotation of pharmacological substances or 
drugs has not been established. This is a difficult task because different corpora are 
annotated with different final objectives. For example, the DDI corpus has been 
annotated for the extraction of DDIs, while the aim of the CLEF corpus is to extract 
clinically significant information from clinical texts (Roberts et al., 2007). Therefore, 
different corpora require different annotation schema and annotation guidelines. 
However, detailed reference works could improve the objectives achieved by future 
research groups in the specific domain. Therefore, when research groups create a new 
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manually annotated corpus, comprehensive annotation guidelines should be written. 
These documents should reflect how the annotation task should be carried out, as well as 
how annotators should deal with specific or complex linguistic phenomena. For example, 
in the annotation of a pharmacological corpus, it should be important to specify how 
annotators should annotate stereoisomers of drugs. These chemical entities are usually 
described by adding a letter S or R before the drug name (e.g., ‘S-warfarin’). To ensure 
consistency between different annotators, a simple rule describing if the annotator should 
include in the annotation span only the drug name (‘warfarin’) or the stereoisomer 
specification (‘S-warfarin’) should be described in the annotation guidelines. 
Thus, when a new research group creates a related annotated corpus with similar 
entities, this group could base its decisions on those adopted in the reference work, 
leading to closest corpora that might be re-used or exchanged in future works. 
3.4.2 Linguistic aspects of drug names 
The manual annotation process of a pharmacological corpus can be a difficult task 
if the terms that should be annotated have not been established previously. As mentioned 
before, drug names are complex entities and they have several nomenclatures, synonyms, 
and term variants. In this section, we describe some of the main linguistic phenomena 
regarding drug nomenclature. 
 Different nomenclatures 
Each drug has a unique and globally recognized name called International Non-
proprietary Name (INN) that facilitates the identification of pharmaceutical substances 
(Ladas, 1975). However, different countries can assign specific non-proprietary names, 
such us United States Adopted Name (USAN) in the USA or the Denominación Oficial 
Española (DOE) in Spain. Examples below show some of these different nomenclatures: 
« The effects of paracetamol are possibly reduced in patients taking 
anticonvulsants. » (i) 
« The absorption of acetaminophen may possibly be reduced if colestyramine is 
given at the same time. » (ii) 
Sentences (i) and (ii) describe two different interactions of the same drug. 
Paracetamol is an INN, while acetaminophen is the USAN for the same drug. Therefore, 
there are two different names referring to the same substance and both of them should be 
annotated. 
On the other hand, every drug can have several brand names - that is, a drug 
marketed under a proprietary, trademark-protected name. There can be several drug brand 
names for every drug in different countries. 
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« Atromid-S may displace acidic drugs such as phenytoin or tolbutamide from 
their binding sites. » (iii) 
Sentence (iii) describes an interaction of the drug clofibrate. However, in this 
sentence it is named using a brand name: Atromid-S. A search in the DrugBank database 
will show that this drug holds more than 90 different brand names. Therefore, these brand 
names are different terms referring to the same substance, and any mention of them in the 
text should be annotated. 
Drug names usually have different synonyms and abbreviations. Two examples are 
shown in the following sentences: 
« HUMIRA has been studied in rheumatoid arthritis patients taking concomitant 
MTX. » (iv) 
« This is typical of the interaction of meperidine and MAOIs. » (v) 
Sentence (iv) refers to the drug named methotrexate using an abbreviation: MTX. 
Sentence (v) describes the group of drugs Monoamine Oxidase Inhibitors by its 
abbreviation MAOIs. All these terms are synonyms for a drug name or a group of drugs 
name. Therefore, they should be annotated in the corpus. 
 Multi-word terms 
Multi-word terms are frequently used to describe drug names and, more often, 
groups of drugs names. Usually, common nouns such as drugs, agents, or products, 
among others, are preceded by an adjective describing the therapeutic effect, the 
mechanism, or other characteristics of the group of drugs. For example: 
« The treatment of depression in diabetic patients must take into account 
variations of glycemic levels at different times and a comparison of the available 
antidepressant agents is important. » 
(vi) 
However, the term can be shortened and the adjective can be used as a noun. 
« In the present study we evaluated the interference of antidepressants with 
blood glucose levels of diabetic and non-diabetic rats. » (vii) 
Two different annotations are possible in sentence (vi): just the shorter term 
<antidepressant> or the larger term <antidepressant agents>. The first option, the 
annotation of the shorter term, agrees with the annotation in sentence (vii), where there is 
only one possibility: the annotation of the term <antidepressants>. However, IE systems 
or techniques would benefit from the addition of common nouns that could help in the 
identification of group of drugs names. Therefore, we decided to annotate the longer 
term, whenever possible. 
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 Nested terms 
A frequent linguistic phenomenon in the pharmacological domain is nested named 
entities. They are frequently used referring to a specific subgroup of drugs within a group 
of drugs. Next, some examples of nested named entities are presented: 
« The concomitant use of allopurinol and thiazide diuretics may contribute to the 
enhancement of allopurinol toxicity. » (viii) 
These nested terms could be annotated in three different ways: as two independent 
entities <thiazide> and <diuretics>; as a unique entity <thiazide diuretics>; as three 
different entities <thiazide>, <diuretics>, and <thiazide diuretics>. When the author 
refers to thiazide diuretics, he or she is alluding to one group of drugs (diuretics with a 
concrete structure defined by the adjective thiazide). The annotation of two (option one) 
or three (option three) different entities would lead to the annotation in the text of more 
entities than those intended by the author and would complicate the annotation of DDIs 
between them. Thus, if we annotate more than one entity, we would express that there are 
two different groups of drugs: one of them thiazide and the other, diuretics. Therefore, we 
decided to annotate a unique entity (option two) <thiazide diuretics>. 
 Discontinuous names 
Another related linguistic phenomenon is discontinuous entities. It is especially 
common when drug names occur in coordinate structures. For example: 
« In some patients, the administration of a non-steroidal anti-inflammatory 
agent can reduce the effects of loop, potassium-sparing and thiazide diuretics. » (ix) 
In sentence (ix) bold terms describe three different groups of drugs. The first one 
refers to a group of diuretics acting in the loop of Hendle, which is a specific portion of 
nephrons in the kidney: the <loop diuretics>.  The second one is a group of diuretics that 
do not promote the loss of potassium, the <potassium-sparing diuretics>. The third one is 
the abovementioned group of diuretics sharing a common structure, <thiazide diuretics>. 
The term thiazide is used commonly without the term diuretics, preserving its 
meaning. However, the terms <loop> or <potassium-sparing> always act as modifiers 
and do not keep the meaning by themselves. This is the reason why we decided to 
annotate three different entities <loop diuretics>, <potassium-sparing diuretics> and 
<thiazide diuretics>. 
 Ambiguity 
Term ambiguity occurs when the same term refers to many concepts (Ananiadou, 
Kell, & Tsujii, 2006). As other biomedical entities, drug names can be ambiguous. 
Below, we describe two different examples of ambiguous terms: 
 
 
41 
 
« Therefore, in patients taking insulin or oral hypoglycemics, regular monitoring 
of blood glucose is recommended. » (x) 
« There is no evidence that EPA supplements have detrimental effects on glucose 
tolerance, insulin secretion or insulin resistance in non-diabetic subjects. » (xi) 
In sentence (x) the context implies that the word <insulin> refers to a drug, since it 
is stated that it is administered by or to a patient. Therefore, it should be annotated as a 
drug in the corpus. However, in sentence (xi) the same word <insulin> names a substance 
produced by the own body. In this case, we decided to do not annotate it as an entity, 
since it does not conform to the previously established definition of drug, which is 
defined in the annotation guidelines as “a substance that is used in the treatment, cure, 
prevention or diagnosis of diseases”. 
« The CNS depressant effect of oxycodone hydrochloride may be additive with 
that of other CNS depressants. » (xii) 
Another source of ambiguity is group of drugs names. In sentence (xii) the first 
term <CNS depressant> refers to the depressant effect on the central nervous system by 
the drug oxycodone hydrochloride. Therefore, it is not a group of drugs, but an effect of a 
drug. However, the second bold term <CNS depressants> refers to the group of drugs 
sharing the common characteristic of having a depressant effect on the central nervous 
system. Therefore, this second term should be annotated as a group of drugs. 
Ambiguity remains an important issue in the development of accurate named entity 
recognition systems. Therefore, the manual annotation rules established for the 
annotation of ambiguity terms is a relevant decision in the development of any annotated 
corpora. 
3.4.3 Syntactic phenomena in pharmacological texts 
As mentioned before, relationships can be expressed in different ways through 
different syntactic phenomena, such as alternation or coordination. In the DDI corpus, a 
DDI relationship is a binary relationship annotated at the sentence level with an attribute 
type (effect, advice, mechanism, int). In this section, we describe some of the main 
annotation problems identified during the annotation of DDI relationships in the DDI 
corpus. 
 Hypernymic propositions 
A hypernymic proposition represents a taxonomic relation between a hyponym and 
a hypernym. Hypernymic propositions, in particular appositive structures consisting of 
several entities, are very common in our texts. 
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« The effects of adenosine are antagonized by methylxanthines such as caffeine 
and theophylline. » (xiii) 
In sentence (xiii) there is an interaction involving the entities described in the 
appositive structure. In this example, <methylxanthines> is the hypernym, while 
<caffeine> and <theophylline> are the hyponyms. Methylxanthines is a group of drugs, 
and caffeine and theophylline are two drugs belonging to this group. Therefore, the 
sentence states that an interaction can occur between the drug adenosine and the members 
of the group methylxanthines, for example, caffeine and theophylline. Thereby, a DDI 
relationship for each one of them should be annotated. 
However, in some appositive structures, the scope of the interaction only remains 
the hyponym and not the hypernym. See the example below: 
« In addition to this pharmacological interaction, this report describes a novel 
chemical reaction between temazepam (a benzodiazepine) and ethanol. » (xiv) 
Sentence (xiv) contains a group, <benzodiazepine> and a drug belonging to this 
group, <temazepam>. In this example, the term benzodiazepine is describing a 
characteristic of the drug temazepam, and we cannot infer from the sentence that the 
interaction between ethanol and temazepam can occurs between ethanol and other 
members of the group benzodiazepine, too. Therefore, we decided to annotate one DDI 
relationship only between <ethanol> and <temazepam>. 
 Coordinate structures 
The same drug can be mentioned several times in the same sentence. In these cases, 
it could be unclear which one should be included in a DDI relationship. 
« The concomitant use of nitrofurantoin is not recommended since 
nitrofurantoin may antagonize the effect of norfloxacin. » (xv) 
Sentence (xv) contains two coordinate clauses with the conjunction ‘since’ joining 
them together. In the first clause, there is just one mention of a drug: <nitrofurantoin>. In 
the second clause, however, there are two mentions of two different interacting drugs: 
<nitrofurantoin> and <norfloxacin>. Therefore, we decided to annotate only those drugs 
mentioned in the second clause as interacting drugs in the DDI relationships. 
« The concomitant use of nitrofurantoin and norfloxacin is not recommended 
since nitrofurantoin may antagonize the effect of norfloxacin. » (xvi) 
In sentence (xvi), however, the first clause contains two different interacting drugs, 
<nitrofurantoin> and <norfloxacin>, in the same fashion that the second one. Therefore, 
two different DDIs should be annotated: one in the first clause and one in the second 
clause. 
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« The concomitant use of nitrofurantoin is not recommended since it may 
antagonize the effect of norfloxacin. » (xvii) 
Finally, in sentence (xvii) the interaction in the second clause is described with an 
anaphora of the term <nitrofurantoin>. Since we did not include anaphora annotation in 
the DDI corpus, a unique DDI relationship should be annotated between the two 
mentioned drugs <nitrofurantoin> and <norfloxacin>. 
3.5 Quantitative features of the DDI corpus 
This section describes the main characteristics of the DDI corpus in terms of the 
frequency of named entities and relationships. Based on the sentence splitting during 
processing, the DDI-DrugBank dataset contains 6,795 sentences, and the DDI-MEDLINE 
dataset is made up of 2,147 sentences. The different nature of the texts determines that 
the types of entities and relationships have different ratios in the two subcorpora. Table 
3.3 and Table 3.4 show the number of the named entity types and relationships annotated 
in each one of them, respectively. 
Regarding entity annotation, the most common type is drug (63%) in both 
subcorpora. Substances not approved for human use (drug_n) are the second most 
common type of entity in DDI-MEDLINE, while these substances account for only about 
1 per cent of the entities in the DDI-DrugBank dataset. Similarly, brand drugs are about 
12% of the entities in the DDI-DrugBank dataset; however, this type had the lowest 
frequency in the DDI-MEDLINE dataset. These observations are to be expected because 
MEDLINE abstracts usually describe results from laboratory experiments, where 
experimental substances not approved to be used in humans are commonly employed, 
while DrugBank texts are mainly compiled from repositories of drug interactions. In fact, 
the highest frequency of brand named entities in the DDI-DrugBank dataset might 
suggest that the database could have used PIs or SPCs – documents created by the 
manufacturer for every branded drug – as an information source.    
 DDI-DrugBank DDI-MEDLINE Total 
drug 9901 (63%) 1745 (63%) 11,646 (63%) 
brand 1824 (12%) 42 (1.5 %) 1866 (10%) 
group 3901 (25%) 324 (12%) 4225 (23%) 
drug_n 130 (1%) 635 (23%) 765 (4%) 
TOTAL 15,756 2746 18,502 
Table 3.3. Numbers of annotated entities in the DDI corpus 
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Table 3.4 shows the numbers of annotated relationships in each subcorpus. The 
main difference between them is that the advice relationship is far more frequent in 
DDI-DrugBank than in DDI-MEDLINE dataset. This is also consistent with the fact that 
the texts from DrugBank seem to be aimed at health-care professionals because these 
texts usually contain recommendations for avoiding any drug interactions and their side 
effects. The most common type of relationship in the corpus is effect. Thus, this corpus 
is annotated with a large amount of information describing PD mechanisms and 
interaction effects. At the same time, the corpus contains a lot of information on PK DDIs 
(mechanism). However, both DrugBank and MEDLINE documents in the corpus 
present a low frequency of management recommendations. These results agree with the 
descriptions of the type of DDI information included in the main DDI information 
sources (Aronson, 2004; Bergk et al., 2005). 
 DDI-DrugBank DDI-MEDLINE Total 
effect 1855 (39.4%) 214 (65.4%) 2069 (41.1%) 
mechanism 1539 (32.7%) 86 (26.3%) 1625 (32.3%) 
advice 1035 (22%) 15 (4.6%) 1050 (20.9%) 
int 272 (5.8%) 12 (3.7%) 284 (5.6%) 
TOTAL 4701 327 5028 
Table 3.4. Numbers of annotated relationships in each corpus 
3.6 Discussion 
In this chapter, we have described the construction and annotation of the DDI 
corpus. Our aim has been to create a benchmark corpus for IE of DDIs that could 
overcome the limitations of the existing ones. As mentioned before (Chapter 2), a gold-
standard corpus is a manually annotated corpus, whose quality is ensured by the creation 
of available annotation guidelines, and the measurement of the IAA. To be useful, it must 
provide rich information, annotating a diversity of documents with all different entities 
and relationships relevant to the intended task, and with a size and number of annotations 
large enough to ensure an appropriate training and evaluation of IE systems. Here, we 
compare the DDI corpus with those corpora relevant to the DDI domain based on these 
required characteristics. 
Firstly, we focus on the annotation of drug entities to assess the value of the 
different reviewed corpora for the drug NER task. We have observed that most of them 
have been manually annotated with pharmacological entities. However, the quality of 
these annotations must be ensured by available annotation guidelines and the 
measurement of the IAA. These three characteristics are accomplished only by four 
corpora: the CLEF corpus (Roberts et al., 2009), the PK DDI corpus (Boyce et al., 
2012), the CHEMDNER corpus (Krallinger et al., 2013) and the DDI corpus. 
Furthermore, other important aspects determining the usefulness of a corpus are the 
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diversity of annotated entities, which should represent the relevant entities for the 
intended task, and the number of these annotations. As we can see in Table 3.5, the 
CLEF corpus has been annotated only with one type of entity drug, which includes not 
only pharmacological substances but medical devices - such as the term “jeringa” -, too. 
Moreover, the number of annotated entities is just 197. In contrast, the PK DDI corpus 
provides a more detailed classification of entities and distinguishes between active 
ingredients, branded drugs and metabolites. The number of annotations in this corpus is 
larger than in the previous one, being 3,896 annotated entities. The CHEMDNER corpus 
is the largest one, with more than 80K annotations. However, this corpus focuses on 
chemical entities mentions, and does not focus on pharmacological substances. Regarding 
their annotation guidelines, drugs mentions must have been mainly annotated as types 
TRIVIAL (25,610 annotations) and FAMILY (11,935). The TRIVIAL type includes 
mentions of chemical entities, but not necessarily substances with pharmacological 
properties, by a generic common name or a brand name, while the FAMILY type 
includes chemical families that can be associated to some chemical structure, 
independently of whether they refer to pharmacological substances or not. 
However, the annotation schema defined in the DDI corpus provides the most 
detailed classification of these entities, including active ingredients, branded drugs, 
groups of drugs, and active substances not approved for human use. Moreover, the 
annotation guidelines in the DDI corpus include a detailed description of these different 
types of entities, a crucial aspect for the quality of the annotations and the agreement 
achieved between annotators. Therefore, our annotation guidelines could serve as a 
standard for annotating drug names. The number of annotated entities (18,502) differs 
considerably from that of the CLEF or the PK DDI corpora. Besides CHEMDNER, this 
number is only exceeded by the DrugDDI corpus (Segura-Bedmar, 2010). However, 
these annotations have been made automatically, without a later manual review. The ITI 
TXM includes a similar number of annotated entities to those in the DDI corpus (18,000 
annotated entities), although they correspond to a unique type DRUGCOMPOUND, 
which includes any chemical used to affect the function of an organism, cell or biological 
process (Alex et al., 2008). 
Corpus Annotation Diversity of entities Annotated entities 
BioText M 1 np 
ITI TXM M 1 18000 
CLEF M 1 197 
BioCaster M 2 1022 
DrugDDI A 1 23190 
ADE M 1 5063 
PK DDI SA 3 3896 
Rubrichi M 3 np 
EU-ADR A 1 1753 
PK A 1 np 
CHEMDNER M 8 84355 
DDI SA 4 18502 
Table 3.5. Comparison of corpora annotated with pharmacological substances (M for 
manual; A for automatic; SA for semi-automatic; np for not provided) 
 46 
 
Corpus 
Diversity of 
documents 
Size 
IAA AAG 
Documents Sentences 
BioText 1 np np   
ITI TXM 1 400 np  * 
CLEF 1 150 np   
BioCaster 1 1000 np  * 
DrugDDI 1 579 5806   
ADE 1 np 4272  * 
PK-DDI 1 68 np   
Rubrichi 1 100 np   
EU-ADR 1 300 np  * 
PK 1 428 5026  * 
CHEMDNER 1 10,000 np   
DDI 2 1025 8942   
Table 3.6. Comparison of corpora annotated with pharmacological substances (IAA for 
inter-annotator agreement; AAG for available annotation guidelines; * for annotation 
guidelines mentioned to have been used in the annotation process, but not available; np 
for not provided) 
Secondly, we analyse and compare the four corpora annotated with DDIs. These 
include the PK-DDI, the PK (Wu et al., 2013), the DrugDDI and the DDI corpus 
(Table 3.7). All the relationships have been manually annotated. However, an important 
difference between them is the scope of the annotation. While the PK DDI and PK 
corpus annotate only PK DDIs, the DrugDDI and the DDI corpus have been annotated 
with all mentions of DDIs, including both PK and PD DDIs. According to the authors of 
the PK DDI corpus, the vocabulary used to describe PK DDIs is significantly different 
from that used to describe PD DDIs because they are discovered in distinct ways. 
Therefore, the annotation of these two types in the same corpus with different labels 
could be useful to test the performance of IE systems dealing with the recognition of each 
one of them. The DrugDDI corpus, however, have established only one type of 
annotation for all DDI relationships. In contrast, the other corpora have established 
different types of DDIs. The PK DDI corpus provides a double classification, 
distinguishing between positives and negatives – based on their assertion or negation of 
the occurrence of an interaction - and quantitative and qualitative DDI statements – 
being the first one assigned when the statement contains quantitative data, and the latter 
one otherwise. Similarly, the PK corpus classifies DDIs based on the quality of the 
evidence provided by the statement - or the level of certainty - as DDIs, ambiguous 
DDIs or non-DDIs. Although these classifications distinguish between different types of 
DDI statements, they focus on linguistic aspects such as negation, and do not differentiate 
between the pharmacological information provided by each sentence. In contrast, the 
DDI corpus proposes a classification of DDIs based on the information requirements for 
the effective management of DDIs: how the interaction occurs (mechanism), what 
consequences can be expected (effect) and how it can be managed to avoid or reduce 
the associated risk (advice). Cases where a sentence only asserts the existence of a DDI 
without providing any additional information are annotated, too (int).  
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Corpus Annotation Scope Diversity of DDIs Annotated DDIs 
PK DDI M PK 4 592 
PK M PK 3 1333 
DrugDDI M PK and PD 1 3160 
DDI M PK and PD 4 5028 
Table 3.7. Comparison of corpora annotated with DDIs (M for manual) 
Besides the annotation-related aspects discussed above, there are other important 
characteristics determining the usefulness of a corpus: its size and the inclusion of 
diversity types of documents (Table 3.6). The DDI corpus is the only available corpora 
made up of two different types of text: MEDLINE abstracts and documents describing 
DDIs from the DrugBank database. Thus, the corpus covers two different styles of 
biomedical text: while the texts taken from the DrugBank database are completely 
focused on the description of DDIs, the main topic of the scientific texts would not 
necessarily be on DDIs. Moreover, while abstracts are usually written in a very scientific 
language, the language used in the texts from DrugBank is similar to the language used in 
PIs. We illustrate this with three different sentences.   
« The second response is due to a release of norepinephrine from nerves and 
was potentiated by ouabain through the increase in the norepinephrine release, 
whereas the first response was not due to the norepinephrine release but to a 
direct action on smooth muscle cell and was inhibited by ouabain. » 
(xviii) 
«ZEBETA should not be combined with other beta-blocking agents. Patients 
receiving catecholamine-depleting drugs, such as reserpine or guanethidine, 
should be closely monitored, because the added beta-adrenergic blocking action 
of ZEBETA may produce excessive reduction of sympathetic activity. » 
(xix) 
« ZEBETA should not be combined with other beta-blocking agents. Patients 
receiving catecholamine-depleting drugs, such as reserpine or guanethidine, 
should be closely monitored, because the added beta-adrenergic blocking action 
of ZEBETA may produce excessive reduction of sympathetic activity […] » 
(xx) 
Example (xviii) shows a sentence from the DDI-MEDLINE dataset, while example 
(xix) corresponds to two sentences from the DDI-DrugBank dataset. In example (xx) we 
show a fragment extracted from the “Drug Interactions” section in the PI for the same 
drug9. As we can see, while the text in the MEDLINE sentence is more complex, the texts 
in DrugBank and the PI are coincident. 
This variety of texts provides a training corpus for IE system with different levels 
of complexity, and, at the same time, their performance can be evaluated against simple 
                                                 
9 http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a11548a0-9c0f-4729-907c-75d8f99a6c85. 
Accessed on 12/02/2015 
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versus complex documents. Lastly, the size of the DDI corpus is significantly larger than 
that of other corpora, being the largest manually annotated corpora for drugs and DDIs. 
Finally, the quality of the annotations must be measured by the IAA. This aspect is 
described and discussed in detail in the next Chapter 4. 
3.7 Conclusions 
The DDI corpus has proven to fulfil all those characteristics required to be a gold-
standard for both drug NER and DDI extraction. The size of the DDI corpus is 
significantly larger than that of other corpora annotated with drugs and DDIs, both in the 
number of documents and in the total number of annotated entities and relationships. 
Moreover, it provides a fine-grained description of pharmacological entities and DDIs, 
established after a thorough study of different types of DDI texts. In next chapter, we 
describe its evaluation by means of the measurement of the IAA. Moreover, we evaluate 
the usefulness of the DDI corpus as gold-standard in the SemEval-2013 DDIExtraction 
shared task (Segura-Bedmar, Martínez, & Herrero-Zazo, 2014). 
The resources described in this work, including both the annotated corpus and the 
annotation guidelines, are available from http://labda.inf.uc3m.es/ddicorpus, and are 
described in (Herrero-Zazo, Segura-Bedmar, Martínez, & Declerck, 2013). 
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Chapter 4 
Evaluation of the DDI corpus 
In order to be useful for the intended task, the quality of a corpus must be 
evaluated. Manual annotation can introduce errors – mainly due to fatigue during the 
annotation process – and bias – or the individual preferences of different annotators. 
These bias can be reduced by methods such as the creation of detailed annotation 
guidelines, a training period prior to the annotation, and the pre-annotation of the 
documents by text mining techniques (Artstein & Poesio, 2005; Fort & Sagot, 2010). All 
these strategies are directed to the same goal: to achieve high inter-annotator reliability, 
or the agreement between different annotators. 
On the other hand, quality and usefulness of annotated corpora should be tested for 
the application tasks they were created for. To this purpose, the corpus has been used in 
the SemEval-2013 DDIExtraction task (Segura-Bedmar et al., 2013), where different 
teams from different countries used the corpus as a gold-standard for the evaluation of IE 
systems applied to the recognition of pharmacological substances and the detection of 
DDIs from biomedical texts. 
In this chapter, we describe the results of the IAA for the DDI corpus (Section 4.1) and 
provide a detailed description of the SemEval-2013 DDIExtraction task (Section 4.2). 
Finally, we provide the main conclusions and our future work in Section 4.3. 
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4.1 Inter-Annotator Agreement (IAA) 
Inter-annotator agreement (IAA) is a quantitative index for the degree of agreement 
between the annotations produced by two or more annotators on the same set of texts, 
using the same annotation guidelines (Müller & Strube, 2006). The annotations are 
compared using some statistical measure, being the Kappa statistic the most commonly 
used standard (Cohen, 1960), which takes into account that a certain degree of agreement 
between annotators can also be ascribed to chance. IAA enables the assessment of the 
quality and consistency of the corpus and the annotation guidelines, as well as the 
complexity of the annotation task. 
The measurement of the IAA requires that more than one annotator annotates the 
same texts in the corpus. This is another important factor in the quality of the annotation 
process, since strategies of multi-annotation, where documents are annotated by more 
than one annotator, have been proposed as the best way to avoid problems related to 
manual annotation (Jagannathan et al., 2009; Wilbur et al., 2006). 
During the annotation of the DDI corpus, a set of documents from each dataset, DDI-
DrugBank and DDI-MEDLINE, is randomly selected and annotated by two different 
expert annotators (Section 3.3.2). We should note that the IAA scores are measured after 
a rigorous process to define strict, comprehensive, and clear guidelines. For this reason, 
IAA scores are calculated using exact matching that requires the annotations to overlap 
completely. For the entities, their annotations should overlap completely and annotators 
should agree on the assigned types, too. Regarding the interactions, the annotators should 
agree on the annotation of the interacting drugs as well as on the type assigned to the 
interaction. IAA results are shown in the following section. 
4.1.1 IAA results 
Both the quality and consistency of the corpus are evaluated by measuring the IAA 
scores, which allows for determining the complexity of the annotation task and provides 
insights into the quality of the guidelines developed. Moreover, IAA also provides an 
upper bound on the performance of the automatic systems for the detection of 
pharmacological substances and the interactions between them. In our corpus, we use the 
Kappa statistic to study IAA. A detailed description of the kappa coefficient of agreement 
can be found in (Cohen, 1960). Table 4.1 and Table 4.2 summarize the obtained results. 
 DDI-DrugBank DDI-MEDLINE 
Kdrug 0.9534 0.8467 
Kbrand 0.9569 0.8853 
Kgroup 0.9563 0.8299 
Kdrug_n 0.4422 0.8122 
K 0.9104 0.7962 
Table 4.1. IAA results of the annotated entities in the DDI corpus 
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In terms of document source type, IAA is higher for the DDI-DrugBank dataset 
than for the DDI-MEDLINE dataset in both entities and relationships. One explanation 
for this is that MEDLINE abstracts have far more complexity than texts from the 
DrugBank database, which are usually expressed in simple sentences. Similar to other 
annotated corpora (Rosario & Hearst, 2004; van Mulligen et al., 2012), IAA scores are 
higher for entities than for relationships. 
In terms of the type of entity, the highest IAA score is obtained for the brand type 
in both DDI-DrugBank and DDI-MEDLINE subcorpora (see Table 4.1). This may be 
because branded drug names are carefully selected by the manufacturer to be short, 
unique, and easy to remember (Boring, 1997). Similarly, a high level of agreement is 
observed for drug and group type entities. These high IAA scores may indicate that 
these types are more clearly defined than others in the annotation guidelines (Pustejovsky 
& Stubbs, 2012). For example, annotators have found the identification of experimental 
drugs (e.g., pempidine), which should be annotated as drug_n type, more difficult than 
the identification of the names referring to approved drugs (drug and brand) or groups 
of drugs (group).  
On the other hand, IAA results show moderate agreement for drug_n entities. 
These results can be due to the large variety of substances included in this type. 
Additionally, since some of these substances can be both endogenous - produced inside 
an organism - and exogenous - produced outside the body -, such as the terms calcium 
or dopamine, their recognition depends substantially on the context in which they appear. 
As we have explained in Section 3.4.2, the mentions of endogenous substances should 
not be annotated as pharmacological substances. In particular, the agreement was lower 
for drug_n in the DrugBank dataset than in the DDI-MEDLINE.  
One of the main sources of discrepancy are metabolite names (e.g., 
descarboethoxyloratadine), which are very similar to drug names (e.g., loratadine) and 
are very frequent in DrugBank texts. We have observed that annotators often have 
difficulty distinguishing between both types. Similarly, another main reason for 
disagreement between annotators is the classifications of substances such as vitamins, 
since some of them can be considered as a group of drugs (e.g., vitamin A) while others 
are drug entities (e.g., betacarotene). All the mentioned differences are discussed and 
resolved in the harmonization process, and subsequently more accurate explanations are 
included in the annotation guidelines (Section 3.3.1). 
In conclusion, the IAA scores show that annotation guidelines have been 
successfully developed and validated for the annotation of complex drug names such as 
stereoisomer (e.g., S-warfarin), drug salts (e.g., oxycodone hydrochloride), or nested 
named terms (e.g., thiazide diuretics). Therefore, the DDI corpus may be a valuable 
resource for developing systems for drug NER.  
In general, fairly high IAA results have been obtained per type of interaction (see 
Table 4.2). The int type presents the highest IAA scores in both the DDI-DrugBank 
and the DDI-MEDLINE datasets. However, this is the least common type of relationship 
(less than 6%) annotated in the corpus (see Section 3.5). The second DDI relationship 
with higher IAA results is the advice type. This type of DDI information is very clear 
and can be easily identified by manual annotators in both types of document. On the other 
hand, two main reasons for disagreement in DDI type advice have been observed. 
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Firstly, annotators are frequently confused with sentences containing a recommendation 
for a specific DDI effect, as in the following sentence:  
« Consider additive sedative effects and confusional states to emerge if 
chlorprothixene is given with benzodiazepines or barbiturates. » (i) 
Similarly, annotators also have problems with sentences describing a PK 
mechanism and suggesting a change in the dosage schedule to avoid undesired 
consequences. For example, the sentence below is considered as advice type by one 
annotator, while the other one classifies it as mechanism type. 
« Fenofibrate should be taken at least 1 h before or 4–6 h after a bile acid 
binding resin to avoid impeding its absorption. » (ii) 
 As shown in Table 4.2, the mechanism type shows the lowest IAA scores in the 
DDI-DrugBank dataset. One reason for this result is that annotators find it difficult to 
distinguish between sentences describing a PD mechanism or an effect. This observation 
has led to the final annotation of PD interactions with the effect type. 
We have observed that most disagreements may be because many sentences 
provide various textual evidence of the same interaction and each piece of textual 
evidence may correspond to a different type of drug interaction. This is very common in 
complex sentences because subordinate clauses often describe different properties of the 
same interaction. In these cases, the guidelines have proposed a priority rule to assign the 
type of interaction. However, sometimes the annotators incorrectly applied this rule, and 
they often tended to assign the first type described in the sentence instead of the type 
according to the priority rule. On the other hand, the guidelines state that clauses in 
compound sentences should be considered as independent sentences, and thereby 
annotators should annotate each of drug interactions described in their clauses. 
 DDI-DrugBank DDI-MEDLINE 
Keffect 0.7525 0.5548 
Kmechanism 0.4214 0.5577 
Kadvice 0.9428 0.5587 
Kint 0.9558 0.7252 
K 0.8385 0.6213 
Table 4.2. IAA results of the annotated relationships in the DDI corpus 
4.2 DDIExtraction shared task series 
The SemEval-2013 DDIExtraction shared task is the second edition of the 
DDIExtraction Shared Task series, a community-wide effort to promote the 
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implementation and comparative assessment of NLP techniques in the field of the 
pharmacovigilance domain and, in particular, to address the extraction of DDIs from 
biomedical texts.  
The first edition, the DDIExtraction 2011 task, attracted the attention of 10 teams 
that submitted a total of 40 runs (Segura-Bedmar, Martínez, & Sánchez-Cisneros, 2011). 
In this edition, the DrugDDI corpus developed by Segura-Bedmar (2010) was used as a 
gold-standard for the training and evaluation of the different participating systems for the 
task of extraction of DDIs. 
  Training Test for NER task Test for RE task 
D
D
I-
D
ru
gB
an
k 
documents 572 54 158 
sentences 5675 145 973 
drug 8197 180 1518 
group 3206 65 626 
brand 1423 53 347 
drug_n 103 5 21 
mechanism 1260 0 279 
effect 1548 0 301 
advice 819 0 215 
int 178 0 94 
D
D
I-
M
E
D
L
IN
E
 
documents 142 58 33 
sentences 1301 520 326 
drug 1228 171 346 
group 193 90 41 
brand 14 6 22 
drug_n 401 115 119 
mechanism 62 0 24 
effect 152 0 62 
advice 8 0 7 
int 10 0 2 
Table 4.3. Frequencies in the DDI corpus 
In the second edition, several improvements in terms of organization, participation 
and results have been achieved. The 6th International Workshop on Semantic Evaluations 
(SemEval), held in summer 2013, scheduled the “Extraction of drug-drug interactions 
from biomedical Texts task”10 (Segura-Bedmar, Martínez, & Sánchez-Cisneros, 2011). 
For this edition, two different subtasks were proposed. The first one consisted in the 
recognition and classification of drug names (NER task), while the second one focused 
on the extraction and classification of DDIs (RE task). The DDI corpus, manually 
annotated with both pharmacological substances and DDIs, was used as a gold-standard 
                                                 
10 http://www.cs.york.ac.uk/SemEVAL-2013/task9/ 
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for the training and testing of the systems developed by a total of 14 participating teams, 
which submitted 38 runs. Although participants were allowed to use other training 
resources, only one of them (LASIGE) used additional training data collection to develop 
its system. 
The DDI corpus was provided as a training dataset and as two different test dataset 
for the NER and RE tasks. Table 4.3 shows the frequencies of annotations in the DDI 
corpus for both the DDI-DrugBank and the DDI-MEDLINE train and test datasets. 
In this section, we describe the two different tasks and the results obtained by the 
participating systems. In addition to this, for the RE task, we describe the major sources 
of errors in these systems, and present a study as to whether the results are significant 
statistically. Furthermore, for the top three methods in RE, we propose an ensemble 
system using majority and union voting strategies. Finally, we close this section with a 
discussion of possible future steps of the DDIExtraction Shared Task series. 
4.2.1 NER task: recognition and classification of 
pharmacological substances 
This task concerned the named entity extraction of pharmacological substances in 
text. This named entity task is a crucial first step for IE of DDIs. In this task, four types of 
pharmacological substances were defined: drug (generic drugs), brand (brand drugs), 
group (group of drugs) and drug_n (active substances not approved for human use). A 
detailed description of these entity types is provided in Section 3.3.1. For evaluation, a 
part of the DDI corpus consisting of 52 documents from DrugBank and 58 MEDLINE 
abstracts, was provided with the golden annotations hidden. The goal for participating 
systems was to recreate the standard annotations. Each participant system must output an 
ASCII list of reported entities, one per line, and formatted as: 
IdSentence|startOffset-endOffset|text|type 
Thus, for each recognized entity, each line must contain the id of the sentence where 
this entity appears, the position of the first character, and the one of the last character of 
the entity in the sentence, the text of the entity, and its type. When the entity was a 
discontinuous name (e.g., ‘aluminum and magnesium hydroxide’), this second field must 
contain the starting and end positions of all parts of the entity, separated by semicolon. 
Multiple mentions from the same sentence should appear on separate lines. 
Participants could send a maximum of three system runs. After downloading the 
test datasets, they had a maximum of two weeks to upload the results. A total of six teams 
participated in this task, submitting 16 system runs. Table 4.4 lists the teams, their 
affiliations, their countries, and a brief description of their systems. Table 4.5, Table 4.6 
and Table 4.7 show the F1 scores for each run in alphabetic order. The full ranking 
information can be found on the SemEval-2013 Task 9 website11, and a detailed 
description of the teams and their systems is available in Segura-Bedmar et al. (2013). 
                                                 
11 http://www.cs.york.ac.uk/SemEVAL-2013/task9/index.php?id=evaluation 
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 Team Institution Country Description 
N
E
R
 T
as
k 
LASIGE University of Lisbon Portugal CRF 
NLM_LHC 
National Library of Medicine, 
National Institute of Health 
USA 
Dictionary-based 
approach 
UMCC_DLSI 
Matanzas University 
Alicante University 
Cuba 
Spain 
j48 classifier 
UEM_UC3M 
European University of Madrid, 
Carlos III University of Madrid 
Spain NCBO tool 
UTurku University of Turku Finland TEES system 
WBI Humboldt University of Berlin Germany 
Token sequence 
labelling 
approach 
Table 4.4. Summary of the SemEval-2013 DDIExtraction NER task participating teams 
The best results were achieved with a token sequence labelling approach proposed 
by the WBI team. Their model was trained on the training dataset as well as on entities 
of the test dataset for the RE task (Section 4.2.2). We should mention that very similar 
results are obtained by the NLM_LHC with a dictionary-based approach combining 
biomedical resources such as DrugBank (Law et al., 2014), the ATC classification system 
(WHO, n.d.), MeSH (Lipscomb, 2000), RxNorm (Nelson et al., 2011) and the UMLS 
Methatesaurus (Bodenreider, 2004), among others. In fact, Table 4.7 shows that the 
dictionary-based approach outperformed the sequence labelling approach in both exact 
and partial evaluations on the DDI-DrugBank dataset. 
Regarding the classification of each entity type, we have observed that brand drugs 
were easier to recognize than the other types. This could be due to the fact when a drug is 
marketed by a pharmaceutical company, its brand name is carefully selected to be short, 
unique, and easy to remember (Boring, 1997). Moreover, there are different 
pharmacological databases and terminologies collecting brand names that can be used as 
dictionaries by the participating systems. In contrast, substances not approved for human 
use (drug_n) are more difficult, due to the greater variation and complexity in their 
naming. In fact, only the UEM_UC3M team was able to recognize this type of 
substances on the DDI-DrugBank dataset. In addition, this may indicate that this type is 
less clearly defined than the others in the annotation guidelines. Another possible reason 
is that the presence of such substances in this dataset is very scarce (less than 1%). 
Finally, the results on the DDI-DrugBank dataset were much better than those 
obtained on the DDI-MEDLINE dataset. While DDI-DrugBank texts focus on description 
of drugs and their interactions, the main topic of DDI-MEDLINE texts would not 
necessarily be on DDIs. Coupled with this, it is not always trivial to distinguish between 
substances that should be classified as pharmacological substances and those not. For 
example, insulin is a hormone produced by the pancreas, but can also be synthesized in 
the laboratory and used as drug to control insulin-dependent diabetes mellitus. The 
participating systems should be able to determine if the text was describing a substance 
originated within the organism, or in contrast, it described a process in which the 
substance is used for a specific purpose and thus should be identified as pharmacological 
substance. 
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Team Run STRICT EXACT PARTIAL TYPE drug brand group drug_n MAVG 
LASIGE 
1 
2 
3 
0,656 
0,639 
0,612 
0,781 
0,775 
0,715 
0,808 
0,801 
0,741 
0,69 
0,672 
0,647 
0,741 
0,716 
0,728 
0,581 
0,541 
0,354 
0,712 
0,696 
0,647 
0,171 
0,182 
016 
0,577 
0,571 
0,498 
NLM_LHC 
1 
2 
0,698 
0,704 
0,784 
0,792 
0,801 
0,807 
0,722 
0,726 
0,803 
0,81 
0,809 
0,846 
0,646 
0,643 
0 
0 
0,57 
0,581 
UMCC_DLSI 
1 
2 
3 
0,275 
0,275 
0,275 
0,3049 
0,3049 
0,3049 
0,367 
0,367 
0,367 
0,334 
0,334 
0,334 
0,297 
0,297 
0,297 
0,313 
0,313 
0,313 
0,257 
0,257 
0,257 
0,124 
0,124 
0,124 
0,311 
0,311 
0,311 
UEM_UC3M 
1 
2 
0,458 
0,529 
0,528 
0,609 
0,585 
0,669 
0,51 
0,589 
0,718 
0,752 
0,075 
0,094 
0,291 
0,291 
0,185 
0,264 
0,351 
0,38 
UTurku 
1 
2 
3 
0,579 
0,641 
0648 
0,639 
0,659 
0,666 
0,719 
0,731 
0,743 
0,701 
0,766 
0,777 
0,721 
0,784 
0,783 
0,603 
0,901 
0,912 
0,478 
0,495 
0,485 
0,016 
0,015 
0,076 
0,468 
0,557 
0,604 
WBI 
1 
2 
3 
0,692 
0,708 
0,715 
0,772 
0,831 
0,833 
0,807 
0,855 
0,856 
0,729 
0,741 
0,748 
0,768 
0,786 
0,79 
0,787 
0,803 
0,836 
0,761 
0,757 
0,776 
0,071 
0,134 
0,141 
0,615 
0,643 
0,652 
Table 4.5. F1 scores for NER task on the whole dataset (DDI-DrugBank + DDI-
MEDLINE datasets). (MAVG for macro-average) 
Team Run STRICT EXACT PARTIAL TYPE drug brand group drug_n MAVG 
LASIGE 
1 
2 
3 
0,771 
0,771 
0,682 
0,834 
0,831 
0,744 
0,855 
0,852 
0,764 
0,799 
0,799 
0,713 
0,817 
0,823 
0,757 
0,571 
0,553 
0,314 
0,833 
0,824 
0,756 
0 
0 
0 
0,563 
0,568 
0,47 
NLM_LHC 
1 
2 
0,869 
0,869 
0,902 
0,903 
0,922 
0,919 
0,902 
0,896 
0,909 
0,911 
0,907 
0,907 
0,766 
0,754 
0 
0 
0,646 
0,644 
UMCC_DLSI 
1 
2 
3 
0,424 
0,424 
0,424 
0,4447 
0,4447 
0,4447 
0,504 
0,504 
0,504 
0,487 
0,487 
0,487 
0,456 
0,456 
0,456 
0,429 
0,429 
0,429 
0,371 
0,371 
0,371 
0 
0 
0 
0,351 
0,351 
0,351 
UEM_UC3M 
1 
2 
0,561 
0,595 
0,632 
0,667 
0,69 
0,721 
0,632 
0,667 
0,827 
0,842 
0,056 
0,063 
0,362 
0,366 
0,022 
0,028 
0,354 
0,37 
UTurku 
1 
2 
3 
0,739 
0,785 
0,781 
0,753 
0,795 
0,787 
0,827 
0,863 
0,858 
0,864 
0,908 
0,905 
0,829 
0,858 
0,847 
0,735 
0,898 
0,911 
0,553 
0,559 
0,551 
0 
0 
0 
0,531 
0,581 
0,578 
WBI 
1 
2 
3 
0,86 
0,686 
0,878 
0,877 
0,894 
0,901 
0,9 
0,914 
0,917 
0,89 
0,897 
0,908 
0,905 
0,909 
0,912 
0,857 
0,865 
0,904 
0,782 
0,794 
0,806 
0 
0 
0 
0,636 
0,642 
0,656 
Table 4.6. F1 scores for NER task on the DDI-DrugBank dataset. (MAVG for macro-
average) 
Team Run STRICT EXACT PARTIAL TYPE drug brand group drug_n MAVG 
LASIGE 
1 
2 
3 
0,567 
0,54 
0,557 
0,74 
0,733 
0,693 
0,772 
0,763 
0,723 
0,605 
0,576 
0,596 
0,678 
0,631 
0,702 
0,667 
0,444 
0,667 
0,612 
0,595 
0,56 
0,183 
0,196 
0,171 
0,577 
0,512 
0,554 
NLM_LHC 
1 
2 
0,559 
0,569 
0,688 
0,702 
0,702 
0,715 
0,575 
0,586 
0,717 
0,726 
0,429 
0,545 
0,548 
0,555 
0 
0 
0,462 
0,486 
UMCC_DLSI 
1 
2 
3 
0,187 
0,187 
0,187 
0,2228 
0,2228 
0,2228 
0,287 
0,287 
0,287 
0,245 
0,245 
0,245 
0,2 
0,2 
0,2 
0,091 
0,091 
0,091 
0,191 
0,191 
0,191 
0,13 
0,13 
0,13 
0,23 
0,23 
0,23 
UEM_UC3M 
1 
2 
0,39 
0,479 
0,461 
0,564 
0,516 
0,628 
0,431 
0,529 
0,618 
0,665 
0,111 
0,182 
0,238 
0,233 
0,222 
0,329 
0,341 
0,387 
UTurku 
1 
2 
3 
0,435 
0,502 
0,522 
0,538 
0,528 
0,551 
0,623 
0,604 
0,634 
0,556 
0,628 
0,656 
0,614 
0,703 
0,716 
0,143 
0,923 
0,923 
0,413 
0,436 
0,426 
0,016 
0,016 
0,08 
0,328 
0,533 
0,582 
WBI 
1 
2 
3 
0,545 
0,576 
0,581 
0,681 
0,779 
0,778 
0,726 
0,807 
0,805 
0,589 
0,612 
0,617 
0,634 
0,673 
0,678 
0,353 
0,444 
0,444 
0,744 
0,729 
0,753 
0,074 
0,14 
0,147 
0,479 
0,534 
0,537 
Table 4.7. F1 score for NER task on the DDI-MEDLINE dataset. (MAVG for macro-
average) 
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Team NLP tools Knowledge resources 
LASIGE MALLET 
Adapted tokenizer from Corbett et al., 2007 
FiGO 
Patent corpus ( ChEBI team) 
ChEBI ontology 
DrugBank 
NLM_LHC  DrugBank 
ATC classification system 
MeSH 
RxNorm 
UMLS Methatesurus 
UMCC_DLSI Freeling tool WordNet 
UEM_UC3M Mgrep analyzer MDDB 
NDF 
NDDF 
Ontology for Drug Discovery 
Investigations 
MeSH 
DrugBank 
PubChem 
ATC classification system 
KEGG 
UTurku Charniak-Johnson reranking parser 
McClosky’s biomodel 
Stanford parser 
MMTx 
DrugBank 
WBI ChemSpot 
Jochem 
ABBREV 
OPSIN 
PHARE ontology 
ChEBI ontology 
Table 4.8. NLP tools and other resources used by the NER participating teams 
(References for the NLP tools and knowledge resources can be found in each individual 
paper in the SemEval-2013 proceedings). 
Table 4.8 shows the NLP components and external resources used by the 
participating systems. The NLP tools often integrated both syntactic (e.g., Standford 
parser) and semantic information (e.g., MetaMap that uses information from UMLS, or 
ChemSpot from the ChEBI ontology). All the teams used external terminological 
resources and/or databases to either create term dictionaries for entity recognition, such as 
UEM_UC3M and NLM_LHC teams, or to post-process and improve the results. All the 
systems used domain-specific resources, such as pharmacological terminologies and 
databases, while only the UMCC_DLSI used the general English lexical database 
WordNet. Finally, LASIGE is the only team that used an additional training data 
collection to develop its system. In addition to the DDI corpus, this team used a patent 
document corpus created by the ChEBI team.  
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4.2.2 RE task: extraction of drug-drug interactions 
The goal of this subtask was the extraction of DDIs from biomedical texts. While 
the previous DDIExtraction 2011 task focused on the identification of all possible pair of 
interacting drugs, the latest edition SemEval-2013 DDIExtaction task also pursued the 
classification of each DDI according to one of the four following types: advice, 
effect, mechanism, and int. A detailed description of these types can be found in 
Section 3.3.1. Gold-standard annotations (correct, human-created annotations) of 
pharmacological substances were provided to participants for both training and test data. 
The test data for this subtask consisted of 158 DrugBank documents and 33 MEDLINE 
abstracts. Each participant system must output an ASCII list including all pairs of drugs 
in each sentence, one per line (multiple DDIs from the same sentence should appear on 
separate lines), its prediction (1 if the pair is a DDI and 0 otherwise), and its type (label 
null when the prediction value is 0) and formatted as: 
IdSentence|IdDrug1|IdDrug2|prediction|type 
The task of extracting DDIs from biomedical text attracted the participation of eight 
teams (see Table 4.9). A detailed description of them and their systems can be found in 
Segura-Bedmar et al. (2014). 
For the evaluation, the test dataset with the golden annotations only for 
pharmacological substances was released to participants. Then, the evaluation was 
conducted by comparing the annotation predicted by each system to the golden 
annotations. The evaluation results were reported using the standard recall/precision/f-
score metrics.  
Table 4.10 shows the results of the DDI detection task. These results are not directly 
comparable with those reported in the DDIExtraction 2011task due to the use of different 
training and test datasets in each edition. However, it should be noted that there has been 
a significant improvement in the detection of DDIs: almost all participants (except for the 
two worst teams) achieved an F-score above 65.4% (the best F1 in the DDIExtraction 
2011 task). The increase in the size of the corpus made for the SemEval-2013 
DDIExtraction task, the inclusion of different types of documents, and the quality of their 
annotations might have been a significant contribution to this improvement.  
The best system (Run1 submitted by the FBK-irst team) had precision of 83.8% and 
recall of 83.8% (F1 82.7%) on the DDI-DrugBank dataset, while it had precision of 
55.8% and recall of 55.5% (F1 53%) on the DDI-MEDLINE dataset. It should be noted 
that there was almost a 30 point F-score difference between the DDI-DrugBank and the 
DDI-MEDLINE datasets. Indeed a common characteristic observed in all systems was 
the strong decrease in their results on the DDI-MEDLINE dataset compared to the DDI-
DrugBank dataset. This may be justified by the different styles of the two sources.  
In the one hand, the texts taken from DrugBank are manually curated to provide brief 
descriptions of DDIs. Therefore, DrugBank contains short and concise sentences. On the 
other hand, the main topic of the scientific texts from MEDLINE would not necessarily 
be on DDIs. Moreover these texts are characterized by a very scientific language and it is 
common the use of long and subordinated sentences. The error analysis (see Section 
4.2.3) shows that the systems failed drastically for long and complex sentences.  
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Another possible reason might be the different size between the two subcorpora. In 
addition, while the best system obtained balanced results in both precision and recall, the 
rest of the participants showed biased scores towards one or the other metric. We have 
observed that the use of biomedical parsers seemed to provide better performance than 
parsers trained for a general domain, and that the kernel-based systems in general 
overcame the feature-based ones. 
The DDI classification task did not only consist of the identification of all possible 
pairs of interacting drugs, but also their classification. The results did not exceed an F1 of 
65.1% (FBK-irst team) on the DDI-DrugBank dataset and 42% (SCAI team) on the 
DDI-MEDLINE dataset (see Table 4.11). These results clearly demonstrate that the 
identification of what type of information (such as an advice, an effect or information 
about the way the interaction occurs) is being used to describe a DDI may be a very 
complex task.  
As in the DDI detection task, all systems (except the runs submitted by the FBK-irst 
team) showed a marked disparity between precision and recall. Figure 4.1 and Figure 
4.2 show the results for each type of DDI on the DDI-Drug-Bank and DDI-MEDLINE 
test datasets, respectively. From each participant, we only select its best run. Figure 4.1 
suggests that some types of DDI were more difficult to classify than others on the DDI-
DrugBank dataset, being the advice type relationship the easiest one. One possible 
explanation for this could be that recommendations or advice regarding a drug interaction 
are typically described by very similar text patterns such as ‘DRUG should not be used in 
combination with DRUG’ or ‘Caution should be observed when DRUG is administered 
with DRUG’. The participating systems achieved very similar performance for the 
mechanism and effect relationships, while the int relationships seemed to be the 
most difficult to extract. This may be because the proportion of instances of int 
relationship (5.6%) in the DDI corpus is much smaller than those of the rest of the 
relations (41.1% for effect, 32.3% for mechanism, and 20.9% for advice). 
 Team Institution Country Description 
R
E
 T
as
k 
FBK-irst 
Fondazione Bruno 
Kessler 
Italy 
hybrid kernel + scope of 
negations and semantic roles 
NIL_UCM 
Complutense 
University of Madrid 
Spain 
SVM classifier (Weka 
SMO) 
SCAI Fraunhofer SCAI Germany 
SVM classifier 
(LibLINEAR) 
UC3M 
Carlos III University 
of Madrid 
Spain SL Kernel 
UCOLORADO
_SOM 
University of Colorado 
School of Medicine 
USA SVM classifier (LIBSVM) 
UTurku University of Turku Finland TEES system 
UWM-
TRIADS 
University of 
Wisconsin-Milwaukee 
USA SVM classifier 
WBI 
Humboldt University 
of Berlin 
Germany 
APG, SL, ST, SST, SpT 
kernels + TEES system + 
Moara system 
Table 4.9. Summary of the SemEval-2013 DDIExtraction RE task participant teams 
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Team Run 
DrugBank MEDLINE Overall 
Rank P R F1 Rank P R F1 Rank P R F1 
FBK-irst 
1 
2 
3 
1 
2 
3 
0.816 
0.186 
0.186 
0.838 
0.838 
0.838 
0.827 
0.827 
0.827 
1 
2 
3 
0.558 
0.558 
0.558 
0.505 
0.505 
0.505 
0.53 
0.53 
0.53 
1 
2 
3 
0.794 
0.794 
0.794 
0.806 
0.806 
0.806 
0.8 
0.8 
0.8 
WBI-DDI 
1 
2 
3 
6 
5 
4 
0.857 
0.874 
0.814 
0.686 
0.696 
0.755 
0.762 
0.775 
0.783 
8 
12 
4 
0.63 
0.651 
0.625 
0.358 
0.295 
0.421 
0.456 
0.406 
0.503 
6 
5 
4 
0.841 
0.861 
0.801 
0.841 
0.861 
0.801 
0.736 
0.745 
0.759 
UTurku 
1 
2 
3 
10 
9 
8 
0.846 
0.861 
0.843 
0.614 
0.624 
0.638 
0.712 
0.724 
0.726 
20 
19 
15 
0.724 
0.778 
0.658 
0.221 
0.221 
0.263 
0.339 
0.344 
0.376 
11 
8 
9 
0.841 
0.858 
0.833 
0.841 
0.858 
0.833 
0.684 
0.696 
0.699 
SCAI 
1 
2 
3 
11 
12 
7 
0.836 
0.837 
0.796 
0.619 
0.617 
0.681 
0.711 
0.71 
0.734 
7 
17 
6 
0.688 
0.686 
0.431 
0.347 
0.253 
0.526 
0.462 
0.369 
0.474 
10 
12 
7 
0.826 
0.829 
0.748 
0.826 
0.829 
0.748 
0.69 
0.683 
0.704 
UC3M 
1 
2 
12 
19 
0.656 
0.415 
0.758 
0.814 
0.703 
0.549 
13 
10 
0.392 
0.313 
0.421 
0.642 
0.406 
0.421 
13 
19 
0.632 
0.404 
0.632 
0.404 
0.676 
0.537 
NIL_UCM 
1 
2 
16 
14 
0.615 
0.673 
0.615 
0.688 
0.615 
0.68 
22 
21 
0.419 
0.548 
0.137 
0.242 
0.206 
0.336 
16 
14 
0.608 
0.667 
0.608 
0.667 
0.588 
0.656 
UWM_TRIADS 
1 
2 
3 
17 
15 
18 
0.525 
0.573 
0.465 
0.689 
0.665 
0.746 
0.596 
0.616 
0.573 
11 
9 
5 
0.415 
0.427 
0.387 
0.424 
0.446 
0.63 
0.419 
0.436 
0.479 
17 
15 
18 
0.517 
0.561 
0.458 
0.517 
0.561 
0.458 
0.581 
0.599 
0.564 
UColorado_SOM 
1 
2 
3 
22 
20 
21 
0.387 
0.391 
0.422 
0.739 
0.765 
0.646 
0.508 
0.518 
0.511 
16 
14 
18 
0.256 
0.28 
0.253 
0.663 
0.663 
0.6 
0.37 
0.394 
0.356 
21 
22 
23 
0.37 
0.378 
0.398 
0.37 
0.378 
0.398 
0.492 
0.504 
0.491 
Table 4.10. Results for the DDI detection task on test dataset (P for precision; R for 
recall; F1 for F-score) 
Team Run 
DrugBank MEDLINE Overall 
Rank P R F1 Rank P R F1 Rank P R F1 
FBK-irst 
1 
2 
3 
3 
1 
2 
0.654 
0.667 
0.664 
0.672 
0.686 
0.682 
0.663 
0.676 
0.673 
4 
2 
3 
0.407 
0.419 
0.419 
0.368 
0.379 
0.379 
0.387 
0.398 
0.398 
3 
1 
2 
0.633 
0.646 
0.643 
0.642 
0.656 
0.653 
0.638 
0.651 
0.648 
WBI-DDI 
1 
2 
3 
6 
5 
4 
0.702 
0.707 
0.657 
0.561 
0.563 
0.609 
0.624 
0.627 
0.632 
7 
12 
5 
0.463 
0.488 
0.453 
0.263 
0.221 
0.305 
0.336 
0.304 
0.365 
6 
5 
4 
0.685 
0.695 
0.642 
0.532 
0.53 
0.579 
0.599 
0.601 
0.609 
UTurku 
1 
2 
3 
9 
7 
8 
0.723 
0.738 
0.706 
0.525 
0.535 
0.534 
0.608 
0.62 
0.608 
18 
16 
13 
0.517 
0.593 
0.5 
0.158 
0.168 
0.2 
0.242 
0.262 
0.286 
9 
7 
8 
0.714 
0.732 
0.694 
0.489 
0.499 
0.502 
0.581 
0.594 
0.582 
NIL_UCM 
1 
2 
12 
10 
0.54 
0.566 
0.541 
0.579 
0.54 
0.573 
22 
19 
0.387 
0.357 
0.126 
0.158 
0.19 
0.219 
12 
10 
0.535 
0.557 
0.501 
0.538 
0.517 
0.548 
UC3M 
1 
2 
11 
21 
0.518 
0.231 
0.598 
0.454 
0.555 
0.306 
15 
21 
0.265 
0.138 
0.284 
0.284 
0.274 
0.186 
11 
21 
0.495 
0.222 
0.568 
0.437 
0.529 
0.294 
SCAI 
1 
2 
3 
15 
16 
14 
0.546 
0.545 
0.513 
0.404 
0.402 
0.439 
0.464 
0.463 
0.473 
1 
8 
6 
0.625 
0.6 
0.31 
0.316 
0.221 
0.379 
0.42 
0.323 
0.341 
14 
16 
15 
0.551 
0.548 
0.486 
0.395 
0.384 
0.433 
0.46 
0.452 
0.458 
UWM_TRIADS 
1 
2 
3 
17 
13 
18 
0.407 
0.452 
0.361 
0.534 
0.524 
0.579 
0.462 
0.485 
0.445 
10 
9 
11 
0.309 
0.312 
0.247 
0.315 
0.326 
0.402 
0.312 
0.319 
0.306 
17 
13 
18 
0.4 
0.439 
0.35 
0.513 
0.505 
0.562 
0.449 
0.47 
0.432 
UColorado_SOM 
1 
2 
3 
22 
20 
19 
0.166 
0.258 
0.288 
0.317 
0.503 
0.441 
0.218 
0.341 
0.349 
20 
14 
17 
0.13 
0.196 
0.173 
0.337 
0.463 
0.411 
0.188 
0.275 
0.244 
22 
20 
19 
0.161 
0.25 
0.272 
0.319 
0.499 
0.438 
0.214 
0.334 
0.336 
Table 4.11. Results for the DDI detection and classification task on test dataset (P for 
precision; R for recall; F1 for F-score) 
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A common characteristic of all participating systems is the use of support vector 
machines (SVMs). While most systems used feature-based methods, only three teams 
(FBK-irst, WBI-DDI and UC3M) applied kernel-based methods, which in general 
achieved better performance than the feature-based ones. Unlike feature-based methods, 
kernel-based methods do not require the explicit definition of feature vectors. A kernel-
based method contains a kernel function and a kernel learner. A kernel function is a 
function that computes the similarity between two instances (for example, drug pairs). A 
kernel learner (such as SVM) is a learning algorithm that performs a learning task in a 
feature space. 
Most participating systems separated the learning problem into two stages: first, the 
DDIs were detected and then, they were classified into one of the types proposed in the 
guidelines. The only exceptions are the UTurku and NIL_UCM teams. The TEES 
system, developed by the UTurku team, uses a multiclass SVM on a rich graph-based 
feature set. The NIL_UC3M team trained a multi-class SVM classifier with five classes 
(mechanism, effect, advice, int and null for negative instances). The NIL_UC3M 
also developed an approach in which the DDI detection and classification stages were 
separated. The evaluation on test dataset showed that the two-stage approach yielded 
better results than those achieved by the multi-class classifier. As regards the two-stage 
approaches, the first stage, the detection of DDIs, was always performed by a binary 
classifier responsible for distinguishing between negative and positive DDIs instances. 
Most teams treated each DDI type as a single classification sub-problem (one-vs-all). The 
SCAI team was the only one that did not use any machine learning techniques in the 
classification task. DDI instances detected in the previous step were classified according 
to a set of trigger words related to each type of DDIs.  
Regarding the NLP tools often integrated into the participating systems, stemming, 
POS tagging, and syntactic parsing were the most common ones. Stanford parser tools 
(Klein & Manning, 2003) were widely used by most systems. Around half of the 
participant systems used the Charniak–Johnson parser (Charniak & Johnson, 2005) with 
David McClosky’s biomodel (McClosky, 2010) trained on the GENIA corpus and 
unlabeled PubMed articles. From the results of the FBK-irst, WBI, and UTurku teams, 
we can confirm that the parsers for the biomedical domain provided better performance 
than parsers trained for a general domain. Some systems also used additional elements, 
such as lemmatization (WBI and UWM_TRIADS teams), semantic parsing provided by 
MMTx (UTurku and NIL_UCM teams), or disease named entity recognition (team 
FBK-irst). Negation detection was only used by one team (FBK-irst). Surprisingly, only 
half of the participating systems used external lexical resources such as dictionaries or 
ontologies. Table 4.12 shows the NLP components and external resources used by the 
participating systems. None of them made use of any additional training data collections 
to develop their systems, which implies that all systems relied only on the training dataset 
provided by the DDI corpus. 
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Figure 4.1. Micro-Avg F1 scores by DDI type on the DDI-DrugBank test dataset 
 
Figure 4.2. Micro-Avg F1 scores by DDI type on the DDI-MEDLINE test dataset 
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Team NLP tools Knowledge resources 
FBK-irst Charniak-Johnson reranking parser 
McClosky’s biomodel 
Standford parser 
BioEnEx (NER tool for diseases) 
 
WBI-DDI Charniak-Johnson reranking parser 
Mc-Closky’s biomodel 
Standford converter 
BioLemmatizer 
DrugBank 
PHARE ontology 
UTurku Charniak-Johnson reranking parser 
Mc-Closky’s biomodel 
Standford parser tools 
MetaMap 
WordNet 
DrugBank 
NIL_UCM TreeTagger 
PaiceHusk Stemmer 
Standford parser tools 
MMTx 
 
UC3M GATE Standford parser plug-in ATC system 
SCAI Porter Stemming algorithm  
Charniak-Lease parser 
 
UCOLORADO_SOM Genia Dependency Parser 
Porter Stemmer 
OpenDMAP 
WordNet 
 
UWM_TRIADS Standford NLP tools 
Dragon tool (a lemmatizer) 
FDA Drug classification  
Table 4.12. NLP tools and other resources used by the RE participating teams 
(References for the NLP tools and knowledge resources can be found in each individual 
paper in the SemEval-2013 proceedings). 
4.2.3 Error analysis of RE systems 
The aim of this section is to perform a detailed error analysis of the results of the 
RE systems with the objective of providing a road map for future work in the extraction 
of DDIs from text, as well as to identify further improvements in the DDI corpus. To this 
end, we focus on the study of the main source of errors produced by the systems 
developed by the following teams: FBK-irst, WBI-DDI, and Uturku. For each team, we 
only analyze their best runs. The reason for this choice is that these systems were the top-
performing in SemEval-2013 DDIExtraction task. 
 Analysis of false negatives:  
Table 4.13 and Table 4.16 present the main causes for the false negatives in the 
DDI-DrugBank and the DDI-MEDLINE datasets, respectively. From Table 4.13, we can 
see that one of the most important factors contributing to false-negatives in DrugBank 
texts was the lack of cataphora resolution in the three systems. The resolution of the 
appositions in sentences, prior to the detection of DDIs, could allow furthering improving 
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the performance, particularly the FBK-irst and UTurku systems. Similarly, the 
resolution of anaphora and the detection of coordinate structures may also help to reduce 
false negatives, though fewer than the resolution of cataphoras and appositions. Another 
major cause of false negatives is that many DDIs are described with very unusual text 
patterns. The high variability of natural language expression allows DDIs to be able to be 
composed using many different lexical and syntactic realizations. Classifiers have 
problems in detecting these cases since they are probably unrepresented in the training 
data.  
Error cause FBK-irst WBI UTurku Example 
Detection of coordinate structures 
required 
14 23 17 E1, E2 
Detection of appositions required 28 18 96 E3, E4 
Unusual patterns for coadministration 11 18 27 E5, E6 
Unusual patterns for DDI 28 51 20 E7, E8 
Long DDI descriptions 6 27 20 E9 
Unobvious DDIs 10 6 27 E11, E12 
Resolutions of percentages, dosages 
and temporal expressions required 
8 4 26 E13, E14 
Resolution of anaphora required 7 17 17 E15 
Resolution of cataphora required 27 40 46 E16 
Resolution of complex and compound 
sentences required 
6 13 36 E17 
Total 143 217 332  
Table 4.13. Analysis of false negatives in the DDI-DrugBank dataset 
Table 4.14 and Table 4.15 show some examples of false negatives in the 
DrugBank dataset. Long, complex, and compound sentences are other sources of false 
negatives. Many DDIs are described in long and complex sentences, which usually have a 
complex syntactic and lexical structure. Sentences with several embedded subordinated 
clauses are often encountered in both DrugBank and MEDLINE texts. Moreover, these 
sentences also pose a challenge to syntactic parsers due to their high levels of ambiguity. 
This might be one of the reasons explaining why the methods using syntactic features 
from parsers (e.g., Standford parser) were not capable of dealing with these type of 
sentences. The FBK-irst system showed a lower rate of false negatives (only 2% were 
classified as long DDI descriptions, and only 4% as complex and compound sentences) 
compared to the other two systems. In this case, the use of semantic roles, which are used 
to rule out possible negative instances, could be helping to overcome a wrong syntactic 
analysis.  
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Some sentences describe DDIs without giving an absolute certainty of their 
existence or using uncommon patterns. For example, in the sentence ‘Lapatinib may have 
the potential to convert Herceptin-refractory to Herceptin-sensitive tumors in HER2-
positive breast cancer by up-regulation of the cell surface expression of HER2’, it is even 
difficult for a human being to determine whether the sentence describes a DDI or not. 
The detection of dosages and numeric and temporal expressions can also help to improve 
the performance of the systems, since many sentences describe DDIs including additional 
information such as dosages, dosage regimen, or per cents of change of parameters, 
among others. 
ID Example DDIs not detected 
E1 Several studies demonstrate a decrease in the bioavailability of 
methyldopae1 when it is ingested with ferrous sulfatee2 or 
ferrous gluconatee3 
(e1, e3) 
E2 Sulfoxonee1 may increase the effects of barbituratese2, 
tolbutamidee3, and uricosuricse4 
(e1, e2); (e1, e4) 
E3 Concurrent administration of bacteriostatic antibioticse1 (e.g., 
erythromycine2, tetracyclinee3) may diminish the bactericidal 
effects of penicillinse4 by slowing the rate of bacterial growth 
(e3, e4) 
E4 Other inhibitors of the cytochrome P450 3A4 enzyme system, 
such as anitmycotic agentse1 (e.g., itraconazolee2 and 
miconazolee3) or macrolide antibioticse4 (e.g., erythromycine5 
and clarithromycine6), may alter oxibutynine7 mean 
pharmacokinetic parameters (i.e., Cmax and AUC) 
(e1, e7); (e2, e7); 
(e3,e7); (e4, e7); (e5, 
e7); (e6, e7) 
E5 The occurrence of stupor, muscular rigidity, severe agitation, 
and elevated temperature has been reported in some patients 
receiving the combination of selegilinee1 and meperidinee2 
(e1, e2) 
E6 The addition of aspirine1 to Streptokinasee2 in the risk of minor 
bleeding 
(e1, e2) 
E7 There is usually complete cross-resistance between 
PURINETHOLe1 and TABLOIDe2 
(e1, e2) 
E8 Concomitant treatment with NEXAVARe1 resulted in a 21% 
increase in the AUC of doxorubicine2 
(e1, e2) 
E9 Other drugs such as cisapridee1 or pimozidee2, which are 
metabolised by hepatic CYP3A isozymes have been associated 
with QT interval prolongation and/or cardiac arrhythmias 
(typically torsades de pointe) as a result of increase in their 
serum levels subsequent to the interaction with significant 
inhibitors of the isozyme, including some macrolide 
antibacterialse3 
(e1, e3); (e2, e3) 
Table 4.14. Examples of false negatives in the DDI-DrugBank dataset 
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ID Example DDIs not detected 
E10 Certain macrolidese1 interact with terfenadinee2 and 
astemizolee3 leading to increased serum concentrations of the 
latter 
(e1, e2); (e1, e3) 
E11 Furosemidee1 and probably other loop-diureticse2 given 
concomitantly with metolazonee3 can cause unusually large or 
prolonged losses of fluid and electrolytes 
(e2, e3) 
E12 Concomitant administration of alcohole1 had a minimal effect 
on plasma levels of mirtazapinee2 
(e1, e2) 
E13 Concomitant administration of aspirine1 (1000 mg TID) to 
healthy volunteers tended to increase the AUC (10%) and 
Cmax (24%) of meloxicame2 
(e1, e2) 
E14 All patients taking NSAIDse1 should interrupt dosing for at least 
5 days before, the day of, and 2 days following ALMINTAe2 
administration 
(e1, e2) 
E15 Although minoxidile1 does not itself cause orthostatic 
hypotension, its administration to patients already receiving 
guanethidinee2 can result in profound orthostatic effects 
(e1, e2) 
E16 Drugs which may potentiate the myeloproliferative effects of 
Leukinee1, such as minoxidile2, lithiume3 and corticosteroidse4, 
should be used with caution 
(e1, e2); (e1, e3); (e1, 
e4) 
E17 Mexitile1 does not alter serum digoxine2 levels but magnesium-
aluminium hydroxidee3, when used to treat gastrointestinal 
symptoms due to Mexitile4, has been reported to lower serum 
digoxine5 levels 
(e3, e5) 
Table 4.15. Examples of false negatives in the DDI-DrugBank dataset (cont. 2) 
As regards the DDI-MEDLINE dataset (see Table 4.16), false negatives have 
similar error sources to those in the DDI-DrugBank dataset. The major cause of false 
negatives for all three systems was their inability to detect those DDIs described by 
patterns that are very scarce, even unrepresented, in the training data. This may be due 
mainly to the small size of the training dataset from MEDLINE. The detection of doses 
and numerical and temporal expressions also seem to be another significant problem that 
these systems would have to face in order to improve their performance in the detection 
of DDIs. Anaphoras, cataphoras, coordinated structures, and appositions have a much less 
significant effect on the false negatives in the DDI-MEDLINE dataset than in the DDI-
DrugBank dataset. A possible reason for this could be that many texts in DrugBank 
provide descriptions of DDIs involving a drug and a list of drugs. The use of these 
linguistic structures is very common and useful in providing these kinds of description. 
Table 4.17 shows some examples of false negatives in the DDI-MEDLINE dataset. 
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Error cause FBK-irst WBI UTurku Example 
Detection of coordinate structures 
required 
3 0 7 E18 
Detection of appositions required 5 6 3  
Unusual patterns for coadministration 17 17 15 E20 
Unusual patterns for DDI 5 10 30 E21 
Long DDI descriptions 3 4 2 E22 
Unobvious DDIs 3 3 2 E23 
Resolutions of percentages, dosages 
and temporal expressions required 
4 7 9 E24 
Resolution of anaphora required 2 2 2 E25 
Resolution of cataphora required 0 0 2 E26 
Resolution of complex and compound 
sentences required 
5 6 2 E27 
Total 47 55 74  
Table 4.16. Analysis of false negatives in the DDI-MEDLINE dataset 
ID Example DDIs not detected 
E18 AAV2e1-mediated retinal transduction is improved by co-
injection of heparinise IIIe2 or chondroitin ABC lyasee3 
(e1, e3) 
E19 It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors 
to women treated with tamoxifene1 for breast cancer, especially 
SSRI antidepressantse2 such as paroxetinee3 and fluoxetine4 
(e1, e2); (e1, e3); (e1, 
e4) 
E20 Warfarine1 users who initiated citaloprame2, fluoxetinee3, 
paroxetinee4, amitriptylinee5, or mirtazapinee6 had an increased 
risk of hospitalization for gastrointestinal bleeding 
(e1, e2); (e1, e3); (e1, 
e4); (e1, e5); (e1, e6) 
E21 Reduction of PTH by cinacalcete1 is associated with a decrease 
in darbepoetine2 requirement 
(e1, e2) 
E22 In an in vitro assay, lapatinibe1 induced HER2 expression at the 
cell surface of HER2-positive breast cancer cell lines, leading to 
the enhancement of Herceptine2-mediated ADCC 
(e1, e2) 
Table 4.17. Examples of false negatives in the DDI-MEDLINE dataset 
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ID Example DDIs not detected 
E23 However, the evidence for a calciume1 effect on irone2 
absorption mainly comes from studies that did no isolate the 
effect of calcium from that of other dietary components, 
because it was detected in single-meals studies 
(e1, e2) 
E24 Systemic and apparent oral midazolame1 clearance were 24% 
(269,73 vs. 354,102 ml/min, P=0.022) and 31% respectively, 
lower in cyclosporinee2-treated patients (n=20) than in 
matched tracrolimus-treated patients (n=20) 
(e1, e2) 
E25 Acute administration of hemantanee1 or doxycyclinee2 failed to 
influence locomotion in mice, while their combination 
normalized motor activity 
(e1, e2) 
E26 Regulatory agencies state that the combination of clopidogrele1 
and the CYP2C19 inhibitors omeprazolee2 and esomeprazolee3 
should be avoided 
(e1, e2); (e1, e3) 
E27 Exposure to oral S-ketaminee1 is unaffected by itraconazolee2 
but greatly increased by ticlopidinee3 
(e1, e3) 
Table 4.17 (cont). Examples of false negatives in the DDI-MEDLINE dataset 
 Analysis of false positives: 
Table 4.18 and Table 4.20 show the main causes of false positives in the DDI-
DrugBank and DDI-MEDLINE datasets, respectively. The major cause of false positives 
in DrugBank refers to sentences in which interacting drugs have more than one mention. 
The systems were able to detect that there was an interaction between two drugs, but 
failed to identify the mentions that were actually involved in this DDI.  
Error cause FBK-irst WBI UTurku Example 
Incorrect pair 57 60 36 E28 
Annotation error 27 19 19 E29 
Resolution of coordinated structures required 31 21 12 E30 
Same drug 8 28 10 E31 
Lack of evidence 41 21 9 E32 
Resolution of apposition structures required 3 3 3  
Total 167 152 89  
Table 4.18. Analysis of false positives in the DDI-DrugBank dataset 
The first example in Table 4.19 (see E28) shows a sentence describing a DDI 
between ibuprofen and ALIMTA®. We can see that both drugs appear twice in the 
sentence, but only their last two mentions are involved in the description of a DDI. 
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However, the three systems failed to detect this DDI, because they proposed the pair 
formed by the first two mentions of the drugs. Annotation errors (see E29) are the second 
source of false positives in DrugBank. The candidate pairs are correctly detected by the 
systems, but are not annotated in the DDI corpus. Another cause of false positives is the 
systems’ incapability to distinguish between drugs constituting a coordinate structure, and 
therefore, to recognize that they are not describing a DDI (see E30). Notably, one of the 
main sources of false positives would be resolved with a simple rule preventing mentions 
of drugs referring to the same drug, which could be considered as a candidate DDI (see 
E31). The lack of evidence to confirm the existence of a DDI is another source of false 
positives (see E32). In fact, it is the main cause of false positives in the  DDI-MEDLINE 
dataset (see Table 4.20 and Table 4.21). 
ID Example FP Gold DDIs 
E28 Although ibuprofene1 (400 mg qid) can be administered 
with ALIMTAe2 in patients with normal renal function 
(creatinine clearance 80 mL/min), caution should be used 
when administering ibuprofene3 concurrently with 
ALIMTAe4 to patients with mild to moderate renal 
insufficiency (creatinine clearance from 45 to 79 mL/min) 
(e1, e2) (e3, e4) 
E29 Careful monitoring of phenytoine1 concentrations in 
patients receiving DIFLUCANe2 and phenytoin is 
recommended 
(e1, e2)  
E30 It may also interact with thiazidese1 (increased 
thrombocytopenia), cyclosporinee2 (increased 
nephrotoxicity), sulfonylurea agentse3 (increased 
hypoglycemic response), warfarine4 (increased 
anticoagulants effect), methotrexatee5 (decreased renal 
excretion of methotrexatee6), phenytoine7 (decreased hepatic 
clearance of phenytoine8) 
(e1, e7); 
(e2, e7); 
(e3, e7); 
(e5, e7); 
(e5, e7) 
 
E31 Severe toxicity has also been reported in patients receiving 
the combination of tricyclic antidepressantse1 and 
ELDEPRYLe2 and selective serotonin reuptake inhbitorse3 and 
ELDEPRYLe4 
(e2, e4) (e1, e2); (e3, 
e4) 
E32 There are no clinical data on the use of MIVACRONe1 with 
other non-depolarizing neuromuscular blocking agentse2 
(e1, e2)  
E33 Tetracyclinee1, a bacteriostatic antibiotice2, may antagonize 
the bactericidal effect of penicilline3 and concurrent use of 
these drugs should be avoided 
(e2, e3) (e1, e3) 
Table 4.19. Examples of false positives in the DDI-DrugBank dataset 
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Error cause FBK-irst WBI UTurku Example 
Incorrect pair 11 10 2 E34 
Annotation error 2 1 1 E35 
Lack of evidence 35 13 3 E36 
Total 48 24 6  
Table 4.20. Analysis of false positives in the DDI-MEDLINE dataset 
ID Example FP Gold DDIs 
E34 Moxifloxacine1 and lomefloxacine2 reacts faster with sucralfatee3 
and gelusile4 in acidic media whereas with erythromycine5 in 
basic media and multi-minerals in neutral media  
(e3, e4) (e1, e2);  
(e1, e4);  
(e1, e5);  
(e2, e3);  
(e2, e4);  
(e2, e5) 
E35 Improved parathyroid hormone control by cinacalcete1 is 
associated with reduction in darbepoetine2 requirements in 
patients with end-stage renal disease 
(e1, e2)  
E36 On day 8, a single panobinostate1 dose was co-administered with 
ketoconazolee2 
(e1, e2)  
Table 4.21. Examples of false positives in the DDI-MEDLINE dataset 
4.2.4 Conclusions and future directions 
The goal of the SemEval-2013 DDIExtraction task was to promote the development 
of IE techniques applied to the detection of drug names and DDIs from biomedical texts. 
There were a total of 38 runs submitted by 14 different teams from 7 different countries 
(6 of the teams participated in the drug name recognition task, while 8 participated in the 
DDI extraction task). The highest F1 scores obtained were 71.5% for drug name 
recognition and classification and 65.1% for extraction and classification of DDIs. 
In the NER task, the participant systems performed well in recognizing generic 
drugs, brand drugs, and groups of drugs, but they failed in recognizing active substances 
not approved for human use. The WBI team achieved the highest F-score on DrugBank 
texts (65.6%), while LASIGE was the best team on the DDI-MEDLINE dataset (57.7%). 
Therefore, although the results were positive, there is still ample room to improve in drug 
NER. 
Concerning the task of detection of DDIs, the participating systems demonstrated 
substantial progress over the previous DDIExtraction 2011 task. The best team, FBK-
irst, achieved a competitive F-score of 82.7% on DrugBank texts. However, performance 
on the DDI-MEDLINE dataset was lower mainly due to the limited size of its training 
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dataset. Another possible reason may be that MEDLINE texts have a greater complexity 
than DrugBank texts. All teams have used machine-learning methods, specifically SVM. 
In general, non-linear kernel-based methods overcame linear SVMs. 
We conclude that research into DDI extraction must continue. The error analysis 
points out the main limitations of the participating systems. Current approaches have 
focused on syntactic aspects, drawing their attention to the sentence structure. The 
resolution of linguistic phenomena such as cataphora, anaphora, appositive and 
coordinate structures, and complex sentences, among others, might lead to better 
performance.  
However, few participating systems took into account the sentence meaning. 
Approaches using domain knowledge have been recently applied with success to the 
pharmacological domain (Garten, Coulet, & Altman, 2010; Kang et al., 2014). The use of 
knowledge resources could reduce the number of false positives generated by the current 
DDI extraction systems, because these resources can help to distinguish between those 
pairs of drugs that are DDIs from those that are not. The information required for a 
semantic-based IE system could be taken, for example, from pharmacological databases 
such as DrugBank, PharmGKB (Hewett et al., 2002), SIDER (Kuhn, Campillos, Letunic, 
Jensen, & Bork, 2010) and KEGG (Kanehisa, Goto, Sato, Furumichi, & Tanabe, 2012), 
among others. Some of them describe specific pairs of interacting drugs. For example, in 
DrugBank 39 different drugs that interact with ciprofloxacin are described. On the other 
hand, a larger number of DDIs can be deduced indirectly by exploiting, for example, the 
drug-protein relationships. Thus, the relationships of two different drugs with the same 
protein can be used to infer the mechanism leading to a DDI (Hage & Tweed, 1997). For 
example, ciprofloxacin is described to inhibit the activity of the metabolic enzyme 
CYP1A2, and duloxetine is described to be metabolized by CYP1A2. Therefore, there 
could be an interaction between ciprofloxacin and duloxetine. Similarly, the relationships 
of two different drugs with the same ADR can be used to infer possible DDIs (Campillos, 
Kuhn, Gavin, Jensen, & Bork, 2008). For example, morphine is related to the side effect 
central nervous system depression. Therefore, other drugs related to the same ADR, such 
as oxycodone, could interact with morphine.  
Up to now, the main limitation for the development of semantic-based approaches 
has been the availability of appropriate knowledge bases in a machine-readable format. 
However, the creation of these knowledge bases is becoming more feasible and common 
in the pharmacological domain (Khelashvili et al., 2010; Whirl-Carrillo et al., 2012). This 
is due to the increasing number of databases and web servers providing structured and 
semi-structured pharmacological information, such as DrugBank or KEGG. Moreover, 
there are different community projects such as Bio2RDF (Belleau, Nolin, Tourigny, 
Rigault, & Morissette, 2008) or LODD (Samwald et al., 2011), which work to link the 
various sources of biological and pharmacological data together, enabling the integration 
of several pharmacological aspects described in different databases (Pathak, Kiefer, & 
Chute, 2013). Another important factor is the proliferation of biomedical ontologies to 
store and formally represent domain knowledge. Ontologies enable the integration of the 
information disperse through different and heterogeneous databases, and provide 
resources that can be exploited by IE systems (Wimalasuriya, 2010).  
Therefore, future directions for DDI extraction might entail the combination of 
syntactic and semantic information. In addition, increasing the size of training dataset, in 
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particular for the DDI-MEDLINE dataset, would also have a very positive impact on the 
results. 
4.3 Conclusions 
In this chapter, we have corroborated the quality of the DDI corpus as a gold-
standard for drug NER and DDI extraction from text. 
On the one hand, the quality of the annotations has been ensured by the IAA. 
However, based on the analysis of these results, we propose further activities that will 
enhance the quality of the corpus. 
- Multiple-annotation process involving at least three annotators. In this 
strategy, all documents are annotated by more than one annotator 
(Jagannathan et al., 2009; Wilbur et al., 2006). 
- More detailed description of drug_n entities, which can be divided into 
different groups, in order to reduce the bias in the annotation of this entity 
type. 
- Inclusion of a larger number of MEDLINE abstracts, in order to obtain a 
more balanced corpus respecting to the number of DrugBank texts. 
On the other hand, we have evaluated the usefulness of the DDI corpus in the final 
application task. In this way, we have used it as a gold-standard in the SemEval-2013 
DDIExtraction task. The DDI corpus has provided a common framework for the 
evaluation of different drug NER and DDI RE systems, which have shown a significant 
improvement with respect to the previous 2011 edition. The increase in size of the 
corpus, the inclusion of different types of documents, and the quality of their annotations 
might have contributed significantly to this improvement. The analysis of the results of 
the participating systems has provided future directions in order to enhance the utility of 
the corpus: 
- Increasing the size of the DDI-MEDLINE dataset, to provide a larger 
coverage of patterns with a scarce representation in the current version. 
- Annotation of linguistic phenomena required for a better understanding of the 
text, such as negation, modality, cataphora, or anaphora. 
- Annotation of relevant pharmacological information, including quantitative 
information (drug dosage, time interval between administration of the drugs, 
alterations in PK parameters, drug concentration, etc.), and qualitative 
information (ADRs, indications, pharmaceutical forms, administration routes, 
etc.). This information can be useful for the development of new IE systems 
for both drug NER and DDI extraction. 
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Chapter 5 
Semantic resources in the 
pharmacological domain: State of 
the art 
The second main contribution of this thesis is the creation of a comprehensive 
ontology for the representation of all DDI-related knowledge, a resource designed for the 
computational community working on applications within the DDI domain. Prior to the 
development of this new ontology, we have studied the current state of the art in the field. 
Here, we provide a review of existing semantic resources in the pharmacological domain 
from a pharmacovigilance perspective, and specially focusing on their scope to represent 
DDI-related information.  
The great amount of biomedical and pharmacological knowledge is organized in 
different terminological resources. Machine-processable artifacts have become important 
resources for NLP techniques. Controlled vocabularies, taxonomies, and thesaurus can be 
used as input for the creation of term lists for NER tasks (Grego & Couto, 2013; 
Lamurias et al., 2013). In addition to this, ontologies provide a contextual framework and 
semantic knowledge base that can be exploited for RE tasks (Yulan He, Road, & Ex, 
2008; Huang, Zhu, Ding, Yu, & Li, 2006; Müller et al., 2004). During the last years, the 
number of biomedical ontologies has increased leading to a great availability of related 
resources. For example, the open repository BioPortal (Noy et al., 2009) provides access 
to more than 360 biomedical ontologies. Integration and mapping among them is a key 
point for the optimal sharing and interchange of information (Bodenreider, 2008; Smith et 
al., 2007). 
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There are several reviews of biomedical ontologies (Bodenreider & Stevens, 2006) 
and their applications (Bodenreider, 2008; Spasic, Ananiadou, McNaught, & Kumar, 
2005; Stevens, Goble, & Bechhofer, 2000). From a pharmacological perspective, 
ontologies have been studied from the point of view of drug discovery (Vázquez-Naya et 
al., 2010), drug repurposing (Andronis, Sharma, Virvilis, Deftereos, & Persidis, 2011) 
and medicinal chemistry (Gómez-Pérez, Martínez-Romero, Rodríguez-González, 
Vázquez, & Vázquez-Naya, 2013). Since one of the main goals of this project is to create 
an ontology that represents all DDI-related information, the aim of this chapter is to 
provide an overview of those ontologies relevant in pharmacovigilance, that is, the 
science and activities related to the collection, analysis, and prevention of ADRs or any 
other drug-related problem, with a special interest in the representation of DDI-related 
information. To this purpose, we focus on the following characteristics: 
1. representation of pharmacological substances: scope and level of 
granularity. 
2. representation of DDIs 
3. representation of other concepts related to pharmacovigilance: ADRs. 
4. intra-relationships: relations between different concepts in every ontology. 
5. inter-relationships: relations between concepts among different ontologies. 
6. use of unique identifiers, synonyms, and definitions in natural language. 
7. format and availability. 
This section is organized as follows. Firstly, we review in Section 5.1 those 
terminological resources collecting chemical substances, including drugs. Section 5.2 
focuses on the terminologies specifically created as repositories for pharmacological 
substances. Then, in Section 5.3, an overview of ontologies for ADRs is provided. 
Section 5.4 deals with ontologies related, in some way, to the DDI domain. The strengths 
and weaknesses of the reviewed resources are discussed in Section 5.5, and a review of 
the main limitation that should be addressed in this thesis is provided in Section 5.6. 
Finally, the main conclusions of this chapter are highlighted in Section 5.7. 
5.1 Terminological resources for chemical 
substances 
The first aspect in the study of DDI-related terminologies is how those substances 
relating to the domain are represented. There are different types of chemical substances 
relevant to the biomedical domain. Pharmacological substances have a key role due to 
their capacity to cure, prevent, or diagnose diseases. However, other entities such as 
proteins or toxins are important, too. All of them are chemical substances that can be 
classified based on their structural characteristics (e.g., small molecular weight chemicals 
such as the vast majority of drugs, or macromolecules such as proteins), their applications 
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(e.g., chemicals used as drugs or chemicals used as pesticides), or their effects in the body 
(e.g., pharmacological substances or toxic substances). 
Comprehensive ontologies in the biomedical domain contain, therefore, different 
types of chemical substances, including drugs. These drugs can be described at different 
levels of granularity or detail. Figure 5.1 shows a simplified view of these levels of 
granularity. 
 
Figure 5.1. Representation of different levels of granularity for drugs 
The word “drug” can be used with different meanings in different sources. An 
“active ingredient” is the specific molecule that bears some pharmacological activity, 
such as paracetamol or omeprazole. They are usually classified according to some 
relevant characteristic, such as chemical structure or pharmacological activity, in 
different “drug classes” (e.g., benzodiazepine, analgesic, etc.) Active ingredients are 
administered as tablets, capsules, solutions, and so forth, with a specific strength or dose. 
An active ingredient, its strength, and the pharmaceutical form are called “clinical drug”. 
Therefore, ‘paracetamol 650 mg oral tablet’, ‘paracetamol 50mg/5ml oral solution’, and 
‘paracetamol 1000 mg oral capsules’ are three different clinical drugs. Every one of 
these clinical drugs can be commercialized with different brand names (e.g., Efferalgan® 
or Gelocatil®), in packages with a specific number of units. They are called “drug 
products”. Therefore, ‘Efferalgan 10mg/ml 250 ml oral solution’, ‘Efferalgan 650mg 40 
oral tablets’, and ‘Gelocatil 650mg 40 oral tablets’ are three different drug products. 
Finally, for safety and commercial reasons, every drug product is unambiguously 
identified in a specific country by a national code. Therefore, in order to compare and 
relate the information collected among different ontologies, it is important to establish the 
level of granularity of drugs represented in each one of them.  
One of the most important controlled vocabularies in biomedicine is the Medical 
Subject Headings (MeSH) thesaurus (Lipscomb, 2000), developed and maintained by 
the U.S. National Library of  Medicine (NLM). The broad scope of MeSH represents the 
knowledge from different areas related to biomedicine, including diseases, proteins, or 
therapeutic techniques, organized by taxonomic relationships. Pharmacological 
substances are arranged under the top-level category ‘Chemicals and Drugs Category’, 
and are hierarchically represented at different levels of granularity: as active ingredients 
organized under different drug classes. However, this main category does not provide a 
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unique subclass for pharmacological substances, but along with other chemicals such as 
proteins, lipids, or toxins.  
Another important top-level category in MeSH is the ‘Pharmacological Actions 
Category’, which represents those pharmacological actions that can be exhibited by drugs 
or chemicals. Each individual drug is manually linked to one or more pharmacological 
actions. In this way, MeSH provides an indirect classification of drugs based on their 
pharmacological activity. Synonyms are provided as ‘Entry terms’, along with other 
related terms (Figure 5.2). Each individual chemical entity is unequivocally identify in 
MeSH through a Registry Number (RN), a reused identifier such as the CAS number12, 
the EC code (Tipton & Boyce, 2000) or the FDA Unique Ingredient Identifier  (UNII)13. 
MeSH trees can be navigated using the MeSH browsers and the complete thesaurus can 
be downloaded in different formats, including XML or ASCII. 
 
Figure 5.2. Different hierarchies and classifications for the drug fluvoxamine in MeSH 
Another important terminological resource in medicine is SNOMED Clinical 
Terms (SNOMED CT) (Stearns et al., 2001), a comprehensive clinical terminology that 
provides clinical content and expressivity for clinical documentation and reporting. Its 
main purpose is to encode the meanings that are used in health information. The 
International Health Terminology Standards Development Organisation (IHTSDO) is the 
owner and is responsible for this terminology. The core of SNOMED CT is the 
international release, available as English and Spanish versions. Every IHTSDO Member 
Country creates their own national extension, which is adapted to their special conditions 
and necessities, including the different drug products commercialized in every country.  
Several important areas of the pharmacological domain, including diseases, are 
organized in SNOMED CT into hierarchies or top-level concepts. Pharmacological 
substances are described in two of them: ‘Substances’ and ‘Pharmacological/biological 
product’.  The main category ‘Substances’ organizes active ingredients, such as diazepam 
                                                 
12 http://www.cas.org/content/chemical-substances 
13 http://www.fda.gov/forindustry/datastandards/substanceregistrationsystem-
uniqueingredientidentifierunii/default.htm 
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or penicillin, as well as other non-pharmacological chemicals and related terms (e.g., 
‘silk’, ‘red wine’ or ‘oncogene protein P53’). The top-level ‘Pharmacological/biological 
product’ organizes clinical drugs, distinguishing them from their chemical constituents or 
active ingredients. Explicit relationships between both hierarchies are established in this 
ontology. For example, ‘furosemide (substance)’, ‘furosemide (product)’ and ‘furosemide 
80mg tablet (product)’ are three different concepts in SNOMED CT. The latter two are 
hierarchically related through an ‘is_a’ relationship. Both of them are related to the 
concept ‘furosemide (substance)’ by a ‘has_ingredient’ relation. Commercialized drug 
products are not included in the international release of SNOMED CT. However, they 
can be represented in the different national versions and related to the corresponding 
clinical drugs and active ingredients. Therefore, SNOMED CT includes drugs at the drug 
class, active ingredients, clinical products, and, for the national extensions, drug product 
levels. SNOMED CT provides unique identifiers for all concepts. It has been converted to 
the common UMLS format, its concept names have been connected to those already in 
the UMLS Metathesaurus, and its content has been assigned UMLS identifiers (CUI), 
semantic types. Content of SNOMED CT is available under licence conditions, which 
allow consultation but limits its use for open source final applications. 
The NCI Thesaurus (NCIT) (Sioutos et al., 2007) is the National Cancer Institute 
(NCI) reference terminology and biomedical ontology. It covers a broad scope of cancer 
related terms, including drugs. The NCI drug model organizes active ingredients based on 
functional, structural, and therapeutic intent hierarchies. Relationships with other 
concepts, such as mechanism of action, physiologic effects, or molecular targets are 
formally represented. Clinical drugs and drug products are not included in this 
terminology, limiting its scope to the active ingredient and drug class levels. However, it 
provides different synonyms, including brand names, and natural language definitions. 
Every class has its own NCI URI, and it is mapped to other ontologies, such as the 
ChEBI ontology. There is information regarding other code systems, including the FDA 
UNIIs. The NCIT is publicly available in the Web Ontology Language (OWL)14, a World 
Wide Web Consortium (W3C) standard language for representing ontological 
information on the semantic web. 
Finally, the European Bioinformatics Institute (EMBL-EBI)15 created and maintains 
the ontology for Chemical Entities of Biological Interest (ChEBI) (Degtyarenko et al., 
2008). This ontology organizes “small” chemical compounds with a relevant role in the 
biomedical domain, including pharmacological substances. Each one of these 
pharmacological substances is related to at least one drug application, such as analgesic 
or antiemetic. To date, there are 3,540 classes in ChEBI that have some drug-related role, 
that is, bearing some pharmacological activity16. Pharmacological substances are 
classified, as well, regarding their molecular structure or other characteristics, such as 
biological or chemical role. Therefore, ChEBI represents drugs at the active ingredient 
and drug class levels. Every chemical entity has a unique ChEBI identifier and ChEBI 
URI. Information of other IDs, such as DrugBank, ChEBML, KEGG, or UniProt IDs, is 
provided, too. The ontology includes synonyms, brand names, and natural language 
definitions for each class. The ontology can be queried and downloaded in different 
formats, including OWL. 
                                                 
14 http://www.w3.org/2001/sw/wiki/OWL 
15 http://www.ebi.ac.uk/ 
16 http://www.ebi.ac.uk/chebi/tools/ontoquery/response.jsp?submit=Submit&hiddenQuery=has_role+some+drug+&page=1 
[Accessed 14/01/2013] 
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5.2 Terminological resources for 
pharmacological substances 
In the previous section, we have reviewed those terminological resources for 
chemical substances that include drugs. Specific terminologies focusing on 
pharmacological substances are available, too. However, although the number of possible 
drug names is limited compared to those of other biomedical entities, such as genes or 
proteins, there is not a single drug vocabulary providing complete and interoperable drug 
names, codes, and relevant information (Cimino et al., 1998; Solomon et al., 1999). 
Different countries use different nomenclatures and synonyms for drugs, which are 
commercialized under different branded or generic names. There are different ontologies 
created to collect all pharmacological substances and their nomenclature variations at 
different levels of granularity. 
The Anatomical Therapeutic Chemical (ATC) Classification System (WHO, n.d.) 
was developed by the World Health Organization (WHO) to provide a standard and 
international taxonomy used to classify and compare therapeutic compounds. Drugs are 
named using their International Non-proprietary Name (INN) and it is one of the most 
important code systems for the identification of pharmacological substances. Each of 
them has an ATC code representing its level in the hierarchy. Drugs are hierarchically 
organized within five different levels of granularity: from the main system where the drug 
realizes its pharmacological activity to the individual active ingredient. Clinical drugs, 
brand names, or synonyms are not included. The ATC classification system has been 
represented in OWL (Croset, Hoehndorf, & Rebholz-Schuhmann, 2012). However, most 
of the ontological design principles have not been addressed, limiting its reuse in other 
ontologies. 
While the aim of the ATC classification system is to provide an international 
resource for the identification of drugs, national drug terminologies are important to 
support the development of national clinical information systems. To this purpose, the 
United States Veterans Health Administration (VHA) created the National Drug File 
(NDF) (Carter et al., 2002), a nationally maintained medication terminology. The aim of 
the NDF is to provide a hierarchical classification of pharmacological substances with 
different levels of granularity. It includes drug classes, active ingredients, clinical drugs, 
and U.S. National Drug Codes. This terminology evolved into a formalized reference 
terminology, the NDF-RT, created as a Description Logic-based reference model. Unlike 
NDF, where drugs are classified into a single-inheritance hierarchy of drug classes, NDF-
RT provides multiple hierarchies for drug classification through the use of specific 
relationships such as ‘may_treat’ or ‘has_mechanism_of_action’, which relate drugs with 
their mechanisms of action, physiological effects, clinical kinetics, and therapeutic 
diseases. Drug classes are maintained, as well, to provide users with a familiar and 
clinically relevant drug terminology. In this way, different levels of pharmacological 
substances are related through formal relationships, such as ‘has_ingredient’ or 
‘product_component_of’. Every concept has a unique identifier NUI and there is a 
relationship with other codes such as FDA UNIIs. NDF-RT is included in the UMLS 
Metathesaurus and in the RxNorm vocabulary. There is an OWL version of this ontology. 
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An important aspect of NDF-RT is that this terminology includes DDIs for specific 
pairs of drugs. They are subclasses of the main class ‘VA Drug Interactions [VA Drug 
Interaction]’ category, with 7,305 subclasses to date. Every [VA Drug Interaction] 
subclass represents an interaction between two drugs organized in the ‘Chemical 
Ingredients [Chemical/Ingredient]’ top-level category. They are related to the DDI 
through two attributes: ‘Ingredient_1’ and ‘Ingredient_2’. Finally, every DDI has related 
information regarding its degree of severity: ‘Critical’ or ‘Significant’. The information 
about specific DDIs and their level of severity is developed by a committee at the 
Department of Veterans Affairs National Drug File Support Group and used in the 
computerized patient record system (CPRS) throughout the VA health care system to 
generate alerts when a interacting drug combination is prescribed by a clinician (Ko et al., 
2007; Olvey, Clauschee, & Malone, 2010a). However, DDI information has been 
recently removed from NDF-RT (Peters, Bodenreider, & Bahr, 2014). 
Another important U.S. drug vocabulary is RxNorm (Nelson et al., 2011),  the U.S. 
NLM standardized drug vocabulary. It was built upon other drug vocabularies, bridging 
the gap between different drug information sources, such as SNOMED CT, the FDA 
National Drug Code Dictionary17, or the previously described NDF-RT. The main 
characteristic of RxNorm is that this resource allows interoperability between different 
concepts describing drug products at different levels of granularity. The core concepts in 
RxNorm are clinical drugs, which are related to active ingredients and drug products 
through specific relationships. Therefore, RxNorm provides the most comprehensive 
description of commercialized drug products and their active ingredients and other 
important information, such us strength or pharmaceutical form. The content of different 
resources is mapped through the use of the RxNorm Concept Unique Identifier (RxCUI). 
Other drug codes systems, such as the FDA UNII, are represented as attributes at 
different levels of abstraction. 
These terminologies can be reused in new ontologies created for specific purposes. 
For example, the Drug Ontology (DrOn) (Hogan, Hanna, Joseph, & Brochhausen, 2011) 
has been developed for the specific purpose of retrieving National Drug Codes (NDC) 
through different queries, such as active ingredient, mechanism of action, physiological 
effect, or therapeutic class. Since no existing resource was appropriate for this purpose, 
authors developed this new ontology, which was populated with RxNorm.  It provided 
the NDCs that were later related to the corresponding branded and generic drug products, 
clinical drugs, and active ingredients. DrOn was mapped, as well, to the ChEBI ontology, 
through mapping of their URIs when possible. It is available in OWL format. 
5.3 Terminological resources for adverse 
drug reactions 
The concept disease, in its broad sense, can be related to drugs in three main ways. A 
disease can be treated by a drug; therefore, the disease is the indication of the drug. A 
drug can be contraindicated in patients with a specific disease; therefore, it is a 
contraindication. Finally, a disease can be an undesirable and harmful consequence of the 
                                                 
17 http://www.accessdata.fda.gov/scripts/cder/ndc/ 
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use of a drug; in this case, it is an adverse drug reaction (ADR). In the DDI domain, the 
observed consequence will be the altered effect of one or both interacting drugs. 
Therefore, knowledge about associated ADRs for each drug is important in the 
development of a DDI ontology. 
The Medical Dictionary for Regulatory Activities (MedDRA) (Brown, Wood, & 
Wood, 1999) is a standard multilingual medical terminology developed under the 
auspices of the International Conference on Harmonisation of Technical Requirements 
for Registration of Pharmaceuticals for Human Use (ICH). It is a fundamental tool in 
pharmacovigilance and is used in the pre- and postmarketing phases of the medicines 
regulatory process by the U.S. Food and Drug Administration (FDA) and the European 
Medicines Agency (EMA). Terms in MedDRA were derived from several sources 
including the formers WHO’s Adverse Reaction Terminology (WHO-ART) (WHO, 
1992) or the Coding Symbols for a Thesaurus of Adverse Reaction Terms (COSTART)18, 
among others. MedDRA provides a classification of ADRs at different levels of 
granularity and with a deep degree of detail. The lowest or most specific one collects 
more than 70,000 terms, which correspond to how information about ADRs should be 
communicated. Therefore, it is useful for recording adverse events and medical history in 
electronic health records. The English version of MedDRA is distributed as sets of 
extended ASCII delimited files. 
The Adverse Event Reporting Ontology (AERO) (Courtot, Brinkman, & 
Ruttenberg, 2011) was developed to support clinicians at the time of data entry, 
increasing quality and accuracy of reported adverse events. It was created to provide an 
adverse event terminology that address some of the current drawbacks observed with 
broad ontologies such as MedDRA. One of the most important is the lack of definitions 
in natural language, which can lead to heterogeneity in the coding of these events. With 
398 classes and 62 object properties, the scope of this ontology is much lower than that of 
MedDRA. AERO is available in OWL and OBO19 formats. 
The Ontology of Adverse Events (OAE) (He, Xiang, Sarntivijai, Toldo, & 
Ceusters, 2011) is a standardization and integration for data on biomedical adverse 
events. This ontology provides a broad scope of adverse events, with natural language 
definitions and mapping to other resources such as SIDER (Kuhn et al., 2010), a database 
for drugs and their side effects, or the aforementioned  MedDRA. The ontology is 
available in OWL format and it has been developed following the OBO Foundry design 
principles (Smith et al., 2007), a collaborative effort for the development and 
maintenance of biomedical ontologies to ensure their integration and interoperability. 
These ontologies have been created to provide formal representations of ADR or AE 
related concepts. However, pharmacological substances are not represented, leading to a 
lack of a formal ontology that relates drugs with theirs ADRs. To address this problem, 
the Adverse Reactions and Mechanism Ontology (ARM) (Zhichkin, Athey, Avigan, & 
Abernethy, 2012) has been proposed. This is an ongoing project for a systematic 
organization of all ADR-related data and information. The aim of the authors is to create 
a knowledge base that will enable linking ADR with biological mechanisms and 
functions. However, for the time being, the ontology has not been published or described 
in any source. 
                                                 
18 http://www.nlm.nih.gov/research/umls/sourcereleasedocs/current/CST/ 
19 Ontologies of Biological and Biomedical Interest format 
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5.4 Ontologies related to the DDI domain 
Up to now, we have described terminological resources for chemical entities -
focusing on pharmacological substances -, drug terminologies, and ontologies for ADRs. 
However, the pharmacological domain involves other relevant areas, such as 
pharmacodynamics, pharmacokinetics or pharmacogenomics. All of them are related to 
DDIs, and have been addressed in different ontologies. We have identified those 
ontologies that could be useful for our purpose of development of a comprehensive 
ontology for DDIs. Here, we describe them in a chronological order. 
The Drug Interaction Ontology (DIO) (Yoshikawa, Satou, & Konagaya, 2004) is a 
formal representation of drug pharmacological actions, depicted by drug-biomolecule 
interactions that are the underlying mechanism in some types of DDIs. The conceptual 
model of this ontology enables the representation of complex pharmacological processes. 
However, relationships are established only at a high level of reality since individual 
drugs and biomolecules are not comprehensively represented. The number of classes is 
179 and the number of relationships is 14. Natural language definitions are provided only 
for the half of the classes. Anatomical-related classes are linked to the Foundational 
Model of Anatomy (FMA) (Rosse & Mejino, 2003) and UMLS CUIs are provided for a 
total of 34 classes. The ontology is available in OWL format. 
The drug-mechanism evidence taxonomy was created in the framework of the 
Drug Interaction Knowledge Base (DIKB) (Boyce, Collins, Horn, & Kalet, 2009) 
project with the aim to provide a way to assign the level of confidence of experts with a 
particular drug-related fact. This evidence taxonomy covers all the kinds of evidence that, 
when combined with a set of inclusion criteria, enables drug experts to specify their 
confidence in a specific drug mechanism assertion. Therefore, the taxonomy does not 
represent specific drugs or interactions between individual pairs of them.  It is 
implemented in OWL, and it consists of 125 classes and 70 object properties. Ninety-five 
per cent of the classes are defined in natural language, and one of each four is formally 
defined in the ontology by an OWL definitional axiom (or ‘equivalent to’ relationships). 
Links or mappings to other resources are not provided. 
Rubrichi & Quaglini created an ontology by acquiring the domain knowledge from 
the drug interactions and contraindications sections from Italian Summaries of Product 
Characteristics (SPCs) (Rubrichi & Quaglini, 2012). The aim of this project was the 
development of a system able to extract automatically drug-related information from 
texts. Therefore, the ontology should represent all DDI-related information that could be 
found in that type of texts. However, the represented concepts are not described at a deep 
level of detail and specific drugs or DDIs are not included. The final ontology, which can 
be obtained by requesting the authors, has been implemented in OWL and has 23 classes, 
17 object properties or relationships, and 7 individuals. Natural language definition or 
OWL definitional axioms are not provided. 
The Pharmacokinetics ontology (PKO) (Wu et al., 2013) is a recent work 
developed for the representation of drug pharmacokinetics information. This ontology 
does not represent specific DDIs or DDI mechanisms, but collects concepts related to the 
DDI domain. Specifically, authors focused on the representation of PK DDI studies and 
their components. PK DDI studies are experiments developed in vitro or in vivo to study 
 82 
 
the existence of drug interactions affecting some of the PK parameters of the interacting 
drugs. The main contribution of this ontology is a manually created representation of PK 
parameters and their definitions in natural language. The utility of this ontology has been 
evaluated in the annotation of texts describing a PK study of DDIs (Wu et al., 2013). 
Pharmacological substances are imported from the ChEBI ontology, although related 
information such as synonyms or cross-references has not been included. The PKO is 
available in OWL format. 
In contrast to the PKO, the Pharmacodynamics ontology (PDO) (Imai, Hayakawa, 
& Ohe, 2013) focuses on the description of the pharmacodynamics domain. Researchers 
at the University of Tokyo have developed a description framework of PDO with the aim 
to support machine-reasoning systems for the detection of possible DDIs based on PD 
mechanisms. However, as the PKO, it does not represent specific DDIs or DDI 
mechanisms. This ontology is only part of a national project for a Medical ontology in 
Japan, and currently it is available in Japanese only. The ontology has not been 
implemented in OWL format. 
In Table 5.1, we provide a summary of the figures comparing the OWL versions of 
these five ontologies. We include here the NDF-RT, too, since, as mentioned before, it 
represents specific DDIs between drugs. 
 NDF-RT DIO DIKB Rubrichi PKO PDO 
C
la
ss
es
 Own - 169 91 23 1,381 - 
Imp - 10 34 0 44,955 - 
Tot 48,978 179 127 0 46,336 - 
R
el
at
io
ns
hi
ps
 
Own 0 9 37 17 12 - 
Imp 0 5 30 0 216 - 
Tot 0 14 70 0 228 - 
Classes with NLD 0 
89 
(49%) 
119 
(95%) 
0 
434 
(31.4%) 
- 
Related IDs 
CUI 
NUI 
UNII 
FMAID 
CUI 
0 0 0 - 
OWL definitional 
axioms 
0 0 
32 
(25,6%) 
0 
2 
(0.15%) 
- 
Table 5.1. Metrics20 and comparison of DDI-related ontologies in OWL format (Own for 
entities created in the ontology; Imp for imported entities; Tot for the total number of 
entities; NLD for natural language definitions.) 
                                                 
20 Metrics from http://bioportal.bioontology.org/ontologies/, http://www.ontobee.org/ (accessed 
24/01/2014) or the manually study of each terminology when appropriate.  
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5.5 Discussion 
In this chapter, we have reviewed existing semantic resources from a 
pharmacovigilance perspective, specially focusing on their scope to represent DDI-
related information. NDF-RT represents specific DDIs between specific pairs of drugs 
with one of two degrees of severity: critical or significant. However, other related 
information such as the mechanism leading to the DDI, the effect or consequence for the 
patient, recommendations for avoiding the DDI, patient-related (age, diseases, genetics, 
etc.) or drug-related (dose, administration route, etc.) affecting factors, are not 
represented. The ontology created by Rubrichi aims to include all these aspects. 
However, the level of detail in the description of concepts is too shallow to provide an 
appropriate description of the DDI domain. DIO provides a formal representation of 
interactions between drugs and biomolecules, which has been used to infer DDIs between 
one particular pair of interacting drugs. This ontology provides a framework for the 
formal representation of DDI mechanisms. However, the scope of the ontology, with 180 
classes, 14 object properties, and 1194 axioms, is too small to represent all the different 
DDI-mechanisms. In a similar way, the description framework of the PDO provides a 
first step in the formal representation of PD processes. However, there is still a lack of 
explicit representation of PD DDI mechanisms. Finally, the PKO and the evidence 
taxonomy (or DIKB) focus on limited areas related to the DDI domain, but do not 
provide a comprehensive representation of the domain.  
With the exception of the PDO, the other four ontologies have been implemented in 
OWL, the World Wide Web Consortium (W3C) standard ontology language for the 
semantic web21. Using standard formats allows interoperability among ontologies and 
increases its usefulness. This recommendation is one of the OBO Foundry principles, a 
collaborative effort for the development and maintenance of biomedical ontologies 
(Smith et al., 2007). These recommendations for building ontologies cover aspects such 
as format, content, naming conventions, collaboration between similar projects, among 
many others. However, the ontologies related to the DDI domain reviewed here have not 
followed clear ontological design principles, such as those proposed by the OBO 
Foundry, limiting their reuse in other ontologies. Therefore, from this study we conclude 
that the knowledge about DDIs has not been comprehensively represented in any existing 
ontology. Table 5.2 summarizes the strengths and limitations of these resources. 
Regarding other pharmacological terminologies, most of them could provide lists of 
drugs (MeSH, ChEBI, ATC, NDF, RxNorm, or DrOn) to be imported in our ontology. 
MedDRA, AERO, or OAE could be imported as a source of ADR terminology. 
However, relationships between drugs and ADRs are not established, limiting the 
representation of DDI-related information. The effect of a DDI is an altered effect of one 
or both interacting drugs. Therefore, drug-ADR relationships are necessary for the formal 
representation of DDI effects. In contrast, the drug model in the NCIT links drugs to 
other concepts, such as mechanism of actions or proteins. Nevertheless, only cancer-
related drugs are included, limiting its use for DDIs representation between other classes 
of drugs. SNOMED CT could be a useful resource for our purposes, since representation 
of pharmacological drugs is comprehensive and there are relationships between them and 
                                                 
21 http://www.w3.org/2001/sw/wiki/OWL 
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other concepts, such as drug-disease relationships. However, licence conditions limit its 
reuse for open source final applications. 
Semantic 
resource 
Strengths Limitations 
NDF-RT 
 Representation of specific       
DDIs between drugs. 
 Inclusion of degree of 
severity. 
 No other DDI-related 
information included. 
 DDIs have been removed 
from the NDF-RT. 
DIO 
 Represents drug-
biomolecule interactions. 
 Useful to infer DDIs on the 
basis of a PK mechanism. 
 No specific or general DDIs 
represented. 
 Low scope and coverage. 
 Not ontological design 
principles followed. 
Evidence 
taxonomy 
(DIKB) 
 Represents the evidence for 
specifying the confidence in 
a DDI assertion. 
 Focuses on a limited area of 
DDI knowledge (evidence). 
 Not ontological design 
principles followed. 
Rubrichi 
 Represents DDI-related 
knowledge (mechanism, 
effect, affecting factors…). 
 No specific DDIs 
represented. 
 Shallow representation of 
DDI-related concepts. 
 Not ontological design 
principles followed. 
PKO 
 Focuses on PK DDI studies 
and their components. 
 Focuses on a limited area of 
DDI knowledge (PK DDI 
studies). 
 Not ontological design 
principles followed. 
PDO 
 Focuses on PD processes. 
 Useful to manually infer 
DDIs on the basis of a PD 
mechanism. 
 Lack of explicit 
representation of PD DDI 
mechanisms. 
 Not ontological design 
principles followed. 
Table 5.2. Summary of strengths and limitations of current DDI-related ontologies 
Therefore, no existing resource provides an appropriate representation of all DDI-
related information. For this reason, a new ontology is developed in the framework of this 
thesis. With the ontological representation of the DDI knowledge in this new resource, 
we provide a formalized model for the general pharmacological principles common to all 
DDIs. These include the formal representation of DDI mechanisms, which are 
comprehensively represented in the ontology, including all possible PK and PD 
mechanisms. The conceptualization of these mechanisms requires the representation of 
different drug-protein relationships, which are included in our ontology. Alongside the 
general representation of DDI knowledge, the ontology is populated with specific DDIs 
between specific pairs of drugs. All this information is integrated in a conceptual model 
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implemented in Description Logics (DL), enabling the use of a reasoning engine to check 
the consistency of the ontology and the inference of new classification hierarchies and 
relationships. Finally, the interoperability of this new ontology is ensured by the adoption 
of ontological design principles proposed by the OBO Foundry. In this framework, the 
ontology is developed as an open source artefact, which is available for the research 
community. 
5.6 Unresolved issues 
Automatic systems for extraction of DDIs can be built upon ontologies providing the 
knowledge of the domain, as a source of the relevant entities and the relationships 
between them. Moreover, combination of semantic annotations among concepts and DL 
can provide a framework for the inference of DDIs based on their mechanisms and the 
intrinsic characteristics of interacting drugs, enabling the development of new systems for 
the early prediction of unknown DDIs in pharmacovigilance. To achieve these goals, 
however, some limitations should be addressed:  
1. There is not a comprehensive ontology for DDI-related information. 
2. DDIs between individual drugs have been represented in the NDF-RT, but 
without providing any additional information such as mechanism, effect, or 
recommendations for avoiding the DDI. 
3. Most DDI mechanisms occur because two different drugs bind the same 
protein in the body. These mechanisms can be formally represented in an 
ontology through the representation of drug-protein relationships, enabling the 
inference of DDIs. However, the different mechanism types leading to DDIs 
have not been represented comprehensively in any ontology. 
4. Ontological representation of DDI mechanisms has been tackled only from a 
PK point of view, but not PD. Moreover, these works have not studied all 
different types of PK mechanisms that can be involved in DDIs and which are 
important for their appropriate understanding and manage.  
5. The consequence of a DDI is frequently related to the exacerbation of the ADR 
of one or two interacting drugs. For example, some antihistaminic drugs used 
to reduce allergic symptoms cause somnolence. With the concomitant use of a 
tranquilizer, such as diazepam, the degree of somnolence in the patient is 
higher. Therefore, the formal representation of the relationships between drugs 
and their related ADRs is important to characterize the consequences of DDIs. 
However, there is not available ontology for drug-ADR representation. 
6. The study of those characteristics influencing DDIs, such as chemical 
structure, ADRs profile, or mechanism of action, could provide interesting 
approaches for the inference of DDIs or the selection of non-interacting 
 86 
 
alternatives. However, there is not existing ontologies representing 
comprehensively all this information and its relationship with DDIs. 
7. Current DDI-related ontologies have not followed ontological design 
principles. This fact reduces their integration and interoperability with other 
ontologies.  
Thus, one of the main contributions of this thesis is to create a DDI ontology that 
covers each of the unsolved issues described in the above list.  
5.7 Conclusions 
 
This chapter has reviewed the current semantic resources in the pharmacological 
domain covering some aspect related to DDIs. Firstly, we have analysed the 
terminologies for chemical entities that include pharmacological substances. The MeSH 
thesaurus, SNOMED CT, the NCIT, and the ChEBI ontology are the outstanding 
resources in this group. Secondly, we have reviewed the terminologies focusing on 
pharmacological substances, such as the ATC classification system, the NDF-RT, or 
RxNorm. In addition to this, we have reviewed terminologies and ontologies for ADRs, 
which include MedDRA, AERO, and OAE. Finally, we have paid special attention to 
those ontologies specifically created to represent DDIs or their mechanisms: DIO, the 
drug-mechanism evidence taxonomy or DIKB, Rubrichi et al. SPCs ontology, the PKO 
and the PDO.  
The existence of these resources proves the interest of the research community in the 
formal representation of DDI knowledge. However, the analysis described in this chapter 
has shown that there are still limitations that should be addressed in a comprehensive 
ontology for DDI knowledge. The development of this new resource requires a detailed 
analysis of how DDI-related knowledge has been represented by other researches and the 
different concepts and relationships covered in current ontologies, in order to reuse useful 
information and to identify deficiencies. Thus, in next Chapter 6, we review in detail 
current modeling efforts in the DDI domain. 
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Chapter 6 
DDI-knowledge modeling: State of 
the art 
In the previous chapter, we have identified and reviewed the semantic resources in 
the pharmacological domain covering some DDI-related aspect, focusing on the analysis 
of resources for DDIs or their mechanisms. In this chapter, we complete this review by 
analysing the main efforts of several research groups to model this DDI-knowledge. In 
other words, we focus here not in the analysis of the final resources, but in the modeling 
approaches followed to create them. 
To perform useful actions for people working in a given domain, a system requires 
knowing something about that domain. Concrete knowledge about a domain (e.g., Maria 
has one sister and one brother, Ana and Diego) requires prior general knowledge or how 
concrete objects are related in the world (e.g., A person can have none or several siblings, 
that can be sisters or brothers. A sister is always a woman and a brother is always a 
man). Conceptual modeling is the activity that elicits and describes the general 
knowledge of a particular domain. The set of concepts used in a particular domain 
constitutes a conceptualization of that domain, and its graphical description is the 
conceptual model (CM) (Olivié, 2007). Usually, the design of a CM relies on the 
perspective that experts have of a specific domain. Since it is the result of an intellectual 
activity performed by humans that serves different objectives, there is not a unique 
representation. Consequently, different CMs representing the same domain can exist. 
These CMs are abstract models that can be translated into different implementations and 
interpretable schemata such as OWL ontologies, relational databases, XML schema, and 
so forth. 
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Therefore, as any other formal representation, the creation of a new ontology for 
DDIs requires a previous conceptualization of the domain knowledge describing how 
relevant concepts relate to each other in the world. Before performing this task, we have 
identified and analysed current research projects that have focused or have required the 
conceptualization of the DDI domain. With this review, we aim to identify which aspects 
of DDIs have been currently conceptualised, how this information has been modelled by 
different research groups, how the different CMs have been translated, and the 
applications given to the final models. 
This chapter is organized as follows. Section 6.1 describes the method used to create 
a common framework for the comparison of different conceptualizations of the DDI 
domain. These different projects are summarized in Section 6.2 and compared in Section 
6.3. Results of our analysis are discussed in Section 6.4, and the unresolved issues that 
will be addressed in the framework of this thesis are presented in Section 6.5. Finally, the 
main conclusions are provided in Section 6.6. 
6.1 Creation of a common framework 
To the best of our knowledge, there are seven different projects that have required a 
total or partial representation of the DDI domain knowledge, which have been described 
in scientific journals or conference proceedings between 2004 to date (July 2014). These 
projects have in common that, for different purposes, they developed and described their 
conceptualizations of the DDI domain, which were subsequently implemented in 
different models. However, every work describes its conceptualization in different ways. 
To compare the different CMs created by each research group, we study: 1) the original 
CM created by the authors; 2) their natural language description of the domain; 3) the 
final implemented model. 
However, a comparative analysis of the seven conceptualizations is difficult. In most 
cases, CMs are not provided and those explicitly included in the publications differ 
considerably. In addition to this, natural language descriptions can lead to a subjective 
interpretation of the described domain, which can be different from that intended by the 
authors. Finally, the final implemented models are complex artifacts (sets of rules in first 
order logic (FOL) or OWL ontologies) and therefore, a straight comparison between them 
is difficult. 
Consequently, to compare the similarities and differences between the seven models, 
we have represented all of them as Unified Modeling Language (UML) class diagrams, a 
standard modeling language that can be applied to diverse independent domains.22 In 
brief, classes are represented as boxes with three parts. The top part contains the name of 
the class, the middle part contains the attributes of the class, and the bottom part contains 
the methods the class can execute. The taxonomical relation ‘is_a’ is represented as a line 
ending in a hollow triangle shape on the superclass. Other relationships between classes 
are represented as arrows, while aggregation or composition relationships are represented 
by a shallow or filled diamond shape, respectively.  
                                                 
22 http://www.uml-diagrams.org/ 
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For those projects that already provided a diagram showing their CMs, we only adapt 
their models to the common one. In cases when we study the final ontologies, they are 
analysed and transformed into the corresponding CM. We do not represent any attribute 
that is not explicitly mentioned in the original project. Moreover, to avoid subjective 
interpretation of ontologies, we include in the model only the relationships that explicitly 
establish their range and domain, and we rule out those where this information is missed. 
In the case of conceptualizations implemented as set of rules in FOL, we consider 
variables as classes and predicates as relationships. Those predicates defining objects are 
represented as attributes or classes as appropriate. Finally, due to the lack of space, we 
only include in the diagrams the top-level classes and their most relevant subclasses. 
Those classes having subclasses not represented in the CM are shown as shaded boxes.   
With this approach, we are able to provide a common representation framework, 
which enables the correct comparison of different conceptualizations. The resulting CMs 
for each conceptualization are shown in the next section with a brief description of the 
projects where they were created. 
6.2 Modeling approaches in the DDI domain 
In this section, we describe the seven different approaches that have dealt, in some 
way, with the task of conceptualization of DDI knowledge. We refer along this chapter to 
each project by the name provided to the final implemented model. When there is not a 
name assigned, we refer to the project by the first author’s name in the corresponding 
publication. 
 Modeling DDI knowledge acquired from DDI monographs (Mille et al.): 
One of the earliest efforts in modeling the DDI domain was carried out in 2007 by 
Mille et al. (Mille, Degoulet, & Jaulent, 2007). They created a simple CM aimed to 
represent the whole DDI domain consisting in only six main classes (Figure 6.1). 
Knowledge represented in this CM was acquired from the study of natural language 
descriptions of DDIs obtained from French drug-drug interaction monographs (Agence 
française de sécurité sanitaire des produits de santé, 2006) with the final aim to create a 
DDI structured knowledge base that could be used by CDSS. The information needed to 
populate the knowledge base was acquired from descriptions of DDIs obtained from the 
previously mentioned monographs. To do this, the CM was used to create an XML 
schema of DDI knowledge for the encoding or markup of textual documents. 
This CM represents the DDI as the central concept, which is related to the other ones. 
The model covers most of the important questions related to the DDI domain: how does 
the interaction occur? (‘Mechanism’); which ones are the interacting drugs? (‘Partner’); 
what is the consequence of the DDI? (‘Consequence’); which factors can increase the 
risk of the DDI? (‘Risk Factor’; ‘Risk Association’); which factors or measures can 
decrease the risk of the DDI? (‘Precaution of Use’; ‘Limitation’).  Although the model 
provides a wide coverage of the DDI domain, a deeper description of each one of these 
aspects is not represented. Even so, this model proved to be useful to encode a total of 
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one thousand and six DDI monographs and to create a knowledge base with the extracted 
information. 
 
Figure 6.1. Conceptual model in Mille et al. 
 An ontology for SPCs representation (Rubrichi & Quaglini): 
Rubrichi & Quaglini required the conceptualization of the DDI domain for the 
creation of an ontology that would be used to create a system able to automatically 
extract drug-related information from text (Rubrichi, Quaglini, Spengler, Russo, & 
Gallinari, 2013).  
This CM explicitly represents the concept of DDI as a class (Figure 6.2). As well as 
in Mille’s CM, this representation includes some of the most important aspects of DDIs: 
what is the consequence of the DDI? (‘Interaction Effect’); which factors can increase 
the risk of the DDI? (‘Intake Route’; ‘Posology’; ‘Personal Conditions’) and which 
actions or measures can decrease the risk of the DDI? (‘Recovering Action’).  An 
important characteristic is that this is the only work that includes the concept ‘Side 
Effect’ in the conceptualization. However, an important aspect is not represented: the 
‘Mechanism’, or how the interaction occurs, which is a crucial aspect in the study, 
understanding, and management of DDIs (see Section 7.1.3). 
As mentioned before, the CM was used to create an ontology, which was used to 
annotate a set of SPCs texts for the training and testing of an IE system (Rubrichi & 
Quaglini, 2012). The extracted information was recently used by the authors in a new 
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experiment aimed to populate automatically the ontology through the representation of 
the extracted entities as instances of concepts. The final number of entities in the 
populated ontology is, however, not provided in the publication  (Rubrichi et al., 2013). 
 The National Drug File Reference Terminology (NDF-RT): 
The National Drug File Reference Terminology (NDF-RT) is the formalized 
reference terminology of the U.S. Veterans Health Administration (VHA) nationally 
maintained medication terminology, the National Drug File (NDF) (Carter et al., 2002). 
NDF-RT is used for modeling drug characteristics including ingredients, chemical 
structure, dose form, physiological effect, mechanism of action, pharmacokinetics, and 
related diseases. It also includes DDIs between pairs of drugs (U. S. Department of 
Veterans Affairs, 2012). 
NDF-RT is used by the VHA computerized systems. Information about specific 
DDIs is established by an expert committee at the Department of Veterans Affairs 
National Drug File Support Group and is used in the computerized patient record system 
(CPRS) throughout the VA health care system to generate alerts when a interacting drug 
combination is prescribed by a clinician (Ko et al., 2007; Olvey et al., 2010a). 
In spite of the detailed description of drug characteristics shown in Figure 6.3, DDI-
related information is represented in a very simple way in the model. In NDF-RT, a DDI 
is related to exactly two active ingredients and has an attribute ‘Severity’ that takes one of 
two values: ‘Significant’ or ‘Critical’. No other information related to the domain is 
included in this model. However, it is important to note that all DDI-related information 
has been recently removed from NDF-RT (Peters et al., 2014). 
 The Drug Interaction Ontology (DIO): 
The Drug Interaction Ontology (DIO) is an OWL-DL ontology developed for the 
formal representation of pharmacological actions depicted by drug-biomolecule 
interactions. The interference of different drugs in the same drug-biomolecule interaction 
is the underlying mechanism of most DDIs. If the interaction between a drug and the 
biomolecule is related to the pharmacodynamics of the drug, the resulting DDI is a PD 
DDI. In contrast, if the drug-biomolecule interaction regulates some of the 
pharmacokinetic processes of the drug in the body, it will lead to a PK DDI (see Section 
7.1.3 for a comprehensive description of these concepts). DIO focuses only on the latter 
one and therefore PD knowledge is not included. It is important to emphasize that DIO 
represents interactions between a drug and a biomolecule, and not interactions between 
two drugs. However, as we explain below, drug-biomolecule interaction information can 
be exploited by a system to predict DDIs. 
Yoshikawa et al. (2004) described their CM as a triadic relationship between three 
concepts: 1) the effector that triggers the interaction; 2) the counterpart object; and 3) the 
output or consequence of that interaction. Since the model represents drug-biomolecule 
interactions and not drug-drug interactions, the concept of DDI was not represented. 
However, a relevant aspect in this model was the location of the drug-biomolecule 
interaction, or where in the body the interaction occurs. 
  
 
 
Figure 6.2. Conceptual model in Rubrichi et al. Shaded boxes represent classes with additional subclasses (Adapted from Rubrichi et al., 2012) 
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Figure 6.3. Conceptual model in NDF-RT. Shaded boxes represent classes with additional subclasses
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The aim of this project was the development of a data model that could represent drug-
biomolecule interactions for knowledge sharing and functional usage. DIO’s developers 
applied their ontology for prediction of PK DDIs and created a system able to identify 
correctly several possible DDI mechanisms between a specific pair of drugs (irinotecan 
and ketoconazole). However, interactions between other drugs have not been studied in 
the framework of this project (Konagaya, 2012). 
The adaptation of the final implemented DIO to the common CM format used in 
this review (Figure 6.4 and Figure 6.5) leads to a more complex CM than that shown in 
their original work (Yoshikawa et al., 2004). In this extended CM, we can see that 
anatomical concepts and cellular components are included in the model to represent the 
anatomical and cellular locations of interactions. ‘Drug’, ‘Metabolites’, and ‘Proteins’ are 
hierarchically represented as chemicals. The intermediate products formed in a drug-
biomolecule interaction, called ‘Drug-Protein Complex’, are represented, too. These 
chemicals participate in different processes that are classified at the organismal level 
(including the PK processes ‘Drug Absorption’, ‘Drug Distribution’ and ‘Drug 
Excretion’), the cellular level (such us the PK process ‘Drug Metabolism’), or the 
molecular level (e.g., different types of enzymatic reactions). Therefore, the 
conceptualization implemented as DIO provides a detailed description of PK processes. 
Moreover, this CM is unique among those studied in this review in terms of including the 
localization of these reactions in the organism. 
 
Figure 6.4. Conceptual model in DIO for the ‘Independent Entities’ top-level class. 
Shaded boxes represent classes with additional subclasses. 
  
 
 
Figure 6.5. Conceptual model for DIO showing the ‘Process’ top-level class and its relationships to the ‘Independent Entities’ and ‘Dependant 
Entities’ classes. Shaded boxes represent classes with additional subclasses. 
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 The Drug Interaction Knowledge Base (DIKB): 
Boyce et al. have worked since 2004 in the domain of DDI knowledge representation 
(Boyce, Collins, Horn, & Kalet, 2004). One of their main contributions to this field is the 
Drug Interaction Knowledge Base (DIKB), a knowledge representation system designed 
to predict DDIs on the basis of their underlying mechanisms and the evidence supporting 
the drug-related facts (Boyce, Collins, Horn, & Kalet, 2010a). These predictions are 
possible through the formal representation of the mechanisms that lead to DDIs, which 
are modelled as a set of rules in FOL (Boyce, Collins, Horn, & Kalet, 2007). 
In their earliest efforts, Boyce et al. studied the formal representation of different 
types of PK mechanisms: induction and inhibition of metabolizing enzymes, change in 
gastro-intestinal pH, and change in gastro-intestinal motility (Boyce et al., 2004). 
However, in further work they focused on the extension of rules that modeled the 
conditions for the specific process of metabolic inhibition, resulting in a closer 
description of this specific DDI mechanism (Boyce et al., 2007). 
 
Figure 6.6. Conceptual Model in the DIKB 
This CM (Figure 6.6) focuses on the relationships that exist between the principal 
actors that take part in a DDI occurring by the inhibition of the enzymatic metabolism of 
a drug: the precipitant drug, the object drug, and the metabolic enzyme. In this model, the 
PK process ‘Metabolism’ is represented as a concept and related to the object drug. For a 
deeper description of DDIs, two drug characteristics that determine the incidence and 
significance of DDIs are included, too. They are the characterization of the object as a 
drug with ‘Narrow therapeutic index’ and/or as a ‘Sensitive substrate’. With the inclusion 
of these characteristics, the model focuses on DDIs that potentially could be more 
relevant in the clinical domain.  
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These classes, relationships, and attributes are combined in a rule-based theory of 
how drugs interact based on this mechanism. Using information of a manually curated 
database of drug-related facts – structured information of specific drugs, metabolites, and 
metabolic enzymes and relationships between them - and the rule-based theory, they 
developed a machine-reasoning system able to predict interactions between individual 
pairs of drugs (Boyce, Collins, Horn, & Kalet, 2010b). The final DIKB contains 
quantitative and qualitative assertions about drug mechanisms and PK DDIs for over 60 
drugs, primarily psychotropics and HMG-CoA reductase inhibitors23. 
In the framework of the same project, uncertainty behind drug information was 
identified as one of the main challenges to represent and use drug-mechanism knowledge. 
To overcome this issue, authors created an evidence-base for the assignment of drug 
experts’ confidence level for every drug-mechanism fact. For this purpose, they 
combined a set of inclusion criteria with a new evidence taxonomy containing 36 
evidence types (Boyce et al., 2010a). This ontology does not model the DDI domain. 
However, it could be reused to categorize the level of evidence of DDI-related 
information. 
 The Pharmacodynamics ontology (PDO) 
Imai et al. (2013), from the University of Tokyo, have focused on the field of PD 
DDIs. With the aim to progress in the development of machine reasoning systems to 
detect DDIs occurring by this type of mechanism, they created the description framework 
of the PDO, which has been created as part of a national project for the creation of a 
Medical Ontology in Japan24. As in DIO, specific information regarding DDIs is not 
included in the model. However, their descriptions of pharmacological processes can be 
used to predict interactions between specific pairs of drugs. 
Five fundamental classes and several relationships among them model the domain of 
drug pharmacodynamics - or how a drug produces a pharmacological effect by 
interacting with a target in the body (Figure 6.7). Therefore, in this CM processes are 
predominantly represented. Specifically, different signal transduction sub-processes that 
can occur when a drug interacts with a target are represented. In these cellular processes a 
signal is conveyed to trigger a change in a cell, leading to a chain of physiological 
responses that will finally produce the pharmacological response. As mentioned before, 
the concept of DDI is not represented in the model. However, the domain was modeled in 
order to allow inferring a DDI when two different single drug molecules have in common 
some of the represented signal transduction processes, or when they have the same 
physiological response. The suitability of the model to predict PD DDIs has been tested 
manually on a limited number of drugs related to the noradrenaline-signal transduction 
process.
                                                 
23 http://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/front-page.html 
24 http://www.m.u-tokyo.ac.jp/medinfo/medont2010-2012proj/ 
  
 
 
Figure 6.7. Conceptual model in the PDO. Shaded boxes represent classes with additional subclasses 
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 The Pharmacokinetics Ontology (PKO): 
The aim of the PKO, developed at Indiana University, was to represent PK-related 
information (Wu et al., 2013). Although the final ontology integrates information from 
different resources, modeling efforts in this project focused on the representation of 
different types of PK DDI studies. PK DDI studies are experiments developed in vitro or 
in vivo to study the existence of drug interactions affecting some of the PK parameters of 
the interacting drugs.   
As shown in the CM in Figure 6.8, the PKO does not include the concept DDI. 
There are five main classes representing the different types of PK studies 
(‘Pharmacokinetic Experiments’) and the entities relevant in that studies (‘Drug’, 
‘Metabolizing enzymes’, ‘Transporters’, and ‘Subjects’). 
The CM was implemented as an OWL ontology that imports other ontological 
resources (such as the ChEBI ontology or  SOPHARM (Coulet, Smaïl-Tabbone, Napoli, 
& Devignes, 2006)), and used for annotation of documents describing PK DDI 
experiments.  
 
Figure 6.8. Conceptual model in the PKO. Shaded boxes represent classes with 
additional subclasses. 
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6.3 Comparison of DDI knowledge modeling 
approaches 
In this review, we have identified seven research works describing their 
conceptualizations of the DDI domain in the last ten years. The main difference between 
their CMs is their scope – that is, the part of the DDI domain studied and covered by their 
representations. The scope determines the representation of the concept DDI in the 
model, as well as which other related concepts are included. Here, we compare the 
different conceptualizations analyzing the representation of the concepts ‘Drug’ and 
‘Drug Class’, other relevant objects in the domain such as metabolites or proteins, the 
concept ‘DDI’, and other qualities and processes required to model the domain. 
As we explained in Section 5.1, the word “drug” can be used with different 
meanings in different sources: as an “active ingredient” or the specific molecule that 
bears some pharmacological activity (e.g., paracetamol), as a “drug class” that gathers 
active ingredients on the basis of some relevant characteristic in the same group of drugs 
(e.g., benzodiazepine, analgesic, etc.) or as a “clinical drug” or “drug product”, which 
refer to the unitary dose of a medicine (e.g., a specific tablet of paracetamol) or a 
commercial unit of a medicine (e.g., a pack containing 20 tablets of paracetamol), 
respectively. In the case of the CMs reviewed in this work, we have observed that all of 
them represent the concept ‘Drug’ at the ‘Active Ingredient’ level. Therefore, all of them 
agree to consider that a DDI should be described to occur between two active ingredients. 
Hence, four of them (Rubrichi’s CM, NDF-RT, PDO and PKO) include in their models 
the fact that an active ingredient is a component of a medicine – that is, an active 
ingredient is the component of a clinical drug or a drug product.  
Regarding the concept of ‘Drug Class’, it is included in the CMs created by Mille 
and Rubrichi, NDF-RT and the PKO. However, all of them represent this concept in 
very different ways. Mille’s represents drug classes as an attribute ‘type’ of an ‘Active 
Ingredient’. In this way, the active ingredient paracetamol would have type analgesic if 
we represent it in this model. In contrast, Rubrichi’s CM establishes that a ‘Clinical 
Drug’ or ‘Drug Product’ belongs to a ‘Drug Class’, instead of establishing the 
relationship for the ‘Active Ingredient’. In a similar way, NDF-RT, which includes 
different classifications of drugs, relates drug classes and clinical drugs hierarchically. In 
this way, the clinical drug acetylcysteine 20% inhalation solution is a subclass of the drug 
class mucolytics. This clinical drug is related to an active ingredient class in NDF-RT 
through the relationship ‘has ingredient’ (e.g., acetylcysteine 20% inhalation solution - 
‘has ingredient’ – acetylcysteine). Therefore, in this model active ingredients and drug 
classes are indirectly related through their respective relationships with clinical drugs. A 
special case is the representation of drug classes in the PKO. As mentioned before, this 
ontology has imported information from other ontologies. In this way, the model 
corresponding to the representation of the concept ‘Drug’ shown in Figure 6.8 was 
imported from SOPHARM, which in turn integrates information from the ChEBI 
ontology. As a result, in this CM an ‘Active Ingredient’ is a subclass of one or more 
‘Drug Class’, which are subclasses of the top-level class ‘Drug’. 
Besides drugs, other object entities are relevant in the DDI domain. Drug metabolites 
(or the molecules produced as the consequence of the metabolism of a drug in the body) 
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are represented only in DIO and DIKB. The reason is that these two works focus on the 
representation of the processes that alter the metabolism of drugs. Therefore, metabolites 
are key concepts in their models. Another important object in the DDI domain is 
‘Proteins’, since they are involved in the mechanisms – both PD and PK – of most DDIs. 
In spite of this, they are represented only in three of the reviewed models. DIO represents 
‘Enzymes’, ‘Transporters’ and ‘Albumins’ as three different types of proteins. 
Meanwhile, ‘Enzymes’ is the unique type represented in the DIKB CM. Finally, the 
PKO represents ‘Metabolizing Enzymes’, ‘Transporters’, and ‘Targets’. 
Regarding the representation of DDIs, we have observed that the concept of a DDI is 
only explicitly represented in four CMs. NDF-RT and Mille and Rubrichi’s CMs use the 
concept DDI as the central class in their models, while the DIKB represents it as the 
relationship ‘metabolic inhibition interaction’, which explicitly represents an interaction 
between two different drugs. The CMs created by Mille and Rubrichi represent the 
relationships between a DDI and other related aspects (risk factors, mechanism, effect, 
etc.). In contrast to them, NDF-RT includes only the relationship between a DDI and the 
two interacting drugs. In spite of their differences, the four of them share a binary 
representation of the DDI. In other words, all the models that explicitly describe a DDI 
consider that it involves exactly two entities. In this way, an interaction is described to 
occur in DIKB’s model between a precipitant and an object drugs. NDF-RT and Mille’s 
CMs specify that an interaction occur between two drugs. In contrast, the CM developed 
by Rubrichi asserts that an interaction occurs between two drugs or between a drug and a 
group of drugs, a drug and a diagnostic test, or a drug and a different substance. 
Another important difference between the seven projects is that only two of them 
(Mille and Rubrichi’s CMs) have attempted a global representation of the DDI domain, 
while the other five focus on some concrete aspect, providing a partial representation of 
the domain. Specifically, the PDO has focused on the representation of drug-molecule 
interactions that lead to different PD processes in the body, and how they are related to 
drugs, pharmacological effects, and the consequent physiological effect. This information 
is useful to represent the underlying processes altered in a PD DDI.  In a similar way, but 
focusing on PK instead of PD processes, DIO represents drug PK processes and their 
relationships with drugs, metabolites, and proteins, providing a representation of those 
processes that can be altered in a PK DDI. Meanwhile, the DIKB model shows how one 
of these specific processes (i.e., metabolism) is altered in a PK DDI caused by the 
inhibition of a metabolic enzyme. This model includes the different drug characteristics 
that influence or determine the significance of a DDI. Meanwhile, the PKO’s CM does 
not focus on the representation of DDI mechanisms as the ones described before, but on 
the representation of PK DDI studies and their components. Finally, as mentioned before, 
NDF-RT focuses only on the representation of the relationship between a DDI and the 
two interacting drugs.  
Up to now, we have focused on the study and comparison of relevant objects in the 
DDI domain that are represented in some of the seven reviewed CMs. However, 
processes and qualities are important concepts that have been represented, too. We have 
identified four main types of processes and/or qualities related to the DDI domain and 
included in some of these models: the effect of the DDI, its mechanism, factors that can 
increase the risk or severity of the DDI, and measures to avoid or manage the DDI. 
The consequence or effect occurring as a result of a DDI is only represented in the 
CMs created for the global representation of the DDI domain (Mille and Rubrichi’s 
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CMs). However, they represent the concept at a very high level of granularity, and 
specializations of the different types of consequences of a DDI are not detailed. In 
contrast, DIKB’s CM does not represent this effect of a DDI as a class, but as 
relationships between different drugs. These relationships represent that a drug can alter 
the clearance of another drug – there is a change in the metabolism of the drug and 
therefore an alteration in its global clearance or elimination from the body (‘inhibit 
metabolic clearance’) – or that a drug can alter the exposure or concentration of the other 
drug in the body (‘increase drug exposure’). 
Mechanism, or the process that leads to the occurrence of a DDI, is represented as a 
class only in the CM created by Mille, while it is not included in the one created by 
Rubrichi. In the same fashion that it represents effects, DIKB’s CM represents DDI 
mechanisms as relationships between two different drugs and an enzyme (e.g., the 
precipitant drug ‘inhibits’ an enzyme while the object drug ‘is substrate of’ the same 
enzyme). PK processes and PK parameters can be altered in a PK DDI mechanism. They 
are represented in DIO and the PKO, respectively. In contrast, DIKB’s CM represents 
only the PK process metabolism. In the same way that PK processes are altered in PK 
DDIs, PD processes and pharmacological effects are altered by a PD DDI mechanism, 
and are represented in the PDO. 
There are different ways to avoid or manage a DDI (Lea, Rognan, Koristovic, 
Wyller, & Molden, 2013). However, only Mille and Rubrichi’s CMs introduce this 
concept, although without a deep level of detail (‘Precaution of Use’ and ‘Recovering 
Action’, respectively). Factors that can increase the severity of a DDI are represented 
only in three models. Mille’s CM includes patient-related factors, while the DIKB 
represents some of the most important drug-related features that can influence the 
severity of a DDI. In contrast, Rubrichi’s model considers both patient and drug related 
factors. 
Finally, we have compared how the authors implemented their different CMs. 
Rubrichi’s CM, DIO and the PKO were implemented as OWL ontologies. The DIKB 
represented the model as a set of rules in FOL, while Mille’s CM was used to build an 
XML schema. The public release version of NDF-RT is available in several forms that 
include XML and OWL formats.25 Finally, the PDO has not been implemented yet.  
To conclude, we provide a summary of the results in Table 6.1. In addition to this, in 
Annex 1 we compare the concepts included in each one of the reviewed CMs, and 
contrast them with the CM in our ontology DINTO (Section 7.1.3). 
6.4 Discussion 
In the last ten years, there have been different projects that have required the 
conceptualization of DDI-related knowledge. The CMs created by these research groups 
have been developed independently and from scratch and, since each one of them was 
created with different purposes, there is not a high degree of overlapping among them. 
                                                 
25 http://www.cancer.gov/cancertopics/cancerlibrary/terminologyresources/fmt 
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The result is a group of different isolated CMs dealing with the representation of different 
aspects of the same domain.  
The two closest works are Mille and Rubrichi’s CMs, which were developed to be 
used in NLP and have been applied to the annotation of texts. These CMs share a wide 
coverage of the DDI domain, but with a very low level of detail. Although their structure 
is similar, there are some differences between them. In this way, Rubrichi’s CM does not 
represent the concept of mechanism while side effects or pharmaceutical characteristics 
of drugs are not included in Mille’s one. Therefore, both are complementary to each other 
and could be combined to provide a more comprehensive view of general aspects related 
to the DDI domain. Another work created for NLP tasks is the PKO. The main difference 
between this model and the two previous ones in that it was designed to describe only PK 
DDI studies and therefore it does not overlap with them. 
The other main application of DDI-related CMs has been the prediction of DDIs on 
the basis of their mechanisms. Three different CMs have demonstrated that the formal 
representation of DDI knowledge can be used successfully to infer or predict interactions 
between specific pairs of drugs. The larger prediction experiment was developed in the 
framework of the DIKB project that predicted PK DDIs occurring by enzymatic 
metabolism inhibition for over 60 drugs. In contrast, the model proposed in DIO was 
used to detect PK DDIs between a specific pair of drugs (irinotecan and ketoconazole). 
Although the evaluation was limited to only one pair of drugs, they identified through 
this model four different processes or DDI mechanisms that could explain the DDI 
between these two drugs. This detailed description of how a PK DDI may occur is 
important and consistent with the pharmacological fact that most DDIs are caused not by 
a single mechanism, but often by two or more mechanisms acting in concert (Baxter, 
2013). In a similar way, the CM implemented as the PDO was used to identify the 
different sub-processes involved in the interactions between drugs participating in the 
same signal transduction process, leading to the identification of different types of PD 
DDI mechanisms. 
Contrary to NLP intended models, CMs used to predict DDIs have in common that 
they focus on a specific aspect of the DDI-related knowledge and model it in detail. 
Consequently, the number of classes in these CMs is larger than in the former ones. 
However, these three CMs have important differences in their scopes. As mentioned 
before, the DIKB model is more specific, since it focuses only on one particular PK DDI 
mechanism. In contrast, the PKO and the PDO cover PK and PD processes, respectively, 
and any DDI mechanism is explicitly represented. The level of detail in which PD and 
PK processes are represented is similar in both models. Therefore, they could be 
considered as complementary to each other. 
However, although these three models proved that they could be used to correctly 
predict DDIs between pairs of drugs, their use in a final system, such as a CDSS for DDI 
alerts, is limited because they rely on the availability of explicit information for every 
individual drug or drug-related facts according to the CM. For example, to be able to 
predict the interaction between two drugs (e.g., irinotecan and ketoconazole) following 
the CM represented in the DIKB project, it is necessary to know that irinotecan is a 
substrate of the enzyme CYP3A4 and that ketoconazole inhibits this enzyme. Also, it is 
required in this model as well to establish if this is the main clearance route for irinotecan 
or not, and if the drug has narrow therapeutic index or if either is a sensitive substrate. In 
the case of DIO, it is necessary to know, as well, where every process occurs (e.g., in the 
 104 
 
liver, a vein, an artery, etc.). Meanwhile, the PDO requires explicit knowledge about how 
a drug acts in a specific signal transduction process (and its sub-processes), and how it is 
related to causal chains of physiological states that lead to the physiological response. 
Therefore, as the degree of detail of the CM increases, the number of necessary drug-
related facts increases, too. The discussed projects identified and gathered these required 
drug-related facts through manual search of the literature.  However, manual curation is a 
highly time-consuming and expensive task and, as a consequence, the models could be 
applied only for a reduce set of drugs. Moreover, new drug-related facts are discovered 
every day and published in the scientific literature (Hunter & Cohen, 2006). Therefore, 
keeping up to date a system for DDI identification that relies on these CMs would be a 
challenging task. 
An alternative to manual curation of drug-related facts could be to exploit the 
increasing pharmacological knowledge stored in structured and machine-readable formats 
in public pharmacological databases and knowledge bases (Khelashvili et al., 2010; 
Whirl-Carrillo et al., 2012) A new approach for the efficient and sustainable prediction of 
DDIs could be the design of CMs that support DDI prediction on the basis of their 
mechanisms, taking into account the availability of structured pharmacological 
information that can be exploited automatically. This method would lead to less detailed 
CMs that, nevertheless, would be able to predict DDIs for larger sets of drugs. 
The aim of this thesis is to create an ontology that provides a complete representation 
of the DDI domain and that, at the same time, describes in a comprehensive way all the 
different aspects of DDIs mentioned in pharmacological text. During the annotation and 
analysis of the DDI corpus (see Section 3.1), we observed that DDIs are mentioned in 
multiple ways: describing how the interaction occurs, through the relations of two 
different drugs with the same protein, as a contraindication, as the effect of the DDI, and 
so forth.  Therefore, the CM of an ontology useful for extracting DDIs from text should 
have a global scope of the DDI domain with a deep degree of detail, at the same time. In 
addition to this, inference of DDIs requires a detailed representation of all different 
pharmacological processes leading to different types of PK and PD DDIs. These 
characteristics, however, are not met by models described in this review. On the one 
hand, CMs created by Mille and Rubrichi are designed at a too high level of abstraction. 
Therefore, different types of DDI mechanism, effects, or risk factors are not represented. 
On the other hand, DIKB’s model focuses only on one of the many PK DDI mechanisms 
that can lead to DDIs, while the PDO and DIO describe pharmacological processes, but 
not explicitly DDI mechanisms. Finally, the PKO focuses on the representation of PK 
studies, and do not meet the requirements described before.  
Consequently, the creation of our ontology requires the design of a new CM 
representing, in an appropriate degree of detail, all DDI-related knowledge. Nevertheless, 
current efforts described in this review will be considered and adopted when appropriate, 
as a way of gathering consensual knowledge regarding the formal representation of DDI 
knowledge. 
  
 
 DIO DIKB Mille NDF-RT Rubrichi PDO PKO 
Year 2004 2005-2007 2007  2012 2013 2013 
Intention Modeling  of drug-
biomolecule 
interactions 
Prediction of 
DDIs 
Development 
of Clinical 
Decision 
Support 
Systems 
Modeling of 
drug related 
information 
Automatic 
information 
extraction 
from texts 
(NLP) 
Prediction 
of DDIs 
Annotation 
and 
extraction 
of DDIs 
from text 
(NLP) 
Representation of 
DDI in the CM 
No Yes Yes Yes Yes No No 
Main application Prediction of PK 
DDIs 
Prediction of 
PK DDIs 
Encoding of 
textual 
documents 
Support of 
computerized 
systems 
Annotation 
of text 
Prediction 
of PD 
DDIs 
Annotation 
of text 
Intentional scope Partial Partial Global Partial Global Partial Partial 
Degree of 
deepness/detail 
Detailed Detailed Shallow Shallow Shallow Detailed Detailed 
Knowledge source - Lectures and 
class notes of 
a graduate 
class on drug 
interactions 
DDI 
monographs 
- SPCs - Textbooks 
and 
literature 
sources 
Implementation 
Language 
OWL FOL XML DL (and 
OWL) 
OWL OWL OWL 
Table 6.1. Results of the comparison of the seven different conceptual models 
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6.5 Unresolved issues 
Current efforts in modeling DDI-knowledge represent a significant contribution to 
the state of the art in this research area. However, some limitations should be still 
addressed to create a comprehensive CM for the DDI domain.   
1. Current CMs do not provide, at the same time, a wide and detailed enough 
representation of the DDI domain, which would entail their use in different 
applications, such as NLP tasks and inference of DDIs. 
2. The CMs created for NLP applications provide a global representation of the 
domain, but with a low level of detail. Therefore, their application to IE tasks 
has been limited to encoding and manual annotation of text. However, their 
performance in extraction of DDIs from text, such as scientific abstracts, has 
not been evaluated. 
3. CMs for prediction of DDIs provide a detailed representation of 
pharmacological processes leading to DDIs. However, they rely on manual 
curation of drug-related facts to be used in inference of DDIs, which restricts 
the number of drugs included in the evaluations and makes it difficult to update 
new information.   
4. There are two main types of mechanisms leading to DDIs: PK and PD DDI 
mechanisms. However, current CMs have not represented both of them in the 
same framework. Therefore, applications relying on these CMs must focus 
only on one type of DDIs, PK or PD DDIs, but not on both of them at the same 
time. 
5. There are different subtypes of PK and PD DDIs. However, current CMs have 
focused only on some of these subtypes, and there is not a comprehensive 
representation of all of them in any CM.  
6. The possible effects of a DDI (e.g., beneficial or harmful, clinically relevant or 
non-clinically relevant effect) have not been represented in the reviewed CMs.  
7. Proteins are relevant substances in DDIs, since they are involved in most DDI 
mechanisms. However, they have been poorly represented in current CMs, and 
their relationships with different drugs have not been represented in detail. 
8. The different strategies to avoid or manage DDIs have not been represented in 
detail in these CMs. 
9. Drug and patient-related factors affecting DDIs are not comprehensively 
included in the reviewed CMs. 
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The new CM in our ontology for DDI knowledge will attempt to cover each of the 
unresolved issues described in the above list. 
6.6 Conclusions 
In this review, we have provided an integrated view of current efforts for the 
representation of DDI knowledge. These CMs have been used for two main applications: 
NLP of pharmacological texts and inference of DDIs. Models created for NLP require a 
global representation of the DDI domain, while models applied to DDI inference need a 
more detailed representation.  These projects have shown that formal representation of 
DDI knowledge can be used successfully in both NLP and prediction of DDIs on the 
basis of their mechanisms. However, they have not been used in DDI extraction from 
text, and the number of drugs included in the inference experiments has been determined 
by the required manual cuaration of drug-related facts. For better performance in IE tasks, 
it is necessary that future CMs combine a global scope of the DDI domain and deeper 
level of detail of the concepts and relationships included in the representation. At the 
same time, we believe that inference of DDIs on a large scale requires the creation of 
models that do not strongly rely on manually curated drug-facts, but which could exploit 
existing computerized drug information sources. Based on these conclusions, we develop 
the conceptualization of our ontology, which is described in Section 7.1.3. 
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Chapter 7 
The Drug-Drug Interactions 
Ontology: DINTO 
As we have seen in previous chapters, there is any ontology representing, in a 
comprehensive way, all of the information related to the DDI domain. Therefore, in this 
thesis we propose the construction of a new ontology, the Drug-Drug Interactions 
Ontology (DINTO). This chapter details in Section 7.1 the process of building the 
ontology, and the resulting ontology is described in Section 7.2. 
7.1 Building the ontology 
There are different approaches for building ontologies that can be divided into two 
main categories: constructing the ontology from scratch and reusing other ontologies. On 
the one hand, the creation of an ontology from scratch implies the design of the 
ontological structure without any general or reference model (Cristani & Cuel, 2004). It is 
generally carried out manually and the ontologists need to identify the concepts in the 
domain and the relationships between them, and implement the ontology in a machine-
readable format. On the other hand, reusing ontologies is becoming a relevant process in 
ontology engineering, mainly due to the increasing amount of available resources 
(Simperl, 2009). This approach enables the interoperability among existing ontologies 
and avoids the duplicity of efforts and content overlap between them.  
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The creation of an ontology is a complex and time consuming task. As a 
consequence, semi-automatic approaches have been used for the partial automation of the 
ontology development process (Gómez-Pérez, Fernández-López, & Corcho, 2004). The 
main contribution of these approaches is the reduction of the efforts required during 
knowledge acquisition (KA), one of the most time and resource-consuming activities in 
the development of an ontology  (Payne, Mendonça, Johnson, & Starren, 2007). This 
automated ontology construction, named ontology learning, is based on natural language 
analysis and machine learning techniques (Gómez-Pérez & Manzano-Macho, 2003). 
Therefore, the main limitation of this approach is that it is strongly dependent on the 
employed technique and the selected data source. Consequently, an extensive verification 
of the final ontology is required to ensure its quality. 
These different approaches can be used in combination. For example, the general 
structure of an ontology can be manually developed from scratch in the first steps, while 
information gathered in other ontologies is reused subsequently (Suárez-Figueroa, 
Gómez-Pérez, & Fernández-López, 2012). In the same way, a manually created ontology 
can be populated later through NLP techniques (Rubrichi et al., 2013). 
Once the most appropriate approaches have been identified, following a method 
defining what specific activities and the order in which they should be carried out can be 
useful in performing the task of ontology creation (Uschold, 1996).  Different researchers 
have proposed methods for building ontologies, with the aim to provide guides that help 
ontologists in the development of a new ontology, and different authors have studied and 
reviewed them. A new analysis of all of them is out of the scope of this chapter. 
However, interested readers can find in Gómez-Pérez et al. (2004) a comprehensive 
review and comparison of classical methodologies and methods for building ontologies 
from scratch or by reusing other ontologies – including a review of ontology learning 
methods. 
For the creation of DINTO, we require starting the development process from 
scratch, since, as we have seen in Chapter 5 and Chapter 6, no existing ontologies have 
dealt with a comprehensive representation of the DDI domain. However, some relevant 
information might be found in other ontologies and databases. Therefore, we need to 
integrate information from different resources, too. To the best of our knowledge, the 
methodology that best fits these requirements is the Neon Methodology (Suárez-Figueroa 
et al., 2012), developed by the Ontology Engineering Group at “Universidad Politécnica 
de Madrid”.26 This methodology focuses on ontology engineering by reuse and supports 
different aspects of the ontology development process. It encompasses, as well, a 
previous work by the same research group: the methodology for building ontologies from 
scratch METHONTOLOGY (Fernández-López, Gómez-Pérez, & Juristo, 1997). 
                                                 
26 http://www.oeg-upm.net/ 
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Figure 7.1. Neon Methodology (from Suárez-Figueroa et al., 2012) 
The Neon Methodology proposes a variety of pathways for developing ontologies or 
scenarios which cover commonly occurring situations. Figure 7.1, originally published in 
(Suárez-Figueroa et al., 2012), represents them. Scenario 1, which describes the different 
activities required for the creation of an ontology from scratch, and the Ontology Support 
Activities (shown in the light blue box at the bottom of the figure) have been previously 
described in the framework of METHONTOLOGY. It proposes an iterative process 
where the different activities are not intended to be carried out in a sequential way.  
Below, we provide a description of the most important activities developed during 
the construction of DINTO: 1) specification, 2) knowledge acquisition, 3) 
conceptualization, 4) implementation, 5) ontological resources reuse, 6) non-ontological 
resources reuse, 7) creation of rules for inference of DDIs, and 8) maintenance. The 
support activity “evaluation” is not included in this section, since it is described in detail 
in Chapter 8, Chapter 9, and Chapter 10. 
7.1.1 Ontology specification 
The aim of the specification activity is “to state why the ontology is being built, what 
its intended uses are, who the end users are, and which requirements the ontology should 
fulfil” (Suárez-Figueroa, Gómez-Pérez, & Villazón-Terrazas, 2009). The output of this 
activity is the ontology requirements specification document (ORSD), which describes 
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the purpose, scope, and intended users and scenarios of the ontology. It also includes a 
series of competency questions (CQs), or natural language questions representing the 
aspects that the final ontology should address, such as “Is the effect of DrugA modified by 
DrugB?” or “Is there a PK interaction between DrugA and DrugB?” 
We have defined the ontological requirements for a comprehensive ontology that 
should represent all the information related to the DDI domain, and that should be 
mapped to other ontologies. It is primarily intended to be used by text miners and 
software developers, although we anticipate that it may find additional use amongst 
domain experts once it is further developed. For a successful application in NLP, 
concepts in the ontology should include alternative terms representing every different 
terminological variation (lemmas, synonyms, abbreviations) and should include semantic 
relationships characteristics of the domain, which is the input to the RE task, for example, 
based on patterns (Lönneker, 2003). On the other hand, the ontology might be used by the 
computational community working on applications within the DDI domain, such as the 
development of CDSS or signal detection systems in pharmacovigilance. For this 
purpose, the ontology must include known DDIs, and allow the inference of new ones on 
the basis of their mechanisms. 
In order to ensure reusability of our ontology, we establish as a requirement that the 
ontology must follow the OBO Foundry recommendations for building ontologies (Smith 
et al., 2007). The OBO Foundry is a collaborative effort for the development and 
maintenance of biomedical ontologies, which aims to ensure their integration and 
interoperability through the establishment of a set of principles that are voluntarily 
accepted by its participants (see Section 8.1.3). 
The CQs identified in this activity are in turn used as a type of requirement 
specification and evaluation for the finished ontology (see Section 8.1.2). The ORSD 
resulting from this activity is shown in Annex 2. 
7.1.2 Knowledge Acquisition 
The knowledge acquisition (KA) activity consists in capturing the knowledge of the 
domain that should be represented in the ontology. This activity is considered in Neon 
Methodology as a support activity that is coincident with other ones. Specifically, the 
effort on KA is greater during the specification and conceptualization activities, and 
decreases during formalization and implementation (Gómez-Pérez et al., 2004).  
There are many different knowledge sources from which the domain knowledge can 
be extracted - domain experts, scientific literature, books, or even other ontologies - and 
different techniques that can be used to elucidate the knowledge from them - interviews 
with experts, brainstorming, informal and formal analysis of texts, or use of knowledge 
acquisition tools (Fernández-López et al., 1997). During our review of current approaches 
for modeling the DDI domain (see Chapter 6), we have observed that most projects 
acquired the domain knowledge from different textual sources: lectures and class notes of 
a graduate class on drug interactions (Boyce et al., 2007), textbooks and literature sources 
(Wu et al., 2013), DDI monographs (Mille et al., 2007), and Summaries of Products 
Characteristics (SPCs) (Rubrichi & Quaglini, 2012). Therefore, it seems that the study of 
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DDI-related texts has proven to be a useful source for the elicitation of this domain 
knowledge. This fact agrees with the theory of sublanguages proposed by Zelling Harris 
(Harris, 1982, 1991), who proposed that the languages of technical domains, such as the 
biomedical, have a limited number of words and possible relationships between them, 
and a structure and regularity that can be observed by examining the corpora of the 
domain and which can be represented in a form suitable for computation (Friedman, Kra, 
& Rzhetsky, 2002).   
According to this, we have selected the previously created DDI corpus as the most 
appropriate resource for KA in the creation of DINTO (Herrero-Zazo, Segura-Bedmar, 
Martínez, et al., 2013). This corpus collects documents from different sources (the 
database DrugBank and scientific abstracts from MEDLINE), which provide a global 
coverage of the DDI domain and descriptions at different levels of detail. Hence, the 
corpus has been previously annotated with different types of DDIs, which enables the 
study of different aspects of the domain (e.g., the manner in which the interaction occurs, 
the effects of the DDI or the different recommendations for avoiding a DDI). An 
additional advantage of using the DDI corpus is that it is available in XML format and 
can be used by different tools that support text analysis, facilitating the examination of 
this large set of documents.  
The final goal of the analysis of the corpus is to identify relevant concepts in the DDI 
domain and the different relationships that can be established between them. Then, these 
concepts and relationships are represented in a CM and implemented in the final 
ontology. However, the corpus includes a large number of documents and sentences, 
where usually different terms refer to the same concept, or different patterns describe the 
same relationship.  
Corpus linguistic techniques and tools can be useful to analyze such a large textual 
information source, since they allow for the reliable and exhaustive analysis of text. In 
this project, we have employed two different strategies. The first one is linguistic pattern 
analysis, which allows identifying the relevant concepts in the domain and the different 
terms used to describe them. The second one is word frequency and concordance 
analyses, which are performed to identify the terms most commonly used in the texts, and 
the different relationships that are established among them. These two approaches are 
described below, along with other general information sources and ontologies also used 
in this KA activity. 
 Linguistic pattern analysis 
The first step in KA is to identify the relevant concepts in the domain, which are 
organized subsequently into taxonomies. The complexity of the DDI domain leads to a 
large number of different concepts, and a huge body of different terms referring to them. 
Their identification can be difficult due to linguistic aspects such as ambiguity, nested 
terms, or coordinate structures (see Section 3.4).  However, corpus linguistic tools can be 
useful, since they support the annotation of sentences and the subsequent analysis of the 
annotated segments.   
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In this project, we use the UAM Corpus tool27, a free environment enabling the 
annotation of selected segments in the corpus with various features or labels. First, we 
create an initial label-schema list representing the main general concepts in the domain, 
such as ‘PK Mechanism’ or ‘Study Subject’. Secondly, the documents in the DDI corpus 
are read, and terms or groups of terms are annotated. The list is iteratively refined during 
the progress of the analysis, when new concepts are identified. The complete annotation 
label-schema list is shown in Annex 3. 
When the desired texts have been annotated, the tool retrieves the segments 
annotated with the same label, which can be studied for the identification of linguistic 
patterns or refinement of the annotation. The most important conclusions of our analysis 
refer to the description of DDI mechanisms and DDI effects in text, which are described 
in detail below. 
- Description of DDI mechanisms in text: 
The analysis of sentences annotated in the DDI corpus as type ‘Mechanism’ (i.e., 
sentences that describe how an interaction occurs) leads to the identification of important 
concepts and the relationships between them expressed in text. Here, we summarize the 
most relevant conclusions. 
1. The mechanism of a PK DDI – or how a PK DDI occurs - is expressed as the 
alteration in a PK process: e.g., “increases the absorption of”, “altered the 
metabolism of”. 
2. The consequence of a PK DDI mechanism is expressed as the alteration in a PK 
parameter or in the levels or concentrations of the drug: e.g., “an increase in the 
AUC”, “has been described to increase the mean half-life”, “decreases the levels 
of”. 
3. There are consequences of a PK DDI mechanism that can be caused by the 
alteration of several PK processes. Therefore, it is not possible to establish a 
causal relation between that consequence and a mechanism: e.g., the 
consequence “increases the levels of” can be caused by an increase in the 
absorption, an alteration in the distribution, or a decrease in the metabolism or 
elimination of the drug. 
4. Mentions of metabolites are frequently related to DDIs occurring via a PK 
mechanism: e.g., “MetaboliteA can be formed with concurrent ingestion of 
DrugA and DrugB”. 
5. There are some mechanisms that can lead to unpredictable DDI effects: e.g., 
“Since DrugA may reduce the gastrointestinal absorption of both DrugB and 
vitamin K, the net effects are unpredictable”. 
6. Some terms used in the pharmacological domain to describe PD mechanisms 
(antagonism, synergism, potentiation, etc.) can be used in texts to describe a PK 
                                                 
27 http://www.wagsoft.com/CorpusTool/ 
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mechanism: e.g., “DrugA may potentiate the action of DrugB by inhibiting its 
metabolism”. 
7. Numerical values are usually used when describing DDIs occurring by a PK 
DDI mechanism: e.g., “resulted in an approximately 60% increase in the AUC”. 
- Description of DDI effects in texts: 
During the analysis of annotated segments in the corpus labelled as 
‘Pharmacodynamic Effect of a Drug’, we identified five main ways a clinical 
consequence of a DDI can be described:  
1. The effect of a DDI is the effect of a drug: e.g., “increase the adrenergic effect 
of”, “reduced the action of”.  
2. The effect of a DDI refers to a negative effect of a drug: e.g., “the adverse effect 
of”, “the ototoxic potential of”.  
3. The effect of a DDI refers to the clinical manifestations, generally related to an 
ADR without explicitly relating them with a drug: e.g., “serious reactions such 
as rigidity, myoclonus, or autonomic instability”.  
4. The effect of the DDI provides information related to some aspect of the DDI: 
e.g., “additive CNS depressant effect”, “observed an excessive reduction of 
blood pressure”. 
5. The effect is expressed through a modification in some analytical test result: e.g. 
“increase in prothrombin time”. 
All this knowledge is used during the next activity, conceptualization of the domain. 
Besides the identification of relevant concepts, it enables the identification of 
relationships between them in an accurate way, such as that the consequence of a DDI 
(the ‘DDI Effect’) is a special type of effect caused by a drug, and therefore, should be 
represented as a subclass of the concept ‘Drug Effect’; or that a ‘PK DDI Mechanism’ is 
always related to one or more ‘PK Process’, and therefore, a specific relationship between 
them should be represented in the ontology. 
It is worthy to note that, in contrast to the annotation of the DDI corpus, this exercise 
does not have the final aim to provide an annotated document. As we have explained in 
this section, the objective is to support the analysis and labelling of sentences to provide 
insights in how information is described in texts, and to identify relevant concepts and 
relationships in the domain. The gained knowledge is later represented in intermediate 
conceptual models and implemented in an ontology. Therefore, annotation of the 
complete corpus or the creation of annotation guidelines is not necessary. 
 Frequency and concordance analysis 
The second approach for the analysis of the DDI corpus is word frequency and 
concordance analyses. The aim is to identify the terms most commonly used in the DDI 
 116 
 
corpus, and then analyze their use in context to identify their relationships with other 
terms and concepts. To this purpose, we use the freeware AntConC28 corpus analysis 
toolkit, which has been previously used in KA for the construction of biomedical 
ontologies (Mendonça, Coelho, Andrade, & Almeida, 2012). 
We perform a word frequency analysis to identify the occurrences of words in the 
1,017 documents forming the whole DDI corpus. We use a stoplist to filter out words that 
are not relevant to this study, such as pronouns or prepositions. The final list includes 
90,382 words distributed over 6,842 word types. Since we are not interested in 
identifying different drug names (e.g., paracetamol, ciprofloxacin, Gelocatil®, etc.), we 
substitute them by the words druglabel, grouplabel, and brandlabel, following the 
manual annotation of the DDI corpus as drug, group, or brand entity types, 
respectively. Using these labels, we can generalize the linguistic patterns and focus on the 
study of other concepts. Indeed, the three most frequent words correspond to these three 
different groups of drug names. We review the 2,436 most frequent types of words, 
excluding those terms that are found in the corpus only once, twice, or three times. This 
list is used then to identify and represent relevant concepts in the conceptualization 
activity.  
In addition to the word frequency analysis, and in order to study how different 
concepts relate to each other in the domain, we conduct a concordance analysis of 
relevant terms. During the linguistic pattern analyses, we have observed that most DDIs 
are expressed through the modification of an effect, PK process, or PK parameter. 
Therefore, we identify the terms used to describe a modification or alteration (increase, 
decrease, potentiation, etc.) and analyze the concepts in the domain that are usually 
related to them. For example, the concept enhanc* can be used with terms labelled as ‘PK 
Parameter’, ‘PK Process’, ‘Effect’, or ‘Toxicity’; however, the term elevat* is only used 
in our corpus with terms labelled as ‘Concentration’ and ‘PK Parameter’. This knowledge 
is used to establish relationships between concepts in the conceptualization activity. The 
complete analysis is shown in Annex 4. 
 General pharmacological information sources and ontologies in KA 
Another important source of information is provided by other ontologies that can 
potentially be reused and imported into DINTO. As a first step, we have reviewed in 
Chapter 5 those different ontologies relevant to the DDI domain. The final selected 
ontologies and the way in which they are reused in DINTO is described in Section 7.1.5.  
Finally, different pharmacological sources have been used as a source of information 
and support during the creation of this ontology, including drug interaction compendia 
(Baxter, 2013; Hansten, 2003; Tatro, 2010), pharmacology books (Levine, Walsh, & 
Schwartz-Bloom, 2005; Sweetman & Martindale, 2006), and specialized publications 
(DuBuske, 2005; Huang et al., 2008; Olvey, Clauschee, & Malone, 2010b; Zhang, 
Reynolds, Zhao, & Huang, 2010; Zhou et al., 2005), among many others. 
 
                                                 
28 http://www.antlab.sci.waseda.ac.jp/ 
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7.1.3 Conceptualization 
This activity consists in capturing the different concepts relevant to the domain and 
their relationships in a graphical representation called conceptual model (CM) (Olivié, 
2007). We have designed a CM for DINTO that reuses and integrates information 
currently available in public information resources, such as chemical entities and roles 
from the ChEBI ontology (Degtyarenko et al., 2008) and drug-protein relationships from 
the database DrugBank (Knox et al., 2011), among others. Therefore, with this approach 
the development of our CM is driven by the combination of both the requirements of the 
final application and the information available to be imported into the ontology. 
In this section, we describe the conceptualization of DINTO depicted in relevant 
aspects within the DDI domain. We describe why that specific information should be 
included in an ontology for DDIs and how we have conceptualised the knowledge. The 
CMs are represented following the common representation framework in UML class 
diagrams explained in Section 6.1. A global view of the final CM is shown in Figure 7.2. 
Due to the lack of space, this figure does not include all classes, relationships, and 
attributes in the ontology, and the model has been simplified. However, this 
representation and the partial CMs shown in this section, provide a detailed description of 
the conceptualization of DINTO. 
 Chemical entities, pharmacological entities, and protein entities: 
A comprehensive representation of the DDI domain requires the inclusion in the CM 
of drugs and proteins, all of them represented as classes. Drugs are imported into DINTO 
from the ChEBI ontology (Degtyarenko et al., 2008), which represents chemical entities 
with small molecular weight as subclasses of the top-class level ‘chemical entity’. 
Proteins are also chemical entities, but with high molecular weight and, therefore, they 
are not included in ChEBI.  
In our CM, we represent this knowledge by creating a new class ‘pharmacological 
entity’, which is the parent class of all imported drugs, independently of their nature. The 
class ‘pharmacological entity’ is defined as “a chemical entity which possesses some 
pharmacological activity. Therefore, it has the capacity to interact within a biological 
system and to produce a physiological effect”.  
We have mentioned several times in this thesis that the term “drug” is used with 
different meanings, which are important from an ontological point of view. Following the 
conceptualization adopted in ChEBI, we consider that the class ‘drug’ is a role, that is, a 
particular behaviour that some entity can exhibit. Therefore, in our ontology there are not 
“drugs” but chemical entities that can exhibit some drug-related role. When we refer to 
these classes in this text, we use the term ‘pharmacological entity’, which is the specific 
class that we have created to list all of them, and to distinguish them from other chemical 
entities such as proteins. In contrast, when referring to the concept of drugs independently 
of any ontological representation, we continue using simply the term “drug”. 
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Figure 7.2. Simplified conceptual model representing the main classes and 
relationships in DINTO 
The CM showing the hierarchy for chemical entities is shown in Figure 7.3. It 
includes an important aspect that is frequently mentioned in DDI texts: the concentration 
of a drug in the body. As shown in the figure, it is represented in the CM as an attribute 
of the class ‘pharmacological entity’.  
 Role 
We have said that a role is the different behaviour that a material entity can exhibit, 
such as ‘drug’, ‘anti-allergic agent’, or ‘hepatotoxic agent’. These roles are important to 
describe the activity of pharmacological entities and are imported from ChEBI (Figure 
7.4). There are three roles that a ‘pharmacological entity’ can exhibit in a DDI and that 
have been manually added to this hierarchy: ‘participant’, ‘precipitant’, and ‘object’. A 
DDI involves two participants; the one that leads to the interaction is the precipitant or 
perpetrator drug, while that one which effect or levels are altered because of the DDI is 
the object or victim. 
 119 
 
 
 
 
Figure 7.3. Conceptual model representing the hierarchy for chemical entities in DINTO. 
Classes imported from the ChEBI ontology are labelled as [CHEBI]. Shaded boxes 
represent classes with additional subclasses. 
 
 
 
 
 
Figure 7.4. Conceptual Model representing the hierarchy for roles in DINTO. Classes 
imported from the ChEBI ontology are labelled as [CHEBI]. Shaded boxes represent 
classes with additional subclasses. 
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From an ontological point of view, a drug such as paracetamol, cannot be said “to 
be” a precipitant, for example. Paracetamol is a chemical entity that, under certain 
circumstances, can exhibit a role precipitant when it participates in a DDI. Therefore, 
paracetamol is a subclass of the anonymous class shown below: 
‘pharmacological entity’ and ‘has role’ some ‘precipitant’ 
That is, ‘paracetamol’ is a ‘pharmacological entity’ that fulfils the condition of 
having a ‘has role’ relationship with the class ‘precipitant’. Therefore, a DDI does not 
have a participant and an object drugs, but a ‘pharmacological entity’ with a ‘participant’ 
role and a ‘pharmacological entity’ with an ‘object’ role, as shown in Figure 7.5. 
 
Figure 7.5. Conceptual model representing the roles ‘participant’, ‘precipitant’, 
and ‘object’ in DINTO. Shaded boxes represent classes with additional 
subclasses. 
 DDI Mechanism: 
A very important aspect of DDI-related information is how the interaction occurs. 
This information is crucial in the study, understanding, and management of DDIs. For 
example, knowing how an interaction occurs enables the prediction of the possible 
consequences of the DDI (e.g., the increase in the toxicity of a drug due to a decrease in 
its enzymatic metabolism) or to identify possible therapeutic alternatives (e.g., the 
selection of a related drug that does not inhibit that specific enzyme). 
The process leading to a DDI is the DDI mechanism. DDIs are broadly classified in 
two main groups by their mechanisms: pharmacokinetic (PK) and pharmacodynamic 
(PD) DDIs. A PK mechanism occurs when one drug affects some PK process of the other 
drug leading to an alteration of the levels of the drug in the body. On the other hand, a PD 
mechanism occurs when one drug alters the effects of another drug without altering its 
levels in the body, but affecting its final effect or its activity in the target. On a molecular 
basis, most DDI mechanisms – including both PK and PD mechanisms – are caused by 
the interactions between the interacting drugs and proteins in the body. For example, two 
drugs interact when one of them inhibits the activity of the target responsible of the 
activity of the other drug (PD DDI), or when one drug alters the activity of a protein 
mediating the absorption of the second one (PK DDI). Therefore, PK or PD mechanisms 
can be sub-classified by the type of protein that is altered. It is important to note, as well, 
that most DDIs occur not by a single mechanism, but often by two or more mechanisms 
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acting in concert (Baxter, 2013). Therefore, an interaction between a unique pair of 
interacting drugs can be preceded by more than one DDI mechanisms. 
This knowledge is represented in the CM shown in Figure 7.6. Two classes represent 
the two types of mechanisms, PK and PD mechanisms, which have different subclasses 
according to the type of protein involved in the mechanism. At the same time, each one 
of them is subdivided on the basis of how the precipitant drug – aka perpetrator or the 
drug that produces the DDI - acts on the protein (agonism and antagonism for targets and 
inhibition, induction, and saturation for other proteins).  
Although most DDI mechanisms involve a protein, some DDIs do not. A common 
example is DDIs caused by the physicochemical properties of the drugs and not by the 
interaction with a protein. This is a PK mechanism occurring by the formation of non-
absorbable complexes.  
 
 
Figure 7.6. Conceptual model representing the hierarchy for DDI mechanisms in DINTO 
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The DDI mechanism is a process that always precedes the DDI, and the occurrence 
of the DDI is determined by the existence of at least one DDI mechanism process. 
Therefore, these two classes are related in DINTO through the inverse relationships 
‘precedes’ and ‘is preceded by’, and formally defined through the ‘equivalent to’ (≡) 
axiom as shown below: 
                             ‘DDI’        ≡       ‘is preceded by’ some ‘DDI mechanism’ 
‘DDI mechanism’ ≡       ‘precedes’ some ‘DDI’ 
These relationships are used in DINTO to link classes at lower levels of granularity, 
too. They relate a specific DDI with its specific mechanism – or mechanisms – when this 
information is available (Figure 7.7). This information is translated from the database 
DrugBank, which provides three possible types of mechanisms for some of the DDIs 
included in this database: “Possible target-based interaction”, “Possible enzyme-based 
interaction”, and “Possible transporter-based interaction”. We added a fourth type of 
mechanism – the previously mentioned ‘non-absorbable complex formation’ – extracted 
from the brief natural language description of the DDI in the database. 
 
Figure 7.7. Conceptual model representing the relationships between a DDI and a DDI 
mechanism in DINTO. Shaded boxes represent classes with additional subclasses. 
Finally, the last relationship described in this section is the one between the DDI 
mechanism and the interacting drugs. As mentioned before, a DDI has two different 
participating drugs. The one leading to the DDI mechanism (precipitant) is the one which 
triggers the DDI mechanism. These two classes are related through the inverse 
relationships ‘is agent in’ and ‘has agent’ (Figure 7.8). 
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Figure 7.8. Conceptual model representing the relationships between a DDI mechanism 
and the precipitant drug. Shaded boxes represent classes with additional subclasses. 
 Pharmacokinetic processes: 
The term “pharmacokinetics” refers to what the body does to the drug, while 
“pharmacodynamics” describes what the drug does to the body (Benet, 1984). There are 
different PK processes that a drug undergoes in the organism from its administration to 
its elimination from the body. These processes are absorption, distribution, metabolism, 
and excretion. 
Most drugs – with the exception of those acting locally or those administered 
intravenously - have to be absorbed from the site of administration in order to reach the 
bloodstream and its site of action. Absorption requires the passage of drugs across 
biological membranes. Sometimes this pass is facilitated or impeded by certain proteins, 
which activity can be altered by other substances, including other drugs, leading to DDIs 
caused by the alteration of the absorption of a drug.  
Distribution is another important PK process by which a drug is transported through 
the bloodstream – frequently binding plasmatic proteins that act as transporters – and 
reaches the different tissues. To do this, the drug has to pass across different membranes. 
For example, only those drugs with certain physicochemical characteristics can cross the 
blood-brain barrier and reach the central nervous system. Alterations in drug distribution 
can be a caused of DDIs, too.  
This is one of the several mechanisms that the body possesses to protect itself from 
strange (and possibly dangerous) substances such as drugs. The most important is 
metabolism. During metabolic processes, different chemical reactions take place mainly 
in the liver in order to transform drugs in inactive and more soluble substances.  
Important types of proteins that catalyse these chemical reactions are enzymes, including 
the cytochrome P450 family (CYP450), which are especially relevant to DDIs. The 
products derived from metabolic reactions are metabolites. Most times metabolites are 
inactive or less active than the drug itself. However, other metabolites are toxic and 
responsible of the harmful effects of the drug. In contrast, some drugs, such as 
fosamprenavir, are administered as inactive compounds. When these substances – known 
 124 
 
as prodrugs – are metabolized in the body, the changes in their chemical structures lead to 
the formation of an active product, which is responsible of the pharmacological effect.  
Finally, the drug is eliminated from the body through the excretion process. The most 
important excretion route is by the kidneys in the urine, although drugs can be also 
excreted in the faeces, breast milk, sweat, and so forth.  
All these PK processes determine the levels of a drug in the body. Therefore, the 
alteration of one of them can lead to unexpected changes in drug concentration. This is 
what happens during a PK DDI, which occurs when one drug alters some of the PK 
processes of the other drug. All the different PK processes are represented in our CM 
under the homonymous class, which is shown in Figure 7.9.  
PK processes are related to other concepts in our CM. In this way, the object drug 
‘undergoes’ a PK process, while the precipitant drug ‘alters’ (which can be an increase or 
a decrease) a PK process. On the other hand, a PK DDI mechanism, as we will see below, 
‘alters’ a PK process, while a protein ‘regulates’ (‘facilitates’ or ‘impairs’) a PK process 
(Figure 7.10).  
 
Figure 7.9. Conceptual model representing the hierarchy for PK processes in DINTO 
 Pharmacokinetic parameters: 
PK processes, as well as the concentration of the drug in the body, are quantitatively 
defined by PK parameters. A fundamental understanding of these parameters is required 
to design appropriate drug regimens for patients. In fact, the effectiveness or toxicity of a 
dosage regimen is determined by the concentration of the drug in the body. 
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PK DDIs produce an alteration of a PK process and, as a consequence, the related PK 
parameters are altered, too. During the linguistic analysis of the corpus we identified that 
sentences reporting a PK DDI usually describe an alteration in a PK parameter (e.g., 
“sertraline increased the AUC and the Cmax of a single dose of pimozide by about 
40%”). Therefore, the representation of PK parameters is important in DINTO. 
The Pharmacokinetics ontology (PKO) (Wu et al., 2013) represents drug PK 
information, including a manually created representation of PK parameters and their 
definitions in natural language. We create a subset of PKO for these concepts, which is 
imported in DINTO under the top-level class ‘pharmacokinetic parameter’.29 
As mentioned before, PK parameters quantify PK processes. Therefore, the classes 
‘pharmacokinetic process’ and ‘pharmacokinetic parameter’ are related by the inverse 
relationships ‘has quality’ and ‘is quality of’ (Figure 7.11). 
 
Figure 7.10. Conceptual model representing the relationships between a PK process and 
other concepts in DINTO. Shaded boxes represent classes with additional subclasses. 
 Physiological effect and DDI effect: 
The effect produced by a drug is always an alteration in a physiological function or 
process that maintains the existence of the living organism. Drugs may increase or 
decrease the normal function of tissues or organs, but they do not confer any new 
functions on them (Levine et al., 2005). For example, the drug glibenclamide, which is 
used to control blood sugar levels in diabetic patients, produces its effect by increasing 
the normal production of insulin (the hormone responsible of regulating the amount of 
glucose in the blood) by the organism. Therefore, the effect produced by glibenclamide is 
an alteration of the physiological production of insulin. 
 
                                                 
29 PKO_DINTO_subset.owl downloadable from https://code.google.com/p/dinto/ 
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Figure 7.11. Conceptual model representing the hierarchy for PK parameters and their 
relationship with PK processes in DINTO. Classes imported from the PKO are labelled as 
[PKO]. Shaded boxes represent classes with additional subclasses. 
This concept is represented in DINTO through the class ‘physiological effect’. Drugs 
can produce different effects that are classified as therapeutic (or the intended effect of 
the drug), adverse (undesirable effects of the drug), and toxic effects (an exaggeration of 
the desired therapeutic effect which appears at high doses). These three possible drug 
effects are represented in DINTO as subclasses of ‘physiological effect’.  
In the same way that drugs do not produce any “new” function in the body, the 
consequence of a DDI is never a “new” effect. The effect of a DDI is always the 
alteration of some of the effects of one or both interacting drugs. Therefore, a ‘DDI 
effect’ is a physiological effect that has been altered (increased or decreased) because of a 
DDI.  
During a DDI, the adverse effect of one or both interacting drugs may be potentiated 
or increased. For example, concomitant administration of several central nervous system 
depressors can increase their adverse effects and produce an excessive depressive 
response. In other cases, the increase in the concentration of a drug or its metabolites can 
produce an exacerbation of its toxic effects. This occurs, for example, when the 
concentration of a toxic metabolite of paracetamol is increased as a consequence of its 
interaction with rifampicin, leading to an exacerbation of paracetamol’s hepatotoxic 
effects (Baxter, 2013). In contrast, a decrease in the concentration of a drug can lead to 
therapeutic failure. For example, the administration of rifampicin with the 
inmunosupressor cyclosporin, used to avoid rejection in transplanted patients, produces a 
decrease in the concentration of cyclosporin and a decrease in the therapeutic effect, and 
the treatment will not be effective (Naqvi, 2000).  
These situations (increase in adverse and toxic effects or decrease in therapeutic 
effect) lead to DDIs that are potentially harmful for patients. However, other DDIs can 
have a beneficial effect. For example, ritonavir is administered in conjunction with 
protease inhibitors used in the treatment of patients with HIV since ritonavir increases the 
absorption of these drugs in the body and allows to reduce the required dose and the 
dosing schedule (Edwards, 2012). As well, it will be a beneficial DDI those situations in 
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which one drug, such as naloxone, decreases the toxic effect of the other interacting drug, 
such as morphine, being an important treatment in cases of overdose (Sweetman & 
Martindale, 2006). 
Both harmful and beneficial DDI effects can have an important impact on patients 
and therefore are relevant from a clinical point of view (‘clinically relevant DDI effect’). 
However, some DDI effects are unnoticeable or unobservable in most patients, and 
experienced physicians accommodate the effects (such as rises or falls in serum drug 
levels) without consciously recognizing that it was the result of an interaction (Baxter, 
2013). These DDI effects are said to have no relevance from a clinical point of view 
(‘non-clinically relevant DDI effect’). 
The CMs representing physiological and DDI effects are shown in Figure 7.12 and 
Figure 7.13. 
 
 
 
Figure 7.12. Conceptual model representing the relationships between a physiological 
effect, a DDI effect and other concepts in DINTO. Shaded boxes represent classes with 
additional subclasses. 
  
 
Figure 7.13. Conceptual model representing the hierarchies for physiological and DDI effects in DINTO 
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 Drug-drug interactions: 
A drug interaction occurs when the levels or effects of one drug are altered by 
another substance, such as environmental substances, food and drinks, herbal medicines 
or other drugs. Interactions between drugs are called drug-drug interactions (DDIs). 
Therefore, a DDI is a process that occurs between two interacting drugs or participants. 
The one producing the interaction is called the precipitant or perpetrator, while the other 
one is called the object or victim.   
On the one hand, a DDI can be classified by its mechanism as ‘pharmacokinetic 
DDI’ or ‘pharmacodynamic DDI’.  Both of them are classified in our CM, in the same 
way that the preceding mechanisms, based on the involved protein and the action 
performed by the precipitant drug (Figure 7.14). On the other hand, DDIs can be 
classified, as well, on the basis of their effects. Thus, we represent the classes ‘clinically 
relevant DDI’, ‘non-clinically relevant DDI’ or ‘uncertain DDI’. 
Specific interactions between two individual drugs have been imported automatically 
from the database DrugBank and represented in two different ways in our ontology. On 
the one hand, there are classes representing the processes that occur when two specific 
drugs interact. For example, the interaction between the pharmacological entities 
‘desvenlafaxine’ and ‘amitryptyline’ is represented as the class 
‘desvenlafaxine/amitriptyline DDI’, which is formally defined by having them as its 
participating drugs: 
‘desvenlafaxine-amitryptyline DDI’     ≡     (‘has participant’ some ‘amitriptyline’) 
 and (‘has participant’ some 
‘desvenlafaxine’) 
In other words, any individual of the ‘desvenlafaxine-amitryptyline DDI’ class is 
equivalent to (≡) any individual that has a ‘has participant’ relationship with at least one 
(some) individual of the class ‘amitriptyline’ and, at the same time, has a ‘has 
participant’ relationship with at least one (some) individual of the class ‘desvenlafaxine’. 
On the other hand, both classes ‘desvenlafaxine’ and ‘amitryptyline’ are related by 
the symmetric relationships ‘may interact with’, which represents the possible interaction 
of ‘amitryptyline’ with ‘desvenlafaxine’ and vice versa. 
Since the DDI mechanisms for the imported DDIs have been also translated from 
DrugBank, the use of a reasoner engine (Cuenca, 2011) enables their classification on the 
basis of the underlying mechanisms (see Section 9.2.1). 
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Figure 7.14. Hierarchies for DDIs and their related mechanisms in DINTO 
 Drug-protein relationships: 
The role of proteins in our bodies is essential. They are constituents of our cells, 
trigger physiological responses, and catalyse chemical reactions that maintain our normal 
physiological functions. Proteins are, furthermore, determinants for the activity of drugs. 
They influence the different PK processes of a drug in the body, and trigger the effects 
(including therapeutic, toxic, and adverse effects) of most drugs. 
The type of interaction between a drug and a protein is determined by the type of 
protein (receptor, enzyme, transporter, etc.) and the activity that the drug produces on that 
protein. For example, a drug might bind a receptor without leading to any response. 
However, this union would prevent other substances – i.e., normal substances originated 
in our body and externally administered substances such as other drugs - from binding to 
that protein. In this case, the drug ‘blocks’ or ‘antagonizes’ the protein. In contrast, when 
a drug decreases the activity of an enzyme (a protein which catalyses chemical reactions 
in the organism), the drug ‘inhibits’ the activity of the enzyme. 
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Therefore, in our CM we have included different possible relationships between 
proteins and pharmacological entities. They have been adapted from the database 
DrugBank, where the relations between drugs and proteins are described as semi-
structured text. With our approach, we can translate in further steps the drug-protein 
information from DrugBank into DINTO (see Section 7.2.2 and Annex 6 for a detailed 
description of these and other relationships). 
 Description of a DDI 
There are different aspects characterizing a DDI that appear frequently in texts 
(Tatro, 2010). They are represented as attributes in our CM, as shown in Figure 7.16.  
Firstly, ‘documentation’ is an important factor to determine the significance of a DDI 
(Tatro, 2010), since it is related to the degree of confidence in the causal association 
between a DDI and an altered clinical response. That is, the more the DDI is documented, 
the more confidence exists in its causal relation with the effect. The DDI compendium 
‘Drug Interaction Facts’ (Tatro, 2010) establishes five types of documentation levels for 
a given DDI (established, probable, suspected, possible, and unlikely) in a way that a 
well-known and documented DDI described in different sources is considered to be 
established, while a possible or unlikely DDI would be that one that has insufficient 
evidence supporting the existence of a clinically relevant interaction. The level of 
documentation of a DDI is represented in DINTO as the data property ‘documentation 
level’, which can adopt one of the five mentioned levels. 
Another two important aspects are the ‘incidence’ of a DDI - or the relative 
frequency of occurring of that interaction -, and its ‘onset’ - or how rapidly the clinical 
effects of a DDI can occur, which determines the urgency with which preventive 
measures should be instituted to avoid the consequences of the interaction. There are two 
levels of onset in our CM: ‘rapid’ and ‘delayed’. 
There are another two concepts frequently used to describe a DDI. On the one hand, 
the potential ‘severity’ of the interaction is particularly important in assessing the risk 
versus benefit of therapeutic alternatives. There are three degrees of severity: ‘major’, 
‘moderate’, and ‘minor’. On the other hand, the concept ‘relevance’ is used, from a 
clinical point of view, to describe the real importance that the DDI has in the clinical 
practice. It can adopt two values: ‘clinical relevance’ or ‘non-clinical relevance’. 
Figure 7.15 shows these five attributes, along with other four attributes describing 
not a DDI, but the strategy to manage or avoid it. They are different types of 
recommendation related to a change in one of the interacting drugs, monitoring of the 
patients, change in the dose of one or both drugs, or performance of some clinical test. 
This model has been adapted from Samwald et al. (2013), where they show a descriptive 
RDF model for representing pharmacogenomics statements in SPCs. Specifically, the 
model represents the different recommendations for those situations when 
pharmacogenomics might influence the levels and effects of some drug treatments. We 
have studied the model and decided that it could be extrapolated to the domain of DDIs. 
Therefore, it has been included in our CM. 
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Figure 7.15. Conceptual model representing the attributes of a DDI and the possible 
recommendations to avoid it in DINTO. Shaded colour represents that this class has 
additional subclasses. 
 Study subject 
An important aspect used when describing a DDI and the study or situation where it 
has been observed is the type of subject. We include this information in our CM, as it is 
shown in Figure 7.16. It is related to the information resource through the relationship 
‘has study subject’ and has three attributes: ‘age’, ‘gender’, and ‘race or ethnic’. 
 DDI Information Resources: 
A DDI can be described in different sources, such as scientific publications, 
databases, DDI compendia, individual case reports, and so forth. Therefore, they are 
important concepts that should be included in our ontology. The Biomedical Resource 
Ontology (BRO) (Tenenbaum et al., 2011) is a controlled terminology of resources used 
by the biomedical research community created to improve the sensitivity and specificity 
of web searches. This ontology represents different information resources in a single 
hierarchy, providing natural language definitions for each one of them. We created a 
subset of BRO to be reused in DINTO consisting in 52 classes.30 Although BRO does not 
conform to the naming conventions followed in the construction of DINTO, we decide 
not to modify the original labels provided by the authors (see Annex 10).  
During the linguistic analysis of the DDI corpus, however, we have identified other 
terms used to describe DDI information resources and not included in BRO. We observed 
that the most frequent type of information resource cited in the texts is different types of 
studies (e.g., ‘animal study’, ‘in vitro’, ‘in vivo’, ‘controlled study’, etc.). They have been 
included in the CM as subclasses of the BRO’s class ‘Clinical_Research_Data’. 
                                                 
30 DINTO_BRO_subset.owl downloadable from https://code.google.com/p/dinto/ 
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 An information resource can be characterized by the type of subjects participating in 
the study and the number of them. This information is represented through the 
relationship between a ‘study subject’ and the ‘information resource’ and by the attribute 
‘subject number’, as it is shown in Figure 7.16. Here, we can see as well that a DDI and 
an information resource are related by the inverse relationships ‘is described in’ and 
‘describes’.  
Figure 7.16. Conceptual model representing the hierarchy for information resources and 
study subjects, and their relationships with a DDI in DINTO. Classes imported from the 
BRO are labelled as [BRO]. Shaded boxes represent classes with additional subclasses. 
 Description of the interacting drugs 
We finish the description of the conceptualization of DINTO with a very important 
aspect: how the interacting drugs should be represented in an ontology. In the state of the 
art in DDI modeling efforts (Chapter 6), we have observed that all reviewed CMs 
represented the interacting drugs at the “active ingredient” level. Therefore, all previous 
efforts agreed to consider that a DDI should be described to occur between two active 
ingredients.  
However, a recent approach aimed to develop a foundational representation of 
evidence for DDIs (called potential DDIs or PDDIs), postulated that this representation of 
DDI knowledge is not correct (Brochhausen et al., 2014). These authors stated that active 
ingredients should not be assigned the status of drugs, because the excipients, route of 
administration, and dose are determinants for their actions, and that therefore DDIs 
should be described at the “clinical drug” level. As we have explained in Section 5.1, 
active ingredients are administered as clinical drugs, that is, as the combination of the 
active ingredient with pharmacological inactive substances (excipients) in a specific 
pharmaceutical form (e.g., tablet, solution, etc.) and with a specific strength or dose. Such 
a representation avoids the extrapolation of DDIs described at the active ingredient level 
to pharmaceutical forms and administration routes, such as interactions with topical 
drugs, which are commonly non-clinically relevant due to the scarce quantity of active 
ingredient absorbed. This would be especially important for clinical oriented applications, 
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such as the creation of CDSS, where a high frequency of irrelevant alerts leads to alert 
fatigue and clinicians getting overloaded with alerts (Bryant, Fletcher, & Payne, 2014). 
However, this new approach possesses some limitations, too. Firstly, it is not an 
accurate representation of the pharmacological domain, since an interaction between two 
drugs occurs at the molecular level, triggered by the molecular structure and/or 
mechanism of action of the active substance. Although the characteristics of the clinical 
drug, such as strength or administration route, can influence this process, it is ultimately 
related to the active ingredient level.  
The representation at the clinical drug level relies on the fact that a single molecule 
of a drug cannot bear by itself a drug role, neither to interact with another drug. This 
premise is correct, since the effect leading to the interaction requires the action of many 
molecules acting in concert in the body. However, the contrary point of view, attributing 
the interaction to the clinical drug, could be considered incorrect in a similar way. Some 
DDIs do not occur subsequently to the single administration of one clinical drug, but 
during a treatment, which implies a posology with repeated administrations of the clinical 
drug. Therefore, the effect leading to an interaction might require, in these cases, the 
administration of several units of a clinical drug. Thus, both approaches fail in the 
representation of this pharmacological knowledge in a similar fashion. 
Figure 7.17 shows an example of how some DDIs rely on the dosage of the 
interacting drugs, being therefore related to a repetitive administration of the clinical 
drugs. In this simplified situation, a patient is in treatment with DrugA, which is 
metabolized by enzyme E. A new drug DrugB is prescribed, which should be 
administered daily. Since DrugB is an inhibitor of enzyme E, the administration of both 
drugs will lead to a DDI. However, when the patient takes the first tablet of DrugB, the 
doses reached in the body are not high enough to produce a potent inhibition of the 
enzyme. Therefore, the levels of DrugA are not altered in the body. The administration of 
a second dose of DrugB leads to a more prolonged inhibition of E, and to an alteration in 
the metabolism of DrugA, leading to an increase of its levels in the body. However, the 
concentrations are not raised high enough to produce a clinical manifestation. With a 
third administration of DrugB, the concentrations of DrugA rises even more. At this 
moment, a laboratory test might identify the abnormal concentration. However, signs or 
symptoms do not appear yet. Finally, with a fourth administration, the clinical 
manifestations of an adverse DDI arise. Therefore, although it is possible that the clinical 
manifestations of a DDI appear after a single administration, sometimes they are not 
apparent until the repeated administration of the clinical drug (Hojo, Echizenya, Ohkubo, 
& Shimizu, 2011; Zaccara et al., 1993). 
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Figure 7.17. Example of influence of repetitive administrations of a clinical drug in a 
DDI 
In addition to this, other aspects must be taken into account to determine the correct 
representation of the interacting drugs. Firstly, the representation of DDIs in our ontology 
must allow for the representation of their mechanisms on a molecular basis, as well. This 
requires the representation of drug-protein relationships, which occur between proteins 
and drug molecules. As we have observed based on our review on the state of the art, this 
type of relationship is always represented at the active ingredient level.  
Secondly, during the analysis of the DDI corpus, we have observed that descriptions 
of DDIs in text can be made at different levels of granularity. General texts usually 
describe the interaction at the active ingredient (or brand) level, without providing 
information about the drug strength or dose (sentence (i)). In contrast, clinical studies or 
case reports usually refer to the specific clinical drugs suspected to interact (sentence 
(ii)). 
« The occurrence of stupor, muscular rigidity, severe agitation, and elevated 
temperature has been reported in some patients receiving the combination of 
selegiline and meperidine.  »31 
(i) 
« A patient taking iproniazid 150 mg daily developed severe orthostatic 
hypotension on two occasions within an hour of taking selegiline 5 mg. »32 (ii) 
From all these facts, we conclude that the most appropriate representation of 
interacting drugs in our ontology is at the active ingredient level. Nevertheless, 
information regarding the strength, pharmaceutical form, and dose of the interacting 
drugs is included, too. It is represented as attributes in our CM. However, as we have 
explained, these attributes cannot be linked with any particular drug, but with a drug that 
has been described to interact with another one in a specific study. Sentences (iii) and (iv) 
show how two different studies describe an interaction between the same interacting 
drugs, carbamazepine and simvastatine, but with different doses.  
                                                 
31 Sentence extracted from the package insert o ELDEPRYL®, retrieved from the database DailyMed 
(http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=106429ad-859a-4b29-babf-42cb85f7236e) 
32 Sentence extracted from the DDI information compedia Stockley’s Drug Interactions (Baxter, 2013) 
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« Carbamazepine reduced the AUC of simvastatin in twelve patients taking a 
single oral dose of simvastatin 80 mg and a daily tablet of carbamazepine 600 
mg. » 
(iii) 
« Carbamazepine reduced the AUC of simvastatin in twelve patients taking a 
single oral dose of simvastatin 40 mg and a daily tablet of carbamazepine 300 
mg. » 
(iv) 
From the above examples, we could assert that an interaction occurs with simvastatin 
40 mg and simvastatin 80mg, but we could not confirm or deny that the interaction might 
occur with simvastatin 10mg or simvastatin 90 mg, too. Indeed, these sentences are 
describing only an observation made in a clinical study or case report. Therefore, 
information regarding dose, administration route, and pharmaceutical form is related to a 
pharmacological entity that has been observed to participate in a DDI and is described in 
an information resource. Therefore, in this ontology, characteristics such as 
‘pharmaceutical form’, ‘administration route’, or ‘dose’ are attributes of the anonymous 
class ‘pharmacological entity’ that is participant in a ‘DDI’ that is described in some 
‘information resource’. 
‘pharmacological entity’ and  (‘is participant in’  
some  (‘DDI’ and (‘is described in’  
some  ‘information resource’))) 
7.1.4 Implementation 
During the implementation activity, the intermediate CMs need to be implemented in 
a formal language. The OBO Foundry (Smith et al., 2007), a collaborative effort for the 
development and maintenance of biomedical ontologies, recommends the use of a 
common shared syntax in order to ensure the integration and interoperability among 
different ontologies. Specifically, it is recommended that ontology members are 
expressed in either the Open Biomedical Ontology (OBO) format or the Web Ontology 
Language (OWL). The OBO format was created for the Gene Ontology and supports 
most of the biomedical ontology content (Tirmizi et al., 2011), while OWL is the World 
Wide Web Consortium (W3C) standard ontology language for the semantic web.33 The 
OBO flat format is human-friendly and is supported by OBO-Edit (Day-Richter, Harris, 
Haendel, & Lewis, 2007), an ontology editing tool. However, OBO-Edit does not support 
importing fragments of other ontologies, which would require the use of different 
strategies in order to reuse ontologies in our project. In contrast, OWL syntax, although 
understandable by humans, can be difficult for non-computer scientist experts. However, 
it provides a higher level of expressive power and better inference capabilities than OBO. 
Moreover, the widely used OWL ontology editor Protégé34 supports importing fragments 
or whole ontologies, and provides a large number of new plugins trying to make easier 
the building of ontologies in OWL. 
                                                 
33 http://www.w3.org/2001/sw/wiki/OWL 
34 http://protege.stanford.edu/ 
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For all these reasons, we have selected as implementation language the Web 
Ontology Language OWL 235 and Protégé 4.3 as the ontology editing software (Figure 
7.18) 
 
Figure 7.18. Screenshot of DINTO in the ontology development environment Protégé 
7.1.5 Ontological resources reuse 
We have identified and reused those ontologies that have currently represented 
aspects of the DDI domain required by our ontology, and imported them keeping their 
original Unique Resource Identifiers (URIs), identifiers, and labels. The imported 
fragments are described below. 
1. The Chemical Entities of Biological Interest ontology (Degtyarenko et al., 2008) 
(Original URI: http://purl.obolibrary.org/obo/CHEBI_11111) 
                                                 
35 http://www.w3.org/TR/owl2-overview/ 
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The ChEBI ontology organizes “small” chemical compounds with a relevant role in 
the biomedical domain, including pharmacological substances. Each one of these 
pharmacological substances is related to at least one drug application, such as ‘analgesic’ 
or ‘antiemetic’, which are subclasses of the top level class ‘role’. Specifically, we have 
imported the following information: 
 ‘Pharmacological entity’ classes: From the total number of chemical 
entities included in ChEBI36, we have selected the 3,026 having some drug-related 
role - that is, all those chemical entities bearing some pharmacological activity. We 
import the classes and their metadata, which is represented in OWL as annotation 
properties: InChI, InChIKey, synonyms, definition, and cross references (3,027 
imported classes).  
 ‘Role’ classes: We import the top-level class ‘role’ and all its subclasses. 
Therefore, the ontology includes not only the ‘drug’ role, but also other possible 
‘application’ roles, such as ‘biological’ and ‘chemical’ roles (903 imported 
classes). 
 ‘has role’ relationships: We import all the relationships between the 
imported ‘pharmacological entity’ classes and the corresponding ‘role’ classes 
(7.845 ‘has role’ relationships). 
2. The Pharmacokinetics Ontology (PKO) (Wu et al., 2013) (Original URI: 
http://www.owl-ontologies.com/2009/11/5/PKO.owl#label) 
The PKO has been used as a source for terminology, definitions, and units in this 
area. Imported information is described below: 
 ‘Pharmacokinetic parameter’ classes: We identify and select those classes 
in the ontology referring to PK parameters. We also import the annotation 
properties included by the original authors, which provide units for the PK 
parameters, definitions and, in some cases, references. This process is carried out 
manually and we generate a fragment of the ontology that should be imported and 
merged in DINTO later (77 imported classes)37. 
3. The Biomedical Resource Ontology (BRO) (Tenenbaum et al., 2011) (Original 
URI: http://biontology.org/ontologies/BiomedicalResourceOntology.owl#label) 
Although BRO is not specifically related to the DDI domain, it is a useful 
representation of different resources used by the biomedical research community to 
conduct research. We have imported into DINTO the following information: 
 ‘Information Resources’ classes: Instead of creating new classes to 
represent those possible information sources where DDIs can be described, we 
manually create a fragment of BRO including that information relevant to our 
                                                 
36 The latest version available at the moment of building DINTO is ChEBI realease 112. 
37 PKO_DINTO_subset.owl downloadable from https://code.google.com/p/dinto/ 
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domain, which has been imported and merged in DINTO later (50 imported 
classes)38. 
4. OBO Ontology Metadata39 (Original URI: http://www.w3.org/2002/07/owl#label 
and http://purl.obolibrary.org/obo/IAO_1111111). 
The OBO ontology metadata project standardises annotation properties for common 
annotation types such as definition, synonym, and so on. We import this metadata 
ontology (a subset of the IAO),40 which provides 38 annotation properties. 
5. Basic Formal Ontology (BFO)41 (Original URI: http://ifomis.org/bfo/1.1#label). 
We follow BFO’s definitions for upper level classes such as ‘process’ and 
‘continuant’ in our work. The complete ontology is imported in the corresponding 
version of DINTO42 (39 imported classes). 
To increase the interoperability of our ontology, we have mapped classes and 
attributes in DINTO with other relevant ontologies. This mapping is represented in the 
ontology through the annotation property ‘maps to’. The most important mapped 
ontologies are: 
 Relation Ontology (RO) (Smith et al., 2005): RO is a collection of relations 
intended primarily for standardization across ontologies in the OBO Foundry and 
wider OBO library. We map our relations to RO where appropriate.   
 Semanticscience Integrated Ontology (SIO) (Dumontier et al., 2014): SIO 
is an ontology to facilitate biomedical knowledge discovery that features a simple 
upper level comprised of essential types and relations for the rich description of 
objects, processes, and their attributes. We map our relations to SIO where no 
appropriate RO mapping is available. 
 Evidence taxonomy for DIKB (Boyce et al., 2009): We map our ‘has 
object’ and ‘has precipitant’ relationships to their equivalents in this taxonomy. 
7.1.6 Non-ontological resources reuse 
Up to now, we have described the conceptualization and implementation of the basic 
skeleton of our ontology and how it has been enriched by importing information from 
other ontologies. However, information included in this version is still limited in terms of 
its applicability to IE and inference of DDIs.  
                                                 
38 BRO_DINTO_subset.owl downloadable from https://code.google.com/p/dinto/ 
39 https://code.google.com/p/information-artifact-ontology/wiki/OntologyMetadata 
40 http://code.google.com/p/information-artifact-ontology/ 
41 http://www.ifomis.org/bfo 
42 DINTO_1BFO.owl downloadable from https://code.google.com/p/dinto/ 
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Firstly, the number of pharmacological entities included in the ontology is limited in 
comparison with all those possible entities manually annotated in the DDI corpus (see 
Section 10.1). Secondly, although general mechanisms of DDIs have been represented, 
specific DDIs between pairs of drugs have not been included. Moreover, relationships 
between specific drugs and proteins for the indirect representation and inference of DDIs 
are not represented, either. Finally, the number of database and code identifiers for drugs 
- which are necessary for the correct mapping and merging of other information sources 
and our ontology - does not show enough coverage.  
To overcome all these limitations, we have integrated information from the 
pharmacological database DrugBank (Wishart et al., 2006), a rich resource combining 
chemical and pharmaceutical information of approximately 4,900 pharmacological 
substances. It covers identification, taxonomical, and interactions aspects, among many 
others. We use the version available at the time of developing the ontology DrugBank 3.0 
as a source of information about drugs, their different code and database IDs, and 
synonyms. We also import specific DDIs between pairs of drugs and interactions between 
drugs and proteins. The activities performed in this process are described below. 
1. Exact mapping between ChEBI and DrugBank 
As mentioned before, 3,026 ‘pharmacological entity’ classes have been imported in 
DINTO from the ChEBI ontology. Integration of additional information for these classes 
requires the unambiguous identification of the same concept in the two sources. 
However, this mapping is not always easy because, among other reasons, two resources 
can represent concepts at different levels of granularity (Brenninkmeijer et al., 2013).  
The most characteristic example is the representation of drug salts. On the one hand, 
ChEBI considers that a drug and its different salts are not the same concept. For example, 
in ChEBI the drug ‘lidocaine’ and its two salts ‘lidocaine hydrochloride’ and ‘lidocaine 
hydrochloride monohydrate’ are considered three different chemical entities and each one 
of them has its own ChEBI unique identifier. On the other hand, in DrugBank there is 
only one entry corresponding to the drug ‘lidocaine’, which describes the drug ‘lidocaine 
hydrochloride’ as its salt, while its relationship with ‘lidocaine hydrochloride 
monohydrate’ is not specified. However, cross-references in ChEBI to DrugBank 
establish that the three of them (‘lidocaine’, ‘lidocaine hydrochloride’, and ‘lidocaine 
hydrochloride monohydrate’) link with the same DrugBank ID entry, which corresponds 
to the entry ‘lidocaine’. We consider that the extrapolation of DDIs described for 
‘lidocaine’ in DrugBank to its different salts ‘lidocaine hydrochloride’ and ‘lidocaine 
hydrochloride monohydrate’ might lead to the inclusion of unknown or unproven 
interactions and, in consequence, to a source of error in the ontology. 
To avoid this possible source of errors, we have adopted a strategy of exact mapping 
between the two sources, which establishes that a drug will be considered to be the same 
in both sources if the cross-referenced IDs are coincident in both ChEBI and DrugBank 
(Figure 7.19). According to this, in the previous example there is only one mapping 
between ‘lidocaine’ in ChEBI and ‘lidocaine’ in DrugBank. Therefore, information from 
DrugBank is imported only for the class ‘lidocaine’. Meanwhile, the classes ‘lidocaine 
hydrochloride’ and ‘lidocaine hydrochloride monohydrate’ are still present in the final 
ontology, but without incorporating any additional information. 
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2. Creation of new drug classes: 
The coverage for drugs in ChEBI is limited in comparison to those drug entities 
annotated in the DDI corpus (see Section 10.1). Therefore, it is necessary to include an 
additional source of drugs. Some drug entries in DrugBank are not represented in ChEBI. 
Therefore, in addition to the 3,026 drug classes imported from ChEBI, we create 5,760 
new classes for those drugs present in the database but not included in the ontology. 
 
Figure 7.19. Cross-references between ChEBI and DrugBank for the drug lidocaine and 
its salts 
In contrast to classes imported from ChEBI, which maintain their original URIs and 
IDs in DINTO, new classes translated from DrugBank are provided a new DINTO URI 
as follows: http://purl.obolibrary.org/obo/DINTO_DBXXX, where DBXXX is the unique 
identifier provided for that drug in DrugBank. In this way, it is easy to know whether a 
drug class in DINTO is originally from ChEBI only based on the URI. 
3. Manual refinement of the automatic mapping: 
Once new drug classes have been added to those previously imported from ChEBI, 
we identify cases where two different classes (one from ChEBI and one from DrugBank) 
have the same label. The reason is that these classes share the same preferred name in 
both DrugBank and ChEBI, but have not been identified as the same concept through our 
exact matching strategy.  
We conduct a manual review to identify and correct all duplicated cases. There are 
66 classes imported from both DrugBank and ChEBI. Most cases are due to the lack of 
the cross-reference to the DrugBank ID in ChEBI or vice versa.  To ensure that the two 
classes refer to the same concept, we check the CAS Registry Number (CASRN) in both 
the database and the ontology. CASRNs are unique numerical identifiers assigned by the 
Chemical Abstracts Service to every chemical substance included in their CAS 
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Registry.43 If the CASRN matches between the two sources, we consider them a unique 
class in DINTO, which conserves the original ChEBI URI and integrates additional 
information from DrugBank. The list of duplicate classes and the error sources is 
provided in Annex 5. 
4. Drug identification information: 
The traditional identification of drugs with natural language names is essential for 
human communication, although associated problems such as ambiguity might arise (see 
Section 3.4.2). To avoid these issues different drug codes systems have been created, 
such as the well-known ATC classification system (WHO, n.d.) or the FDA Substance 
Registration System and its unique ingredient identifiers (UNIIs) for ingredients in 
drugs.44 Similarly, in the field of pharmacological databases and other computerized 
information sources, the problem of unique identification of a drug has been tackled by 
the assignment of unique numerical or alpha-numerical identifiers in a way that each 
dataset has created their own IDs (Brenninkmeijer et al., 2013).  
This framework has led to a proliferation of different identifiers for the same concept 
among different information resources, which can play a crucial role in data integration 
(Hassanzadeh, Zhu, Freimuth, & Boyce, 2013). As we have seen, information from 
DrugBank and ChEBI can be integrated by using the correspondent cross-references 
between ChEBI and DrugBank IDs (Figure 7.19), while another identifier such as the 
CASRN can be used to identify unequivocally those cases where correspondence 
between concepts is not clear. However, not all data sets have cross-references to other 
identifiers. In these cases, this strategy for data integration cannot be used. For example, 
NDF-RT and MeSH do not have cross-references to ChEBI or DrugBank IDs. In the 
same way, the latter ones do not have cross-references to NUIs (NDF-RT unique 
identifiers) or MeSH IDs. Therefore, it would not be possible to integrate data from the 
four sources. However, NDF-RT provides MeSH IDs, while MeSH provides CASRN for 
drugs.  Therefore, it would be possible to integrate data from ChEBI or DrugBank and 
MeSH by using the CASRNs and then, between these and NDF-RT by means of the 
MeSH IDs. 
Therefore, inclusion of cross-references to different data identifiers and drug systems 
codes could increase the interoperability and further development by data integration of 
DINTO. Some cross-references (such as the KEGG database45) are currently imported 
from ChEBI, but some of them are missing. Therefore, we integrate identification 
information from DrugBank in order to increase the number of cross-references for each 
drug. 
Following the model used in ChEBI, this information is represented in the ontology 
as annotation properties (see Section 7.2.4). During the process, we have identified that 
the annotation property for CASRN is provided in terms of different annotation 
properties in ChEBI (e.g., it is usually described as a cross-reference to ChemIDPlus, but 
sometimes it can be found as a cross-reference to KEGG Compound or KEGG Drug). As 
                                                 
43 http://www.cas.org/content/chemical-substances 
44http://www.fda.gov/forindustry/datastandards/substanceregistrationsystem-
uniqueingredientidentifierunii/default.htm 
45 http://www.genome.jp/kegg/compound/ 
 143 
 
an additional step, we identify and provide a unique format for all values, through the 
creation of the annotation property CASRN. 
5. Proteins and drug-protein relationships: 
DrugBank provides information about interactions between drugs and proteins, 
which is translated into our ontology. Firstly, we create proteins as classes, providing 
them with a URI, an identifier, and identification information such as the UniProt IDs 
(Consortium, 2008). Then, we represent relationships between them and individual drugs 
at the class level (see Section 7.1.3).  
6. DDI relationships: 
Finally, we have translated information about DDIs drugs from DrugBank into 
DINTO. DDIs are represented in two different ways: i) through the ‘may interact with’ 
relationship between two pharmacological entities; and ii) as classes representing an 
interaction between two pharmacological entities (Figure 7.20). Information related to 
the mechanism leading to the DDI is also imported from DrugBank, when available. 
 
Figure 7.20. Representation of the DDI between ‘doxorubicin’ and ‘zidovudine’ in 
DINTO 
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7.1.7 Rules for DDI mechanisms representation 
One of the objectives of this thesis is to create an ontology supporting different 
application and, in particular, NLP tasks and inference of DDI-knowledge. The latter one 
might be useful for the development of pharmacovigilance tools, such as CDSS or signal 
detection systems, among others. Specifically, our aim is to infer new DDIs exploiting 
structured knowledge reused from other resources and automatically imported in DINTO, 
in a way that would avoid the high costs of manual curation of pharmacological 
information.  
To do this, we propose to infer new relationships ‘may interact with’ between classes 
in our ontology on the basis of existing drug-protein relationships. Despite the richness of 
OWL’s set of relational properties, its expressivity does not allow us to express all 
possibilities for object relationships (Holford, Khurana, Cheung, & Gerstein, 2010; 
Horrocks, Patelschneider, Bechhofer, & Tsarkov, 2005). This limitation can be overcome 
by the combination of an OWL ontology with inference rules (Golbreich, 2005). The 
Semantic Web Rule Language (SWRL)46 is an expressive OWL-based rule language that 
provides more powerful deductive reasoning capabilities than OWL alone and has 
become the most widely used rule language in the semantic web community (Holford et 
al., 2010). SWRL rules are expressed in terms of OWL concepts (classes, properties, 
individuals), and it is supported by the ontology development environment Protégé and 
the reasoner engines HermiT (Glimm, Horrocks, Giorgos, & Zhe, 2014) and Pellet (Sirin, 
Parsia, Grau, Kalyanpur, & Katz, 2007).  
In the recent years, SWRL rules have been used to model biomedical knowledge 
aimed to support the development of clinical decision support systems (CDSS) applied to 
clinical pathways compliance checking (Alexandrou, Pardalis, Bouras, Karakitsos, & 
Mentzas, 2012; Z. Huang, Bao, Dong, Lu, & Duan, 2014; Ye, Jiang, Diao, Yang, & Du, 
2009), supervision and treatment of critical patients (Martínez-Romero et al., 2013), or 
remote patient monitoring systems (Shojanoori & Juric, 2013), for example. The 
combination of OWL and SWRL has been used to represent EHRs information and 
support the interoperability between heterogeneous systems (Lezcano, Sicilia, & 
Rodríguez-Solano, 2011), and the reasoning capabilities provided by SWRL rules have 
been exploited to query patient datasets at different levels of abstraction (Taboada et al., 
2012) or to infer new relationships in the pseudogenes domain (Holford et al., 2010). 
Furthermore, these rules have been used to evaluate the performance of novel semantic-
based methods for IR (Hassanpour et al., 2011).   
SWRL rules are written as antecedent-consequent pairs, where the antecedent is 
referred to as the rule “body” and the consequent is referred to as the “head”. The head 
and body consist of a conjunction of one or more atoms. Atoms can be of the form C(x), 
P(x, y), sameAs(x, y) or differentFrom(x, y), where C is an OWL DL description, P is an 
OWL property, and x, y are either variables, OWL individuals, or OWL data values. The 
example below shows a SWRL rule describing that two drugs interact when one inhibits 
the metabolizing enzyme of the other one: 
                                                 
46 http://www.w3.org/Submission/SWRL/ 
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inhibits(?othery, ?z), metabolizes(?z, ?y),  
DifferentFrom (?othery, ?y) -> 'may interact 
with'(?othery, ?y) 
This rule establishes that if one pharmacological entity (?othery) inhibits the activity 
of an enzyme (?z), which metabolizes another pharmacological entity (?y), therefore 
there might be an interaction between the two pharmacological entities ?othery and ?y. 
Since SWRL adopts OWL’s open world assumption (OWA), it is not straightforward to 
assume that two individuals are automatically distinct if they have different names. 
Therefore, it is necessary to include the differentFrom atom, which determine that the 
variables ?othery and ?y do not refer to the same underlying individual. SWRL rules 
reason about OWL individuals. Therefore, to perform the inference, the ontology should 
include at least three individuals (two pharmacological entities and one enzyme) and the 
relationships ‘inhibits’ and ‘metabolizes’ among them. 
 
Figure 7.21. SWRL rules in Protégé 
In this project, we have created two main groups of rules in SWRL, each one of them 
consisting of 59 rules. The first one formalizes different types of DDI mechanisms, 
including both PD and PK mechanisms, in a set of rules that allows for inferring new 
‘may interact with’ relationships between drugs (Figure 7.21). The second one assigns a 
specific type to a DDI on the basis of its inferred mechanism, which is inferred from 
drug-protein relations information. A detailed description of these rules is provided in 
Section 7.2.5, and the results obtained when combining our OWL ontology and the 
SWRL rules are described in Section 9.2.2 and Section 9.2.3. 
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7.1.8 Maintenance 
An important aspect of any ontology is its evolution and maintenance. Ontologies 
might include errors, lack of information, or may need to evolve in order to adapt to 
changes or new discoveries in the domain (Stojanovic, 2004). There is not a standard for 
ontology maintenance. Nevertheless, we have established a strategy for the maintenance 
of DINTO, which will ensure consistency between different releases, documentation of 
any change made, and tracking of users’ suggestions or requests (Shaban-Nejad & 
Haarslev, 2009). The proposed activities are described below. 
1. Assignment of one person responsible for maintaining DINTO. 
2. Creation of an online system enabling users to make requests for 
modifications and addition of new terms, which tracks the suggestions and 
manages the change requests (https://code.google.com/p/dinto/issues/list). 
3. Enhancement of the ontology through activities aimed to:  
- identify missing or misplaced relationships and terms,  
- add new information not covered in the current version of the 
ontology, 
- provide definitions for remaining undefined terms, 
- identify redundancy. 
4. Notification of changes via reports at DINTO site 
https://code.google.com/p/dinto/ 
5. Management of identifiers and tracking of all those that are deleted or merged 
in order to provide lists of this changes with every release of DINTO. 
6. Technical evaluation (as described in Chapter 8) of each new version prior 
to its public release. 
7.2 Description of DINTO 
In the previous section, we have provided a detailed description of the process of 
building the ontology. Here we describe the final resource and the different constituents 
of its CM - that is, the elements that, in combination, formally represent the 
pharmacological domain of drug interactions knowledge. 
On the one hand, concepts in the domain are represented as classes in DINTO and 
organized into nine different hierarchical taxonomies. Top-level classes represent 
concepts that are more general, while subclasses represent specializations of them.   On 
the other hand, object properties represent relationships between classes, while data 
properties represent characteristics of concepts. Additional information or metadata is 
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represented in the ontology as annotation properties, including mapping to other 
ontological resources. All these entities are described in the following sections. 
7.2.1 Classes 
Each class in DINTO represents a unique concept. They are organized in nine non-
overlapping (disjoint) taxonomies or top-level classes that represent all the DDI-related 
knowledge. A description of them is provided below. 
 ‘chemical entity’: The top class ‘chemical entity’ is imported from the 
ChEBI ontology and maintains its original URI. However, only a fragment of 
ChEBI is imported in DINTO, and the structure is therefore different between both 
sources. This top class has two subclasses in DINTO: ‘pharmacological entity’ and 
‘protein entity’.  
- ‘pharmacological entity’: this class collects all chemical entities that can 
exert a pharmacological activity. In other words, this class represents all 
substances that can produce any pharmacological effect in the organism, 
which are described as active ingredients. Most of these subclasses have 
been imported from the ChEBI ontology corresponding to those classes 
having some ‘drug’ role. However, to increase the coverage of DINTO, 
other pharmacological entities not present in ChEBI have been imported 
from the DrugBank database. All of them are subclasses of 
‘pharmacological entity’ class and siblings between them.  However, it is 
possible to distinguish their original source since classes imported from the 
ChEBI ontology maintain their original URI 
(http://purl.obolibrary.org/obo/CHEBI) while the new ones created from 
DrugBank have a DINTO URI (http://purl.obolibrary.org/obo/DINTO). 
- ‘protein entity’: the class ‘protein entity’ collects proteins related to the 
previously describe ‘pharmacological entities’. They are organized into 
five subclasses (‘carrier’, ‘enzyme’, ‘target’, ‘transporter’, and ‘receptor’) 
although the same protein (e.g., ‘5'-nucleotidase’) can be a member of 
more than one of them (e.g., ‘target’ and ‘enzyme’). 
 ‘DDI mechanism’: this class represents the different processes that can 
lead to a DDI. It is subdivided into two subclasses: ‘pharmacodynamic DDI 
mechanism’ and ‘pharmacokinetic DDI mechanism’. Each one of them is 
subdivided into more specific mechanisms (Figure 7.14) 
 ‘drug interaction’: This class represents all possible drug interactions. The 
subclass ‘DDI’ represents interactions between two drugs (or drug-drug 
interactions). This structure allows for the representation, in future versions of the 
ontology, of interactions other than DDIs, such as food-drug interactions or 
environmental substance-drug interactions.  
- The class ‘DDI’ represents DDIs by different classification criteria. 
Subclasses ‘pharmacodynamic DDI’ and ‘pharmacokinetic DDI’ represent 
DDIs on the basis of their preceding mechanisms, while subclasses 
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‘clinically relevant DDI’, ‘non-clinically relevant DDI’ and ‘uncertain 
DDI’ aim to classify DDIs by their type of effects or consequences.  
- The subclass ‘DDI described in DB’ includes specific interactions between 
pairs of drugs with a common source of information. Each one of the 
subclasses represents the interaction between two subclasses of the 
‘pharmacological entity’ class.47  
  ‘Information Resource’: This top class represents the different 
information resources that can describe some aspect of a DDI. This class has been 
imported from the BRO (Tenenbaum et al., 2011), although some additional 
relevant concepts have been included as subclasses of the class 
‘Clinical_Research_Data’.  
 ‘pharmacokinetic parameter’: This top class represents different PK 
parameters, which are concepts frequently used in the DDI literature. Subclasses 
have been imported from the PKO (Wu et al., 2013) and maintain their original 
URIs. 
 ‘pharmacokinetic process’: It represents the different processes that a 
pharmacological substance undergoes in the body (‘absorption’, ‘distribution’, 
‘metabolism’, and ‘excretion’) and that are altered in a PK DDI. 
 ‘physiological effect’: The class ‘physiological effect’ represents the 
different effects that a pharmacological substance can produce in the body. Based 
on their consequences for patients, drug effects are classified as adverse, toxic, or 
therapeutic effects. In the domain of drug interactions, the effect of a DDI is the 
consequence of the alteration of the effects of one or both interacting drugs. 
Therefore, the class ‘altered physiological effect’ has a subclass named ‘DDI 
effect’, which can be an altered adverse, toxic, or therapeutic effect. Regarding the 
consequences for patients, the effect of the DDI can be classified by its clinical 
relevance, and/or as a potentially beneficial or harmful DDI effect. 
 ‘role’: A role represents a particular behaviour which a material entity may 
exhibit and describes their activities. This class and its subclasses have been 
imported from the ChEBI ontology and maintained their original URIs. Only one 
new class ‘participant’ and its two subclasses ‘object’ and ‘precipitant’ have been 
created to represent the different roles that an interacting drug can have in a DDI. 
 ‘study subject’: This class represents the different types of individuals that 
can take part in a DDI study. 
7.2.2 Object properties 
Object properties represent relationships between two classes. They are used to 
describe and define concepts in the ontology. As definitional relationships, they support 
                                                 
47 In order to follow ontological design principles, in the next release of DINTO this information will be 
substituted by an annotation property called ‘Provenance’ and the string value ‘DrugBank database’.  
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automated classification by reasoning engines, and are inherited into descendant concepts 
in the resulting inferred taxonomy. There are 72 object properties in DINTO. Some of 
them are organized into hierarchies showing specialization, while others are organized in 
property chains to allow the inference of new relationships between concepts. 
Domain – the class whose definition may use the object property – and range – the 
class that the object property can refer to – are established when appropriate to provide 
accurate definitions of both object properties and classes, and all of them have a natural 
language definition.  
Figure 7.22 shows part of the object property hierarchy in Protégé. A complete list 
and description of these relationships can be found in Annex 6. 
 
Figure 7.22. Partial view of the object property hierarchy in DINTO 
 
7.2.3 Data properties 
Some important characteristics of concepts need to be represented as data. 
Relationships between classes and data are represented in the ontology through data 
properties, which are informational attributes of concepts. A data property value is a text 
string or an integer attached to a single concept, without any inheritance to descendant 
concepts in the inferred taxonomy.  There are 17 data properties in DINTO that relates 
five classes in the ontology with data values.  These classes are ‘pharmacological entity’, 
‘study subject’, ‘DDI’, ‘Information Resource’, and the anonymous class representing a 
DDI interacting drug.48 
                                                 
48 This anonymous class is defined in the ontology as: ‘pharmacological entity’ and (‘is participant in’ 
some (‘DDI’ and (‘is described in’ some ‘Information Resource’))). For abbreviation purposes, we refer to 
it in the text as DDI interacting drug. 
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 ‘pharmacological entity’: There is only one data property used to describe 
information about a pharmacological substance.    
o has concentration  integer 
The measure of the amount of pharmacological substance in a 
determine tissue and at a specific moment. 
 ‘DDI’: There are different data properties providing information about a 
specific DDI. 
o has documentation level     {"established", "possible", 
"probable", "suspected", "unlikely"} 
The degree of confidence that the interaction can cause a specific 
effect. 
o has incidence  string 
Relative frequency of occurrence of the DDI. 
o has onset  {"delayed" , "rapid"} 
How rapidly the clinical effects of an interaction can occur. 
o has relevance  {"clinical relevance", "non-clinical 
relevance"} 
The real importance that the DDI has in the clinical practice. 
o has severity  {"major" , "minor" , "moderate"} 
Degree of the undesirable effect of the DDI. 
o has dose recommendation  {"change dose schedule", 
"decrease from baseline", "increase from baseline", 
"no change necessary", "use specific dose"} 
A recommendation to avoid or decrease the effect of a DDI related to 
the dose of the interacting drugs. 
o has drug selection recommendation  {"add medication", 
"change administration route", "no change 
necessary", "not-restart", "use alternative"} 
A recommendation to avoid or decrease the effect of a DDI related to 
the selection of the interacting drugs. 
o has drug monitoring recommendation  {"change monitoring 
strategy", "not-necessary", "recommended", 
"required"} 
A recommendation to avoid or decrease the effect of a DDI related to 
monitoring some aspect or parameter of patients. 
o has test recommendation  {"not-necessary", 
"recommended", "required", "take note it is 
available"} 
A recommendation to avoid or decrease the effect of a DDI related to 
testing recommendations. 
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 ‘study subject’: The main characteristics of subjects participating in a DDI 
study are described through data properties. 
o has age  integer 
The age of the subject participating in a study or other information 
source describing a DDI. 
o has gender  {"female", "male"} 
The gender of the subject participating in a study or other information 
source describing a DDI. 
o has race or ethnic  string 
The race or ethnic of the subject participating in a study or other 
information source describing a DDI. 
 ‘Information Resource’: In some cases, it is important to know the number 
of subjects participating in a DDI study. This information is described through a 
data property. 
o has subject number  integer 
The number of subjects participating in a study or other information 
source describing a DDI. 
 DDI interacting drug49: Characteristics related to the pharmaceutical 
presentation of the interacting drugs in one specific DDI study or information 
resource are described as data properties in DINTO. 
o has administration route  string 
The route use to administrate the drug described in the study or other 
information source describing a DDI. 
o has dose  integer 
The dose of the drug described in the study or other information source 
describing a DDI. 
o has pharmaceutical form  string 
The dose of the drug described in the study or other information 
source describing a DDI. 
7.2.4 Annotation properties 
Annotation properties represent metadata of concepts in the ontology. This 
information is established at the class level. It is non-definitional and is not used in 
automated classification. Therefore, it is not inherited into descendant concepts in the 
resulting inferred taxonomy. 
                                                 
49 This anonymous class is defined in the ontology as: ‘pharmacological entity’ and (‘is participant in’ 
some (‘DDI’ and (‘is described in’ some ‘Information Resource’))). For abbreviation purposes, we refer to 
it in the text as DDI interacting drug. 
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DINTO imports the OBO ontology metadata file,50 a standard representation of 
annotation properties to be used across OBO ontologies with 38 annotation properties. In 
those cases where the ontology requires additional metadata, we have created specific 
annotation properties. 
Annotation properties can represent metadata for any class in the ontology. However, 
they are most frequently used to provide information about chemical entities. Here, we 
describe the most important annotation properties used in DINTO. 
 Annotation properties for synonyms and alternative names:  
DINTO provides different synonyms and alternative names for classes, especially for 
pharmacological entities, that are included in the ontology as annotation properties. 
- Synonym (original source: ChEBI): It is the annotation property used in 
ChEBI for alternative names and synonyms. This annotation property is 
used for synonyms entered manually in DINTO. 
- DBSynonyms (original source: DINTO): This annotation property represents 
all possible alternative generic names described in the database DrugBank 
for every drug entry. 
- DBName (original source: DINTO): Annotation property specifically 
created to represent the preferred name for a pharmacological substance 
used in the DrugBank database. 
- DBBrand (original source: DINTO): This annotation property represents the 
different brand names for a pharmacological entity translated from 
DrugBank. 
- DBSalt (original source: DINTO): Annotation property specifically created 
to represent salts of a pharmacological entity described in the database 
DrugBank. 
 Annotation properties for code systems and chemical identification: 
There are several chemical and pharmacological code systems included in the 
ontology as annotation properties. They are important for the unambiguous identification 
of chemical entities among different information sources and necessary for integration of 
information in the ontology or related projects. 
- AHFSCode (original source: DINTO): The American Hospital Formulary 
Service (AHFS) Pharmacologic-Therapeutic Classification code(s) for a 
pharmacological entity. 
- ATCCodes (original source: DINTO): The Anatomical Therapeutic 
Chemical Classification System code(s) for a pharmacological entity. 
                                                 
50 https://code.google.com/p/information-artifact-ontology/wiki/OntologyMetadata 
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- CASRN (original source: DINTO): The Chemical Abstracts Service 
Registry Number (CASRN) for a pharmacological entity. 
- InChI (original source: ChEBI): The IUPAC International Chemical 
Identifier for a pharmacological entity. 
- InChIKey (original source: ChEBI): The InChIKey for a pharmacological 
entity. 
- SMILES (original source: ChEBI): The Simplified Molecular-Input Line-
Entry System for a pharmacological entity. 
- altId (original source: ChEBI): Previously assigned ChEBI IDs for a 
pharmacological entity. 
- xref (original source: ChEBI): Cross reference to other pharmacological 
resources and database IDs. The following are of special interest for 
mapping purposes: 
 KEGG DRUG 
 KEGG COMPOUND 
 DrugBank 
 National Drug Code Directory 
 Drugs Product Database (DPD)  
 Drugs.com 
 Protein Data Bank (PDB) 
 Wikipedia 
 PharmGKB 
 RxList 
 UniProt Knowledge Base (UniProtKB) 
 PubChem Substance and PubChem Compound 
 Reaxys 
 ChemSpider 
 etc. 
 Annotation properties for useful information and data: 
There is relevant information providing a better description of entities that, however, 
is not formally represented. Therefore, it is included in natural language as annotation 
properties. 
- Definition (original source: ChEBI): A brief natural language description of 
the entity. 
- Gene (original source: DINTO): Regarding protein entities, the gene that 
codifies for that protein. 
- OrganismClass (original source: DINTO): Regarding protein entities, the 
corresponding organism for that protein. 
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- mapsTo (original source: DINTO): Link to an entity in a different ontology 
that represents the same entity in DINTO. 
7.2.5 SWRL rules 
SWRL rules are used to extend the expressivity of OWL 2 and to exploit their 
reasoning capabilities for the inference of new information in DINTO. There are a total of 
118 SWRL rules that can be divided into two main groups: i) rules modeling DDI 
mechanisms that define new ‘may interact with’ relationships between pharmacological 
entities, and ii) rules assigning a DDI type on the basis of the inferred mechanism for a 
DDI. These types include ‘target related DDI’ and its subtypes ‘agonistic DDI’  and 
‘antagonistic DDI’;  ‘enzyme related DDI’ and the subtypes ‘enzyme inhibition DDI’, 
‘enzyme induction DDI’, and ‘enzymatic saturation DDI’; ‘carrier related DDI’ and its 
subtypes ‘carrier induction DDI’, ‘carrier inhibition DDI’, and ‘carrier saturation DDI’; 
‘transporter related DDI’ and the subtypes ‘transporter inhibition DDI’, ‘transporter 
induction DDI’, and ‘transporter saturation DDI’. Other 17 rules simply assign the type 
‘DDI’ when the relationships are too ambiguous to know the type of interaction between 
two drugs (e.g., when the only known relationship between two pharmacological entities 
and a protein is the object property ‘related to’ (Table 7.1). 
 
 
SWRL rules in DINTO Number 
SWRL rules to infer DDIs 59 
SWRL rules to infer DDI mechanisms 59 
 ‘target related DDI’ type 17 
 ‘agonistic DDI’ subtype 4 
 ‘antagonistic DDI’ subtype 3 
 ‘enzyme related DDI’ type 9 
 ‘enzyme inhibition DDI’ subtype 1 
 ‘enzyme induction DDI’ subtype 2 
 ‘enzymatic saturation DDI’ subtype 2 
 ‘transporter related DDI’ type 3 
 ‘transporter inhibition DDI’ subtype 2 
 ‘transporter induction DDI’ subtype 2 
 ‘transporter saturation DDI’ subtype 1 
 ‘carrier related DDI’ type 3 
 ‘carrier inhibition DDI’ subtype 2 
 ‘carrier induction DDI’ subtype 2 
 ‘carrier saturation DDI’ subtype 1 
 ‘DDI’ type 5 
Table 7.1. Types of SWRL rules in DINTO  
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7.2.6 DINTO in numbers 
To end this chapter, we provide a table describing the final number of entities in the 
first version of DINTO 1.0.0 (Table 7.2) and describe the different owl files that can be 
downloaded from https://code.google.com/p/dinto/ (Table 7.3). 
Ontology Metrics Total 
Number of classes 
25,809 
   11,555 DDIs     
   8,786 drugs 
Number of individuals 0 
Number of properties 161 
Number of object properties 73 
Number of data properties 17 
Number of annotation properties 71 
Classes with natural language definition 9,392 
Classes with OWL definitional axiom 11,587 
Table 7.2. Final number of entities in DINTO 
Files available to download Description 
DINTO_1.owl The first version of DINTO. 
DINTO_1BFO.owl 
The first version of DINTO mapped to the 
top-level ontology BFO. 
BRO_DINTO_subset.owl 
The fragment imported from BRO to 
DINTO. 
PKO_DINTO_subset.owl 
The fragment imported from PKO to 
DINTO. 
DINTO_rules_inferenceDDI.owl 
The file containing the 59 SWRL rules 
created to infer DDIs in DINTO. 
DINTO_rules_inferenceDDI_types.owl 
The file containing the 59 SWRL rules 
created to infer types of DDIs in DINTO. 
DINTO_inf_classification.owl 
The version of DINTO intended to be used 
with a reasoner engine to obtain an inferred 
classification of DDIs on the basis of their 
asserted mechanism (IExp1 in Section 
9.2.1). 
DINTO_SEMEVAL2_inf.owl 
The version of DINTO created to be 
evaluated in the framework of the SemEval-
2013 DDI Extraction task. It contains the 
DDIs inferred using a reasoner for a 
reduced number of pharmacological entities 
(IExp2 in Section 9.2.2)  
DINTO_inf_mech.owl 
The version of DINTO intended to be used 
with a reasoner engine to obtain and 
inferred classification of DDIs on the basis 
of their inferred mechanisms (IExp3 in 
Section 9.2.3). 
Table 7.3. Description of the DINTO-related files available to download
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Chapter 8 
Evaluation of DINTO 
Ontologies are engineering artifacts that, as all other engineering artifacts, need to be 
evaluated (Vrandečić, 2010). This evaluation is required during the development of a new 
ontology, not only to ensure the quality of the resulting resource but also to guide 
ontologists during the construction process and refinement steps. Moreover, ontology 
reuse requires previous evaluation of ontology candidates in order to provide new users 
with a way to assess their quality (Brank, Grobelnik, & Mladeni, 2005).  
In spite of the relevance of ontology evaluation, this area is still an open research 
field (Hastings, Brass, Caine, Jay, & Stevens, 2014). There is a lack of clear evaluation 
methodologies that leads to the adoption of different approaches by different ontology 
development groups (Gómez-Pérez, 1999). The main reason for this lack of consensus is 
that the establishment of objective measures for ontology evaluation is limited by the 
intrinsic nature of these resources. 
 Ontology evaluation can be divided into two main groups: technical and application-
based evaluation. The former one is a validation of the content and consistency of the 
ontology, while the latter one assesses the quality and usefulness of the ontology for an 
intended application.  
On the one hand, there are ontological aspects that can be objectively measured from 
a technical perspective. These include taxonomical aspects, naming conventions, 
completeness, or consistency. During the recent years, there have been important efforts 
to identify these aspects and to provide standards to ensure the development of reusable 
ontologies. There are three research groups and/or projects that have strongly contribute 
to the development of principles and standards for ontology technical evaluation. Firstly, 
the most important efforts regarding domain-independent ontology evaluation have been 
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addressed by the Ontology Engineering Research Group at “Universidad Politécnica of 
Madrid”.51 Secondly, principles for the creation of reusable and high quality ontologies in 
the biomedical domain have been established by the OBO Foundry community, a 
collaborative effort for the development and maintenance of biomedical ontologies to 
ensure their integration and interoperability (Smith et al., 2007). Thirdly, another 
important work in the field of controlled medical vocabularies is Cimino et al.’s 
Desiderata (Cimino, 1998),  which delineates desirable characteristics for controlled 
medical terminologies and attempts to summarize emerging consensus regarding 
structural issues of such terminologies. These three works provide standards, principles 
and recommendations for ontologies in the general and biomedical domain that contribute 
to the creation of high quality and reusable ontologies. 
On the other hand, there are ontological aspects that cannot be assessed objectively. 
The reason is that, although domain ontologies are formal representations of a body of 
knowledge, conceptualization is a subjective procedure open to different representations. 
In this way, the same aspect of the real world (e.g., a pharmacological process) can be 
represented in different ways in different ontologies (Olivié, 2007). Consequently, there 
can be several ontologies representing the same knowledge. Assessing their quality and 
usefulness depends on users’ requirements and their suitability for the application where 
they are used.  Therefore, application-based evaluations are necessary to ensure the 
quality and usefulness of ontologies.  
The evaluation of DINTO integrates both mentioned approaches: technical and 
application-based evaluations. With the aim to provide an objective and complete 
evaluation of this new ontology, we propose a strategy based on the combination of 
different evaluation methods that, in conjunction, provide a comprehensive description of 
the consistency, quality, and re-usability of the ontology. This strategy is summarized as 
follows, and described in this chapter and the following Chapter 9 and Chapter 10: 
1. TECHNICAL EVALUATION: The ontology is evaluated in its form and 
content to assess its consistency and expressivity, as well as for the detection of errors 
such as circularity, partition, or semantic inconsistency (Gómez-Pérez et al., 2004). This 
evaluation process is  divided into the following subtasks:  
 Classification scenario testing: evaluation of the CM of the ontology is 
carried out by means of the representation of real examples for DDIs taken 
from the pharmacological literature. Protégé enables the logical inference of 
new entity classification and new relationships using a reasoning engine. 
The representation of real examples from the DDI domain allows the 
checking of consistency and expressivity of the CMs.  
 Supporting or answering of previously established competency 
questions: CQs are pre-established and natural language questions created 
during the specification activity representing the aspects that the final 
ontology should address. They are used in the evaluation of ontologies as a 
pre-established set of content requirements for the new ontology.  
 Peer-review or human performed evaluation: A manual review of the 
ontology is carried out to ensure that the ontology meets a set of predefined 
                                                 
51 http://www.oeg-upm.net/ 
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criteria, standards, or requirements (Lozano-Tello & Gómez-Pérez, 2004). 
Specifically, the ontology is created on the basis of the principles of the 
OBO Foundry community (Smith et al., 2007) to standardize and reuse 
ontologies. Indeed, DINTO has been reviewed by the OBO Foundry and has 
been accepted and listed in their website as one of the “OBO Foundry 
candidate ontologies and other ontologies of interest”.52 
2. APPLICATION-BASED EVALUATION: Biomedical ontologies should 
be evaluated against the task for which they were developed (Hoehndorf, Dumontier, & 
Gkoutos, 2012). Moreover, an ontology is said to be robust if it performs well in multiple 
heterogeneous tasks. Therefore, the usefulness of our ontology is evaluated in two 
different scenarios: 
 Inference of DDIs: The ontology is used to infer DDIs on the basis of their 
mechanisms. Information represented in the ontology is combined with 
SWRL rules to infer DDIs between individual pairs of drugs and their 
mechanisms. These inferences are evaluated against asserted information 
imported from the database DrugBank (see Chapter 9). 
 DDI Information Extraction: DINTO is used by an IE system in order to 
recognize pharmacological substances and extract DDIs from texts. This 
system is evaluated on the DDI corpus, and results are compared to those 
obtained by participating systems on the SemEval-2013 DDIExtraction task 
(Segura-Bedmar et al., 2013) (see Chapter 10). 
8.1 Technical evaluation 
Technical evaluation checks the quality of the ontology from an objective point of 
view and independently of the requirements of final users and applications. Because there 
is not a unique methodology for ontology technical evaluation (Gómez-Pérez, 1999), our 
approach consists in combining three different methods in order to evaluate the ontology 
in a comprehensive way. These methods are: i) classification scenario testing, ii) 
supporting or answering of competency questions, and iii) peer-review evaluation. With 
this strategy, it is possible to evaluate if the ontology is consistent, complete,and free of 
taxonomical errors  
8.1.1 Classification scenario testing 
Classification scenario (CS) testing is performed to check if the knowledge 
represented in the ontology is consistent and complete. As we explained in Section 7.1.3, 
during conceptualization of DINTO the domain knowledge is organized and structured 
into CMs that are then implemented using the ontology editor Protégé to construct a 
formal representation of the DDI domain. During these processes, different errors could 
                                                 
52 http://www.obofoundry.org/ 
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be introduced, leading to the inference of inconsistent information. A useful method to 
identify these conceptualization and implementation mistakes is the representation of real 
DDI examples taken from the pharmacological literature in the ontology. Protégé enables 
the logical inference of new entity classification and new relationships through the use of 
a reasoning engine, a program that infers logical consequences from a set of explicitly 
asserted facts or axioms (Cuenca, 2011). Therefore, the representation of real examples 
from the DDI domain as individuals in the ontology allows for validating the consistency 
and the expressivity of the CMs.  
This evaluation is carried out iteratively during the processes of conceptualization 
and implementation, making possible the correction of inconsistences during the creation 
of the ontology. Hence, in a final evaluation, we select three CS testing examples to 
evaluate the consistency of the final ontology. The two first are well known interactions 
described in different sources representing one of the two main types of DDIs (PK and 
PD DDIs). The third one is an unknown DDI recently described in a case report and 
published in a medical journal. These examples are explained below (CS1, CS2, and CS3, 
respectively) and results of the CS testing are graphically represented in Figure 8.1, 
Figure 8.2, and Figure 8.3. In these figures, boxes represent individuals, black arrows 
are explicitly represented relationships between individuals and red dashed arrows 
represent inferred relationships obtained when using a reasoner engine. Green ellipses are 
attributes manually added for individuals. Every individual’s box shows the ‘is a’ 
relationships used to classify them in the ontology. Black lines show information 
manually added in the experiment, while red italic lines show the inferred classification 
of individuals in the ontology. 
 CS1: PK DDI between rifampicin and cyclosporin A 
Rifampicin is an antibiotic used in the treatment of tuberculosis. This drug 
is important in the field of DDIs since it is a potent inducer of numerous 
metabolic enzymes and transporters. Therefore, it interacts with a large 
number of drugs. One of them is the immunosuppressant cyclosporine A. 
Among other applications, this drug is used in transplanted patients to avoid 
organ rejection. Therefore, therapeutic failure in patients treated with 
cyclosporin A can have serious consequences.  
Concomitant administration of rifampicin and cyclosporin A decreases the 
serum levels of the immunosuppressant due to the increase in its metabolism. 
This occurs because rifampicin induces the activity of different CYP 450 
isoenzymes, including CYP 3A4, which is involved in the metabolism of 
cyclosporin A. 
This is a very well documented, established, and clinically important DDI. 
Transplant rejection may occur unless the cyclosporin A dosage is markedly 
increased. The interaction develops within a few days (within a single day in 
some cases). It is necessary to monitor the effects of concurrent use and 
increase the cyclosporin A dosage appropriately (Baxter, 2013; Tatro, 2010); 
(see Figure 8.1). 
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 CS2: PD DDI between morphine and naloxone 
Morphine is the principal member of a group of drugs called opioid 
analgesics. These drugs are potent pain killers used to treat moderate to severe 
pain. Their effects are exerted by their activity in the opioid receptors family. 
Activation of these receptors leads to the analgesic effect. However, other 
severe adverse effects, such as depression of the central nervous system (CNS), 
are produced, too. Therefore, administration of excessive doses of opioid 
analgesics can produce severe respiratory depression, coma, and even death.  
The drug naloxone is used to reverse these symptoms. Naloxone has 
affinity for the opioid receptors but, in contrast to morphine, which activates 
these receptors, naloxone blocks them. Therefore, naloxone decreases the 
activity and the effects of morphine, as well as other opioid agonists, and is 
used in recovery of opiated-induced CNS depression (Baxter, 2013; Tatro, 
2010); (see Figure 8.2) 
 
 CS3: “Propafenone associated severe central nervous system and 
cardiovascular toxicity due to mirtazapine: a case of severe drug interaction” 
(Rajpurohit, Aryal, Khan, Stys, & Stys, 2014) 
«We describe a rare case of severe drug-drug interaction between 
propafenone and mirtazapine leading to propafenone toxicity. A 69-year-old 
Caucasian male taking propafenone for atrial fibrillation was prescribed 
mirtazapine for insomnia. Subsequent to the first dose of mirtazapine the 
patient experienced seizures, bradycardia and prolonged QRS as well as QTc 
intervals on EKG. The patient was admitted to the ICU and recovered after 
supportive management. Propafenone is an established class IC 
antiarrhythmic drug commonly used in the treatment of atrial fibrillation. It is 
metabolized through the CYP4502D6 pathway. Five to 10 percent of 
Caucasians are poor metabolizers. Mirtazapine is a commonly prescribed 
antidepressant drug, which is also metabolized through and may modulate the 
CYP4502D6 pathway leading to altered metabolism of propafenone and 
possible adverse effects. In this case, toxicity was reversed once the offending 
drugs were discontinued. An extensive review of the literature revealed this to 
be the first described case of drug interaction between propafenone and 
mirtazapine» (original abstract in (Rajpurohit et al., 2014); (see Figure8.3). 
 
 
 
 
 
 
  
 
   
Figure 8.1. Classification Scenario 1 (CS1) representing the interaction between rifampicin and cyclosporin a. 
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Figure 8.2. Classification Scenario 2 (CS) representing the interaction between morphine and naloxone 
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Figure 8.3. Classification Scenario 3 (CS3) representing the interaction between propafenone and mirtazapine 
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 Results and conclusions 
In this evaluation approach, we have represented three different real DDIs as 
individuals in the ontology (represented as boxes in Figure 8.1, Figure 8.2, and Figure 
8.3). Each one of these individuals is classified in the corresponding classes (shown as ‘is 
a’ relationship in each box) in the ontology, and we establish different relationships 
between them (black arrows) following the real information provided by the 
pharmacological literature. Attributes, represented as data properties (green ellipses), are 
manually included, too. After leveraging a reasoner engine, we obtain inferred 
information in the form of inferred classification of individuals (red italic ‘is a’ lines in 
boxes) and inferred relationships (represented as red dashed arrows). From this 
evaluation, we have drawn two main conclusions, which are described below. 
Firstly, we have observed that the ontology is consistent, since two different reasoner 
engines - FacT++ (Tsarkov & Harrocks, 2006a) and Hermit 1.3.8 (Glimm et al., 2014) – 
can be leveraged without leading to inconsistences within the three versions representing 
the DDI examples. This means that the ontology conforms to the underlying logical 
theory -a variant of DL (Plessers & De Troyer, 2006) - of the OWL ontology language 
and that, therefore, the knowledge in the ontology has been correctly represented from a 
logical point of view. 
Secondly, this method has demonstrated that the knowledge represented in the 
ontology allows for inferring important implicit information, and that these inferences are 
correct from a pharmacological point of view.  
On the one hand, individuals are correctly classified in different classes. In this way, 
the interaction between ‘rifampicin’ and ‘cyclosporin A’ and the interaction between 
‘propafenone’ and ‘mirtazapine’ are classified as ‘pharmacokinetic DDIs’, that is, as 
DDIs occurring due to a PK mechanism. Moreover, a more detailed description of the 
DDI mechanism is inferred in a way that the first one is classified as an ‘enzyme 
induction DDI’, and the second one as an ‘enzyme inhibition DDI’. Furthermore, these 
DDIs are classified in the ontology as ‘potentially harmful’, since their consequences 
could be dangerous for patients. In contrast, the interaction between ‘naloxone’ and 
‘morphine’ is classified as a ‘pharmacodynamic DDI’, and specifically as an 
‘antagonistic DDI’, a type of PD DDI occurring due to the opposed effect of both drugs 
on the same target. Furthermore, regarding the potential consequences for the patient, the 
DDI is correctly classified as a ‘beneficial DDI’.  
On the other hand, important information is inferred as new relationships between 
individuals. In addition to the inference of inverse relationships for every explicitly 
established relation (e.g., the relationship ‘is participant in’ is inferred when the 
relationship ‘has participant’ is represented between two individuals in the ontology, and 
vice versa), DINTO allows for inferring new relationships that provide a more detailed 
description of the DDI mechanism and the effect. In this way, it is inferred that 
‘rifampicin’ increases the metabolism of ‘cyclosporin A’ (mechanism) and decreases its 
‘immunosuppressant effect’ (effect). Regarding the mirtazapine-propafenone example, it 
is inferred that ‘mirtazapine’ decreases the metabolism of ‘propafenone’ (mechanism) 
and increases its adverse effect ‘bradycardia’ (effect). Finally, it is inferred that 
‘naloxone’ decreases the CNS depression induced by ‘morphine’ (effect).  
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Therefore, besides proving the consistency of the ontology, this technical evaluation 
has shown other important aspects. In this way, the results prove that the CM in the 
ontology is a correct representation of different types of DDIs including those occurring 
by a PD mechanism and those occurring by a PK mechanism. Moreover, the CM enables 
the representation and inference of important aspects of the DDI domain, including how a 
drug alters the effect of another one, how it modifies a PK process, or the type of 
consequence – beneficial or harmful – for patients. These findings are further confirmed 
in the application-based evaluation in Chapter 9. 
8.1.2 Supporting or answering of previously established 
competency questions 
During the specification activity, we have created a set of CQs in natural language 
representing the aspects that the final ontology should address (see Section 7.1.1). 
Therefore, they constitute a useful resource to check if the ontology represents all that 
information required in first development stages or, in other words, if the ontology is 
complete.  
Ontology evaluation by identifying a set of CQs was firstly introduced by (Grüninger 
& Fox, 1995) and later on included in the methodologies for ontology creation 
METHONTOLOGY (Fernández-López et al., 1997) and NeOn Methodology (Suárez-
Figueroa et al., 2012). Therefore, it is a key step in the creation of DINTO. During the 
development process, CQs are used to identify the information that should be included in 
the ontology in an iterative process. Finally, the list of CQs is used to evaluate the 
completeness of the ontology using specific examples of DDIs extracted from the 
pharmacological literature. 
To show if content in the ontology satisfies our pre-established requirements, we use 
the same three DDI examples as in previous section (CS1, CS2 and CS3), which are a 
good representation of how DDIs are represented in text, and that include DDIs occurring 
by different mechanisms. Annex 7, Annex 8, and Annex 9 show the CQs lists, the 
corresponding answers, and the corresponding axioms as an example of how the ontology 
corresponds to the CQs. 
 Results and conclusions 
To perform this evaluation we use the three DDI examples represented at the 
individual level in the ontology on the basis of the textual information shown in CS1, 
CS2, and CS3. As it is shown in Annex 7, Annex 8, and Annex 9, most CQs could be 
answered at least in one example.  
This exercise shows that important DDI-related information is explicitly represented 
as classes in the current version of the ontology. These include interactions between two 
drugs (CQs 1), the type of mechanism leading to the DDI (CQs 3, 5-7), and drug-protein 
relationships (CQs 24-27). In contrast, other information is not explicitly described at the 
class level, but it can be manually added at the individual level without leading to 
inconsistences. This includes information related to the effect of the DDI (CQs 2, 8-11), 
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specific alterations in PK parameters (CQ 4), the characteristics of the interacting drugs 
(CQs 22), the source of information describing the DDI (CQs 29-33), patient 
characteristics (CQs 18-21), and recommendations (CQs 12-17). This demonstrates that 
the CM is complete and flexible enough to allow for the representation of this knowledge, 
although specific drug and DDI-related facts have not been included yet in the ontology. 
As we have established in the maintenance strategy for DINTO (Section 7.1.8), this 
information will be consecutively included in further versions of the ontology. 
There are two questions, however, that could not be answered in any of the 
examples. These questions are related to the topics of description of an alternative non-
interacting drug (CQ 23) and the characterization of interacting drugs as agents with 
narrow therapeutic index (CQ 28). Although this information is relevant to the DDI 
domain, it has not been included it in the current CM. Therefore, this task should be 
addressed during maintenance activities in order to include these aspects in next versions 
of the ontology. 
8.1.3 Peer-review or human performed evaluation 
To evaluate the content and structure of DINTO, we perform a manual review to 
ensure that the ontology meets a set of predefined criteria, standards or requirements 
(Lozano-Tello & Gómez-Pérez, 2004). These requirements are adopted from three main 
research efforts that have identified those characteristics desirables for reusable and high 
quality ontologies (Cimino, 1998; Fernández-López et al., 1997; Smith et al., 2007). A 
brief description of them is provided below. 
1. The Ontology Engineering Research Group: The Ontology Engineering 
Research Group at “Universidad Politécnica de Madrid” has worked during the last 
years on the creation of methodologies for domain-independent ontology 
development (Gómez-Pérez et al., 2004; Suárez-Figueroa et al., 2012). They have 
studied and described ontology evaluation aspects to ensure the quality of an 
ontology from a technical point of view (Gómez-Pérez, 1999). In this way, they 
identified a set of criteria that should be evaluated in a given ontology (consistency, 
completeness, conciseness, expandability, and sensitiveness), and a set of possible 
errors that can be made by ontologists when building taxonomic knowledge into an 
ontology (circularity, partition, redundancy, and semantic errors). 
2. The OBO Foundry: The OBO Foundry (Smith et al., 2007) is a 
collaborative effort based on the voluntary acceptance by its participants of an 
evolving set of principles specifying best practices in ontology development. These 
principles are designed to foster interoperability of ontologies within the biomedical 
domain, and to ensure a gradual improvement of quality and formal rigor in 
ontologies in ways designed to meet the increasing needs of data and information 
integration in the biomedical domain. The OBO Foundry principles establish that 
new ontologies should: i) be developed in a collaborative effort, ii) use common 
relations that are unambiguously defined, iii) provide procedures for user feedback 
and for identifying successive versions, and iv) have a clearly bounded subject 
matter. The long-term goal of the OBO Foundry is that the data generated through 
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biomedical research should form a single, consistent, cumulatively expanding and 
algorithmically tractable whole.  
3. Desiderata for controlled medical terminologies: Cimino et al. described a 
set of delineated desirable characteristics or desiderata for controlled medical 
terminologies, which attempted to summarize consensus regarding structural issues 
of such terminologies (Cimino, 1998). The desiderata covers aspects such as content, 
structure, and naming conventions and provides a detailed description of the most 
important characteristics needed to make controlled vocabularies sharable and 
reusable, that can be made extensible to biomedical ontologies (Cimino, 2006). 
The review of their recommendations and their combination has led to the 
construction of an evaluation template establishing the requirements that our ontology 
should adhere to. This template (see Annex 10) is used as a guide during the 
development of DINTO and as a checklist for the evaluation of the final ontology. In this 
way, the final version of DINTO is evaluated and refined until complete adherence to all 
evaluation criteria included in the template are addressed. 
 Results and conclusions 
The resulting evaluation template is used as a guide during the development process 
and all requirements are considered during the creation of DINTO. Once the final version 
of the ontology is created, we perform a deep evaluation against the template 
requirements. Final version has not been considered correct until all of them have been 
met. The final evaluation template for DINTO is shown in Annex 10.  
As shown in the template, all the requirements have been fulfilled. Naming 
conventions and use of numerical labels for URIs are only violated for those entities 
imported from PKO and BRO. However, we maintain them in order to preserve the 
original source. Analysis of inconsistences is carried out using ontology reasoner engines, 
and manual review of incompleteness and redundancies is performed, too.  Finally, it is 
important to note that DINTO has been developed in collaboration with an important 
OBO Foundry member, the ChEBI ontology.  
8.1.4 Conclusions 
In this chapter, we have introduced ontology evaluation and have presented our 
strategy to validate the quality of DINTO from a technical and application-based 
perspective. 
The technical evaluation described here consists of three different approaches. The 
first one is classification scenario testing, which has shown that the knowledge 
represented in the ontology is consistent and complete enough to represent three real DDI 
examples. The second one, supporting or answering previously established CQs, has 
proven that the ontology is complete and covers the aspects established in the 
specification activity. Finally, the third technical evaluation approach is the manual 
evaluation of the content and structure of the ontology following a set of predefined 
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requirements. Supported by a specifically created evaluation template, we have shown 
that all the requirements have been met by the final version of DINTO. 
In the next chapters, we describe two different application-based evaluations of 
DINTO that, in combination with the technical evaluation described here, provide a 
comprehensive description of the consistency, quality, and re-usability of the ontology. 
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Chapter 9 
Inference of DDIs and their 
mechanisms 
In the framework of this thesis, we propose the creation of a new ontology for the 
NLP research community working within applications in the DDI domain. However, high 
quality and robust ontologies are those that perform well in multiple tasks and that can be 
reusable across different applications. To assess its “robustness”, the ontology should be 
evaluated on multiple heterogeneous tasks (Hoehndorf et al., 2012). Therefore, we decide 
that a complete evaluation of DINTO should include the assessment of its performance in 
an additional application.  
Two main reasons have driven our selection of computational inference of DDIs as 
an alternative application scenario. First of all, during the study of current efforts in DDI-
knowledge modeling (Section 6.4) we have observed that, besides NLP, prediction of 
DDIs has been the other main application of these projects (Arikuma et al., 2008; Boyce 
et al., 2010b; Imai et al., 2013). These research groups have demonstrated that the formal 
representation of pharmacological information can be successfully applied to the 
inference of DDIs on the basis of their underlying mechanisms. Therefore, this additional 
evaluation approach could provide a supplementary method to those described in 
Chapter 8 to assess if the CM in our ontology is correct and complete.  
In addition to this, computational inference or prediction of DDIs is a research field 
that has attracted a great deal of attention during the recent years. Many different 
approaches have been proposed to achieve this goal: i) extrapolation of in vitro data to the 
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in vivo situation; ii) similarity-based methods and data mining; iii) text mining of 
scientific literature; and iv) knowledge representation and reasoning. 
Firstly, some authors have adopted traditional approaches using in vitro data to 
predict in vivo DDIs (Zhang, Zhang, Zhao, & Huang, 2009) in order to automatically 
obtain predictions for a larger number of drugs (Bonnabry et al., 1999; Fahmi et al., 2009; 
Ito et al., 2004; Quinney et al., 2010). In contrast to this one, that extrapolates in vitro 
information to in vivo situations, similarity-based methods exploit pharmacological 
information, such as molecular structure or target similarity, to identify potential DDIs 
(Gottlieb et al., 2012; Vilar et al., 2012, 2014). Mostly, these projects are based on data 
mining. For example, within this group several research groups have studied the use of 
ADRs data from spontaneous report databases to identify new DDIs (Harpaz, Haerian, 
Chase, & Friedman, 2010; Thakrar et al., 2007; van Puijenbroek et al., 2000).   
Besides these approaches, text mining has emerged in the recent years as a new and 
promising approach to identify DDIs from texts (Duke et al. 2012; Tari et al. 2010; 
Segura-Bedmar, Martínez & de Pablo-Sánchez 2011a; Segura-Bedmar, Martínez & de 
Pablo-Sánchez 2011b; Zhang et al. 2012) that hence can be used in combination with 
other methods, such as Tari et al. (2010), who combined text mining and automated 
reasoning techniques, or Percha & Altman (2012), who combined text mining and 
semantic network representation. 
Finally, pharmacological knowledge representation and reasoning has been widely 
used for the prediction of DDIs. It can be divided into two main subtypes: i) those using 
semantic networks or ii) those based on DL representations and/or rules. Semantic 
networks - representing drugs as nodes and interactions between drugs as edges or arcs - 
have been used by different authors to infer DDIs through reasoning (Cami et al., 2013; 
Guimerà & Sales-Pardo, 2013; J. Huang et al., 2013; Percha & Altman, 2012; Takarabe, 
Shigemizu, Kotera, Goto, & Kanehisa, 2011). However, there is an increasing interest on 
more expressive representation formalisms (Brochhausen et al., 2014), such as DL and/or 
rules, which support additional inferences and have proven to be useful to predict 
different types of DDIs (Imai et al., 2013; Moitra, Palla, Tari, & Krishnamoorthy, 2014; 
Tari et al., 2010; Wu et al., 2013; Yoshikawa et al., 2004).  
For all these reasons, we consider that inference of DDIs – that in the framework of 
this project is defined as the automatic identification of DDIs or DDI-related knowledge, 
such as type of mechanism, from implicit information in the ontology - is an adequate 
application to evaluate DINTO. In this chapter, we provide a review of the projects that 
have studied the inference of DDIs using DL or rule-based representation of DDI 
knowledge (Section 9.1), analysing their unresolved issues and the possible contributions 
of our work. In Section 9.2, we describe three different experiments performed to 
evaluate the inference capabilities of DINTO. Finally, main conclusions of this chapter 
are provided in Section 9.3. 
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9.1 Related work on DDI prediction using 
DL, rules, and reasoning 
In the previous section, we have provided a broad review of the state of the art in 
computational inference of DDIs. Here, we focus on those projects relying on knowledge 
representation as DL and/or rules to infer DDIs. To the best of our knowledge, five 
research groups have exploited this type of formally represented information to the 
inference of DDIs on the basis of their underlying mechanisms. 
Arikuma et al. (2008)  used the formal representation of PK molecular events of 
drugs in the OWL ontology Drug Interaction Ontology (DIO) and an inference 
program based on drug interaction rules to infer PK DDIs. In their experiment, they 
predicted four different mechanisms leading to a PK DDI occurring between two drugs 
(irinotecan and ketoconozale), that were considered as four different DDIs. These DDIs 
were manually evaluated against pharmacological literature. Two of them were 
confirmed by published papers, while the other two could not be supported by current 
literature and were considered to be negligible by the authors – i.e., clinically 
unobservable or irrelevant when the drug doses are low.  
In the framework of the Drug Interaction Knowledge Base (DIKB) project, Boyce 
et al. (2010) conducted an experiment to infer DDIs occurring via a specific PK 
mechanism. They combined i) the drug-related facts or assertions manually curated in the 
DIKB about a total of 35 drugs and drug metabolites and their relationships with 
enzymes, ii) a set of FOL rules, called rule-based theory, of how drugs interact by 
metabolic inhibition and iii) the evidence-base, which provides evidence for, or against, 
each one of the assertions and is used to distinguish between relevant and negligible 
DDIs. A total of 586 possible interacting pairs were assigned a value true or false 
regarding the prediction provided by an inference program. To evaluate the inferences, 
the authors created an experiments’ validation set, constituted by 48 interacting pairs 
found to be described in the pharmacological literature as interacting or non-interacting 
pairs. The remaining 538 pairs were not found in the literature. Therefore, it is not 
possible to assert if they are non-interacting pairs or they have not been described yet. A 
total of 65 DDIs were predicted by the system; 34 of them were in the validation set and 
therefore considered as correct inferences, while 31 predicted DDIs belonged to the group 
of 538 pairs not known to be interacting or non-interacting drugs.   
DIKB information was reused in a different project. Moitra et al. (2014) proposed a 
system that integrates the capabilities of semantic modeling and temporal reasoning to 
identify quantitatively PK DDIs occurring via a metabolism-related mechanism. DDI 
information was modelled in the Semantic Application Design Language (SADL),53 
which was then translated to OWL models. The semantic model incorporates information 
from the DIKB, and the logic rules for DDI inference were represented in the declarative 
logic programming language Answer Set Programming (ASP) (Niemelä, 1999). To 
evaluate the system, the authors studied the interactions between three drugs (fluoxetine, 
clozapine, and olanzapine) and concluded that fluvoxamine had a greater impact on the 
metabolism of clozapine than on the metabolism of olanzapine. Manual review of the 
                                                 
53 http://sadl.sourceforge.net/sadl.html 
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literature confirmed this results, although evaluation in a larger set of drugs was not 
performed yet.  
Similarly focusing on metabolism-related DDIs, Tari et al. (2010) combined a 
logical representation of the domain, text mining techniques, and automated reasoning to 
infer DDIs. Drug-related facts, such as drug-protein relationships, were extracted through 
NLP techniques from MEDLINE abstracts and stored in a parse tree database. DDI 
domain knowledge representing how a drug alters the metabolism of another one was 
represented as AnsProlog (Gelfond & Lifschitz, 1991) logic rules, a declarative language 
useful for reasoning, and an AnsProlog solver called clingo (Gebser, Ostrowski, & 
Schaub, 2009) was used to compute the inferences. To evaluate this approach, 496 DDIs 
described in DrugBank between 295 drugs were used as a gold-standard. A total of 979 
DDIs were inferred from drug-facts extracted from texts, of which 123 were included in 
the gold-standard, and 856 were not. A sample of 345 of these remaining DDIs (40%) 
was manually reviewed to evaluate if there was evidence supporting them - that is, if the 
extracted drug-protein relationships were consistent with a possible mechanism 
underlying the DDI -, and it was found that this was the case for 286 (82%) of the 
reviewed DDIs. 
In contrast to the former projects, Imai et al. (2013) addressed the inference of PD 
DDIs. To do this, they manually included drug-related facts in the Pharmacodynamics 
Ontology (PDO) as subordinate classes for 89 drugs related to noradrenaline. They 
identified 14 different types of PD DDIs that could occur between two drugs, and 
checked how many pairs could lead to a DDI by one or more of these mechanisms. In 
contrast to the previous projects, Imai et al. did not implement any inference system, and 
inferences were identified manually in accordance with the information represented in the 
ontology and the different types of DDIs established. To evaluate the predictions made, 
they selected 22 drugs leading to 231 predicted DDIs and checked if they were described 
in the Japanese SPCs. They found descriptions for 72 of the DDIs, while the remaining 
159 were not mentioned. 
These five projects demonstrate that formal representation of drug-related facts and 
DDI knowledge can be combined to infer interactions between drugs. However, one of 
the main limitations encountered by most of them is the low coverage of drugs included 
in their experiments. Indeed, the PDO was used to infer DDIs between 89 drugs and the 
DIKB predicted interactions between 35 pharmacological substances, while Moitra et 
al.’s approach and the DIO were used to predict the interaction between only three and 
two drugs, respectively. The main reason for this low coverage is that all these methods 
rely on manual curation to identify, gather, and structure the drug-related facts required as 
basic information to infer the DDIs. Although expert manual curation provides high 
quality information, this activity is both cost-intensive and time-consuming. Moreover, 
new pharmacological information is discovered and published every day in the scientific 
literature, which makes keeping up to date a knowledge base with this information a 
difficult task. As an alternative to manual curation, Tari et al. automatically extracted 
drug-related facts through text mining and could test their system on 295 drugs. However, 
a different solution could be brought by the increase in pharmacological information 
stored in structured and machine-readable formats as public databases and knowledge 
bases that has emerged during the last years (Khelashvili et al., 2010; Whirl-Carrillo et 
al., 2012). Exploiting this information and integrating it automatically in a knowledge 
base could overcome the limitation of manual curation.  
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Another limitation of these works is that none of them dealt with the inference of 
different types of DDIs in the same framework. On the one hand, the projects using the 
DIO or the DIKB, as well as Moitra et al.’s and Tari et al.’s projects, focused on PK 
DDIs. More specifically, the four latter addressed only the inference of metabolism-
related DDIs. On the other hand, the experiment performed using the PDO included only 
PD DDIs. Therefore, it has not been demonstrated yet if the same CM and inference 
system can be used to predict, at the same time, DDIs occurring via both PK and PD 
mechanisms and their respective subtypes. 
Evaluation of the inferred results was a challenging task, too. Most of the projects 
performed a manual review of pharmacological literature to evaluate their inferences. The 
only exception was Tari et al., who created a gold-standard from DrugBank to compare 
their inferences, and then performed a manual evaluation of the non-matching results. 
However, manual review leads to three main issues. Firstly, this is a time consuming task 
that cannot be applied to a great set of inferred DDIs. Indeed, Arikuma et al. could only 
evaluate the interactions predicted based on DIO for 22 representative drugs since the 
number of all combination of the original 89 drugs was too large. Secondly, manual 
review of the large pharmacological literature can introduce bias in the evaluation, since 
many clinically-relevant DDIs could be missed during the review process or they could 
be not reported in the consulted sources (Boyce et al., 2010b). Thirdly, it is not possible 
to know when a DDI is not described in the literature because there is not an interaction 
between the interacting pair or because, although this interaction exists, it has not been 
described yet (Tari et al., 2010). Therefore, the evaluation of false positives - or incorrect 
inferences - and false negatives - true information that, however, has not been inferred - 
can never be performed in a comprehensive way. 
In short, the main unresolved issues are: 
1. Low coverage of drugs included in the experiments. 
2. Representation of only one interaction type: PK or PD DDIs. 
3. Manual evaluation in most cases.  
With our experiment, we attempt to contribute to the research in the field of 
computational inference of DDIs by overcoming the limitations encountered by former 
efforts. To do this, firstly we automatically integrate pharmacological information 
available in databases and ontologies instead of manually curate it in our ontology. With 
this strategy, we expect that the coverage of drugs will be larger than in previous projects. 
Secondly, we address the inference of both PK and PD DDIs in order to know if they can 
be predicted in the same representation framework. Thirdly, in order to obtain a more 
detailed description, different subtypes of DDI mechanisms, such as enzyme inhibition, 
antagonism, or transporter induction, are represented. Therefore, we expect that our 
representation of DDI-knowledge will be correct and complete enough to infer both DDIs 
and the specific mechanisms preceding them. 
Another contribution of our DDI-inference experiment is that we employ exclusively 
resources and tools for the semantic web and the ontology engineering field. It has been 
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postulated that “having the inference mechanism and the descriptive knowledge 
combined under the same syntactic structure provides means for interoperability of rule 
systems” (Lezcano et al., 2011). Moreover, some authors consider that using ontologies 
in conjunction with rules is a major challenge for the Semantic Web (Golbreich, 2005). 
Therefore, in contrast to the previous efforts that represented differently drug-related 
facts and inference rules, we use only the Web Ontology Language OWL 2 and its 
extension the Semantic Web Rule Language (SWRL) to formally represent all the 
information required. Our supporting tool during the whole process is the ontology editor 
Protégé and, instead of implementing a new inference program, we use existing ontology 
reasoner engines compliant with the OWL semantics.   
Therefore, this experiment provides a unique and novel framework for the 
assessment of the contributions that semantic web technologies and ontology engineering 
can provide in projects requiring i) the storage of large amounts of structured 
information, ii) a formal and highly expressive representation of complex processes, and 
iii) powerful inference capabilities to apply machine reasoning to large amounts of 
semantic data. 
9.2 Inference of DDIs and DDI mechanisms 
using DINTO 
To evaluate the inference capabilities of DINTO, we have designed three different 
experiments. In the first experiment (IExp1), we analyse how a reasoner classifies known 
DDIs by using only explicit information about their mechanisms. The aim is to check if 
the information explicitly represented in the ontology is consistent, and if the 
relationships established between DDIs and their mechanisms allow for their correct 
classification. However, inferences that are more complex rely on the formal 
representation of DDI mechanisms. For this purpose, we have created two sets of SWRL 
rules to infer DDIs and their mechanisms (see Section 7.2.5). Therefore, in the second 
experiment (IExp2) we validate if the combination of the first set of rules and drug-
protein relationships in DINTO can be used to infer new DDIs. Finally, in the third 
experiment (IExp3) we combine the second set of rules to infer both, DDIs and their 
mechanisms. With this third experiment, we validate if the formal representation of DDIs 
mechanisms by means of drug-protein relationships can be used to identify automatically 
the underlying mechanism of a DDI. 
In this section, we firstly introduce ontology reasoner engines and discuss their 
current limitations, and then we describe the methods, results, and evaluation of the three 
inference experiments, providing a brief discussion of each one of them. 
Ontology reasoning plays a key role in ontology engineering and has become an 
indispensable activity to help ontologists during the development and evaluation of 
ontologies, as well as users to query their contents. It is performed by a reasoner engine, a 
program that infers logical consequences from a set of explicitly asserted facts or axioms 
(Cuenca, 2011). With the advancement of ontology languages, many ontology reasoners 
have been developed. Some of them are available as plugins for the ontology editor 
Protégé. This provides a user-friendly interface for the study of the resulting inferences. 
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Some of the most widely used ontology reasoners are FacT++ (Tsarkov & Harrocks, 
2006b), Pellet (Sirin et al., 2007), or HermiT (Glimm et al., 2014). The three of them 
support the features of OWL 2 ontology language. However, as we explained in Section 
7.1.7, OWL 2 cannot express all type of relations and its expressivity can be extended by 
adding SWRL rules, which are supported by Pellet and HermiT.  
 
Ontology reasoner engines facilitate the following tasks: 
 Checking the consistency of the ontology: Reasoners check if the ontology 
axioms conform to the underlying logical theory of the ontology language and 
detect any inconsistency within it (Plessers & De Troyer, 2006). We use the 
reasoner engines FacT++ and HermiT to check the consistency of our ontology, as 
we explain in Chapter 8. 
 Classification: Implicit classification of classes and individuals can be 
obtained when leveraging a reasoner engine. Different axioms can lead to these 
inferred classifications: i) the ‘is a’ relationships that shows a taxonomical 
classification of classes and, therefore, of their individuals; ii) OWL definitional 
axioms or ‘equivalent to’ assertions; iii) object properties domains and ranges, 
which are used as axioms in reasoning; iv) specific SWRL rules. 
 Inference of relationships between classes or individuals: New 
relationships can be obtained when a reasoner engine is used in an ontology. They 
are inferred when some of the following axioms have been included in the 
ontology: i) object properties characteristics, such as transitivity or symmetry; ii) 
‘inverse of’ axioms between two object properties, that infers inverse relationships; 
iii) property chains, which infer a relationship x between two classes a and c when 
they are linked by two specific relationships y and z and another class b (Figure 
9.2); iv) specific SWRL rules. 
 Answering queries over ontology classes and instances: Reasoners can be 
used to query and search the ontology content. They are capable of finding more 
general or specific classes or retrieving individuals or triples matching a given 
query.   
Although current ontology reasoner engines perform all the activities mentioned 
above, their performance with very large and complex ontologies is still compromised 
(Cuenca, 2011; Holford et al., 2010). As we have observed during the development of 
DINTO, reasoners can crash with a consistent ontology when: i) it has a very large TBox 
(i.e., the terminological box which handles the axioms around classes.); ii) it has a large 
ABox (i.e., the assertional axioms or assertional box used to assert the truth about 
individuals); or iii) it has a complex level of DL expressivity. Due to the complexity of 
our ontology (DL ALCRIQ(D)), the large number of classes and properties that it 
covers (25,809 classes and 73 object properties), and the large number of corresponding 
individuals required to infer DDIs, we cannot use any of the available OWL reasoners 
with the final version of DINTO. Therefore, in order to test its consistency or to infer new 
information,  we adopt different strategies to simplify the ontology while maintaining that 
information necessary to retrieve the desired inferences (Holford et al., 2010). Some of 
these strategies include reducing the number of classes, relationships, or individuals, for 
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example. In order to ensure the reproducibility of our results, we describe in detail the 
modifications done for each experiment, and the corresponding files are available at 
https://code.google.com/p/dinto/. 
9.2.1 IExp1: Classification of DDIs on the basis of explicitly 
asserted mechanisms 
The objective of this experiment is to evaluate if the ontology is consistent when 
classifying DDIs imported from DrugBank on the basis of their asserted mechanisms as 
PK or PD DDIs.  
 Methods: 
DINTO 1.0.0 includes a total of 11,555 classes representing DDIs that have been 
imported from the database DrugBank. Information regarding their mechanisms (‘target 
activity alteration’, ‘enzyme activity alteration’, ‘transporter activity alteration’, or ‘non-
absorbable complex formation’) has been imported as well when it was provided by the 
original source (Section 7.1.3). In this way, the interaction between the drugs 
‘abciximab’ and ‘tirofiban’ is described in the ontology to be preceded by a ‘target 
activity alteration’, which is a type of PD DDI mechanism. 
We have established in DINTO that all those classes preceded by a PD DDI 
mechanism belong to the class PD DDI. In a similar way, we have defined that every 
class preceded by a PK DDI mechanism is a PK DDI. In other words, any individual of 
the ‘pharmacodynamic DDI’ class is equivalent to (≡) any individual that has a ‘is 
preceded by’ relationship with at least one (some) individual of the class 
‘pharmacodynamic DDI mechanism’. Therefore, when running an ontology reasoner, 
DDI classes are classified regarding their mechanisms as PD or PK DDIs. In this way, the 
interaction between abciximab and tirofiban should be classified as a PD DDI, since it is 
described in the ontology to be caused by the alteration of the activity of a target. 
 ‘pharmacodynamic DDI’   ≡    ‘is preceded by’ some 
                ‘pharmacodynamic DDI mechanism’ 
 
‘pharmacokinetic DDI’      ≡    ‘is preceded by’ some 
               ‘pharmacokinetic DDI mechanism’ 
Performing this reasoning task requires a reduction on the size of the ontology, while 
maintaining all the DDIs imported from DrugBank and their mechanisms. We create a 
reduced version of DINTO including only the top classes ‘DDI mechanism’ and ‘drug 
interaction’ and their subclasses.  The resulting inferred classification of DDIs has been 
exported as a new version that can be imported in DINTO 1.0.0 and downloaded from 
https://code.google.com/p/dinto/. 
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 Results: 
We use the reasoner engines HermiT 1.3.8 and FacT ++ to classify the ontology, 
which show that there are no inconsistencies. A total of 1,101 DDI classes are classified 
as PD DDIs, while 5,711 are classified as PK DDIs (Figure 9.1). It is important to note 
that some DDIs are described in DrugBank to be preceded by both a PK and a PD DDI 
mechanism. This is the case of the interaction between ‘didanosine’ and ‘zalcitabine’, 
which is preceded by a ‘target activity alteration’ and a ‘transporter activity alteration’. 
Therefore, the class ‘didanosine/zalcitabine DDI’ is classified as both PD and PK DDI. 
This information is correct from a pharmacological perspective since, although most 
DDIs are frequently assigned a type PK DDI or PD DDI, there could be situations where 
both types of mechanisms can lead to the occurrence of DDIs (Baxter, 2013).  
Similarly, the same pair of interacting drugs can be classified at the same time as two 
different subtypes of PK DDIs (e.g., ‘transporter related DDI’ and ‘enzyme related 
DDI’). Due to this fact, from the 5,711 PK DDIs, 5,283 are classified as ‘enzyme related 
DDI’ and 1,673 are classified as ‘transporter related DDI’. Finally, 128 DDIs are 
classified as ‘non-absorbable complex formation DDI’. None of them is classified, 
however, as ‘carrier related DDI’, since the mechanism ‘carrier activity alteration’ is 
not assigned in DrugBank to any DDI. Finally, those DDIs for which any DDI 
mechanism is established in DrugBank are not classified in the ontology. These results 
are summarized in Table 9.1. 
 
Figure 9.1. Protégé screenshot showing the inferred class hierarchies for PD and PK 
DDIs 
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Classification of DDIs # 
PK DDIs  5,711 
PD DDIs 1,101 
PK DDIs + PD DDIs 659 
enzyme related DDIs  5,283 
transporter related DDIs 1,673 
non-absorbable complex formation DDIs 128 
enzyme related + transporter related DDIs 1,367 
enzyme related + target related DDIs 631 
enzyme related + transporter related + target related DDIs 140 
transporter related + target related DDIs 166 
unclassified DDIs 6,061 
Table 9.1. Results of the classification of DDIs on the basis of their asserted 
mechanisms. 
 Discussion: 
This experiment shows that the conceptualization and implementation of DINTO is a 
correct representation of the relations between DDIs and their mechanisms. Explicit 
information of the mechanism of a DDI imported into DINTO from DrugBank is used to 
obtain a classification of DDIs as ‘PK DDI’, ‘PD DDI’, ‘enzyme related DDI’, 
‘transporter related DDI’, ‘non-absorbable complex formation DDI’, or ‘target related 
DDI’. However, more specific descriptions, such as if the interaction is due to the 
induction of an enzyme, the inhibition of a transporter or the antagonistic effect of two 
drugs on the same target, cannot be obtained with that knowledge.  
However, we believe that other knowledge represented in the ontology, such as drug-
protein relationships, can be exploited to obtain a more detailed classification of DDIs 
based on their mechanisms. This premise is tested in the other two experiments IExp2 and 
IExp3. 
9.2.2 IExp2: Inference of DDIs 
The purpose of this experiment is to determine if the knowledge represented in the 
ontology can be used to infer new DDIs on the basis of their mechanisms. To do this, we 
test two different approaches, which are described in this section: i) inference of DDIs 
using property chains and ii) inference of DDIs using SWRL rules. 
 Methods: 
Our first approach to infer new DDIs is the creation of different property chains 
describing the relationship ‘may interact with’. Property chains are a feature in OWL 2 
used to assert a single property based on the existence of several properties. Through the 
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use of these chained properties, we represent ordered pharmacological events (Herrero-
Zazo et al. 2013). An example of one of this property chains is shown in Figure 9.2. 
 
Figure 9.2. Property chain of the relationships ‘may interact with’ and ‘decreases’ 
In this example, the object property ‘may interact with’, which is a symmetric 
relationship that has domain and range the class ‘pharmacological entity’, is a 
subproperty of the property chain:  
‘decreases’ o ‘is effect of’ → ‘may interact with’ 
At the same time, the object property ‘decreases’ is a subproperty of different 
chained properties, such as, for example:  
‘blocks’ o ‘facilitates’ → ‘decreases’ 
This means that if a drug D1 blocks the activity of a protein P that, at the same time, 
facilitates an effect E, the drug D1 decreases the effect E. Meanwhile, if this effect E is 
the effect produced by another drug D2, then the drug D1 may interact with drug D2 and 
vice versa. 
These and other inferences are successfully obtained when representing different real 
examples of DDIs at the individual level. These examples are described in detail in a 
conference proceeding presented at the International Semantic Web Applications and 
Tools for Life Sciences (SWAT4LS) Workshop in Edinburgh, Scotland (Herrero-Zazo et 
al. 2013), where we describe our first steps and achievements in the construction of 
DINTO. 
However, those examples are always performed representing only two drugs at the 
individual level. When we try to extend this approach to a version including a larger 
number of individuals and their relationships, we observe that the use of property chains 
leads to incorrect inferences, such as that every drug interacts with itself or erroneous 
‘may interact with’ relationships between unrelated pharmacological entities. Therefore, 
from this approach we conclude that the inference of DDIs by representing 
pharmacological mechanisms as property chains is not appropriate to infer DDIs between 
multiple pharmacological entities. 
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As an alternative to property chains, we decide to create rules representing DDI 
mechanisms and use them to infer new ‘may interact with’ relationships between 
pharmacological entities. Boyce et al. (2007) demonstrated that a set of rules in FOL 
could represent how one drug alters the metabolism of another drug. The same PK DDI 
mechanism was represented by Tari et al. (2010) and by Moitra et al. (2014), who chose 
the logic programming language ASP (Bonatti, Calimeri, Leone, & Ricca, 2010). 
Although use of logic programming in combinations with ontologies can be useful, it was 
not conceived as an ontology language for direct interchange of knowledge, which 
hinders the interoperability required by the semantic web and ontologies (Hitzler, 
Krötzsch, & Rudolph, 2009). In contrast to them, in our approach we use the Semantic 
Web Rule Language (SWRL),54 an expressive rule language built on the same description 
logic foundation as OWL. Moreover, instead of focussing on a specific DDI mechanism, 
we address the representation of different types of mechanisms leading to both PK and 
PD DDIs on the basis of object properties represented in the ontology. The result is a total 
of 59 SWRL rules representing the different pharmacological processes involved in PK 
and PD DDI mechanisms (Section 7.2.5).  
The first step is to create a version of the ontology suitable for use with a reasoner 
supporting SWRL. As we explained before, reasoner engines cannot process the whole 
version of DINTO due to its large size. Moreover, when including SWRL rules, 
leveraging a reasoner without crashing becomes an even more difficult task. Therefore, 
we adopt different strategies in order to reduce the size and complexity of the ontology. 
Other authors, such as Holford et al. (2010), have employed this method, too. In our case, 
we eliminate all OWL definitional axioms (or ‘equivalent to’ axioms), simplify the object 
properties hierarchy and delete their characteristics, and eliminate all classes but 
subclasses of the ‘pharmacological entity’ and ‘protein entity’ top classes. Even after this 
reduction in size, the ontology is too large to be used with a reasoner and the 59 SWRL 
rules. The same results are obtained when experimenting with further versions of DINTO 
containing the half or containing a quarter of the total 8,786 pharmacological entities in 
DINTO. Finally, with a version reduced to only 607 pharmacological entities and 429 
proteins, and the 59 rules, the reasoner HermiT 1.3.8 can classify it and show the 
inferences. However, processing the whole ontology through this strategy would require 
the creation of 32 reduced subsets that should be combined 496 times, and would require 
the exclusive dedication of a person during almost 9 months.  
Given this situation, we decide to create a reduced version of the ontology for the 
evaluation of DINTO in the two different applications proposed in this thesis: NLP and 
inference of DDIs. To do this, we create a version of the ontology containing only those 
pharmacological entities mentioned in the DDI corpus test dataset. This version is 
necessary to conduct the evaluation approach described in Section 10.2 and to compare 
the performance of an IE system when it exploits only known DDIs versus using known 
and inferred DDIs. This version of the ontology includes 426 pharmacological entities 
and 752 protein entities having at least one relationship with any of the included drugs. It 
is important to note that, in order to evaluate the coverage for drugs of DINTO, those 
pharmacological entities mentioned in the corpus but not presented in the original version 
are not included in the new one. Therefore, although it is not possible to obtain an 
inferred version of the whole ontology, we can obtain a proof-of-concept for our 
hypotheses in both applications NLP and inference of DDIs.  
                                                 
54 http://www.w3.org/Submission/SWRL/ 
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Inferences from SWRL rules are made in the ABox, that is, at the individual level. 
Therefore, the second step to infer new DDIs is to automatically create individuals for 
every class in the ontology - ‘pharmacological entity’ and ‘protein entity’ subclasses - 
and the corresponding relationships among them. OWL semantics are based on the open 
world assumption (OWA), or the assumption that what is not known to be true must be 
unknown but not false (Groppe, 2011). Therefore, it is necessary to establish that all the 
individuals are distinct among them. This functionality is provided by Protégé and can be 
easily carried out using the ontology editor. 
The third and final step consists in importing the file containing the SWRL rules into 
this version of DINTO, and leveraging the reasoner.  
 Results: 
It takes 3.86 days for the reasoner HermiT 1.3.8 to classify the ontology. A total of 
59,696 new ‘may interact with’ relationships are inferred. However, not all of them are 
established between two drugs, and some relationships are inferred to occur between 
proteins. We automatically rule out those relationships between proteins, although in 
further versions it is possible to modify the SWRL rules to avoid these nuisance 
inferences.  
Using a functionality provided by Protégé, we can export the inferred axioms as a 
new ontology. Thereafter, we automatically translate the ‘may interact with’ relationships 
between two individuals to the corresponding class level and create 10,780 new DDI 
classes of the type ‘drugA/drugB DDI’. Finally, all the individuals are eliminated. The 
result is an inferred ontology with 21,560 ‘may interact with’ relationships and 10,781 
inferred DDI classes. This version can be downloaded from 
https://code.google.com/p/dinto/. 
 Evaluation: 
To evaluate the results of this experiment, we compare the inferred DDIs (from now 
on named the inferred set I) with the DDIs in DrugBank involving some of the 426 drugs 
included in the ontology (the asserted set A). The I set consists of 10,780 inferred DDIs, 
while the A set includes 2,245 asserted DDIs. There is a total of 656 DDIs common to 
both sets. Therefore, the 29% of the DDIs in DrugBank have been inferred in DINTO. 
These results are summarized in Table 9.2. 
Due to the large number of DDIs resulting from this experiment, it is difficult to 
study in detail the above results. However, we can study as well the coincidences and 
differences between the I and A sets regarding not to the DDIs, but to the drugs involved 
on them. In this way, we observe that from the 426 drugs included in the experiment, 
only 219 participate in at least one inferred DDI, while only 309 drugs are involved in at 
least one asserted DDI. Specifically, there are 172 that are common to both sets. 
Therefore, we can consider them as drugs correctly described to participate in at least one 
DDI (true positives). On the contrary, there are 70 drugs that are not included in any of 
the two sets. They represent, therefore, those drugs for which any interaction has been 
incorrectly inferred (true negatives). Finally, 47 drugs are involved in at least one inferred 
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DDI only, while 137 drugs participate in at least one asserted DDI only. The former ones 
can be considered as false positives – i.e., drugs for which at least one DDI has been 
incorrectly inferred – and the latter ones represent false negatives – i.e., drugs for which 
at least one DDI has not been correctly inferred. These results are summarized in Table 
9.3. 
Coincidences between I and A sets (for the 426 drugs) 
 DDIs in A DDIs not in A Total 
DDIs in I 656 10,124 10,780 
DDIs not in I 1,589 - 1,589 
Total 2,245 10,124  
Table 9.2. Number of DDIs in the inferred (I) and asserted (A) sets for the total 426 drugs 
 # % 
Drugs coincident in both sets 
(true positives) 
172 40,38 
Drugs not present in any of the sets 
(true negatives) 
70 16,43 
Drugs only in the inferred set I 
(false positives) 
47 11,03 
Drugs only in the asserted set A 
(false negatives) 
137 32,16 
Total 426 100 
Table 9.3. Comparison of the number of drugs in the inferred (I) and asserted (A) sets. 
Finally, we focus our analysis on those DDIs involving the same drugs in both sets. 
With this approach, we can analyse in detail the disagreements between them. In this 
case, the new inferred set I2 consists of 7,039 inferred DDIs, while the new asserted set 
A2 consists of 815 asserted DDIs. The number of common DDIs in both sets is the same 
(656 DDIs). This means that the 80% of the DDIs in A2 have been correctly inferred. The 
remaining 20% represent the false negatives, or those DDIs in A2 that have not been 
inferred by our method. In contrast, those inferred DDIs that are not included in A2 
represent the false positives. Table 9.4 summarizes these results. 
We randomly select 15 false positives and 10 false negatives to perform a 
qualitative analysis of these results. On the one hand, we find evidence supporting all the 
studied false positives. This means that there is an underlying DDI mechanism, such as, 
for example, that one of the drugs inhibits one or more of the metabolizing enzymes of 
the other drug. As a complementary evaluation source we use the tenth edition of the DDI 
compendia ‘Stockley’s Drug Interactions’ (Baxter, 2013).55 However, none of these false 
positives is included. Regarding false negatives, on the other hand, only the half of the 
studied DDIs is included in the compedia. We identify that this DDIs are not inferred in 
                                                 
55 At the time of performing this evaluation the most recent edition is the tenth (2013) edition. 
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DINTO because they occur through mechanisms that cannot be represented based on 
currently known drug-protein relationships. A more detailed description is provided in 
the following subsection Discussion.  
Coincidences between I2 and A2 sets (for the 172 common drugs) 
 DDIs in A2 DDIs not in A2 Total 
DDIs in I2 656 6,383 7,039 
DDIs not in I2 159 - 159 
Total 815 6,383  
Table 9.4. Number of DDIs in the inferred (I2) and asserted (A2) sets for the common 
172 drugs 
 Discussion: 
In this experiment, we have inferred a large number of DDIs by means of our 
knowledge representation and reasoning approach based on the information represented 
in DINTO. Due to the limitations associated to manual evaluation discussed in this 
chapter, we compare our inferences with the DDIs included in the database DrugBank. 
Results show a high number of false positives, or inferred DDIs that are not included 
in the pharmacological database. Similar results, with a large number of false positives, 
were obtained by Tari et al. (2010), who compared their inferences with a gold-standard 
created from DrugBank, too. As they did, we find evidence supporting the inferred DDIs 
for our studied false positives, which means that there is a plausible mechanism that could 
produce the DDIs. This reveals that the SWRL rules created in DINTO are correct 
representations of the pharmacological processes underlying DDIs. 
However, the elevated number of inferred DDIs not included in DrugBank can be 
explained by the fact that our SWRL rules have been modeled to infer DDIs on the basis 
of different mechanisms, but independently of other related facts, such as their 
significance or level of documentation. Therefore, for any pair of drugs for which an 
underlying DDI mechanism exists, no matter if it would lead to a clinically relevant DDI 
or a not-clinically relevant or unobservable DDI, the interaction is inferred. However, it 
would be incorrect to assume that all those DDIs not included in DrugBank are non-
clinically relevant. Indeed, the evaluation against DrugBank has some limitations. First of 
all, DrugBank - or any other DDI information source - cannot be considered a gold-
standard of “true DDIs” (Imai et al., 2013). Due to the large number of possible DDIs 
(that can have different degrees of significance or can be influenced by drug or patient-
related facts), it is not possible to manually study, identify, and collect all of them in a 
unique information source. The most important compendia for drug-drug interactions, 
such as ‘Stockley’s Drug Interactions’ (Baxter, 2013), ‘Drug Interactions Facts’ (Tatro, 
2010) or ‘The Top 100 Drug Interactions’ (Hansten & Horn, 2014), have an editorial 
board that establishes different inclusion criteria for the described DDIs (Brochhausen et 
al., 2014). Even the SPCs or PIs, the documents provided by drug manufacturers and 
approved by the administrative licensing authorities, have been reported to be 
inconsistent and/or incomplete regarding DDI information (Bergk et al., 2005). For all 
these reasons, it is not possible to know if the false positives DDIs are not included in 
DrugBank because i) they are interacting pairs but have not been included yet in the 
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database, ii) they are interacting pairs but the interaction between them has not been 
described in the scientific literature, or iii) they are not interacting pairs of drugs. 
In the case of false negatives - or DDIs included in DrugBank but not inferred in 
DINTO – we have observed their number is smaller in comparison to false positives. 
Most of them are DDIs whose mechanism cannot be explained by known drug-protein 
relationships. During our analysis, we have identified three different types of them. The 
first one consists of DDIs occurring by non-absorbable complex formation. These DDIs 
occur by the chelation or physicochemical binding of the two drugs in the gastrointestinal 
tract, resulting in a complex with different physicochemical characteristics that cannot be 
absorbed (Levy & Reuning, 1964). Therefore, they cannot be inferred by means of our 
inference rules. The second one is DDIs due to the additive effects of two drugs leading 
to the same ADR. For example, both protriptyline and voriconazole produce prolongation 
of the QT interval, and their concomitant administration can lead to additive effects and 
finally produce a ventricular tachycardia known as Torsade de Pointes (TdP). The final 
type is DDIs for those that, although observed in the clinical setting and described in the 
scientific literature, the underlying mechanism is not known or understood yet (Kulkarni, 
Bora, Sirisha, Saji, & Sundaran, 2013; Patel, Rana, Suthar, Malhotra, & Patel, 2014).  
In spite of these limitations, it has been proven that the combination of information 
about drug-protein relationships and SWRL rules can be used to represent and infer 
different types of DDIs on the same representation framework. Moreover, the results and 
analysis performed in this experiment are useful to identify further information that 
should be included in our ontology, and to refine our inference rules to reduce the number 
of false positives. For this purpose, it could be useful to include information regarding the 
therapeutic index of drugs (Boyce et al., 2007) or drug bioactivity data (Gaulton et al., 
2012). On the other hand, including information about physicochemical properties of 
drugs, ADRs (Kuhn et al., 2010), or new discoveries about drug-protein relationships 
could be useful to reduce the number of false negatives. 
9.2.3 IExp3: Inference and classification of DDIs on the basis of 
implicit mechanisms 
We perform this experiment to evaluate if the implicit representation of DDI 
knowledge as SWRL rules and drug-protein relationships information can be used to 
infer DDIs and provide a more accurate description of their mechanisms than asserted 
information only.   
 Methods: 
To do this, we randomly select 93 DDIs imported to DINTO from the database 
DrugBank. We create a version of the ontology containing only the drugs involved in 
some of the DDIs (146 ‘pharmacological entities’), their related proteins (4,141 ‘protein 
entities’), and the mentioned 93 DDIs. Then, we create individuals and the relationships 
among them for all these classes. In order to ensure that the classification is obtained only 
from implicit information, we delete the OWL definitional axioms (or ‘equivalent to’) 
that relates DDIs and their mechanisms (see Figure 7.14).  
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This version is merged with the file containing the 59 SWRL rules representing the 
different types of DDI mechanisms (a detailed description of these rules is provided in 
Section 7.1.7 and Section 7.2.5). The reasoner engine HermiT 1.3.8 infers a new 
classification of the DDIs describing the mechanisms preceding them. An example is 
shown in Figure 9.3, where the class representing the interaction between ‘amiodarone’ 
and ‘cisapride’ is classified, based on the implicit mechanisms, as a ‘target related DDI’, 
‘enzymatic saturation DDI’, and ‘enzyme inhibition DDI’. 
 
Figure 9.3. Protégé screenshot showing the inferred classification (as yellow boxes) of a 
DDI on the basis of its different DDI mechanisms 
 Results and Evaluation: 
Once the inferences have been obtained, we compare them with the mechanism-
based classification asserted in the DrugBank dataset. As we have mentioned before, the 
database uses data on drug-target, drug-enzyme, and drug-transporter associations to 
establish the “possible based DDI mechanism” for some of the DDIs (Law et al., 2014). 
We translate this information into DINTO as classes and relationships and use the 
classification of DDIs as ‘target related DDI’, ‘enzyme related DDI’, or ‘transporter 
related DDI’ to classify DDIs on the basis of their mechanisms. However, drug-carrier 
associations are not included for any DDI in the original source and therefore, none of the 
DDIs imported from DrugBank are classified as ‘carrier related DDI’. In addition to this 
information, during the importing process we have added an additional mechanism ‘non-
absorbable mechanism formation’, which is described in natural language for the 
corresponding DDIs. 
In contrast to this five-level classification of DDIs in DrugBank, our SWRL rules 
lead to 15 different types of DDIs. These different types are the most general class ‘DDI’ 
and its four subclasses: i) the target related class ‘target related DDI’ and its subclasses 
‘agonistic DDI’ and ‘antagonistic DDI’; ii) the enzyme related class ‘enzyme related 
DDI’ and its subclasses ‘enzymatic saturation DDI’, ‘enzyme induction DDI’, and 
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‘enzyme inhibition DDI’; iii) the transporter related class ‘transporter related DDI’ and 
its subclasses ‘transporter saturation DDI’, ‘transporter induction DDI’, and 
‘transporter inhibition DDI’; iv) and the carrier related class ‘carrier related DDI’ and its 
subclasses ‘carrier saturation DDI’, ‘carrier induction DDI’, and ‘carrier inhibition 
DDI’. Since there is not information supporting it, there are no rules for the inference of 
the mechanism ‘non-absorbable complex formation’ (Figure 7.14). 
Classification of each DDI following the previously described hierarchy for both the 
inferred and asserted sets is shown in Annex 11. Due to the different granularity of both 
classifications, we consider that a DDI has compatible mechanisms in both sets if there is 
an exact coincidence in the type of protein(s) involved (target, enzyme, transporter, or 
carrier). As shown in Table 9.5, most of the inferences correspond to this case. Only for a 
single DDI the classification is not coincident between the two sources, while one of the 
mechanisms for seven of the DDIs asserted in DrugBank is not inferred in DINTO. In 
contrast, there are three DDIs with at least one additional mechanism inferred in DINTO 
in comparison with the asserted set. Finally, we observe there are ten DDIs for which no 
mechanism is inferred. They correspond in DrugBank to DDIs occurring by a ‘non-
absorbable complex formation’ mechanism that, as mentioned before, is not included in 
our SWRL rules. 
 # % 
DDIs with compatible mechanisms 72 77,42 
DDIs with additional mechanisms in the asserted (DrugBank) set 
(12) (38) (56) (64) (73) (74) (86) 
7 7,53 
DDIs with additional mechanisms in the inferred (DINTO) set 
(2) (19) (92) 
3 3,22 
DDIs with any coincident mechanism in both sets 
(82) 
1  1,08 
DDIs corresponding to the non-absorbable complex formation mechanism 
type 
(4) (11) (13) (15) (16) (48) (54) (60) (81) (93) 
10 10,75 
Total 93 100 
Table 9.5. Results and comparison of the inferred classification of DDIs based on 
implicit mechanisms versus classification on the basis of asserted mechanisms (Numbers 
in brackets correspond to the numeration of the DDIs in Annex 11) 
 The results of this experiment show that most of our inferences are correct in 
comparison with DrugBank. However, there are 21 DDIs for what inferences yield to 
differences between both sets. Here, we analyse each one of them in order to identify the 
causes of theses discrepancies. 
 DDIs with additional mechanisms in the asserted (DrugBank) set: There are 
seven DDIs for which DrugBank establishes an additional mechanism that is not 
inferred in DINTO. In all these cases both interacting drugs have a relationship 
‘induces’ or ‘inhibits’ with the same protein and, as a consequence, a DDI is 
established between them in the asserted set. However, SWRL rules describing 
 189 
 
these patterns have not been created in DINTO since, from a pharmacological point 
of view, it would not be correct to infer that this situation leads to a DDI. 
To illustrate this, we discuss the example of the interaction between 
midodrine and dexamethasone. Midodrine inhibits the activity of the enzyme 
Cytochrome P450 2D6 (CYP2D6). Similarly, the drug dexamethasone inhibits the 
same enzyme. From this information DrugBank establishes that there could be a 
possible enzyme-related interaction between both drugs. However, this assumption 
is incorrect, since this interaction can occur only if this enzyme is involved in the 
metabolism or activity of one of the two drugs - or their metabolites. If this is not 
the case, both drugs alter the activity of the enzyme, but their activities or 
concentrations are not modified. Since any other relationship is described in 
DrugBank between CYP2D6 and the two drugs, we cannot establish that this is the 
mechanism of interaction between them. Similar circumstances occur for the other 
non-coincident six DDIs, with the difference that, on these cases the protein is a 
transporter instead of an enzyme.  
Therefore, from the discussion above, we conclude that a DDI should not be 
established when the information available is only that two drugs ‘induce’ and/or 
‘inhibit’ the same protein. However, this event can be very relevant in multiple 
drug-drug interactions, where the adverse consequences of a DDI are observable 
only when a third or more concomitant drugs are added (Cone, Fant, Rohay, & 
Associates, 2004; Klarin, 2007). 
An example could be provided by the DDI between carvedilol, ergotamine, 
and digoxin. The two former drugs inhibit the activity of multidrug resistance 
protein 1 (commonly known as P-glycoprotein or P-gp), a protein that transports a 
wide range of drugs from the inside of the cell to the outside. P-gp located at the 
intestine reduces the penetration of drugs into the body. Therefore, it can be 
considered as a defense mechanism against xenobiotics or strange substances. 
When a substrate of P-g, such as digoxin, penetrates into the endothelial cells in the 
intestine, it binds to the transporter at the intracellular part of the membrane and is 
extruded to the extracellular site. As a consequence, the bioavailability - or fraction 
of drug absorbed that reaches the systemic circulation - is decreased (Fromm & 
Kim, 2011). Since neither carvedilol nor ergotamine are substrates of P-gp, if they 
are administered concomitantly, their levels in the body are not influenced by the 
alteration in the activity of this transporter. Therefore, there is not a transporter-
based DDI between them (Figure 9.4a). In contrast, digoxin is a substrate of P-gp 
that, when administered concomitantly with carvedilol, can have changes on its 
bioavailability due to the inhibitory effects of carvedilol. Nevertheless, the absolute 
change in digoxin pharmacokinetics is small and not clinically significant 
(Wermeling et al., 1994) (Figure 9.4b). However, the inclusion of a third drug in 
the therapeutic regime, such as ergtamine, could produce more accentuated 
inhibitory effects on P-gp, and might lead to an increase in the bioavailability of 
digoxin and possible toxic clinical manifestations (Figure 9.4c). 
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Figure 9.4. Multiple-interaction between carvedilol, digoxine, and ergotamine 
 DDIs with additional mechanisms in the inferred (DINTO) set: There are 
three DDIs with an additional mechanism in the inferred set in comparison to the 
asserted set. Two of them have been classified as ‘carrier related DDI’ and one as 
‘carrier saturation DDI’. As mentioned before, any possible carrier-related 
mechanism has been specified in DrugBank. However, our SWRL rules enable the 
inference of this type of mechanism, too.   
 DDIs with any coincident mechanism in both sets: We can divide the DDIs 
included in this section into two main groups: the ten DDIs occurring by non-
absorbable complex formation, and the unique DDI for which any of the inferred 
and asserted mechanisms is coincident.  
On the one hand, for the first ten, no DDI mechanism is inferred in DINTO 
because there is not any rule defining a non-absorbable complex formation DDI. 
The main reason is that there is not information in the ontology supporting it. 
Therefore, currently it is not possible to predict DDIs occurring via this mechanism. 
On the other hand, there is not any coincident mechanism for the interaction 
between sulindac and bumetanide. In DrugBank this DDI is described as a possible 
‘transporter related DDI’, while the type inferred in DINTO is ‘target related 
DDI’. The last one is inferred because both drugs have the relationship ‘has 
pharmacological target’ with the protein prostaglandin G/H synthase 2. In this 
case, there is a SWRL rule establishing that the coadministration of both drugs can 
lead to a target related DDI. On the other hand, the mechanism asserted in 
DrugBank is established because both drugs inhibit the protein solute carrier family 
22 member 6. However, as we explained before, this information is not sufficient to 
establish a possible DDI between both drugs.   
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 Discussion: 
   The results of this experiment show that our representation of DDI mechanisms as 
SWRL rules infers correctly the mechanisms of most of the DDIs included in the study. 
Moreover, only three causes lead to differences for the remaining ones, and all of them 
have been identified. 
The first one is due to the inference of PK DDIs when the two interacting pairs have 
a inhibits and/or induces relationship with the same protein. We have observed that the 
inference of a DDI just on the basis of these two relationships might be incorrect. 
However, this fact becomes very interesting to study the representation of multiple DDIs, 
where the consequence of one DDI can be exacerbated by the presence of a third or more 
drugs. This phenomenon has not been represented in previous approaches, and it could be 
relevant on the study of DDIs in polymedicated patients.  
The second reason for discrepancies between the inferred and asserted sets is due to 
those DDIs occurring by the formation of non-absorbable complexes. There is not SWRL 
rules in DINTO for the inference of this type of mechanism, since the information 
required supporting them, such as cationic and anionic moieties of drugs, has not been 
included in the ontology yet.  
Finally, differences between both sets arise because there are SWRL rules in DINTO 
to infer carrier-related DDIs and its subtypes, while in DrugBank this mechanism is not 
assigned to any DDI.  
Therefore, our approach infers more accurate and detailed descriptions of the DDI 
mechanisms than those established in the asserted set, for both PK and PD mechanisms. 
For example, in the case of PD DDIs, for which modeling has been less deeply studied 
than for PK DDIs (Section 6.4), we have inferred that thirteen DDIs occur due to the 
agonistic effect of two drugs on the same target, five due to antagonism, and that in two 
cases both mechanisms are involved. 
In fact, usually more than one mechanism is inferred for the same DDI. Sometimes 
they could seem incompatible: enzyme inhibition and enzyme induction, agonism and 
antagonism, and so forth. However, from a pharmacological point of view the 
information is correct, since one drug can act at the same time as both an agonist and an 
antoginist on the same target, or as an inducer or inhibitor on the same enzyme. The final 
response depends on several factors, such as the affinity, efficacy, and selectivity of a 
drug for the protein (Kenakin, 2012). Specifically, the attraction that a drug molecule has 
for a protein - or the pharmacological affinity - can be quantified, and it is described in 
different databases (Gaulton et al., 2012). This bioactivity data can be used to identify the 
mechanism that is more relevant and that determines the clinical manifestations of the 
DDI. Since SWRL supports the use of data values, we hypothesize that the same 
approach based on the combination of drug-related information represented in OWL 2 
and SWRL rules could be applied to obtain descriptions of DDI mechanisms that are 
more accurate. Therefore, in our future work we will import into DINTO bioactivity data, 
and will refine our SWRL rules to provide a more detailed representation of the DDI 
mechanisms. 
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9.3 Discussion and conclusions 
In this study, we have demonstrated that the use of currently available semantic web 
technologies, standards, and tools support the formal representation of complex 
pharmacological knowledge and the prediction of DDIs on a large scale by exploiting 
large amounts of semantic data. To the best of our knowledge, this is the first work 
proving that any of these two objectives can be achieved without the intervention of 
technologies other than those created for the semantic web.  
DDIs and their underlying mechanisms are complex pharmacological processes and 
their conceptualization and implementation require an expressive representation 
language. Despite the richness of OWL’s set of relational properties, its expressivity does 
not allow to express all possibilities for object relationships (Holford et al., 2010; 
Horrocks et al., 2005). Indeed, we have observed that the use of advanced OWL 2 
features such as property chains is not adequate for the consistent representation of this 
knowledge. However, this limitation can be overcome by the combination of an OWL 
ontology with inference rules (Golbreich, 2005).  In this work, we have demonstrated that 
standard language SWRL is adequate to represent different types and subtypes of DDI 
mechanisms in a unique framework, while, in contrast to programming languages used by 
former efforts (Moitra et al., 2014; Tari et al., 2010), ensuring interoperability between 
ontologies.  
Moreover, these rules have been successfully applied to the inference of DDIs. A 
previous work in this domain had concluded that OWL-DL was not suitable for the 
detection of DDIs and that it should be used only for ontology consistency checking 
(Konagaya, 2012). However, in this study we have shown that DL formalisms can be 
successfully used for the inference of DDIs by means of combining drug-related facts as 
an OWL ontology, and DDI mechanisms as SWRL rules.    
The bottleneck in this process has been, however, the limited performance of 
ontology reasoning engines with very large and complex ontologies. None of the most 
popular OWL reasoners, such as FacT ++, HermiT, or Pellet could process a whole 
version of DINTO. Therefore, following prior experiences of similar projects (Holford et 
al., 2010), we had to employ different strategies in order to reduce the size and 
complexity of our ontology. Ontology reasoning plays a key role in ontology engineering 
and has become an indispensable activity to help ontologists during the development and 
evaluation of ontologies, as well as users to query their contents. Therefore, research into 
ontology reasoner engines development continues, and it is boosted by efforts such as the 
annual OWL Reasoner Evaluation Workshop,56 which brings together developers and 
users and provides an opportunity to promote their systems. Therefore, it should be 
expected that more robust and reliable engines would be available in the near future. 
In spite of this limitation, we have achieved the largest coverage for drugs included 
in a DDI inference experiment. The closest project, which combined NLP with 
knowledge formal representation and reasoning (Tari et al., 2010), could test the 
inference system on a smaller number of drugs (295 drugs against the 426 included in our 
experiment). The main reason for the low coverage of the other projects is that they relied 
                                                 
56 http://ceur-ws.org/Vol-1207/ 
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on manual curation to identify, gather, and structure the drug-related facts required as 
basic information to infer the DDIs. Although expert manual curation provides high 
quality information, this activity is both cost-intensive and time-consuming. Moreover, 
new pharmacological information is discovered and published every day in the scientific 
literature, which makes keeping up to date a knowledge base with this information a 
difficult task. However, during the last years there has been a huge increase of 
pharmacological information stored in structured and machine-readable formats as public 
databases and knowledge bases (Khelashvili et al. 2010; Whirl-Carrillo et al. 2012). 
Exploiting this information and integrating it automatically in a knowledge base might 
overcome the limitation of manual curation. In this project, we have demonstrated that 
this premise can be applied to the ontological engineering field, too. In this way, to 
overcome this issue, we have designed a CM for DINTO that reuses and integrates 
information currently available in public information resources, such as drug-protein 
relationships from the database DrugBank. With this approach, the development of the 
ontology is driven by the combination of both the requirements of the final application 
and the information available to be imported into the ontology. 
The inference experiments performed in this study show that DINTO is a correct and 
comprehensive ontology for the DDI domain. While other ontologies have focused on the 
separate representation of PK (Arikuma et al., 2008; Boyce et al., 2010b; Moitra et al., 
2014) and PD (Imai et al., 2013) DDI mechanisms, DINTO is the first resource that 
represents both of them in the same framework. Moreover, previous works have 
addressed only the representation of one specific subtype of PK DDIs: those occurring by 
an alteration in drug metabolism. In contrast to this, we have represented different 
subtypes of both PK and PD DDI mechanisms, leading to the most complete and detailed 
formal description of these processes.  
Evaluation of the inferences obtained in the experiments has been performed against 
DDIs included in the database DrugBank. However, this database, or any other DDI 
information source, cannot be considered a gold-standard of “true DDIs” (Imai et al., 
2013). The large number of possible DDIs, with different degrees of significance and that 
can be influenced by drug or patient-related facts, makes it not possible to manually 
study, identify, and collect all of them in a unique information source. Indeed, important 
differences have been found in the coverage for DDIs among different information 
sources (Fulda, Valuck, Zanden, & Parker, 2000; Olvey et al., 2010a). As a consequence, 
it is not possible to ascertain if the false positive DDIs inferred in DINTO are not 
included in DrugBank because i) they are interacting pairs but have not been included yet 
in the database, ii) they are interacting pairs but the interaction between them has not 
been described in the scientific literature, or iii) they are not interacting pairs of drugs. In 
spite of this, the other main reason for the high number of false positives is that our 
SWRL rules have been modeled to infer DDIs on the basis of different mechanisms, but 
independently of other related facts such as their significance or level of documentation. 
Therefore, for any pair of drugs for which an underlying DDI mechanism exists, 
regardless of whether it would lead to a clinically relevant DDI or a non-clinically 
relevant or unobservable DDI, the interaction is inferred. 
In contrast to this, other DDIs could not be predicted by our SWRL rules.  Most of 
them are DDIs for which their mechanisms cannot be explained by known drug-protein 
relationships, including DDIs occurring by the chelation or physicochemical binding of 
the two drugs in the gastrointestinal tract (Levy & Reuning, 1964), those due to the 
addition of an ADR (Antonelli, Atar, Freedberg, & Rosenfeld, 2005), and DDIs for 
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which, although observed in the clinical setting and described in the scientific literature, 
the underlying mechanism is not known or understood yet (Kulkarni et al., 2013; Patel et 
al., 2014).  
The analysis of these results is useful to identify further information that should be 
included in our ontology, and provides guidelines to refine our inference rules. For this 
purpose, in our future work we will include in the ontology the following information: 
 Therapeutic index of drugs, which can be used to identify clinically 
significant DDIs (Boyce et al., 2007). 
 Drug bioactivity data for the identification of the principal DDI mechanism 
(Gaulton et al., 2012). 
 Physicochemical properties of drugs, which can be used to identify DDIs 
occurring by chelation. 
 ADRs for the inference of DDIs occurring by additive effects. 
 New discoveries about drug-protein relationships, which can lead to the 
prediction of DDIs that cannot be explained by current knowledge. 
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Chapter 10 
DDI Information Extraction 
One of the two main contributions of this thesis is the creation of a comprehensive 
ontology for DDI knowledge that will be made available to the NLP research community 
to be exploited in IE from pharmacological texts. We hypothesize that ontologies are a 
useful resource for IE that can contribute to a better performance of current systems 
(Cimiano et al., 2014; Müller et al., 2004; Wimalasuriya, 2010). The evaluation of 
DINTO’s usefulness for this task is limited, however, since the development of a new IE 
system based on DINTO is out of the scope of this project. Nonetheless, to provide a 
proof-of-concept of its suitability for IE, we propose to use DINTO with a simple system 
for the two different tasks of drug NER and DDI extraction from texts. We use the 
previously developed DDI corpus and compare our results in the framework of the 
SemEval-2013 DDIExtraction shared task (Segura-Bedmar et al., 2014) (see Section 
4.2). In this evaluation, we compare the results obtained by this approach based on 
DINTO with those obtained by the participating systems. Moreover, the best runs 
submitted by each team are combined with DINTO in order to study its impact on their 
performance.  
This chapter is organized as follows. In Section 10.1, we describe the evaluation of 
DINTO for NER. After describing the system developed to perform this task, we present 
and discuss the achieved results. Then, we provide a brief summary of the evaluation 
process in the SemeEval DDIExtraction task and compare our results with those obtained 
by the participants. Section 10.2 describes the evaluation of DINTO for DDI extraction. 
We provide a description of the system used in this task and the results obtained. Again, 
we compare our results with those achieved by the participants on the task and describe 
the results obtained with an ensemble for each one of them and DINTO. Finally, in 
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Section 10.3 we present and discuss the main conclusions of this evaluation and highlight 
our lines of future work. 
10.1 DINTO-based named entity recognition 
To evaluate DINTO for NER we develop a system combining different components 
from ‘The General Architecture for Text Engineering’ (GATE),57 a free open-source 
infrastructure for developing and deploying software components that process human 
language (Bontcheva, Tablan, Maynard, & Cunningham, 2004). GATE is one of the most 
widely used systems of its type and has many active users. It has been used in NLP tasks 
in different domains, including life science and medicine projects (Cunningham, Tablan, 
Roberts, & Bontcheva, 2013). We select GATE to create our NER system because, in 
contrast to other automatic annotation tools (Jonquet et al., 2009; Uren et al., 2006), it 
enables automatic ontology-based annotation of texts using any external ontology. 
Combining different components of GATE, we create a pipeline for NER based on 
DINTO, for which the architecture is shown in Figure 10.1. 
 First, we split the text into sentences using Regex Sentence Splitter, provided by 
GATE and based on regular expressions.  GATE’s default tokeniser is used to split the 
previously obtained sentences into very simple tokens (words, numbers, symbols, 
punctuation marks, and space-tokens). Then, the Part Of Speech Tagger - a modified 
version of the Brill tagger (Hepple, 2000) - produces POS tags as an annotation on each 
word or symbol using a default lexicon and ruleset. The GATE Morphological Analyser 
(Morpher) is used afterwards. This GATE plugin is based on certain regular expressions 
rules and it takes as input the tokenized documents. Considering one token and its part of 
speech tag, one at a time, it identifies its lemma and an affix. These values are then added 
as features of the token annotation.  
GATE provides different gazetteers and gazetteer tools to perform NER. A gazetteer 
consists of a set of lists containing names of entities, which are used to find occurrences 
of these names in text. We combine two different GATE plugins to recognize drug names 
using the information contained in DINTO. On the one hand, Flexible Gazetteer provides 
the flexibility to choose our own customized input (in this case, the processed DDI 
corpus) and an external gazetteer.  It performs a lookup over the document based on the 
values of an arbitrary feature of an arbitrary annotation type by using an externally 
provided gazetteer. The external gazetteer is Ontology Resource Root (OntoRoot) 
Gazetteer, a dynamically created gazetteer capable of producing ontology-based 
annotations over the given content according to the given ontology. The OntoRoot 
Gazetteer is created by extracting human-understandable content from DINTO (drug 
classes, preferred labels, synonyms, and brand names) which is then used by the Flexible 
Gazetteer to recognize drug names in the corpus.  
The DDI corpus is processed with this GATE pipeline, and it is evaluated using the 
gold-standard annotations. In the next section we provide the results for the NER task and 
                                                 
57 https://gate.ac.uk/ 
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compare them with those obtained by participating teams in the SemEval-2013 
DDIExtraction task (Segura-Bedmar et al., 2014). 
 
Figure 10.1. Architecture of the DINTO-based NER system 
10.1.1 Results 
The DDI corpus is processed with the GATE pipeline using two different versions of 
DINTO in two different experiments. In order to conform to the nomenclature used by 
the DDIExtraction task participating systems, we refer to them as Run 1 and Run 2. Run 1 
relies on a version of DINTO containing only drugs imported from the ChEBI ontology 
(Hastings et al., 2013). The number of classes for pharmacological substances is 3,026. 
Original annotation properties are maintained. Therefore, each class has a preferred label 
and different synonyms – including brand names and chemical formula. In Run 2 we use 
a second version of DINTO enriched with information from DrugBank and with a larger 
number of synonyms and brand names. Moreover, those drugs present in DrugBank and 
not included in the first version of DINTO are represented as new classes in the ontology, 
leading to a total of 8,854 classes for pharmacological substances.  With these two 
different experiments, we aim to assess the impact of integrating different information 
resources in the results of the NER task.    
Evaluation results are reported using the standard precision/recall/f-score metrics 
(Chinchor & Sundheim, 1993). Table 10.1 and Table 10.2 show results for Run 1 and 
 198 
 
Run 2, respectively. We provide results for the whole corpus and separately for the DDI-
DrugBank and DDI-MEDLINE datasets. 
Dataset cor inc para mis spu total precision recall F1 
DDI Corpus 198 0 6 482 40 686 0,8238 0,293 0,4323 
DDI-DrugBank 107 0 2 195 7 304 0,931 0,3553 0,5143 
DDI-MEDLINE 91 0 4 287 33 382 0,7266 0,2435 0,3647 
Table 10.1. Results for NER task using a ChEBI-based version of DINTO (Run 1) 
As shown in Table10.1, Run 1 (ChEBI-based ontology) achieves moderate results 
for F-score. Although precision values are high, results for recall are lower. The best 
results are obtained on the DDI-DrugBank dataset. Therefore, a version of DINTO based 
only on a unique information resource provides a limited coverage for drug entities in 
pharmacological texts. 
Dataset cor inc para mis spu total precision recall F1 
DDI Corpus 334 0 38 314 118 686 0,7204 0,5146 0,6003 
DDI-DrugBank 187 0 15 102 28 304 0,8457 0,6398 0,7285 
DDI-MEDLINE 147 0 23 212 90 382 0,6096 0,4149 0,4938 
Table 10.2. Results for NER task using a ChEBI plus DrugBank-based version of 
DINTO (Run 2) 
In contrast, in Run 2 we use a version of the ontology combining two information 
resources, ChEBI and DrugBank. This run achieves better results for the three datasets. 
With this extended version of the ontology, recall increases considerably. Therefore, the 
inclusion of more pharmacological substances and more synonyms for the existing ones 
increases the coverage for drug named entities of the ontology and, therefore, the results 
for recall. However, a slight decrease in precision is observed. This decrease is due to an 
increase in false positives - or the incorrect identification of drug named entities that are 
not annotated in the gold-standard.  
Performing error analysis of these results, we have identified two main reasons for 
the identification of false positives (Table 10.3). The first and dominant is the 
identification as named entities of non-drug names that are frequently used in 
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pharmacological texts. These include terms such as ‘control’, ‘results’, ‘labelling’, 
‘duration’ or ‘mg’. These terms are not drug names. However, they might be present in 
the ontology (e.g., one of the brand names for the drug ‘loperamide’ imported from 
DrugBank is ‘Pepto Diarrhea Control’) and, therefore, extracted by the OntoRoot 
Gazetteer. Therefore, the system used in this evaluation incorrectly identifies these terms 
as drug named entities. A future system based on DINTO for NER might avoid this issue 
by using a stop list including this type of terms, for example.  
The second main reason for the identification of false positives is ambiguity (see 
Section 3.4.2). During the creation of the DDI corpus, we have identified the existence of 
ambiguous terms as one of the most challenging problems in the manual annotation of 
pharmacological texts  (Herrero-Zazo, Segura-Bedmar, & Martínez, 2013) and remains 
an important issue in the development of accurate named entity recognition systems. 
Therefore, our system is unable to identify them. As a consequence, each mention of the 
term ‘insulin’, for example, is annotated as a drug named entity, independently of the 
term referring to the drug ‘insulin’ (correct annotation) or to the substance produced by 
the body (incorrect annotation).  
Error cause DrugBank-DDI MEDLINE-DDI  Example 
Non-drug names 20 65 ‘control’, ‘results’ 
Ambiguous terms 8 25 ‘adrenaline’, ‘dopamine’ 
Total 28 90  
Table 10.3. Analysis of false positives for Run2 
As mentioned before, recall results for Run 2 increase considerably with respect to 
Run 1. This reveals an increase in the coverage for drug entities of DINTO. However, the 
system still fails to identify a considerable number of drug named entities. Performing the 
error analysis of false negatives – drug named entities annotated in the gold-standard and 
not identified by the system – we classified them in different types (Table 10.4).  
The first type is terms describing groups of drugs. The DDI corpus is annotated 
with those terms describing a group of drugs (e.g., ‘analgesic agent’). However, these 
terms are not included in the GATE gazetteer and therefore, none of those terms 
annotated in the corpus as group type are recognized by the system. For Run 2, this type 
of error represents more than the 50% and 40% of false negatives in the DDI-DrugBank 
and DDI-MEDLINE dataset, respectively.  
The second type of false negatives is due to the fail of the system to correctly 
recognize some terms included in the ontology. These include drug names such as 
‘warfarin’, ‘fludarabine’, or ‘insulin’. We have not been able to find a common pattern in 
these entities to explain this unexpected behaviour of the software. It should be expected, 
however, that this error would not be reproduced with a system specifically created to use 
DINTO for IE. This issue influences the results obtained for Run 2 with the DDI-
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DrugBank dataset, where this unrecognized terms represent more than the 30% of false 
negatives terms. In the DDI-MEDLINE dataset, this type of error is less frequent (minor 
to 5% of false negatives). However, an important reason for false negatives in the DDI-
MEDLINE dataset is the non-recognition of drug_n type entities (representing almost 
the 40% of false negatives in this dataset), substances with pharmacological activity but 
not approved as drugs. This type of false negatives is more relevant in the DDI-
MEDLINE dataset than in DDI-DrugBank dataset due to the frequent mention of this 
type of entities in MEDLINE texts (see Section 3.5). From these results, we conclude 
that, although ChEBI and DrugBank have information about drug_n substances, DINTO 
does not provide enough coverage for them. To overcome this issue, we plan to extend 
the ontology integrating resources with a broad coverage of these entities, such as the 
PubChem database (Bolton, Wang, Thiessen, & Bryant, 2008).  
Finally, another source of false negatives are spelling variations in drug names, 
which the system is unable to recognize as drug named entities (e.g., the system fails to 
recognize the term ‘temezepam’, an incorrect variation of the drug name ‘temazepam’). A 
future system for NER based on DINTO could overcome this problem through the 
integration of lemmatization or stemming techniques. 
Error cause DDI-DrugBank DDI-MEDLINE Example 
Missed group entity type 53 89 
‘anticoagulants’, ‘loop 
diuretic’ 
Missed drug_n entity type 5 79 
‘methylene blue’, ‘tween 
80’ 
Missed drug entity type 3 26 ‘b-carotene’, ‘etizolam’ 
Missed brand entity type 4 - ‘ertaczotm’, ‘synagis’ 
Entity present in the 
ontology but not annotated 
by unexpected behaviour 
of the software 
34 17 ‘tofranil’, ‘colestipol’. 
Spelling variations 3 1 
‘lorezepam’, 
‘temezepam’ 
Total 102 212  
Table 10.4. Analysis of false negatives for Run 2 
10.1.2 Comparison in the framework of the SemEval-2013 
DDIExtraction shared task 
In the previous section, we have presented and discussed the results achieved by a 
simple system exploiting DINTO for drug NER in pharmacological texts. Although the 
aim of this thesis is the creation of a new ontology for DDIs that could be useful for the 
NLP community, and the development of a new IE system is out of the scope of our 
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work, we want to provide better insights into the potential usefulness of DINTO for drug 
NER. To do this, we perform a comparative analysis with the participating systems in the 
SemEval-2013 DDIExtraction task.  
In the second edition of the DDIExtraction task, six teams participated in the subtask 
of named entity extraction of pharmacological substances in text. Each participant was 
allowed to submit a maximum of three system runs. For evaluation, a part of the DDI 
corpus (the train dataset) was provided with the golden annotations hidden. The goal for 
participating systems was to recreate the golden annotations and to output an ASCII list 
of reported entities. System performance was scored automatically by how well the 
generated pharmacological substance list corresponded to the gold-standard annotations. 
In this task, several evaluation criteria were used to evaluate the results of the participant 
systems. These included strict matching (exact-boundary and type of entity matching), 
exact boundary matching (regardless of the type of entity), and partial boundary matching 
(regardless of the type of entity). Strict evaluation demands exact boundary match and 
requires that both mentions have the same entity type. This strict and exact criterion may 
be too restrictive for the overall goal - extraction of drug interactions – as it could miss 
partial matches, which can provide useful information for a DDI extraction system. 
Therefore, we compare the results obtained by the best run for each participant team with 
the result of our best run (Run 2, Table 10.2) for partial matching evaluation criteria.  
A deeper description of this task, the participating systems, and their results is 
described in Section 4.2.1. To provide a brief overview we should highlight that the best 
results were achieved with a token sequence labelling approach based on CRF proposed 
by the WBI team (Huber, Linden, & Rockt, 2013). Substances not approved for human 
use (drug_n) were more difficult to identify by all the participant systems. In fact, only 
the UEM_UC3M team (Sanchez-Cisneros & Aparicio, 2013), using a system based on 
the combination of several ontologies and other information resources – ontologies from 
the UMLS collection (Bodenreider, 2004) combined with information extracted from 
MeSH (Lipscomb, 2000), DrugBank (Wishart et al., 2006), PubChem (Bolton et al., 
2008), the ATC classification system (WHO, n.d.), and KEGG database (Kanehisa et al., 
2012) - was able to recognize this type of substances on the DDI-DrugBank dataset. For 
all participant systems, results on the DDI-DrugBank dataset were much better than on 
the DDI-MEDLINE dataset. This fact could be explained by the higher complexity of 
MEDLINE texts and the current mentions of drug_n type entities that, as mentioned 
before, were challenging to identify. 
Figure 10.2 shows a comparison between participant systems and the DINTO-based 
system for the NER task. Results are provided for the whole DDI corpus and the DDI-
DrugBank and DDI-MEDLINE datasets. These results show that the system based on 
DINTO obtains comparable results to that obtained by a dictionary-based system  
developed by the participant team UEM_UC3M (Sanchez-Cisneros & Aparicio, 2013). 
Like other systems, DINTO obtains better results for the DDI-DrugBank dataset than for 
the DDI-MEDLINE dataset. This can be attributed to the use of the DrugBank database 
as a source of information for our ontology – as other systems such as NLM_LHC or 
UEM_UC3M - but it is also influenced by the lack of challenging drug_n type entities 
in this dataset. As mentioned above, we do not evaluate the coverage of DINTO for 
group type entities. We believe that including this type of entities would provide even 
better results for the NER task, and we will include them in our future work. Even so, 
from this evaluation in the framework of the DDIExtraction task we can anticipate that 
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future combination of DINTO with other techniques, such as CRF (Lafferty, Mccallum, 
& Pereira, 2001), may provide better results for the recognition of drug named entities 
from pharmacological texts. 
 
Figure 10.2. Results for the NER task for participants’ best runs and for DINTO-based 
system (Run 2) 
10.2 DINTO-based relation extraction 
In this thesis, we have developed an ontology representing information about drugs 
and other pharmacological substances (8,854 classes) and the relationships between them 
describing a DDI. Some of these DDIs are well known and have been described in the 
literature and collected in the database DrugBank (11,555 DDIs). Other DDIs, however, 
can be inferred in DINTO on the basis of drug-protein relationships (see Section 9.2). 
These inferred DDIs might not have been described as DDIs in the literature yet, but 
there is a plausible mechanism underlying them. Therefore, they could potentially be 
described as unknown, suspected, or new DDIs in the scientific literature.  
We hypothesize that a formal representation of the DDI domain can be exploited by 
IE systems to improve their performance in the task of DDI extraction from 
pharmacological texts. However, as mentioned before, the development of a new system 
able to use the knowledge represented in DINTO is out of the scope of this thesis. 
However, to provide a proof-of-concept of the potential usefulness of DINTO for DDI 
extraction, we develop a simple system that uses the information represented in DINTO 
to identify DDIs from the DDI corpus. We compare these results with those obtained by 
participants of the DDIExtraction task. Moreover, to assess the strengths and weaknesses 
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of our ontology, we adopt another evaluation approach. To do this, we combine by means 
of ensemble methods the participant systems and DINTO, in order to measure the impact 
of using the ontology on their results. 
10.2.1 Results 
To assess the contribution of DINTO to the DDI extraction task we develop a simple 
system able to select candidate interacting drug pairs in the DDI corpus and to identify if 
the interaction between them is formally represented in the ontology. We compare a 
baseline using a version of DINTO containing those known DDIs described in DrugBank 
(Run 1) versus a version of the ontology including both known and inferred DDIs (Run 
2). With these two experiments, we aim to evaluate the influence of an increased number 
of DDIs in the ontology. 
The system selects candidate drug pairs in the DDI corpus, which are labelled in the 
gold-standard annotations as interacting pair (true value in the XML) or no-interacting 
pair (false value in the XML), and looks them up in the ontology. To do this, annotation 
properties as preferred labels and synonyms are checked. In the case that both drugs are 
present in the ontology, the system looks for the ‘may interact with’ relationship between 
them, that is used in DINTO to describe an interaction between two drugs.  Those pairs of 
drugs in the DDI corpus that are described to interact in the ontology are considered 
interacting pairs (true), while those pairs not described to have an interaction in the 
ontology are considered as non-interacting pairs (false) (Figure 10.3).  
Dataset tp fp fn total precision recall F1 
DDI corpus 164 376 815 979 0.3037 0.1675 0.2159 
DDI-DrugBank 154 368 730 884 0.295 0.1742 0.2191 
DDI-MEDLINE 10 8 85 95 0.5556 0.1053 0.177 
Table 10.5. Results for the DDI extraction task using a known-DDIs version of DINTO 
(Run 1) 
Table 10.5 and Table 10.6 show results obtained using this system with two 
different versions of DINTO. On the one hand, Run 1 uses a version of the ontology 
containing only known DDIs imported from DrugBank (Table 10.5). On the other hand, 
results for Run 2 are achieved using a version of the ontology representing known DDIs 
plus DDIs inferred from drug-protein relationships (Table 10.6).  
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Dataset tp fp fn total precision recall F1 
DDI corpus 220 793 759 979 0.2172 0.2247 0.2209 
DDI-DrugBank 206 759 678 884 0.2135 0.233 0.2228 
DDI-MEDLINE 14 34 81 95 0.2917 0.1474 0.1958 
Table 10.6. Results for the DDI extraction task using an inferred and known-DDIs 
version of DINTO (Run 2) 
F1 scores achieved by both runs are low and, although there is a slight improvement 
in the results for Run 2 with respect to Run 1, this is not prominent. When the version of 
the ontology including inferred DDIs is used (Run 2), the number of correctly identified 
DDIs increases lightly. However, the number of false positives – non-interacting drug 
pairs incorrectly identified by the system to be interacting pairs – increases considerably.  
 
Figure 10.3. Architecture of the DINTO-based-RE system 
The reason for this is that our system cannot take into account context. In our 
approach, we consider that if a candidate drug pair in text is described to interact in the 
ontology, then it is a DDI description. However, two interacting drugs can be mentioned 
in a sentence that is not discussing the DDI between them. Therefore, they should not be 
identified as a DDI. For example, the following sentence has two interacting drug pairs 
between the entities ibuprofen and cyclosporin A: 
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« Although ibuprofene1 can be administered with cyclosporin Ae2 in patients with 
normal renal function, caution should be used when administering ibuprofene3 
concurrently with cyclosporin Ae4 to patients with mild to moderate renal 
insufficiency. » 
(i) 
In this example, both drugs appear twice in the sentence, but only their last two 
mentions are involved in the description of a DDI. As ibuprofen and cyclosporin A are 
described to interact in DINTO, the system recognized both drug interacting pairs (e1-e2 
and e3-e4) as two DDIs.  
Another reason for the increase in false positives for Run 2 is the system’s 
incapability to distinguish between drugs constituting a coordinate structure and 
therefore, to recognize that they are not describing a DDI. Coordinate structures are 
usually used in pharmacological texts to show specialization. Therefore, they do not 
describe a DDI. For example, the following sentence uses a coordinate structure to 
numerate drugs belonging to the same group.  
« The absorption of fluoroquinolone antibioticse1 such as moxifloxacine2, 
ciprofloxacine3 or lomefloxacine4 could be reduced in patients in treatment with 
aluminiume5.  » 
(ii) 
This coordinate structure shows a specialization of the group of drugs 
fluoroquinolone antibiotics in three of its members: moxifloxacin, ciprofloxacin, and 
lomefloxacin. The sentence is describing the interaction of moxifloxacin, ciprofloxacin 
and lomefloxacin with aluminium. However, moxifloxacin is described in DINTO to 
interact with ciprofloxacin and lomefloxacin, too. Therefore our system identifies them as 
interacting pairs, although this information is not provided in the sentence. These false 
positives could be resolved with a simple rule that prevents mentions of drugs referring to 
the same drug to be considered as a candidate DDI. Coordinate structures are generally 
used to indicate specialization. In the example, moxifloxacin, ciprofloxacin, and 
lomefloxacin are members of the group of drugs fluoroquinolone antibiotics. This 
information is represented in DINTO with the ‘has role’ relationship. We believe that a 
more advance system could avoid these false positives by using this information (e.g., a 
combination of pattern recognition identifying the coordinate structure and the ‘has role’ 
information to discard those drug pairs showing the specialization). 
The lack of evidence to confirm the existence of a DDI is another source of false 
positives. An example is the following sentence: 
« There are no clinical data on the use of amantadinee1 with ziprasidonee2.  » (iii) 
The interaction between amantadine and ziprasidone is represented in the ontology. 
Therefore, the system incorrectly recognizes this drug pair as a DDI mention. These false 
positives could be avoided integrating negation recognition (Chowdhury & Lavelli, 
2013a). Moreover, identification of sentences denying or showing lack of certainty  for a 
DDI with a plausible underlying mechanism – and therefore inferred in DINTO - could 
be an useful tool in the study of new DDIs, where documentation of existing literature 
about the DDI is an important fact to establish its relevance (Tatro, 2010). 
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10.2.2 Comparison in the framework of the SemEval-2013 
DDIExtraction shared task 
In the previous section, we have presented and discussed the results achieved by a 
simple system exploiting DINTO for DDI extraction from pharmacological texts. Here, 
we compare them with the results obtained by participants on the second DDIExtraction 
task. 
The substask for DDI extraction from pharmacological texts attracted the attention of 
eight different teams, each of them submitting a maximum of three different runs. Gold-
standard annotations - correct, human-created annotations - of pharmacological 
substances were provided to participants for both train and test data. Each participant 
system must output an ASCII list including all pairs of drugs in each sentence and its 
prediction (1 if the pair is a DDI and 0 otherwise). Evaluation was relation-oriented and 
based on the standard precision, recall and F-score metrics. 
A detailed description of this task, the participating systems, and their results are 
described in Section 4.2.2. We can summarize that, in general, approaches based on 
kernels methods achieved better results than the classical feature-based methods. It is 
important to emphasize, as well, that most systems used primarily syntactic information, 
while semantic information was poorly used. The best results were submitted by the team 
from FBK-irst (Chowdhury & Lavelli, 2013b) who applied a novel hybrid kernel-based 
RE approach and exploited the scope of negations and semantic roles for negative 
instance filtering. The second best results were obtained by the WBI team (Thomas et 
al., 2013) combining several kernel methods. Regarding the different datasets, results on 
the DDI-DrugBank dataset were much better than on the DDI-MEDLINE dataset for all 
systems. 
As expected based on results in Table 10.5 and Table 10.6, our system based on 
DINTO obtains lower results than those systems specifically created to participate on the 
DDIExtraction task (Figure 10.4). As mentioned before, our main limitations are related 
to the lack of a system able to exploit ontological knowledge. Another important issue is 
that the ontology only covers fifty per cent of entities annotated in the test-dataset corpus. 
Therefore, it is not possible to identify DDIs for the other fifty per cent of entities. Most 
absent entities belong to the entity types group of drugs (group) and not-approved drugs 
(drug_n). The strategy to avoid the low coverage for drug_n entities has been exposed 
previously in Section 10.1.1. Regarding the first ones, the main problem is that DDIs 
between two groups of drugs, or between a group of drugs and an individual drug, have 
not been represented in the ontology. Therefore, a high number of DDIs have not been 
processed by our system. A future more sophisticated system could recognize group of 
drugs names in text using the ‘role’ classes in the ontology (for a better description of this 
class, see Section 7.1.3) and use the information within the ontology to infer DDIs 
between groups of drugs. For example, we could identify as a group of drugs all those 
classes in the ontology with a ‘has role’ relationship with the class ‘beta-blockers.’ If all 
– or almost all - members have a ‘may interact with’ relationship with the drug 
‘rifampicin’, we could infer that there is an interaction between members of the ‘beta-
blockers’ group and ‘rifampicin’.  
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Figure 10.4. Results for the DDI extraction task for participants’ best runs and for 
DINTO-based system (Run 2) 
10.2.3 Ensemble SemEval-2013 DDIExtraction task participants 
and DINTO 
Hybrid approaches combine different methods with the final aim to attain the best of 
each method and to exploit knowledge from different source. In order to investigate the 
impact of using DINTO on the performance obtained by participants on the SemEval-
2013 DDIExtraction shared task, we have built different ensemble systems by combining 
each one of the participants’ best runs with DINTO. The aim of this experiment is to 
identify the strengths and weaknesses of our ontology in a RE task. 
The ensemble system is very simple. We take the output for each one of the eight 
best participants’ runs. Those DDIs detected as non-interacting pairs by their systems are 
looked up in the ontology. If the drug pair has an interaction in DINTO, then it is 
confirmed as describing a DDI. Thus, the ensemble method would improve the recall of 
each system in the hopes of not adversely affecting precision. Since this approach was 
similar to that performed previously, it could be expected that drug coverage and 
identification of false positives would again be limited.  
We compare the results achieved by each one of the original systems with two 
different versions of the ontology. The first one is an ensemble using a version of DINTO 
with only known DDIs (Baseline), while the second one is an ensemble using an 
extended version of DINTO with known and inferred DDIs (Extended). Again, our aim is 
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to investigate how the increase in the number of DDIs represented in the ontology would 
influence the results. 
Figure 10.5 and Figure 10.6 show the comparison of F1 scores in the DDI-
DrugBank and the DDI-MEDLINE datasets, respectively. For all participants’ systems, 
the combination with DINTO (both Baseline and Extended versions) leads to a decrease 
in performance for the DDI-DrugBank dataset. The reason is the previously discussed 
increase in false positives deriving from the use of DDI relationships without any 
additional technique to detect contextual information. Therefore, it is not possible to 
detect which sentence describes a DDI and which one does not. Therefore, although the 
ensemble with DINTO leads to the detection of new DDIs in the DDI-DrugBank dataset 
- as manifested by recall results (Figure 10.7) - the increase in false positives leads to a 
decrease in precision (Figure 10.8). Therefore, F1 final scores are lower for ensembles of 
the original system with the ontology. Regarding the two different versions tested, we 
observe that results are lower when the number of DDIs included in the ontology 
increases (Extended version). The reason is that as the number of possible interacting 
pairs increases, the number of false positives rises. Therefore, the use of DINTO as 
resource for IE should be combined with a mechanism that takes into account the context 
in which the pair drug is described in the text. 
In contrast, all systems obtain better results for the DDI-MEDLINE dataset when 
they are combined with the first version of DINTO (Baseline). Regarding the second 
version (Extended), most systems achieve results similar to those obtained by the original 
system. Moreover, three of them improve their performances (UTurku (Björne, 
Kaewphan, & Salakoski, 2013), NIL_UC3M (Bokharaeian & Diaz, 2013), and 
UWM_TRIADS (Rastegar-Mojarad, Boyce, & Prasad, 2013)).  Therefore, DINTO has 
proven to be more useful with scientific texts such as those from the DDI-MEDLINE 
dataset, which describe new DDIs not described elsewhere but that might have been 
inferred in DINTO, than with DrugBank descriptions, which collect known DDIs already 
represented in the ontology. As for the comparison of the two different versions, the 
reason for obtaining better results with the Baseline than with the Extended version is the 
weight of the decrease in precision derived from the increase in possible DDIs. As can be 
seen in Figure 10.7, there is an increase in Recall using Extended versus using Baseline 
for all systems in the DDI-MEDLINE dataset. However, the considerable number of false 
positives leads to a decrease in Precision (Figure 10.8) and therefore, a decrease in the 
overall F1 values. 
From the results of this evaluation, we can conclude and anticipate that the creation 
of a new system able to exploit ontological knowledge from DINTO could increase the 
performance of current systems for the extraction of DDIs from texts. Specifically, we 
believe that the combination of advanced techniques, specifically approaches based on 
kernel methods that exploit lexical and syntactic information from sentences, and 
ontologies would demonstrate to be especially useful in complex scientific texts such as 
those conforming the DDI-MEDLINE dataset. 
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Figure 10.5. Results for the ensemble systems with DINTO for the DDI-DrugBank 
dataset 
 
Figure 10.6. Results for the ensemble systems with DINTO for the DDI-MEDLINE 
dataset 
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Figure 10.7. Recall results for the ensembles with DINTO for both DDI-DrugBank (solid 
colours) and DDI-MEDLINE (shaded colours) datasets 
 
Figure 10.8. Precision results for the ensembles with DINTO for both DDI-DrugBank 
(solid colours) and DDI-MEDLINE (shaded colours) datasets. 
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10.3 Discussion and conclusions 
The main objective of this evaluation is to provide a proof-of-concept of the 
usefulness of DINTO for IE. The content of the ontology has been previously evaluated 
from a technical point of view, showing that DINTO is consistent and that it adheres to 
ontological recommendations and standards (see Section 8.1).   However, we want to 
provide insights into the potential role that our ontology could play in NER and RE. 
Moreover, we are interested in highlighting the strengths but also the weaknesses of 
DINTO, in a way that we can identify future work directions. Our main limitation is, 
however, the lack of a robust system able to exploit ontology knowledge for IE. 
Nevertheless, we have created two very simple systems to perform this evaluation, which 
we expect would draw some preliminary results of the potential usefulness of applying 
DINTO for NER and RE. 
On the one hand, NER is a prior and essential step for mining useful knowledge from 
the biomedical literature and therefore, the extraction of drug named entities is crucial for 
the development of a DDI extraction system. The evaluation of a simple system based on 
DINTO for drug NER in text obtains comparable results to that obtained by the 
dictionary-based system in the SemEval-2013 DDIExtraction shared task (Segura-
Bedmar et al., 2013). We have observed that using an extended version of the ontology – 
integrating information from two different resources ChEBI and DrugBank – leads to 
better results than using a baseline version – including only information from ChEBI.  
In this evaluation, we have identified that the coverage of DINTO for two types of 
entities - groups of drugs (group) and not-approved pharmacological substances 
(drug_n) - is low in comparison with drug and brand type entities. Although the first 
ones are covered by the ontology as subclasses of the top-class ‘role’, they have not been 
included in the current system. Therefore, the coverage of DINTO for group of drugs has 
not been evaluated. To address this limitation, we plan to create in our future work a new 
OntoGazetteer including terms describing group of drugs that are presented in the 
ontology. The second ones, drug_n substances, present a greater variation and 
complexity on their naming, which makes them challenging to be recognized for all 
different participants on the DDIExtraction task. Even when several of these substances 
have been imported from our information resources (e.g., more than five thousand 
substances imported in DINTO are classified as non-approved in DrugBank) the coverage 
is still low. The inclusion of other resources, such as the PubChem database (Bolton et 
al., 2008), could contribute to an even larger representation of these substances in 
DINTO.  
Ambiguous terms and spelling variations are another important source of errors in 
this evaluation. Our current system is unable to overcome these problems. While 
ambiguity resolution is still challenging (Segura-Bedmar et al., 2013), we believe that a 
future system based on DINTO and integrating approximate string matching, 
lemmatization, or stemming techniques could overcome the spelling variation-related 
problem. 
On the other hand, the goal of the RE task is to detect semantic relations between 
entities in texts. Therefore, semantic resources such as ontologies could be useful 
resources (Müller et al., 2004; Wimalasuriya, 2010; Zhang et al., 2012). For example, 
 212 
 
Percha & Altman (2012) used an ontology to normalize relationships extracted from text 
through text mining techniques. Similarly, Coulet et al. (2011) used an ontology to map, 
normalize, and compare heterogeneous biomedical relationships extracted via text 
mining, to identify those having similar semantics but different syntax. In our case, we 
have evaluated DINTO for DDI extraction on the basis of a simple premise. It relies on 
the fact that the task of understanding a natural language sentence can be seen as 
identifying possible situations that the sentence in question might describe (Cimiano et 
al., 2014). If there were a plausible mechanism that could lead to a DDI between two 
drugs, it would be possible that the interaction between them might be described in the 
literature.  
Therefore, we use a version of DINTO with known DDIs and another one with 
known and inferred DDIs and establish that, if a candidate interacting pair in the text is 
described to interact in the ontology, then the sentence is likely to be describing a DDI. 
The main limitation of this approach is that it does not take into account any contextual 
features. Therefore, the number of false positives increases considerably with the number 
of potential DDIs represented in the ontology. We use the results of the best systems 
presented by the eight different participant teams of the SemEval DDIExtraction task and 
ensemble their systems with DINTO. Although the number of correctly identified DDIs 
(Recall) increases for all systems in both the DDI-DrugBank and the DDI-MEDLINE 
datasets, overall F1 results decrease due to the increase in the number of false negatives.  
During the analysis of these results, we have identified different characteristics that 
might contribute to the development of an IE system that could exploit the information in 
DINTO. For example, the use of relationships other than ‘may interact with’ – the only 
one used in this experiment – could contribute to reducing the number of false positives 
due to coordinate structures or the identification of interactions between groups of drugs. 
For example, the system could rule out those interacting pairs of drugs appearing in a 
coordinate structure and having a relationship ‘has role’ between them (e.g., 
‘moxifloxacin’ ‘has role’ some ‘fluoroquinolone’) or with the same group of drugs (e.g., 
‘moxifloxacin’ ‘has role’ some ‘fluoroquinolone’, and ‘ciprofloxacin’ ‘has role’ some 
‘fluoroquinolone’). Another strategy could be to employ negation detection to identify 
sentences denying or showing lack of certainty for a given DDI (Bokharaeian, Diaz, 
Neves, & Francisco, 2014). We believe, furthermore, that the creation of a system 
combining DINTO with advanced techniques for RE such as kernel-based methods, 
which integrate contextual information from sentences, could achieve better results than 
those obtained in this evaluation.  
In spite of the modest results obtained in this preliminary evaluation, we believe that 
DINTO will be a useful resource for the NLP research community. Approaches using 
domain knowledge have been recently applied with success to the pharmacological 
domain (Garten et al., 2010; Kang et al., 2014). The use of knowledge resources can 
reduce the number of false positives generated by the current DDI extraction systems 
because these resources can help to distinguish between those pairs of drugs that are 
DDIs from those are not. The information required for a semantic-based IE system can be 
taken, for example, from pharmacological databases such as DrugBank, PharmGKB 
(Hewett et al., 2002), SIDER (Kuhn et al., 2010), or KEGG (Kanehisa et al., 2012), 
among others. Some of them describe specific pairs of interacting drugs. For example, for 
the creation of DINTO we have used the database DrugBank. Moreover, as we have 
demonstrated in this thesis, a larger number of DDIs can be deduced indirectly by 
exploiting, for example, the drug-protein relationships. Thus, the relationships of two 
 213 
 
different drugs with the same protein can be used to infer the mechanism leading to a 
DDI (Hage & Tweed, 1997). A similar approach could consists in using the relationships 
of two different drugs with the same ADR to infer possible DDIs (Campillos et al., 2008). 
For example, morphine is related to the side effect CNS depression. Therefore, other 
drugs producing the same ADR, such as oxycodone, could interact with morphine. 
Up to now, the main limitation for the development of semantic-based approaches 
has been the availability of appropriate knowledge bases in a machine-readable format. 
However, the creation of these knowledge bases is becoming more feasible and common 
in the pharmacological domain (Khelashvili et al., 2010; Whirl-Carrillo et al., 2012). This 
is due to the increasing number of databases and web servers providing structured and 
semi-structured pharmacological information, such as Drug- Bank or KEGG. Moreover, 
there are different community projects such as Bio2RDF (Belleau et al., 2008) or LODD 
(Samwald et al., 2011), which work to link the various sources of biological and 
pharmacological data together, enabling the integration of several pharmacological 
aspects described in different databases (Pathak et al., 2013). Another important factor is 
the proliferation of biomedical ontologies to store and formally represent domain 
knowledge. Ontologies enable the integration of the information disperse through 
different and heterogeneous databases and provide resources that can be exploited by IE 
systems (Cimiano et al., 2014; Wimalasuriya, 2010).  
To conclude, the results obtained in this evaluation outline the potential of DINTO as 
a useful resource for IE from pharmacological texts. We believe that future directions for 
DDI extraction might entail the combination of syntactic and semantic information and 
we believe that DINTO will be a useful and practical resource. We propose several 
specific ideas for future works, both regarding the ontology itself and with a future 
ontology-based IE system: 
 To evaluate the coverage for groups of drugs of DINTO. 
 To increase the number of substances non-approved for human use 
(drug_n) through the integration of the PubChem database. 
 To design a new information extraction system able to exploit the 
information from DINTO. This system will have the following 
characteristics: 
- It should be able to recognize different types of entities (including 
group of drugs names). 
- It should integrate approximate string matching algorithms, 
lemmatization, or stemming techniques. 
- The system should exploit relationships in the ontology others than 
‘may interact with’, such as the ‘has role’ relationship. 
- It should integrate CRF techniques for NER and kernel-based 
methods exploiting lexical and syntactic information for RE. 
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Chapter 11 
Conclusions 
Drug-drug interactions (DDIs) are common adverse drug reactions (ADRs) 
representing an important risk to patients safety, and an increase in healthcare costs 
(Pirmohamed et al., 2004). Their early detection is, therefore, a main concern in the 
clinical setting (Kulkarni et al., 2013; Moura, Acurcio, & Belo, 2009; Patel et al., 2014). 
Although there are different databases supporting healthcare professionals in the 
detection of DDIs, the quality of these databases is very uneven and the consistency of 
their content is limited (Clauson, Seamon, Clauson, & Van, 2004; Fulda et al., 2000; 
Olvey et al., 2010a). On the other hand, these databases do not scale well to the large and 
growing number of pharmacovigilance literature in recent years (Paczynski et al., 2012). 
In addition, large amounts of current and valuable information are hidden in published 
articles, scientific journals, books and technical reports (Aronson, 2007). Thus, the large 
number of DDI information sources has overwhelmed most healthcare professionals 
because it is not possible to remain up to date on everything published about DDIs. 
Computational methods can play a key role in the identification, explanation and 
prediction of DDIs on a large scale, since they can be used to collect, analyze and 
manipulate large amounts of biological and pharmacological data (Percha & Altman, 
2013). Natural language processing (NLP) techniques can be used to retrieve and extract 
DDI information from pharmacological texts, supporting researchers and healthcare 
professionals on the challenging task of searching DDI information among different and 
heterogeneous sources (Hansten, 2003). However, these methods rely on the availability 
of specific resources providing the domain knowledge, such as databases, terminological 
vocabularies, corpora, ontologies, and so forth, which are necessary to address the 
Information Extraction (IE) tasks. The main objective of this thesis is to contribute to the 
early detection of DDIs by developing semantic resources useful for the development of 
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these IE systems. In this chapter, we review the research objectives and discuss how they 
have been accomplished in this work, describe the dissemination of our work, and 
propose the future work on both the DDI corpus and DINTO as a direction for further 
related research. 
11.1 Evaluation of research objectives 
Our first objective (Objective 1) is the study of existing corpora relevant to the DDI 
domain, in a way that we can analyze their strengths and weaknesses. Since our aim is to 
provide a benchmark for the development and evaluation of IE systems, we review those 
characteristics defining a gold-standard corpus. By reviewing the literature, we establish 
that a gold-standard corpus is a manually annotated corpus, whose quality has been 
proven by the measurement of the agreement between different annotators and the 
creation and publication of detailed annotation guidelines. We also find that, to be useful, 
a gold-standard corpus must be rich in information and include a large variety of 
documents and annotated instances representing the diversity of document types and 
instances and relationships relevant to the intended task. Finally, another important 
characteristic of a gold-standard is its acceptance and usage by the research community. 
Based on these characteristics, we review and analyze the different available corpora 
annotated i) with pharmacological substances, and ii) with DDIs. From this analysis, we 
conclude that there is not existing corpora that can be used as gold-standard for training 
and evaluation of NLP techniques for the DDI domain. 
Consequently, we pursue our second objective: the creation of the DDI corpus 
(Objective 2). To do this, we try to overcome the main limitations found in previous 
corpora, and attempt to fulfil the characteristics of a gold-standard corpus. The starting 
point is the DrugDDI corpus, on which several improvements have been made. Firstly, 
new documents are included in the corpus, in a way that the DDI corpus consists of 
DrugBank texts and MEDLINE abstracts. With these two types of documents, the size of 
the corpus is significantly increased and we provide a source of texts with different 
complexity and linguistic patterns. Thus, NLP systems can be trained to extract 
information from different types of document. Secondly, a new annotation process is 
defined. In the DDI corpus, two experts in pharmacology and two text miners with 
background in pharmacovigilance participate in the annotation task. A new annotation 
schema is created during the annotation of a training set, and annotation guidelines are 
developed in an iterative process. They provide a detailed description of different types of 
pharmacological entities, along with different types of DDIs, too. In this way, the 
resulting corpus is the most richly semantically annotated resource for pharmacological 
text processing built to date. Thirdly, the agreement between annotators is measured in 
order to assess the level of difficulty of the annotation task, along to the quality of the 
corpus. The annotated corpus and the annotation guidelines are made freely available for 
the research community at http://labda.inf.uc3m.es/ddicorpus. 
With the aim to validate the usefulness of the DDI corpus to the intended task, we 
use it as a benchmark for training and evaluation of NLP systems devoted to the NER and 
RE tasks in the DDI domain (Objective 3). The second edition of the DDIExtraction 
shared task series provides a benchmarking framework for the evaluation of IE systems. 
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These systems are trained and evaluated using the DDI corpus for two different tasks: i) 
drug named entity recognition and classification, and ii) extraction and classification of 
DDIs. The task has attracted a great deal of attention from several research groups, which 
have shown a significant improvement with respect to the previous 2011 edition. The 
increase in size of the corpus, the inclusion of different types of documents and the 
quality of their annotations might have been a significant contribution to this 
improvement. The participating systems and their results are described in detailed in this 
thesis.  
In addition to the SemEval DDIExtraction task participants, we believe that the DDI 
corpus will be used by other NLP research groups working on the pharmacological 
domain. Indeed, our research group keeps encouraging research on this field and has 
organized the “Special Issue Special Issue on Mining the Pharmacovigilance Literature” 
in the Journal of Biomedical Informatics, a special issue on automatic extraction of 
relationships between biomedical entities relevant to the pharmacovigilance field 
launched on June 2014 and that will be published in 2015. In the call for papers, 
submissions that use the DDI corpus are especially welcomed because their results can be 
compared with those reported in the second DDIExtraction  task.58 Therefore, we 
anticipate that the DDI corpus will be further used by different research groups in 
different settings. 
From this, we conclude that one of the main objectives of this thesis, the creation of a 
corpus that contributes to the research and development by the NLP research community 
of automatic tools for the early detection of DDIs, has been achieved. 
The DDI corpus is used to study the different linguistic phenomena in texts 
describing DDI information (Objective 4). Linguistic aspects of drug names and 
common syntactic phenomena in pharmacological text, such as hypernymic propositions 
or coordinate structures, make the manual annotation of documents difficult and, 
therefore, might represent obstacles for automatic IE systems. We believe that the review 
of these annotation issues provided in this thesis can be a useful guide for their 
developers. In addition to this, we have used the DDI corpus to perform a linguistic 
pattern analysis, which shows how the different relevant concepts are described in 
pharmacological texts, and keyword and concordance analyses, which show how these 
concepts relate to each other in this domain. The gained knowledge is applied to the 
development of the CM of the ontology for drug-drug interactions ontology DINTO. 
However, before creating this new resource, we have studied the existing semantic 
resources relevant in pharmacovigilance, with special interest on the representation of 
DDI-related information (Objective 5). We have focused on their scope and level of 
granularity for the representation of pharmacological substances and DDIs, and the 
representation of other relevant concepts, such as ADRs, too. Furthermore, we have 
reviewed and compared the different approaches that, to the best of our knowledge, have 
dealt in some way with the task of conceptualization of DDI knowledge, and have 
identified and studied their unresolved issues (Objective 6). From these reviews, we 
conclude that no existing ontology or conceptual model represents in a comprehensive 
way all the DDI-related information necessary for its application to IE or computational 
prediction of DDIs.  
                                                 
58 http://www.sciencedirect.com/science/journal/15320464/49 
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Based on this analysis, we have created an ontology for the representation of all 
DDI-related knowledge (Objective 7). To the best of our knowledge, DINTO is the first 
ontology representing both PK and PD DDIs, and all their related mechanisms. The 
conceptualization in DINTO provides the most comprehensive CM for the DDI domain, 
including crucial aspects such as DDI mechanism, effect, or recommendations. It reuses 
information from related ontological and non-ontological resources, decreasing the costs 
of ontology population and increasing its coverage. It has been evaluated from a technical 
point of view in a three-step strategy to ensure its consistency, completeness and quality. 
DINTO adheres to the OBO Foundry principles and other ontology development 
standards. Specifically, it has been developed in collaboration with the ChEBI ontology, 
one of the most important OBO Foundry ontologies. Moreover, DINTO has been 
reviewed by the OBO Foundry community and has been accepted and listed as one of the 
“OBO Foundry candidate ontologies and other ontologies of interest.”59 In addition to 
this, we have been invited to collaborate in the development of a new resource named the 
Drug-drug International and Drug-drug Interaction Evidence Ontology (DIDEO), a 
project involving people from different Institutions and leaded at the Division of 
Biomedical Informatics at the University of Arkansas and the Department of Biomedical 
Informatics at the University of Pittsburgh (Brochhausen et al., 2014).  
In addition to this technical evaluation, we have tested the robustness of DINTO in 
two different applications (Objective 8). Firstly, we have used it to infer new DDIs and 
their mechanisms. The combination of OWL drug-protein relationships and SWRL rules 
representing DDI mechanisms has led to the first experiment inferring both PK and PD 
DDIs in the same representation framework and in a large scale. Moreover, it has 
provided the most detailed inference of different DDI mechanisms. Therefore, this 
evaluation has shown that DINTO is a good resource for inference of DDIs and DDI-
related knowledge. Secondly, we have evaluated the usefulness of DINTO in an IE 
system for NER and DDI extraction, and have compared the results with those obtained 
by the DDIExtraction-2013 task participants. The preliminary results are modest due to 
the simplicity of the IE method used, because the development of an IE system is out of 
the scope of this thesis. Nevertheless, we think that a more sophisticated method using 
our ontology may obtain better results. Furthermore, in this evaluation we have identified 
the main characteristics that should fulfil a future IE system based on DINTO, which 
might serve as a roadmap for future work in this field. 
From this, we can conclude that the twofold objective of this thesis has been 
achieved. Firstly, we have contributed to the improvement of the early detection of DDIs 
from scientific literature through the development of two different resources, an 
annotated corpus and a comprehensive ontology, which have enabled the development, 
training and evaluation of automatic NLP systems for pharmacological texts in the field 
of DDIs. And secondly, we have applied the ontology to the inference of new knowledge, 
and in particular, to the inference of new DDIs and their mechanisms that could not have 
been reported in biomedical publications. 
 
                                                 
59 http://www.obofoundry.org/ 
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11.2 Publications 
As a result of this work, several publications have been presented in workshops, 
conferences, and specific journals. 
In The DDI corpus: an annotated corpus with pharmacological entities and drug-
drug interactions (Journal of Biomedical Informatics 46 (2013), pp. 914-920), we have 
described the construction of the DDI corpus, including how the text were collected and 
processed, the annotation guidelines and the annotation process, and the evaluation 
through the measurement of the agreement between different annotators. 
In Annotation issues in pharmacological texts (Procedia – Social and Behavioral 
Sciences. 5th International Conference on Corpus Linguistics (CILC2013) 2013, vol. 95, 
pp. 211–219), we have reviewed the main sources of annotation problems that affect in 
general the manual annotation process, the linguistic phenomena that complicate the 
manual annotation of drug named entities, and the different syntactic phenomena that 
should be considered during the annotation of DDIs. 
In Lessons learnt from the DDIExtraction-2013 Shared Task (Journal of Biomedical 
Informatics 51 (2014), pp.152–164), we have described the second edition of the 
DDIExtraction Shared Task series, which provided the DDI corpus as a benchmark for 
the implementation and comparative assessment of IE systems for drug NER and DDI 
extraction. The paper focuses on the latter one, providing a description and comparison of 
the systems and their results, an analysis of the major sources of their errors, and 
proposes an ensemble system combining the top three methods using majority and union 
voting strategies. 
In An ontology for drug-drug interactions (6th International Workshop on Semantic 
Web Applications and Tools for Life Sciences (SWAT4LS) 2014, Edinburgh, UK), we 
have described the first steps in the development of DINTO that were carried out during 
the internship at the European Bioinformatics Institute (EMBL-EBI). 
All the work described here has been supported by three research projects: the 
Research Network MA2VICMR [S2009/TIC-1542] of the Regional Government of 
Madrid, the project MULTIMEDICA [TIN2010-20644-C03-01] supported by the 
Spanish Ministry of Education, and the TrendMiner project [FP7-ICT287863] in the 
European Commission Seventh Framework Programme.  
11.3 Future work 
From the experience gained in the construction of the DDI corpus, the identification 
of annotation issues in the pharmacological literature (Section 3.4), the quantitative 
features of the annotation process (Section 3.5), and the IAA (Section 4.1), as well as 
from the lessons learnt from the SemEval-2013 DDIExtraction shared task (Section 4.2), 
we have identified directions for future improvements of the DDI corpus: 
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1. Inclusion of a larger number of MEDLINE abstracts, in order to obtain a 
more balanced corpus respecting to the number of DrugBank texts, as well 
as other information resources such as package inserts, patient records, case 
studies, and discharge summaries, among others. 
2. More detailed description of drug_n entities, which can be divided into 
different groups in order to reduce the bias in the annotation of this entity 
type. 
3. Multiple-annotation process involving at least three annotators. In this 
strategy, all documents are annotated by more than one annotator 
(Jagannathan et al., 2009; Wilbur et al., 2006). 
4. Selection of a more advanced annotation tool, facilitating the annotation by 
multiple-annotators (Neves & Leser, 2014). 
5. Annotation of linguistic phenomena required for a better understanding of 
the text, such as negation, modality, cataphora, or anaphora. 
6. Annotation of DDIs at the document level instead of sentence level, to 
capture those interactions spanning several sentences. 
7. Annotation of relevant pharmacological information, including quantitative 
information (drug dosage, time interval between administration of the drugs, 
alterations in PK parameters, drug concentration, etc.), and qualitative 
information (adverse drug reactions, indication, pharmaceutical form, 
administration route, etc.). This information can be useful for the 
development of new IE systems for both drug NER and DDI extraction. 
8. Annotation of relevant DDI-related information, such as protein entities 
involved in the DDI mechanism and their relationships with other instances 
in the text.  
9. Inclusion of metadata in the annotated corpora, such as provenance of the 
documents, alternative IDs for the pharmacological entities, annotator 
identification, etc.   
10. Integration of the DDI corpus with other related corpora, such as the PK and 
PK-DDI corpus. One of the approach proposed to achieve this 
interoperability between corpora is the conversion of corpora and the 
systems output to appropriate formats, such as the Resource Description 
Framework (RDF) format to represent the annotations, and the use of OWL 
ontologies to model meaning of annotations (Klein et al., 2014). 
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Regarding DINTO, the evaluations in inference of DDIs and their mechanisms 
(Chapter 9) and ontology-based IE (Chapter 10) and have brought future lines of 
research that could increase the usefulness of the ontology. 
1. Evaluation of the coverage of group of drugs in DINTO. 
2. Inclusion of a larger number of substances not approved for human use 
(drug_n type entities), integrating for example information from the 
PubChem database (Bolton et al., 2008). 
3. Inclusion of ADR information, integrating the OAE (He et al., 2011) or 
AERO (Courtot et al., 2011) ontologies, for example, and translating drug-
ADR relationships from the SIDER database (Kuhn et al., 2010).  
4. Inclusion of therapeutic index of drugs, which can be used to identify 
clinically significant DDIs (Boyce et al., 2007) 
5. Inclusion of drug bioactivity data for the inference of the principal DDI 
mechanism (Gaulton et al., 2012). 
6. Inclusion of physicochemical properties of drugs, which can be used to 
identify DDIs occurring by chelation. 
7. Inclusion of new drug-protein relationships, which can lead to the prediction 
of DDIs that cannot be explained by current knowledge. 
8. Maintenance of DINTO and collaboration with other related efforts, such as 
the Drug-drug Interaction and Drug-drug Interaction Evidence Ontology 
(DIDEO) (Brochhausen et al., 2014). 
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Glossary 
ADE Adverse Drug Event 
ADR Adverse drug reaction 
AE Adverse Effect 
AERO Adverse Event Reporting Ontology 
ARM Adverse Reactions and Mechanism Ontology 
ASP Answer Set Programming 
ATC Anatomical, Therapeutic and Chemical 
BFO Basic Formal Ontology 
BRO Biomedical Resource Ontology 
CDSS Clinical Decision Support System 
ChEBI Chemical Entities of Biomedical Interest 
CHEMDNER Chemical compound and Drug Name Recognition 
CLEF Clinical E-Science Framework 
CM Conceptual Model 
CNS Central nervous system 
COSTART Coding Symbols for a Thesaurus of Adverse Reaction 
Terms 
CPRS Computerized Patient Record System 
CQ Competency Question 
CRF Conditional Random Fields 
CS Classification Scenario 
CUI Concept Unique Identifier 
DDI Drug-Drug Interaction 
DIDEO Drug-drug Interaction and Drug-drug Interaction Evidence 
Ontology 
DIKB Drug Interaction Knowledge Base 
DINTO Drug-drug Interactions Ontology 
DIO Drug Interaction Ontology 
 224 
 
DL Description Logics 
DOE Denominación Oficial Española 
DrOn Drug Ontology 
DTD Document Type Definition 
EHR Electronic Health Record 
EMA European Medicines Agency 
EMBL-EBI European Bioinformatics Institute 
EU-ADR Exploring and Understanding Adverse Drug Reactions 
FDA Food and Drugs Administration 
FMA Foundational Model Anatomy 
FOL First Order Logic 
GO Gene Ontology 
IAA Inter-annotator agreement 
ICH International Conference on Harmonisation 
IE Information Extraction 
IHTSDO International Health Terminology Standards Development 
Organisation 
INN International Nonproprietary Name 
IR Information Retrieval 
IUPAC International Union of Pure and Applied Chemistry 
Jochem Joint Chemical Dictionary 
KA Knowledge Acquisition 
MedDRA Medical Dictionary for Regulatory Activities 
MEMM Maximum Entropy Markov Model 
MeSH Medical Subject Headings 
MMTx MetaMap Transfer Tool 
NCI National Cancer Institute 
NCIT National Cancer Institute Thesaurus 
NDC National Drug Code 
NDF National Drug File 
NDF-RT National Drug File Reference Terminology 
NER Named Entity Recognition 
NLM National Library of Medicine 
NLP Natural Language Processing 
OAE Ontology of Adverse Events 
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OBO Foundry Open Biological and Biomedical Ontologies Foundry 
OSCAR Open-Source Chemistry Analysis Routines 
ORSD Ontology Requirements Specification Document 
OWA Open World Assumption 
OWL Web Ontology Language 
PD Pharmacodynamic 
PDO Pharmacodynamics Ontology 
PI Package Insert 
PK Pharmacokinetic 
PKO Pharmacokinetics ontology 
POS Part-of-speech 
RDF Resource Description Framework 
RE Relation Extraction 
RN Registry Number 
RO Relation Ontology 
SADL Semantic Application Design Language 
SIO Semanticscience Integrated Ontology 
SNOMED CT SNOMED Clinical Terms 
SPC Summary of Product Characteristics 
SVM Support Vector Machines 
SWRL Semantic Web Rules Language 
ITI TXM Tissue Expressions and Protein-Protein Interactions 
UML Unified Modeling Language 
UMLS Unified Medical Language System 
UNII Unique Ingredient Identifier 
URI Unique Resource Identifier 
USAN United States Adopted Name 
VA Veterans Affairs 
VHA Veterans Health Administration 
W3C World Wide Web Consortium 
WHO World Health Organization 
WHO-ART WHO’s Adverse Reaction Terminology 
XML Extensible Markup Language 
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Annex 1 
Comparison of concepts included in the different CMs 
 
 Mille Rubrichi NDF-
RT 
DIO DIKB PDO PKO DINTO 
Active Ingredient  x x x x x x x 
Drug Product  x x   x x  
Drug Class  x x     x 
DDI x x x     x 
DDI participant x  x     x 
Precipitant     x   x 
Object     x   x 
Risk 
factor 
patient-related x x      x 
drug-related x x   x   x 
DDI mechanism x       x 
DDI effect x x      x 
Recommendations x x      x 
ADR x x x     x 
Indication  x x      
Significance   x     x 
PK 
process 
absorption   x x    x 
distribution   x x  x  x 
metabolism   x x x   x 
excretion   x x    x 
Molecular interaction   x x  x  x 
Metabolite   x x    x 
Protein 
target        x 
enzyme    x x  x x 
transporter    x   x x 
carrier    x    x 
Drug-
protein 
relation 
inhibits     x x  x 
activates      x  x 
…        x 
Physiological effect      x   
PK parameter       x x 
PK study       x x 
Drug dose   x    x x 
Pharmaceutical form  x x     x 
Administration route   x     x 
Adm. frequency       x  
Excipient  x      x 
Study subject       x x 
 
 257 
 
Annex 2 
Ontology Requirements Specification Document (ORSD) for DINTO 
Ontology Requirements Specification Document (ORSD) for DINTO 
1 Purpose 
 To create a formal representation of DDI knowledge that covers all relevant aspects 
related with the domain and that allows both humans and machines consulting and 
obtaining established information and/or inferred knowledge about specific DDIs. 
2 Scope 
 The DDI domain and all relevant information that is used to describe DDIs in texts.  
3 Implementation Language 
 OWL2 
4 Intended End-Users 
 User 1. Text miner (working in the development of an information extraction (IE) 
system). 
User 2. Developer working on clinical decision support or signal detection systems. 
User 3. Curator (trying to identify DDI-related information quickly and easily). 
User 4. Researcher (looking for information about a suspected DDI). 
User 5. Clinician (looking for information about a suspected DDI). 
5 Intended Uses 
 Use 1. Creation of a system that automatically recognizes and extracts DDIs and 
related information from texts. 
Use 2. Development of alert systems supporting the detection of DDIs in clinical 
practice. 
Use 3. Annotation of scientific literature with known and inferred DDIs to support 
database curators.    
Use 4. Description of known and inferred DDIs that can be searched and consulted 
by researchers at clinical institutions. 
Use 5. Description of possible mechanisms underlying known and inferred DDIs to 
support signal detection in pharmacovigilance. 
6 Ontology Requirements 
 a. Non-Functional Requirements 
 NFR 1.  The ontology must cover standard nomenclatures as well as synonyms and 
term variants. 
NFR 2.  The ontology must cover all DDI-related information that can be used to 
describe the existence and characteristics of a DDI. 
NFR 3. The ontology must follow the OBO Foundry recommendations for building 
ontologies. 
NFR 4. The ontology must include known DDIs and allow the inference of new 
ones on the basis of their pharmacokinetic and pharmacodynamic 
mechanisms. 
 b. Functional Requirements: Groups of Competency Questions 
 CQs related to the EXISTENCE of a DDI 
CQ1. Is there an interaction between DrugA and DrugB? 
CQ2. Is the effect of DrugA modified by DrugB? 
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 Ontology Requirements Specification Document (ORSD) for DINTO 
(Continuation) 
 b. Functional Requirements: Groups of Competency Questions 
 CQs regarding the MECHANISM of the DDI 
CQ3. What is the mechanism of the interaction between DrugA and DrugB? 
CQ4. Is a PK parameter of DrugA modified by DrugB? 
CQ5. What is the type of the interaction between DrugA and DrugB? 
CQ6. What is the type of PD interaction between DrugA and DrugB? 
CQ7. Is there a PK interaction between DrugA and DrugB? 
CQs regarding the EFFECT of the DDI 
CQ8. Is the toxicity of DrugA exacerbated by DrugB? 
CQ9. Is the effect of the DDI an adverse effect of DrugA or DrugB? 
CQ10. Is the effect EFFECT1 produced by an interaction between DrugA and 
DrugB? 
CQ11. What is the effect of the interaction between DrugA and DrugB? 
CQs regarding the MANAGE of a DDI 
CQ12. Can be DrugA and DrugB used concomitantly? 
CQ13. Should be discontinued the treatment with DrugA when DrugB is 
administered? 
CQ14. Should be modified the dosage of DrugA when DrugB is administered? 
CQ15. How could be avoided the effect of the interaction between DrugA and 
DrugB? 
CQ16. Is there any minimal elapse of time to administer DrugA after stopping the 
administration of DrugB? 
CQ17. Is there any recommendation in order to avoid the DDI between DrugA and 
DrugB? 
CQs related to FACTORS affecting to the DDI 
CQ18. What patient’s characteristics affecting the DDI are present? 
CQ19. What is the age of the patient? 
CQ20. What is the sex of the patient? 
CQ21. What is the race or ethnic of the patient? 
CQ22. What administration form of DrugA interacts with DrugB? 
CQ23. Is there any alternative administration form of DrugA that does not produce 
the interaction with DrugB? 
CQs related to the interaction of a drug and a PROTEIN 
CQ24. What protein does DrugA interacts with? 
CQ25. Is DrugA metobolized by any of the cytochrome P450 isoenzymes? Which 
ones? 
CQ26. Is DrugA transported by P-glycoprotein? 
CQ27. Has DrugA got any effect (inhibitor or inductor) of any of the cytochrome 
P450 isoenzymes? 
CQ28. Has DrugA got a narrow therapeutic index? 
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 Ontology Requirements Specification Document (ORSD) for DINTO 
(Continuation) 
 b. Functional Requirements: Groups of Competency Questions 
 CQs related to the SIGNIFICANCE of the DDI 
CQ29. How frequently the DDI has been described? 
CQ30. What type of study describes the DDI? 
CQ31. What is the certainty of the DDI? 
CQ32. Has been the DDI established in well performed and controlled studies? 
CQ33. What is the severity of the DDI? 
7 Pre-glossary of terms 
 a. Terms from CQs and Frequency 
 DrugA/DrugB                    
effect                                   
interaction                             
modified                                  
mechanism                             
PK parameter 
PK interaction                       
PD interaction                        
toxicity                                 
exacerbated                        
adverse effect                    
concomitantly        
discontinued                                
43 
9 
10 
3
2
1 
1
1
1
1 
1
1 
1
treatment                     
administered        
avoid*               
elapse of time       
recommendation                
patient                       
age                                        
sex     
ethnic                                    
race                                      
administration form               
alternative                             
protein                                                                       
 1 
6 
2 
1 
1 
4 
1 
1 
1
1 
1
1
1
cytochrome P450        
P-glycoprotein                     
transported                          
metabolized                          
inhibitor                                
inductor                                 
narrow therapeutic 
index   
frequently                               
study                                       
controlled studies                  
certainty                                 
established            
severity                                    
2  
1
1 
1
1
1
1 
1 
1
1
1
1 
1
 b. Relevant terms identified during manual annotation of the DDI corpus 
 pharmacokinetics 
absorption 
area under the curve 
bioavailability 
half life 
concentration 
maximum concentration 
steady-state 
distribution volume 
protein binding 
free fraction 
biotransformation 
metabolism 
first pass metabolism 
enzyme induction 
enzyme inhibition 
enzyme 
cytochromeP450 enzyme 
system 
P-glycoprotein 
metabolite 
prodrug 
elimination 
elimination constant 
excretion 
clearance 
pharmacodynamics 
drug synergism 
additive effect 
potentiation 
antagonism 
monitorization 
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 Labels used in the linguistic pattern analysis 
Type Description 
certainty 
Those words indicating the degree of confidence or 
certainty in the information given 
coadministration-pattern 
Refers to those concepts describing WHEN the two 
drugs are or should be administered. 
concentration-location  
consequence 
A term or group of terms showing a relation between 
different statements. 
control-group  
cyp-role  
dosage  
final-effect 
Decrease in effectiveness, increase in toxicity (or 
increase in effectiveness, if this is a beneficial DDI, etc.) 
int-assertion  
metabolite  
monitorization  
object The drug ‘suffering’ the interaction 
object-ad-effect  
object-pharma-effect 
The pharmacological effect of the object interacting 
drug 
pd-effect  
pd-mechanism  
pharmaceutical-form  
phisyological-process  
pk-effect The alteration in a pk-parameter due to a DDI 
pk-effect-value 
A value describing the extent of the alteration of the pk-
parameter 
pk-mechanism The alteration in a pk-process due to a DDI 
pk-parameter  
pk-process  
precipitant The drug ‘causing’ the interaction 
recommendation  
recommendation-degree 
This feature refers to those concepts describing the 
encouragement for the realization of the 
recommendation previously made 
significance  
study-subject  
study-subject-type 
The type of subject: animal, dog, rat, human, patient, 
volunteer… 
study-subject-condition 
Some characteristic distinguishing the subjects, such as 
renal function. 
study-subject-number The number of subjects included in the study. 
study-type  
unkown-role 
The interacting drug which role as precipitant or object 
cannot be known. 
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Analysis of terms expressing modification in the DDI corpus 
Main groups of terms 
↑ increases induces ↓ decreases inhibits 
accelerating increase induce antagonize decrease inhibit 
add increased induced blocks decreased inhibited 
added increases inducer decrease decreases inhibiting 
elevate increasing (inducers) decreased decreasing inhibition 
elevated elevate inducing decreases reduce inhibitor 
elevation elevated induction decreasing reduced inhibits 
elevations elevation  delay reduces antagonize 
enhance elevations  delayed delaying reduction 
enhanced accelerating  depresses   
enhancing   discontinuation   
greater   inhibit   
high   inhibited   
higher   inhibiting   
increase   inhibition   
increased   inhibitor   
increases   inhibits   
increasing   less   
induce   lowered   
induced   reduce   
inducer   reduced   
(inducers)   reduces   
inducing   reduction   
induction   depresses   
potentiate   shortened   
potentiated      
prolong      
prolongation      
prolonged      
twice      
double      
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Annex 4 (continuation 2) 
Analysis of terms expressing modification in the DDI corpus 
Main groups of terms (continuation) 
→ causes  changes influences is associated 
with 
cause cause affect change influence interact 
caused caused alter changes   
causes causes altered alter   
causing causing avoided altered   
leading leading binding    
produce  change    
produce  changes    
produced  indicate    
promotes  influence    
release  interact    
result  interfere    
resulted  interferes    
resulting  occur    
results  reported    
  showed    
 
Analysis Results: 
↑ 
acceler*: It is used related to a PK mechanism. Accelerating refers to the rate of 
the process. Therefore, it is a term that describes an increase in the rate (velocity) 
of a PK process. 
add*: add refers to an increase (in this case, in the risk of toxicity). However, 
added and addition are terms related with a coadministration pattern. 
elevat*: This term is related with the levels or concentrations of one drug or 
substance. Therefore, if we consider levels and concetrations as a PK parameter, 
this term shows an increase in PK parameter. 
enhanc*: It is used to indicate an increase in PK parameter, PK process, effect 
and toxicity. 
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Annex 4 (continuation 3) 
Analysis of terms expressing modification in the DDI corpus 
↑ (continuation) 
high*: It is used related to doses, levels or concentrations and “risk of toxicity”. 
Higher is used related to concentration or levels and PK parameters. Higher and 
greater can be associated with a numerical value. Highly is used mainly related to 
the affinity of a drug or substance for plasmatic proteins (therefore, it is related 
with an specific PK process). 
increas*: The word increase is mostly associated with a PK parameter and less 
frequently with a PK process, concentration or levels, dosage of a drug (in this 
case, it seems to refer to a recommendation), an effect, toxicity or toxic effect, a 
risk of an effect. The word “increase” usually has a value (%), although, 
sometimes it doesn’t have it (a generic reference to “an increase”). When it is 
preceded by a modal verb (e.g., may) it does not refer to a PK parameter (an 
exception occurs with bioavailability). This fact could be related with the certainty 
of the described observation. The word “increase” can be related with the term 
“significant”, which could provide important information related to the 
significance of the interaction. An increase is caused by something, which 
sometimes is described in the texts.  
We have not found other important patterns with the rest of words increased, 
increases or increasing. 
induc*: It is an important term, too. The different variation of the lemma induc* 
present interesting characteristics: 
- induce: The word “induce” is used referring to the PK process metabolism 
(e.g., to induce the metabolism of) or the activity of a specific enzyme (e.g., 
induce CYP3A4 activity).  
- induced: in this study we found that this word is used only to describe the 
effect caused by the inducting drug, for example: an increase in 
DRUGLABEL-induced toxicity. 
- inducer: this word is used referring to the “inducting” drug.  
- inducing: this word is used only in the following way: with enzyme-inducing 
GROUPLABEL. 
- induction: refers the process. 
potentiat*: potentiate and potentiated refer to the activity, effect or toxicity of 
one drug.  
prolong*: This concept is related with “time”, since it means “to lengthen in 
duration or space; extend”. The term prolong is used with both, effects of a drug 
and PK parameters (including drug concentrations). 
twice: this word is mainly used to refer to the posology of the drugs (treatment) 
and not to referring to a modification in some value. 
double*: It is used to show an increase (with a specific extend) of a PK parameter. 
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Analysis of terms expressing modification in the DDI corpus 
↓ 
antagon*: The mentions refer to an effect, so this term is not used regarding PK 
features in this corpus. 
block*: blocks and blocking, both referring to mechanism. 
decreas*: A high frequency in the corpus. The word “decrease” is used in the 
same way that has been described for “increase”.  An important difference is that 
decrease is used to describe a ↓ in the effectiveness of the drug that can be related 
with therapeutic failure. The word decreased is used in the same way that 
“decrease” and it can be used as well regarding to the efficacy or effectiveness of 
the drug (e.g., resulting in decreased contraceptive effectiveness). 
This can be an interesting pattern, since it should not be frequently the use of the 
word “increase” related to the efficacy of one drug. 
“decreasing” seems to relate a cause and a consequence. Therefore, the study of 
gerund verbs could be useful for the study of relationships between different types 
of outputs. 
delay*: is used with PK processes, although there is a mention with an effect. 
discontinu*: these terms refers to the interruption of the treatment of one drug. 
Therefore, it seems to be related with the label “co-administration pattern”. 
inhibit*: High frequency in the corpus. The word “inhibit” is used in two main 
ways: 
- Is used to describe a characteristic of one drug (drugs that inhibit 
CYP3A4). This can be an indirect way to describe a DDI. 
- Is used to express a modification in a PK process (mainly with 
metabolism, but with other processes too), in the activity of an enzyme (study the 
relation of this with the metabolic process), in the effect or activity of one drug, 
but NOT with PK parameters (at least in the sentences included in the analysis). 
“inhibited” is used in a similar way, although it is important to remark the 
example “DRUGLABEL is inhibited by GROUPLABEL”. Here we can see that the 
term is used referring to the drug (in general). 
“inhibitor” is used as a characteristics of drugs and to express the inhibition of the 
metabolism process (no others processes have been identified in the analysis). 
“inhibitory” refers to the activity or effect of a drug.  
The other terms do not present interesting characteristics. 
less: This term does not describe a modification. 
lower*:  the words “lowered”, “lowering” and “lowers” (not “lower”) are the 
ones that describe a modification. Is used with PK parameter (including 
concentration or levels). 
reduc*: These terms are broadly used related to a PK process, a PK parameter, 
drug concentration or levels, an effect or efficacy of one drug, and with the drug 
requirements (the latter one is related with dosages or recommendations, and not 
with showing a modification). 
short*: This term does not present interesting characteristics. 
depress*: This term does not present interesting characteristics. 
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Analysis of terms expressing modification in the DDI corpus 
→ 
caus*: This term is not used to express a modification. Moreover, it usually 
precedes a “modification term”, such as “increase” or “decrease”. It is used 
(without a modification term) with an adverse effect. 
lead*: the terms “lead” and “leads” are not very frequent and are used in the same 
way that cause. The term “leading to” is interesting, since it describes a 
relationship between two outputs. As well as the previous one, most times it is 
followed by a modification term. 
produc*: The same use than the previous one: it refers to a modification term. 
promot*: It is not very frequent. It is used in the corpus with a PK process. 
releas*: It is not important in this context. Mostly related with “pharmaceutical 
forms”. 
result*: It is quite frequent. The same characteristics than the previous ones. 
 
 
affect*: This term is does not describe the type of modification produced (↓,↑ or 
→) . It is frequently used with negation and referring to concentrations, drug 
effects, PK processes (most frequently) and PK parameters. 
alter*: It is used with PK processes, concentrations and PK parameters. 
avoid*: It is mostly related with recommendation sentences. 
bind*: This term is directly related with two processes (plasma proteins binding 
and physicochemical binding). 
chang*: This term is used with PK parameters, concentrations, effects (e.g., 
menstrual changes) and PK processes. 
indicat*: It is related with a type of study describing the DDI. 
influenc*: It is used with PK parameters and concentrations. 
interact*: This term  does not show a modification. 
interfer*: This term are mainly used with PK processes, although it is used with 
PK parameters too. 
occur*: It refers to an output (something that occurred or something that may 
occur). Therefore, it is not relevant to express a modification. 
report*: More relevant regarding the type of study. 
show*: Although “shown” is frequently used in the corpus, it is not very important 
to express modification. It is more relevant regarding the type of study. 
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Reasons and solutions for duplicated classes in DINTO 
Reasons and solution for duplicated classes in DINTO 
label Error reason Manual change 
abiraterone 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
aclidinium 
There is not link in ChEBI to DrugBank. 
The link in DrugBank to ChEBI is not to 
aclidinium but to aclidinium bromide. 
CASRN between them are not coincident. 
There is an error in the cross-reference 
from DrugBank to ChEBI. 
We keep the one from 
DrugBank, since it is the one 
that has the DDI-related 
information and eliminate the 
one from ChEBI. 
alogliptin 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
aminophylline 
This class is no longer presented in 
ChEBI (CHEBI_2659).  
It is eliminated from DINTO. 
amphetamines 
DrugBank uses the plural from 
amphetamines while ChEBI uses the 
singular form amphetamine. There is not 
DDI information for amphetamines in 
DrugBank.  
We eliminate the new class. 
asenapine 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
avanafil 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
axitinib 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
azilsartan medoxomil 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
However, CASRN do not match. The 
correct one is ChEBI’s, while the one in 
DrugBank corresponds to azilsartan. 
We eliminate the CASRN from 
the class imported from 
DrugBank and assign the URI 
from ChEBI. 
bedaquiline 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
bicalutamide 
There is link in ChEBI to DrugBank and 
in DrugBank to ChEBI. However, the 
latter one is an old (alternative) ChEBI 
ID. Match between the CASRN.  
We merge both classes keeping 
the ChEBI URI. 
boceprevir 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
bosutinib 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
cabozantinib 
There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
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Reasons and solution for duplicated classes in DINTO 
label Error reason Manual change 
calcium carbonate There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. There is 
not CASRN or KEGG IDs in DrugBank.  
 
We study and compare all the 
information provided in ChEBI 
and DrugBank entries and 
decide that they refer to the 
same substance. We merge 
both classes keeping the ChEBI 
URI. 
canagliflozin There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
carfilzomib There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
ceftaroline fosamil There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
However, CASRN do not match. The 
correct one is ChEBI’s, while the one in 
DrugBank corresponds to ceftaroline. 
We eliminate the CASRN from 
the class imported from 
DrugBank and assign the URI 
from ChEBI. 
dabigatran etexilate There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
dabrafenib There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. There is 
not CASRN in DrugBank, but there is 
KEGG DRUG ID, which matchs with the 
one in ChEBI. 
We merge both clases keeping 
the ChEBI URI. 
deferiprone There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
enzalutamide There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
eribulin There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
ezogabine There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
fidaxomicin There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
fluticasone furoate There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
both CASRN and KEGG IDs match. 
We merge both classes keeping 
the ChEBI URI. 
gabapentin enacarbil There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
geldanamycin There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
both CASRN and KEGG IDs match. 
We merge both classes keeping 
the ChEBI URI. 
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Reasons and solution for duplicated classes in DINTO 
label Error reason Manual change 
iloperidone There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
both CASRN and KEGG IDs match. 
We merge both classes keeping 
the ChEBI URI. 
ivacaftor There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
linagliptin There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
lomitapide There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
lorcaserin There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
both CASRN and KEGG IDs match. 
We merge both classes keeping 
the ChEBI URI. 
lurasidone There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
lysergic acid diethylamide There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
both CASRN and KEGG IDs match. 
We merge both classes keeping 
the ChEBI URI. 
monastrol There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. There is 
not CASRN or KEGG IDs in DrugBank.  
 
We study and compare all the 
information provided in ChEBI 
and DrugBank entries and 
decide that they refer to the 
same substance. We merge 
both classes keeping the ChEBI 
URI. 
monothioglycerol There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. There is 
not CASRN or KEGG IDs in DrugBank.  
 
We study and compare all the 
information provided in ChEBI 
and DrugBank entries and 
decide that they refer to the 
same substance. We merge 
both classes keeping the ChEBI 
URI. 
mycophenolate mofetil There is not link in DrugBank to ChEBI 
but there is link in ChEBI to DrugBank. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
octreotide This class is no longer presented in 
ChEBI (CHEBI_7726). 
It is eliminated from DINTO. 
ospemifene There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
oxcarbazepine There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
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Reasons and solution for duplicated classes in DINTO 
label Error reason Manual change 
parecoxib There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. There is 
not CASRN or KEGG IDs in DrugBank.  
We study and compare all the 
information provided in ChEBI 
and DrugBank entries and 
decide that they refer to the 
same substance. We merge 
both classes keeping the ChEBI 
URI. 
pasireotide There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
pazopanib There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
perampanel There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
pitavastatin There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
pomalidomide There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
pralatrexate There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
regorafenib There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
roflumilast There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
ruxolitinib There is not link in ChEBI to DrugBank 
but there is link in DrugBank to ChEBI. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
salicylamide There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
CASRN match. 
We merge both classes keeping 
the ChEBI URI. 
saxagliptin There is link in ChEBI to DrugBank and 
in DrugBank to ChEBI. However, the 
latter one is an old (alternative) ChEBI 
ID. Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
sibutramine There is not link in DrugBank to ChEBI. 
This class is no longer presented in 
ChEBI (ChEBI_9137). 
We eliminate the class from 
ChEBI and keep the new class 
from DrugBank. 
teduglutide There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
CASRN match. 
We merge both classes keeping 
the ChEBI URI. 
teleprevir There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
CASRN match. 
We merge both classes keeping 
the ChEBI URI. 
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Annex 5 (continuation 5) 
Reasons and solutions for duplicated classes in DINTO 
Reasons and solution for duplicated classes in DINTO 
label Error reason Manual change 
telavancin There is not link in ChEBI to DrugBank. 
The link in DrugBank to ChEBI is not to 
telavancin but to telavancin 
hydrochloride. CASRN between them are 
not coincident. There is an error in the 
cross-reference from DrugBank to 
ChEBI. 
We eliminate the CASRN from 
the class imported from 
DrugBank and assign the URI 
from ChEBI corresponding to 
ChEBI_71226. 
teriflunomide There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
CASRN match. 
We merge both classes keeping 
the ChEBI URI. 
thioproline There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. CASRN 
do not match, because the one in 
DrugBank is an older one.  
We study and compare all the 
information provided in ChEBI 
and DrugBank entries and 
decide that they refer to the 
same substance. We merge 
both classes keeping the ChEBI 
URI. 
ticagrelor There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
both CASRN and KEGG IDs match. 
We merge both classes keeping 
the ChEBI URI. 
valacyclovir/valaciclovir There is a spelling variation between the 
both labels. 
Son en el mismo. Llamo a valaciclovir 
DBName 
We merge both classes keeping 
the ChEBI URI. We manually 
change the label valaciclovir to 
the annotation property 
DBName 
vandetanib There is not link in DrugBank to ChEBI, 
but there is link in ChEBI to DrugBank. 
However, it corresponds with a different 
substance (DB08764) 
We merge both classe keeping 
the ChEBI URI and manually 
eliminate the incorrect cross-
reference from ChEBI.  
vanoxerine There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. There is 
not CASRN or KEGG IDs in DrugBank.  
We study and compare all the 
information provided in ChEBI 
and DrugBank entries and 
decide that they refer to the 
same substance. We merge 
both classes keeping the ChEBI 
URI. 
vemurafenib There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
CASRN match. 
We merge both classes keeping 
the ChEBI URI. 
vismodegib There is not link in ChEBI to DrugBank, 
neither in DrugBank to ChEBI. However, 
CASRN match. 
We merge both classes keeping 
the ChEBI URI. 
ximelagatran There is not link in DrugBank to ChEBI 
but there is link in ChEBI to DrugBank. 
Match between the CASRN. 
We merge both classes keeping 
the ChEBI URI. 
 
 
  
 
Annex 6 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
adsorbs A relationship between two chemicals in 
which one of them is retained by the other one. 
is adsorbed by    No 
alters A relationship between an entity x (process or 
continuant) and a process y, which bears a 
quality that is altered by x, leading to a change 
compare to normal or previous value. 
is altered by    No 
decreases A relationship between an entity x (process or 
continuant) and an entity y, which bears a 
quality that is decreased by x, leading to a 
change that is decreased compare to normal or 
previous value. 
is decreased by alters   Yes (8) 
 
 
increases A relationship between an entity x (process or 
continuant) and an entity y, which bears a 
quality that is increased by x, leading to a 
change that is increased compare to normal or 
previous value. 
is increased by alters   Yes (7) 
binds A relationship between a pharmacological 
entity and a protein. 
is binded by    No 
has 
pharmacologi
cal target 
A relationship of a pharmacological entity that 
interacts with a protein - denominated target – 
producing the pharmacological effect of the 
entity.   
is pharmacological 
target of 
binds pharmacological 
entity 
target No 
induces A relationship between a pharmacological 
entity and a protein where the entity increases 
the activity of the protein. 
is induced by binds pharmacological 
entity 
protein entity No 
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Annex 6 (continuation 2) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
inhibits A relationship between a pharmacological 
entity and a protein where the entity decreases 
the activity of the protein. 
is inhibited by binds pharmacological 
entity 
protein entity No 
is substrate of A relationship between a chemical entity and a 
protein where a substrate interaction can occur 
between them. 
 
Substrate Interaction involves temporary non-
covalent binding through intermolecular 
physical forces of attraction and spatial 
complementarity between biologically-active 
molecules and their target molecule or between 
a biological molecule and an underlaying 
surface. 
has substrate binds    
is carried by A relationship between a pharmacological 
entity and a protein which carries the entity. 
carries is substrate 
of 
pharmacological 
entity 
carrier  
is 
metabolised 
by 
A relationship between a chemical entity and 
an enzyme involved in the metabolism of the 
entity. 
metabolizes is substrate 
of 
pharmacological 
entity 
enzyme  
is 
transported 
by 
A relationhip between a pharmacological 
entity and a protein which transports the entity. 
transports is substrate 
of 
pharmacological 
entity 
transporter  
modulates A relationhip between a 
pharmacological entity which binds a protein, 
triggering a response or blocking it. 
is modulated by binds pharmacological 
entity 
protein entity  
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Annex 6 (continuation 3) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
activates A relationship between a pharmacological 
entity and a protein, where the chemical entity 
selectively binds to and activates the protein. 
is activated by modulates    
blocks A relationship between a pharmacological 
entity and a protein, where the entity binds to 
but does not activate the protein, thereby 
blocking the actions of endogenous or 
exogenous agonists. 
is blocked by modulates    
related with A relationship between a pharmacological 
entitiy and a protein that are known to interact 
in some way, although more specific details 
about the interaction are still ignored. 
symmetric binds    
chelates A relationship between two chemicals 
describing ‘the formation or presence of bonds 
between two or more separate binding sites 
within the same ligand and a single central 
atom’ that leads to the formation of a 
compound called chelate. 
is chelated by     
describes A relationship between an information 
resource describing a DDI and this DDI. 
is described by information 
resource 
DDI   
determines A relationship between an entity a and an 
entity b, which existence or some characteristic 
of b depends directly in the entity a. 
is determined by     
 
273 
 
  
 
Annex 6 (continuation 4) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
has agent A relationship between a DDI mechanism and 
the precipitant entity that triggers the process. 
is agent in DDI 
mechanism 
pharmacological 
entity and (has 
role) some 
precipitant) 
  
has DDI 
effect 
A relationship between a DDI and the altered 
physiological effect that occurs as a 
consequence of the DDI. 
is DDI effect of DDI DDI effect   
has effect A relationship between a pharmacological 
entity and its physiological effect. 
is effect of  pharmacological 
entity 
physiological 
effect 
 
has 
metabolite 
A relationship between a pharmacological 
entity and the metabolite produced as a 
consequence of the metabolism of the entity. 
is metabolite of 
 
 pharmacological 
entity 
pharmacological 
entity 
 
has 
parameter 
A relationship between a pharmacokinetic 
process and the pharmacokinetic parameter 
describing it. 
is parameter of 
 
 pharmacokinetic 
process 
pharmacokinetic 
parameter 
 
has 
participant 
A relationship between a DDI and the two 
drugs - one object and one precipitant - 
participating in it. 
is participant in   DDI pharmacological 
entity 
 
has object A functional relationship between a DDI and 
an object. 
is object in has 
participant 
DDI 
 
pharmacological 
entity 
 
has 
precipitant 
A functional relationship between a DDI and a 
precipitant. 
is precipitant in 
 
has 
participant 
DDI pharmacological 
entity 
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Annex 6 (continuation 5) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
has product A relationship between the pharmacokinetic 
process ‘drug metabolism’, by which a drug is 
metabolized, and the metabolite that is formed 
as a consequence. 
is product of  drug metabolism   
has quality Has quality is a relation between an entity and 
the quality that it bears. 
is quality of     
has role The relationship between a chemical and the 
role that it can exhibit in a chemical or 
biological context. 
is role of  pharmacological 
entity 
role  
has study 
entity 
A relationship between an information 
resource describing some aspect of a DDI and 
the two pharmacological entities that are 
studied as interacting drugs. 
  information 
resource 
pharmacological 
entity and (is 
participant in 
some (DDI and is 
described in some 
information 
resource)) 
 
has study 
subject 
A relationship between an information 
resource describing some aspect of a DDI and 
the individual that is subject in the study. 
  information 
resource 
study subject  
is adsorbed 
by 
A relationship between two chemicals in 
which one of them is retained by the other one. 
adsorbs 
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Annex 6 (continuation 6) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
is agent in  A relationship between a pharmacological 
entity and a DDI mechanism that leads to a 
DDI where the entity is the precipitant or 
perpetrator of the interaction. 
has agent  pharmacological 
entity and (has 
role some 
precipitant) 
DDI mechanism 
 
 
is altered by A relationship between a process y that bears a 
quality that is altered by an entity x (process or 
continuant), leading to a change with compare 
to normal or previous value. 
alters     
is decreased 
by 
A relationship between an entity y that bears a 
quality that is decreased by an entity x (process 
or continuant), leading to a change that is 
decreased compare to normal or previous 
value. 
decreases    Yes (8) 
is increased 
by 
A relationship between an entity y that bears a 
quality that is increased by an entity x (process 
or continuant), leading to a change that is 
increased compare to normal or previous 
value. 
increases    Yes (7) 
 
is binded by A relationship between a protein and the 
pharmacological entity that interacts with the 
protein. 
binds     
carries A relationhips between a protein and a 
pharmacological entity that is carried by the 
protein. 
is carried by has substrate carrier pharmacological 
entity 
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Annex 6 (continuation 7) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
metabolizes A relationship between an enzyme and a 
pharmacological entity which is metabolized 
by it. 
is metabolised by has substrate enzyme pharmacological 
entity 
 
transports A relationship between a protein and a 
pharmacological entity that is transported in 
the body by that protein. 
is transported by 
 
has substrate 
 
transporter pharmacological 
entity 
 
has substrate A relationship between a protein and a 
chemical entity when a substrate interaction 
can occur between them. 
Substrate Interaction involves temporary non-
covalent binding through intermolecular 
physical forces of attraction and spatial 
complementarity between biologically-active 
molecules and their target molecule or between 
a biological molecule and an underlying 
surface. 
is substrate of 
 
 
is binded by    
is induced by A relationship between a protein and a 
pharmacological entity which increases the 
activity of this protein. 
induces is binded by protein entity pharmacological 
entity 
 
is inhibited 
by 
A relationship between a protein and a 
pharmacological entity which reduces the 
activity of this protein. 
inhibits is binded by protein entity 
 
pharmacological 
entity 
 
is modulated 
by 
A relationhip between a protein and a 
pharmacological entity, which binds to it 
triggering a response or blocking it. 
modulates is binded by protein entity 
 
pharmacological 
entity 
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Annex 6 (continuation 8) 
Description of object properties in DINTO 
Annotation 
property 
Definition inverse of 
Sub 
Property of 
domain range 
Sub 
property 
chain 
is activated 
by 
A relationship between a protein and a 
pharmacological entity, where the protein is 
selectively binded and activated by the 
chemical entity. 
activates is modulated 
by 
   
is blocked by A relationship between a protein and a 
pharmacological entity, where the protein is 
binded, but not activated, by the entity, thereby 
blocking the actions triggered by endogenous 
or exogenous agonists.  
blocks is modulated 
by 
   
is 
pharmacolgoi
cal target of 
A relationship between a protein denominated 
target and a pharmacological entity that 
interact producing the pharmacological effect 
of the entity.   
has pharmacological 
target 
is binded by 
 
target 
 
pharmacological 
entity 
 
is chelated by A relationship between two chemicals 
describing ‘the formation or presence of bonds 
between two or more separate binding sites 
within the same ligand and a single central 
atom’ that leads to the formation of a 
compound called chelate. 
chelates 
 
 
    
is DDI effect 
of 
A relationship between an altered 
physiological effect and the DDI responsible 
of the alteration  
has DDI effect  DDI effect DDI  
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Annex 6 (continuation 9) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
is described 
in 
A relationship between a DDI and an 
information resource describing some aspect of 
the interaction. 
describes 
 
 DDI 
 
information 
resource 
 
is determined 
by 
A relationship between an entity b and an 
entity a, when the existence or some 
characteristic of b depends directly in the 
entity a. 
determines     
is effect of A relationship between a physiological effect 
and the chemical entity that produces the 
effect. 
has effect  physiologic effect pharmacological 
entity 
 
is metabolite 
of 
A relationship between a metabolite and a 
pharmacological entity, where the metabolite 
is produced as a consequence of the 
metabolism of the entity. 
has metabolite 
 
  pharmacological 
entity 
 
is  parameter 
of 
A relationship between a pharmacokinetic 
parameter and the pharmacokinetic process 
that it describes. 
has parameter  pharmacokinetic 
parameter 
pharmacokinetic 
process 
 
is participant 
in 
A relationship between a drug, precipitant or 
object, and the DDI in which it is one of the 
two participating drugs. 
has participant  pharmacological 
entity 
DDI 
 
 
is object in A relationship between a drug and the DDI in 
which it is the object participating drug. 
has object  pharmacological 
entity 
DDI  
is precipitant 
in  
A relationship between a drug and the DDI in 
which it is the precipitant participating drug. 
has precipitant 
 
 pharmacological 
entity 
DDI  
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Annex 6 (continuation 10) 
Description of object properties in DINTO 
Annotation 
property 
Definition inverse of 
Sub 
Property of 
domain range 
Sub 
property 
chain 
is preceded 
by 
A transitive, temporal relation in which one 
process is preceded (has occurred later than) 
another process. 
precedes 
 
    
is product of A relationship between a metabolite and the 
pharmacokinetic process drug metabolism in 
which a drug is metabolized into this 
metabolite. 
has product  drug metabolism 
 
  
is quality of Is quality of is a relation between a quality and 
the entity that it is a property of. 
has quality     
is regulated 
by 
A relationship between a process and a 
physiological entity (continuant or process), 
where the entity modulates a measurable 
attribute of the process, quality or function. 
regulates     
is facilitate by A relationship between a process y and an 
entity x (continuant or process), where the 
occurrence of y depends directly or is heavily 
dependent on x. 
facilitates is regulated 
by 
   
is impaired 
by 
A relationship between a process y and an 
entity x (continuant or process), where x 
avoids the occurrence or reduces the 
magnitude of process y. 
impairs is regulated 
by 
   
is role of The relationship between a role and the 
chemical that can exhibit it in a chemical or 
biological context. 
has role 
 
 role pharmacological 
entity 
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Annex 6 (continuation 11) 
Description of object properties in DINTO 
Annotation 
property 
Definition Inverse of 
Sub 
Property of 
Domain Range 
Sub 
property 
chain 
is undergone 
by 
A relationship between a pharmacokinetic 
process and the chemical entity that undergoes 
the process. 
undergoes  pharmacokinetic 
process 
pharmacological 
entity 
 
may interact 
with 
A relationship between two pharmacological 
entities, y and x, where the levels or effects of 
one of them (y) are altered by the other (x). 
Symmetric     
precedes A transitive, temporal relation in which one 
process precedes (has occurred earlier than) 
another process. 
is preceded by     
regulates A relationship between a physiological entity 
(continuant or process) and a process, where 
the entity modulates a measurable attribute of 
the process, quality or function. 
is regulated by     
facilitates A relationship between an entity x (continuant 
or process) and a process y, which occurrence 
depends directly or is heavily dependent on x. 
is facilitated by regulates 
 
   
impaires A relationship between an entity x (continuant 
or process) and a process y, where x avoids the 
occurrence or reduces the magnitude of 
process y. 
is impaired by regulates 
 
   
undergoes A relationship between a chemical entity and 
the pharmacokinetic process that the chemical 
entity undergoes in the body. 
is undergone by  pharmacological 
entity 
pharmacokinetic 
process 
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Annex 7 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
1 Is there an interaction between 
rifampicin and cyclosporin A? 
Yes, there is an interaction between 
both drugs. This information is 
explicitly represented in the ontology 
at the class level. As well, the 
interaction can be asserted between 
individuals. 
rifampicin may_interact_with some cyclosporin A 
cyclosporin A may_interact_with some rifampicin 
cyclosporin A/rifampicin DDI equivalent to ((has_participant some 
cyclosporin A) and (has_participant some rifampicin)) 
Rifampicin may_interact_with Cyclosporin A 
Cyclosporin A may_interact_with Rifampicin 
Cyclosporin A/Rifampicin DDI has_participant CyclosporinA 
Cyclosporin A/Rifampicin DDI has_participant Rifampicin 
2 
Is the effect of cyclosporin A 
modified by rifampicin? 
Cyclosporin A’s effects represented in 
this example (immunosuppressant 
effect and transplant rejection) are 
modified by rifampicin. The first one is 
decreased, while the second one is 
increased. 
Cyclosporin A has_effect ImmunosuppresantEffect 
Cyclosporin A has_effect TransplantRejection 
Rifampicin decreases ImmunosuppresantEffect 
Rifampicin increases TransplantRejection 
3 
What is the mechanism of the 
interaction between 
cyclosporin A and rifampicin? 
It is a pharmacokinetic mechanism: 
specifically the induction of the enzyme 
cytochrome P450 3A4. 
Cyclosporin A/rifampicin DDI is_preceded_by CytochromeP4503A4Induction 
CytochromeP4503A4Induction is_a enzyme activity induction 
Cyclosporin A/rifampicin DDI is_preceded_by CytochromeP4503A4Induction 
4 
Is a PK parameter of 
cyclosporin A modified by 
rifampicin? 
Yes, rifampicin alters Cmax of 
cyclosporin A. 
Rifampicin alters Cmax 
Cmax is_a pharmacokinetic parameter 
classes; object_properties; Individuals; attributes 
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Annex 7 (continuation 2) 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
5 
What is the type of the 
interaction between 
cyclosporin A and rifampicin? 
The DDI is classified in two different 
ways in the ontology. Firstly, it is 
classified as an enzyme induction DDI. 
Therefore, it is a PK DDI. Secondly, it 
is classified in basis of the 
consequence for the patient as a 
potentially harmful DDI. 
CyclosporinA/Rifampicin DDI is_a enzyme induction DDI 
CyclosporinA/Rifampicin DDI is_a potentially harmful DDI 
6 What is the type of PD 
interaction between 
cyclosporin A and rifampicin? 
There is not a PD DDI between these 
two drugs.  
7 
Is there a PK interaction 
between cyclosporin A and 
rifampicin? 
Yes, the interaction between these two 
drugs is a PK DDI. 
CyclosporinA/Rifampicin DDI is_a enzyme induction DDI 
enzyme induction DDI is_a enzyme alteration DDI 
enzyme alteration DDI is_a pharmokinetic DDI 
8 
Is the toxicity of cyclosporin A 
exacerbated by rifampicin? 
No, the effect of this DDI is a 
decreased in the therapeutic effect of 
cyclosporin A, not an increase in the 
toxicity. 
CyclosporinA/Rifampicin DDI has_DDI_effect TransplantRejection 
TransplantRejection is effect of CyclosporinA 
TransplantRejection is_a decreased therapeutic effect 
decreased therapeutic effect is_a  altered therapeutic 
effect 
classes; object_properties; Individuals; attributes 
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Annex 7 (continuation 3) 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
9 
Is the effect of the DDI an 
adverse effect of cyclosporin 
A or rifampicin? 
No, the effect of this DDI is a 
decreased in the therapeutic effect of 
cyclosporin A, not an increase in the 
adverse effect. 
CyclosporinA/Rifampicin DDI has_DDI_effect TransplantRejection 
TransplantRejection is_effect_of CyclosporinA 
TransplantRejection is_a decreased therapeutic effect 
decreased therapeutic effect is_a  altered therapeutic 
effect 
10 Is the effect transplant 
rejection produced by an 
interaction between 
cyclosporin A and rifampicin? 
Yes, the effect of the interaction 
between cyclosporin A and rifampicin 
is transplant rejection. 
CyclosporinA/Rifampicin DDI has_DDI_effect TransplantRejection 
11 
What is the effect of the 
interaction between 
cyclosporin A and rifampicin? 
The effect of the interaction between 
cyclosporin A and rifampicin is 
transplant rejection, the consequence 
of the decrease in the therapeutic effect 
of cyclosporin A. 
CyclosporinA/Rifampicin DDI has_DD_ effect TransplantRejection 
TransplantRejection is_effect_of CyclosporinA 
TransplantRejection is_a decreased therapeutic effect 
decreased therapeutic effect is_a  altered therapeutic 
effect 
12 
Can be cyclosporin A and 
rifampicin used 
concomitantly? 
No, it is necessary to change the dose 
schedule in order to not administrate 
both drugs concomitantly. 
CyclosporinA/Rifampicin DDI has_dose_recommendation change dose 
schedule 
13 
Should be discontinued the 
treatment with cyclosporin A 
when rifampicin is 
administered? 
It is necessary to change the dose 
schedule in order to not administrate 
both drugs concomitantly. 
CyclosporinA/Rifampicin DDI has_dose_recommendation change dose 
schedule 
classes; object_properties; Individuals; attributes 
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Annex 7 (continuation 4) 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
14 
Should be modified the dosage 
of cyclosporin A when 
rifampicin is administered? 
Yes, it is necessary to increase the 
dose of cyclosporin A. CyclosporinA/Rifampicin DDI  has_dose_recommendation increase 
from baseline 
15 
How could be avoided the 
effect of the interaction 
between cyclosporin A and 
rifampicin? 
To avoid the DDI it is necessary to 
change the dose schedule in order to 
not administrate both drugs 
concomitantly and to to increase the 
dose of cyclosporin A.  
CyclosporinA/Rifampicin DDI  has_dose_recommendation change dose 
schedule 
CyclosporinA/Rifampicin DDI  has_dose_recommendation increase 
from baseline 
16 Is there any minimal elapse of 
time to administer cyclosporin 
A after stopping the 
administration of rifampicin? 
Yes, it is necessary to change the dose 
schedule in order to not administrate 
both drugs concomitantly. The 
numerical value is not represented in 
the ontology. 
CyclosporinA/Rifampicin DDI  has_dose_recommendation change dose 
schedule 
 
17 
Is there any recommendation 
in order to avoid the DDI 
between cyclosporin A and 
rifampicin? 
Yes, to avoid the DDI it is necessary to 
change the dose schedule in order to 
not administrate both drugs 
concomitantly and to increase the dose 
of cyclosporin A. 
CyclosporinA/Rifampicin DDI  has_dose_recommendation change dose 
schedule 
CyclosporinA/Rifampicin DDI  has_dose_recommendation increase 
from baseline 
18 
What patient’s characteristics 
affecting the DDI are present?  
Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
classes; object_properties; Individuals; attributes 
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Annex 7 (continuation 5) 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
19 
What is the age of the patient? Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
20 
What is the sex of the patient? Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
21 What is the race or ethnic? Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
22 
What administration form of 
cyclosporin A interacts with 
rifampicin? 
Information related to drugs’ 
pharmaceutical forms is not included 
in the description of the DDI in the text 
source. 
 
23 
Is there any alternative 
administration form of 
cyclosporin A that does not 
produce the interaction with 
rifampicin? 
This information is not represented in 
the ontology. 
 
classes; object_properties; Individuals; attributes 
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Annex 7 (continuation 6) 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
24 What proteins interact with 
cyclosporin A? 
This information is explicitly 
represented in the ontology at the class 
level: calcineurin subunit b isoform 2, 
calcium signal-modulating  cyclophilin 
ligand, cytochrome p450 3a4, 
cytochrome p450 3a7, cytochrome 
p450 3a5, cytochrome p450 2c8, 
cytochrome p450 2c9, cytochrome 
p450 2c19, cytochrome p450 2d6,  
multidrug resistance protein 1, atp-
binding cassette sub-family g member 
2, bile salt export pump, canalicular 
multispecific organic anion 
transporter 2, canalicualr 
multispecific organic anion 
transporter 1, ilial sodium/bile acid 
cotransporter, multidrug resistance-
associated protein 7, multidrug 
resistance-associated protein 1, 
sodium/bile acid cotransporter, solute 
carrier family 22 member 6, solute 
carrier organic anion transporter 
family member 1a2 and solute carrier 
organic anion transporter family 
member 1b1. 
cyclosporin A … 
 
has_pharmacological_target some calcineurin subunit b isoform 
2 
has_pharmacological_target some calcium signal-modulating  
cyclophilin ligand 
is_metabolized_by some cytochrome p450 3a4 
is_metabolized_by some cytochrome p450 3a7 
is_metabolized_by some cytochrome p450 3a5 
is_transported_by some multidrug resistance protein 1 
binds some calcium signal-modulating cyclophilin ligand 
induces some cytochrome p450 3a7 
induces some cytochrome p450 3a5 
induces some multidrug resistance protein 1 
inhibits some atp-binding cassette sub-family g member 2 
inhibits some bile salt export pump 
inhibits some calcineurin subunit b isoform 2 
inhibits some canalicular multispecific organic anion 
transporter 2 
inhibits some canalicualr multispecific organic anion 
transporter 1 
inhibits some cytochrome p450 2c8 
inhibits some cytochrome p450 2c9 
inhibits some cytochrome p450 2c19 
etc. 
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Annex 7 (continuation 7) 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
25 
Is cyclosporin A metobolized 
by any of the cytochrome P450 
isoenzymes? Which ones? 
Yes, it is metabolized by several 
CYP450 isoenzymes:  cytochrome 
p450 3a4, cytochrome p450 3a7 and 
cytochrome p450 3a5. 
is_metabolized_by some cytochrome p450 3a4 
is_metabolized_by some cytochrome p450 3a7 
is_metabolized_by some cytochrome p450 3a5 
26 
Is cyclosporin A transported 
by P-glycoprotein? 
Yes, it is transported by P-glycoprotein 
(which synonym is multidrug 
resistance protein 1). 
is_transported_by some multidrug resistance protein 1 
27 Has cyclosporin A got any 
effect (inhibitor or inductor) of 
any of the cytochrome P450 
isoenzymes? 
Yes, cyclosporin A inhibits several 
CYP450 isoenzymes (2C8, 2C9, 2C19, 
2D6 and 3A4) and induces others, as 
well (3A7, 3A5) 
induces some cytochrome p450 3a7 
induces some cytochrome p450 3a5 
inhibits some cytochrome p450 2c8 
inhibits some cytochrome p450 2c9 
inhibits some cytochrome p450 2c19 
inhibits some cytochrome p450 2d6 
inhibits some cytochrome p450 3a4 
28 
Has cyclosporin A got a 
narrow therapeutic index? 
This information is not represented in 
the ontology. 
 
classes; object_properties; Individuals; attributes 
 
 
 
 
288 
 
  
 
Annex 7 (continuation 8) 
CQs, answers and axioms for the DDI between rifampicin and cyclosporin A 
 Question Answer Axioms 
29 How frequently has the DDI 
been described? 
This DDI have not been described 
frequently. 
CyclosporinA/Rifampicin DDI has_incidence low 
30 
What type of study describes 
the DDI? 
The DDI is described in a clinical 
study carried out in patients. 
CyclosporinA/Rifampicin DDI is_described_in Study1 
Study1 is_a patient study 
31 
What is the certainty of the 
DDI? 
The DDI is well-known and 
established. 
CyclosporinA/Rifampicin DDI has_documentation_level established 
32 
Has been the DDI established 
in well performed and 
controlled studies? 
The DDI is described in a clinical 
study carried out in patients*. 
CyclosporinA/Rifampicin DDI is_described_in Study1 
Study1 is_a patient study 
33 What is the severity of the 
DDI? 
It is a major and clinically relevant 
DDI. 
CyclosporinA/Rifampicin DDI has_severity major 
CyclosporinA/Rifampicin DDI has_relevance clinical relevance 
classes; object_properties; Individuals; attributes 
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Annex 8 
CQs, answers and axioms for the DDI between naloxone and morphine 
 Question Answer Axioms 
1 
Is there an interaction between 
morphine and naloxone? 
The interaction between morphine and 
naloxone is not explicitly described in 
the ontology, since it is not described 
in the original information source (the 
database DrugBank). However, the 
information can be represented in the 
ontology60. 
naloxone may_interact_with some morphine 
morphine may_interact_with some naloxone 
naloxone/morphine DDI equivalent to ((has_participant some 
morphine) and (has_participant some naloxone)) 
Naloxone may_interact_with Morphine 
Morphine may_interact_with Naloxone 
Naloxone/Morphine DDI has_participant Morphine 
Naloxone/Morphine DDI has_participant Naloxone 
2 Is the effect of morphine 
modified by naloxone? 
The effect of morphine represented in 
this example (CNS depression) is 
decreased by naloxone.  
Morphine has_effect CNSDepression 
Naloxone decreases CNSDepression 
3 
What is the mechanism of the 
interaction between naloxone 
and morphine? 
It is a pharmacodynamic mechanism, 
specifically the antagonism of the mu-
opioid receptor. 
Naloxone/Morphine DDI  is_preceded_by MuReceptorAntagonism 
MuReceptorAntagonism is_a antagonistic DDI mechanism 
4 
Is a PK parameter of morphine 
modified by naloxone? 
No, in this interaction there is not a 
PK parameter altered.  
 
classes; object_properties; Individuals; attributes 
 
 
 
                                                 
60 We manually create the class ‘naloxone/morphine DDI’. 
290 
 
  
 
Annex 8 (continuation 2) 
CQs, answers and axioms for the DDI between naloxone and morphine 
 Question Answer Axioms 
5 
What is the type of the 
interaction between morphine 
and naloxone? 
The DDI is classified in two different 
ways in the ontology. Firstly, it is 
classified as an antagonistic DDI. 
Therefore, it is a PD DDI. Secondly, it 
is classified in basis of the 
consequence for the patient as a 
potentially beneficial DDI. 
Naloxone/Morphine DDI  is_a antagonistic DDI 
Naloxone/Morphine DDI  is_a potentially beneficial DDI 
6 What is the type of PD 
interaction between morphine 
and naloxone? 
The type of interaction is antagonistic 
DDI. Naloxone/Morphine DDI  is_a antagonistic DDI 
7 
Is there a PK interaction 
between  
morphine and naloxone? 
No, the interaction between these 
drugs in the type pharmacodynamic.  
8 
Is the toxicity of morphine 
exacerbated by naloxone? 
No, the effect of morphine is decreased 
by naloxone. 
Naloxone/Morphine DDI has_DDI_effect CNSDepressionRecovery 
CNSDepressionRecovery is_a decreased adverse effect 
9 
Is the effect of the DDI an 
adverse effect of morphine or 
naloxone? 
No, the effect of the DDI is a decrease 
in the adverse effect of morphine. 
Naloxone/Morphine DDI has_DDI_effect CNSDepressionRecovery 
CNSDepressionRecovery is_a decreased adverse effect 
10 
Is the effect CNS depression 
recovery produced by an 
interaction between naloxone 
and morphine? 
Yes, the effect of the interaction 
between naloxone and morphine is the 
recovery of the CNS depression 
induced by morphine. 
Naloxone/Morphine DDI has_DDI_effect CNSDepressionRecovery 
classes; object_properties; Individuals; attributes 
291 
 
  
 
Annex 8 (continuation 3) 
CQs, answers and axioms for the DDI between naloxone and morphine 
 Question Answer Axioms 
11 
What is the effect of the 
interaction between morphine 
and naloxone? 
The effect of the interaction between 
naloxone and morphine is the recovery 
of CNS depression induced by 
morphine. 
Naloxone/Morphine DDI has_DDI_effect CNSDepressionRecovery 
12 
Can be morphine and 
naloxone used concomitantly? 
Since the interaction between these 
drugs in beneficial, this question is not 
relevant in this example. 
 
13 Should be discontinued the 
treatment with naloxone when 
morphine is administered? 
Since the interaction between these 
drugs in beneficial, this question is not 
relevant in this example. 
 
14 
Should be modified the dosage 
of morphine when naloxone is 
administered? 
Since the interaction between these 
drugs in beneficial, this question is not 
relevant in this example. 
 
15 
How could be avoided the 
effect of the interaction 
between morphine and 
naloxone? 
Since the interaction between these 
drugs in beneficial, this question is not 
relevant in this example. 
 
16 
Is there any minimal elapse of 
time to administer morphine 
after stopping the 
administration of naloxone? 
Since the interaction between these 
drugs in beneficial, this question is not 
relevant in this example.  
17 
Is there any recommendation 
in order to avoid the DDI 
between morphine and 
naloxone? 
Since the interaction between these 
drugs in beneficial, this question is not 
relevant in this example. 
 
classes; object_properties; Individuals; attributes 
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Annex 8 (continuation 4) 
CQs, answers and axioms for the DDI between naloxone and morphine 
 Question Answer Axioms 
18 
What patient’s characteristics 
affecting the DDI are present?  
Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
19 
What is the age of the patient? Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
20 What is the sex of the patient? Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
21 
What is the race or ethnic? Information related to patient 
characteristics is not included in the 
description of the DDI in the text 
source. 
 
22 
What administration form of 
morphine interacts with 
naloxone? 
Information related to drugs’ 
pharmaceutical forms is not included 
in the description of the DDI in the text 
source. 
 
23 
Is there any alternative 
administration form of 
morphine that does not 
produce the interaction with 
naloxone? 
This information is not represented in 
the ontology. 
 
classes; object_properties; Individuals; attributes 
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Annex 8 (continuation 5) 
CQs, answers and axioms for the DDI between naloxone and morphine 
 Question Answer Axioms 
24 What proteins morphine 
interacts with? 
This information is explicitly 
represented in the ontology at the class 
level. Morphine interacts with several 
proteins: delta-type opioid receptor, 
kappa-type opioid receptor, mu-type 
opioid receptor, cytochrome p450 1a2, 
cytochrome p450 2c8, cytochrome 
p450 2d6, cytochrome p450 3a4, udp-
glucuronosyltransferase 1-1,udp-
glucuronosyltransferase 1-3, udp-
glucuronosyltransferase 1-8, udp-
glucuronosyltransferase 2b15, udp-
glucuronosyltransferase 2b4, udp-
glucuronosyltransferase 2b7 and 
multidrug resistance protein 1.  
morphine … 
has_pharmacological_target some delta-type opioid receptor 
has_pharmacological_target some kappa-type opioid receptor 
has_pharmacological_target some mu-type opioid receptor 
is_transported_by some multidrug resistance protein 1 
activates some delta-type opioid receptor 
activates some kappa-type opioid receptor 
activates some mu-type opioid receptor 
inhibits some multidrug resistance protein 1 
is_metabolized_by some cytochrome p450 1a2 
is_metabolized_by some cytochrome p450 2c8 
is_metabolized_by some cytochrome p450 2d6 
is_metabolized_by some cytochrome p450 3a4 
is_metabolized_by some udp-glucuronosyltransferase 1-1 
is_metabolized_by some udp-glucuronosyltransferase 1-3 
is_metabolized_by some udp-glucuronosyltransferase 1-8 
etc. 
25 
Is morphine metobolized by 
any of the cytochrome P450 
isoenzymes? Which ones? 
Yes, it is metabolized by several 
CYP450 isoenzymes:  cytochrome 
p450 1a2, cytochrome p450 2c8, 
cytochrome p450 2d6 and cytochrome 
p450 3a4. 
morphine is_ metabolized_by some cytochrome p450 1a2 
morphine is_ metabolized_by some cytochrome p450 2c8 
morphine is_ metabolized_by some cytochrome p450 2d6 
morphine is_ metabolized_by some cytochrome p450 3a4 
classes; object_properties; Individuals; attributes 
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Annex 8 (continuation 6) 
CQs, answers and axioms for the DDI between naloxone and morphine 
 Question Answer Axioms 
26 
Is morphine transported by P-
glycoprotein? 
Yes, it is transported by P-glycoprotein 
(which synonym is multidrug 
resistance protein 1) 
morphine is_transported_by some multidrug resistance 
protein 1 
27 
Has morphine got any effect 
(inhibitor or inductor) of any 
of the cytochrome P450 
isoenzymes? 
No, morphine does not induce or 
inhibit any CYP 450 isoenzyme. 
 
28 
Has morphine got a narrow 
therapeutic index? 
This information is not represented in 
the ontology.  
29 How frequently the DDI has 
been described? 
This is a well-known DDI. 
Naloxone/Morphine DDI has_incidence high 
30 
What type of study describes 
the DDI? 
The DDI is described in a 
pharmacological information 
resource.  
Naloxone/Morphine DDI is_described_in PharmacologicalLiterature 
31 
What is the certainty of the 
DDI? 
The DDI is described in different 
sources.  
Naloxone/Morphine DDI has_documentation_level established 
32 
Has been the DDI established 
in well performed and 
controlled studies? 
This information is not included in the 
description of the DDI in the text 
source. 
 
33 
What is the severity of the 
DDI? 
Since the interaction between these 
drugs in beneficial, this question is not 
relevant in this example. 
 
classes; object_properties; Individuals; attributes 
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Annex 9 
CQs, answers and axioms for the DDI between propafenone and mirtazapine 
 Question Answer Axioms 
1 Is there an interaction between 
propafenone and mirtazapine? 
The interaction between propafenone 
and mirtazapine is not explicitly 
described in the ontology, since this is 
a new interaction not described in the 
original information source (the 
database DrugBank). However, the 
information can be represented in the 
ontology.61 
propafenone may_interact_with some mirtazapine 
mirtazapine may_interact_with some propafenone 
propafenone/mirtazapine DDI equivalent to (has_participant some 
mirtazapine) and (has_participant some propafenone) 
Propafenone may_interact_with Mirtazapine 
Mirtazapine may_interact_with Propafenone 
Propafenone/Mirtazapine DDI has_participant Mirtazapine 
Propafenone/Mirtazapine DDI  has_participant Propafenone 
2 
Is the effect of mirtazapine 
modified by propafenone? 
The effect of mirtazapine represented 
in this example (bradycardia) is 
increased by propafenone.  
Mirtazapine has_effect Seizure 
Propafenone increases Seizure 
3 
What is the mechanism of the 
interaction between 
mirtazapine and propafenone? 
It is a pharmacokinetic mechanism, 
specifically the inhibition of the 
enzyme Cytochrome P450 A 2D6 
Propafenone/Mirtazapine DDI  is_preceded_by CytochromeP4502D6Inhibition 
CytochromeP4502D6Inhibition is_a enzyme activity inhibition 
4 
Is a PK parameter of 
mirtazapine modified by 
propafenone? 
There is not a direct relationship 
between propafenone and a PK 
parameter in the ontology. 
 
classes; object_properties; Individuals; attributes 
 
                                                 
61 We manually created  the class ‘propafenone /mirtazapine DDI’. 
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Annex 9 (continuation 2) 
CQs, answers and axioms for the DDI between propafenone and mirtazapine 
 Question Answer Axioms 
5 
What is the type of the 
interaction between 
mirtazapine and 
propafenone? 
The DDI is classified in two different 
ways in the ontology. Firstly, it is 
classified as an enzyme inhibition 
DDI. Therefore, it is a PK DDI. 
Secondly, it is classified in basis of the 
consequence for the patient as a 
potentially harmful DDI. 
Propafenone/Mirtazapine DDI is_a enzyme inhibition DDI 
Propafenone/Mirtazapine DDI is_a potentially harmful DDI 
6 What is the type of PD 
interaction between 
mirtazapine and 
propafenone? 
There is not a PD DDI between these 
two drugs. 
 
7 
Is there a PK interaction 
between  
mirtazapine and 
propafenone? 
Yes, the interaction between these two 
drugs is a PK DDI. 
Propafenone/Mirtazapine DDI is_a enzyme inhibition DDI 
enzyme inhibition DDI is_a enzyme alteration DDI 
enzyme alteration DDI is_a pharmokinetic DDI 
8 
Is the toxicity of mirtazapine 
exacerbated by propafenone? 
Yes, the effect of this DDI is an 
increase in the toxic effect of 
mirtazapine. 
Propafenone/Mirtazapine DDI has_DDI_effect Bradycardia 
Bradycardia is_effect_of Mirtazapine 
Bradycardia is_a increased toxic effect 
increased toxic effect is_a  altered toxic effect 
9 
Is the effect of the DDI an 
adverse effect of mirtazapine 
or propafenone? 
Yes, the effect of this DDI is an 
increase in the adverse effect of 
mirtazapine. 
Propafenone/Mirtazapine DDI has_DDI_effect Bradycardia 
Bradycardia is_effect_of Mirtazapine 
Bradycardia is_a adverse effect 
Bradycardia is_increased_by Propafenone 
classes; object_properties; Individuals; attributes 
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Annex 9 (continuation 3) 
CQs, answers and axioms for the DDI between propafenone and mirtazapine 
 Question Answer Axioms 
10 
Is the effect bradycardia 
produced by an interaction 
between mirtazapine and 
propafenone? 
Yes, the effect of the interaction 
between mirtazapine and propafenone 
is bradycardia. 
Propafenone/Mirtazapine DDI has_DDI_effect Bradycardia 
11 
What is the effect of the 
interaction between 
mirtazapine and propafenone? 
The effect of the interaction between 
mirtazapine and propafenone is 
bradycardia, the consequence of the 
increase in the toxic effect of 
mirtazapine. 
Propafenone/Mirtazapine DDI has_DDI_effect Bradycardia 
Bradycardia is_effect_of Mirtazapine 
Bradycardia is_a increased toxic effect 
increased toxic effect is_a  altered toxic effect 
12 Can be mirtazapine and 
propafenone used 
concomitantly? 
Information related to 
recommendation is not included in the 
description of the DDI in the text 
source. 
 
13 
Should be discontinued the 
treatment with mirtazapine 
when propafenone is 
administered? 
Information related to 
recommendation is not included in the 
description of the DDI in the text 
source. 
 
14 
Should be modified the dosage 
of mirtazapine when 
propafenone is administered? 
Information related to 
recommendation is not included in the 
description of the DDI in the text 
source. 
 
classes; object_properties; Individuals; attributes 
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Annex 9 (continuation 4) 
CQs, answers and axioms for the DDI between propafenone and mirtazapine 
 Question Answer Axioms 
15 
How could be avoided the 
effect of the interaction 
between mirtazapine and 
propafenone? 
Information related to 
recommendation is not included in the 
description of the DDI in the text 
source. 
 
16 
Is there any minimal elapse of 
time to administer mirtazapine 
after stopping the 
administration of 
propafenone? 
Information related to 
recommendation is not included in the 
description of the DDI in the text 
source. 
 
17 Is there any recommendation 
in order to avoid the DDI 
between mirtazapine and 
propafenone? 
Information related to 
recommendation is not included in the 
description of the DDI in the text 
source. 
 
18 
What patient’s characteristics 
affecting the DDI are present?  
The patient is a 69 years old 
Caucasian male. 
Patient 1 has_age 69 
Patient 1 has_race_or_ethnic caucasian 
Patient 1 has_gender male 
19 What is the age of the patient? The patient is 69 years old. Patient 1 has_age 69 
20 What is the sex of the patient? The patient is male. Patient 1 has_gender male 
21 What is the race or ethnic? Patient is Caucasian. Patient 1 has_race_or_ethnic caucasian 
22 
What administration form of 
mirtazapine interacts with 
propafenone? 
Mirtazapine is administered as 
tablets*.  Mirtazapine has_pharmaceutica_ form tablet 
classes; object_properties; Individuals; attributes 
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Annex 9 (continuation 5) 
CQs, answers and axioms for the DDI between propafenone and mirtazapine 
 Question Answer Axioms 
23 
Is there any alternative 
administration form of 
mirtazapine that does not 
produce the interaction with 
propafenone? 
 
 
24 What proteins mirtazapine 
interacts with? 
This information is explicitly 
represented in the ontology at the class 
level. Mirtazapine interacts with 
several proteins: 5-hydroxytryptamine 
2a, 5-hydroxytryptamine 3 receptor, 
alpha-2a adrenergic receptor, 
cytochrome p450 1a2, cytochrome 
p450 2c8, cytochrome p450 2c9, 
cytochrome p450 2d6, cytochrome 
p450 3a4, kappa-type opioid receptor, 
5-hydroxytryptamine 2c receptor and 
histamine h1 receptor. 
mirtazapine… 
has_pharmacological_target some 5-hydroxytryptamine 2a 
has_pharmacological_target some alpha-2a adrenergic receptor 
activates some  kappa-type opioid receptor 
blocks some 5-hydroxytryptamine 2a receptor 
blocks some 5-hydroxytryptamine 2c receptor 
blocks some 5-hydroxytryptamine 3 receptor 
induces some cytochrome p450 2d6 
inhibits some cytochrome p450 2d6 
inhibits some cytochrome p450 3a4 
is_metabolized_by some cytochrome p450 1a2 
etc. 
25 
Is mirtazapine metobolized by 
any of the cytochrome P450 
isoenzymes? Which ones? 
Yes, it is metabolized by several 
CYP450 isoenzymes:  cytochrome 
p450 1a2, cytochrome p450 2c8, 
cytochrome p450 2c9 and cytochrome 
p450 3a4. 
mirtazapine is_metabolized_by some cytochrome p450 1a2 
mirtazapine is_metabolized_by some cytochrome p450 2c8 
mirtazapine is_metabolized_by some cytochrome p450 2c9 
mirtazapine is_metabolized_by some cytochrome p450 2d6 
mirtazapine is_metabolized_by some cytochrome p450 3a4 
classes; object_properties; Individuals; attributes 
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Annex 9 (continuation 6) 
CQs, answers and axioms for the DDI between propafenone and mirtazapine 
 Question Answer Axioms 
26 
Is mirtazapine transported by 
P-glycoprotein? 
No, it is not. 
 
27 
Has mirtazapine got any effect 
(inhibitor or inductor) of any 
of the cytochrome P450 
isoenzymes? 
Yes, mirtazapine inhibits cytochrome 
p450 isoenzymes 3a4 and 2d6 and 
induces 2d6. 
mirtazapine induces some cytochrome p450 2d6 
mirtazapine inhibits some cytochrome p450 2d6 
mirtazapine inhibits some cytochrome p450 3a4 
28 
Has mirtazapine got a narrow 
therapeutic index? 
This information is not represented in 
the ontology. 
 
29 How frequently the DDI has 
been described? 
This is the first description of the DDI. 
Propafenone/Mirtazapine DDI has_incidence rare 
30 
What type of study describes 
the DDI? 
The DDI is described in case report in 
a unique patient. 
Propafenone/Mirtazapine DDI is_described_in PMID:24791374 
PMID:24791374 is_a Individual Human Data 
PMID:24791374 has_subject_ number 1 
31 
What is the certainty of the 
DDI? 
The DDI has only been observed in a 
case report. 
Propafenone/Mirtazapine DDI has_documentation_level suspected 
32 
Has been the DDI established 
in well performed and 
controlled studies? 
The DDI has only been observed in a 
case report. 
Propafenone/Mirtazapine DDI is_described_in PMID:24791374 
PMID:24791374 is_a Individual Human Data 
33 
What is the severity of the 
DDI? 
It is a major and clinically relevant 
DDI. 
Propafenone/Mirtazapine DDI has_severity major 
Propafenone/Mirtazapine DDI has_relevance clinical relevance 
classes; object_properties; Individuals; attributes 
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Annex 10 
Evaluation template for DINTO 
Version:   1.0.0 
Evaluation date: 23/06/2014  
OBO FOUNDRY PRINCIPLES 
Open  
Format OWL 
URIs Every class and relation have a unique identifier  
The URI is constructed from a base URI, a unique 
prefix and a numerical identifier 
1 
Versioning The ontology provider has procedures for identifying 
distinct successive versions. 
 
Delineated content Coherent natural language definitions of top-level 
term(s) 
 
Cross-product links to other OBO Foundry 
ontologies 
 
Textual Definitions Textual definitions (SOP) for a substantial and 
representative fraction of terms 
 
Equivalent formal definitions for at least a substantial 
number of terms 
 
There is evidence of implementation of a strategy to 
provide definitions for all remaining undefined terms 
 
Relations The ontology uses relations which are 
unambiguously defined following the pattern of 
definitions laid down in the OBO Relation Ontology. 
 
Documented The ontology is well-documented (e.g., in a 
published paper describing the ontology or in 
manuals for developers and users) 
 
Plurality of users The ontology has a plurality of independent users  
Collaboration The ontology is developed collaboratively with other 
OBO Foundry members. 
 
Locus of authority There is a single person who is responsible for the 
ontology, ensuring its maintenance and prompt 
response to users feedback. 
 
Naming conventions Explicit and concise names  
Context independent names  
Avoiding taboo words  
Avoiding encoding administrative metadata in names  
Unequivocal names, avoiding homonyms 7 
Avoiding conjunctions  
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Annex 10 (continuation 2) 
Evaluation template for DINTO 
 
Naming conventions 
(continuation) 
Singular nominal form 2 
Using positive names  1 
Avoiding catch-all names  
Recycling strings  
Using genus-differentia style names  
Using space as word separators 4 
Expanding abbreviations and acronyms 5 
Expanding special symbols to words  
Lower case beginnings 6 
Avoiding character formatting  
Naming conventions for relations is consistent along 
the ontology 
 
Maintenance   
 
CIMINO’S DESIDERATA FOR CONTROLLED MEDICAL VOCABULARIES 
Content The content of the ontology increased over  previous  
versions 
-8 
The ontology allows compositional extensibility  
A methodology for further expanding content has 
been established 
 
Concept orientation Each concept in the ontology has a single, coherent 
meaning (‘nonvagueness’, ‘nonambiguity’, 
‘nonredundacy’) 
7 
Concept 
permanence 
None meaning of concepts have been deleted -8 
Number of preferred terms that have been changed -8 
Non-semantic 
Concept Identifier 
Concepts have a unique non-hierarchical numerical 
identifier 
1 
Concepts have a preferred term  
Different names are included as synonyms  
Polyhierarchy The controlled vocabulary is s strict hierarchy or a 
polyhierarchy 
P 
Formal definitions Concepts have formal definitions  
“Not Elsewhere 
Classified” 
The controlled vocabulary rejects the use of “not 
elsewhere classified” terms. 
3 
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Annex 10 (continuation 3) 
Evaluation template for DINTO 
CIMINO’S DESIDERATA FOR CONTROLLED MEDICAL VOCABULARIES 
Multiple 
granularities 
Concepts are described at multiple levels of 
granularity 
 
Multiple consistent 
views 
Multiple views of the vocabulary, suitable for 
different purposes, are provided 
 
Representing 
concepts 
The controlled vocabulary contains context 
representation through formal information 
 
The controlled vocabulary contains context 
representation through natural language information 
 
Evolving Gracefully Clear and detailed descriptions of what changes 
occur and why are documented 
-8 
Recognize 
redundancy 
There is a mechanism enabling redundancy 
recognition 
YES 
 
GÓMEZ-PÉREZ EVALUATION 
Analysis of 
inconsistences 
The ontology is 
consistent10 
using FaCT++ 12897219 
ms 
using HermiT 1.3.8. 230723 
ms 
using Pellet - 
There is not circularity errors at distance zero  
There is not circularity errors at distance 1  
There is not circularity errors at distance n  
There is not partition error at the class level  
There is not partition error at the instance level  
There is not semantic inconsistency  
Analysis of 
incompleteness 
There is not concepts existing in the domain that 
have been overlooked in the classification 
 
Disjoint classes have been identified and represented 9 
There is not omission of the completeness constraint 
between subclasses and the base class. 
 
Analysis of 
redundancies 
There are not redundancies of Subclass-Of relations  
There are not redundancies of Instance-Of relations - 
There are not identical formal definitions of classes  
There are not identical formal definitions of classes   
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Annex 10 (continuation 4) 
Evaluation template for DINTO 
1. Numerical identifiers. 
All those entities created in DINTO have an URI constructed from a base URI 
(http://purl.obolibrary.org/), a unique prefix (DINTO_) and a numerical identifier.  
However, imported classes from the PKO have URIs that do not follow this structure. They 
have a base URI (www.owl-ontologies.com/2009/11/5/), a unique prefix (PKO.owl#) and a 
non-numerical identifier (e.g., AUC). In the same way, those classes imported from BRO 
have URIs with non-numerical identifiers. They have a base URI 
(www.bioontology.org/ontologies/), a unique prefix (BiomedicalResourceOntology.owl/) and 
a non-numerical identifier (e.g., Structured_Knowledge_Resource). 
We decided to maintain these URIs in order to preserve the original source. 
Another exception to this recommendation is annotation properties. Following the example of 
annotation properties used in other resources, such as the ChEBI ontology (e.g., 
http://purl.obolibrary.org/obo#Definition) new annotation properties in DINTO have not 
numerical identifiers. In this way, the annotation property ‘ATCcode’ URI is 
‘http://purl.obolibrary.org/obo#ATCcode’. 
2. Naming conventions: Singular nominal form: 
There are two classes imported from the PKO that used plural forms: 
‘PK_Parameters_invivo’ and ‘PK_Parameters_invitro’. 
We decided to maintain the plural nominal form in order to preserve the original source. 
3. Naming conventions: Using positive names: 
There are exceptions to this naming convention in DINTO, since we have created the classes: 
- ‘non-clinically relevant DDI’  
- ‘non-clinically relevant DDI effect’ 
- ‘uncertain DDI’ 
- ‘uncertain DDI effect’ 
- ‘unobservable DDI effect’  
Although one of the OBO Foundry recommendations is to avoid use of negation, which could 
decrease precision in the interpreted meaning, we decided to maintain these names. The main 
reason is that these terms are commonly used in DDIs texts, as we observed during the study 
of the DDI corpus and other pharmacological resources. To ensure a correct interpretation of 
these concepts all of them have natural language definitions in the ontology. 
4. Naming conventions: Using space as word separators: 
We have used space as word separators for all those new entities created in DINTO. 
However, classes imported from the PKO and BRO use symbol ‘_’ as word separator. We 
decided to maintain it in order to preserve the original source. 
5. Naming conventions: Expanding abbreviations and acronyms. 
We have expanded abbreviations and acronyms in DINTO with the exception of the term 
drug-drug interaction (DDI) since it is a widely known acronym. Moreover, it is frequently 
used in the ontology. Therefore, we believed that the use of the acronym would increase 
readability.  
Another exception is the use of the acronym PK and PD in the PKO’s classes 
‘PK_Parameters_invivo’ and ‘PK_Parameters_invitro’. In this case, we decided to maintain 
the acronyms in order to preserve the original source. 
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Annex 10 (continuation 5) 
Evaluation template for DINTO 
It is important to note that pharmacokinetic parameters imported from the PKO are named 
using abbreviations, as well (e.g., ‘AUC’ instead of ‘area under the curve’). We believe that 
this naming procedure is correct, since the abbreviated form is the most commonly used for 
these concepts and they are unequivocal representations of the corresponding concept in the 
pharmacological domain.  
6. Naming conventions: Lower case beginnings. 
We have used lower case beginnings for all new classes created in DINTO. However, classes 
imported from the PKO and BRO use upper case beginnings. We decided to maintain them in 
order to preserve the original sources. 
7. Unequivocal names, avoiding homonyms. 
We identified that some classes of ‘pharmacological entity’ class shared the same label. The 
reason is that there was an unexpected problem during the automatic mapping between our 
two information resources (ChEBI ontology and DrugBank database). We manually reviewed 
all classes and found 66 duplicate classes. We merged them and eliminated the incorrect ones 
(see Section 7.1.6). 
8. Previous versions of the ontology. 
This is the first version of the ontology. Therefore, it does not proceed to describe changes 
related to previous versions.  
9. Disjoint classes: 
We identified disjoint classes in DINTO. However, it should be taken into account that many 
times it is not possible to establish disjointness in this domain. For example, we have 
explained in this thesis that DDIs are commonly classified in two main groups as 
pharmacodynamic (PD) and pharmacokinetic (PK) DDIs in basis of their mechanisms. 
However, different mechanisms can contribute to the apparition of a DDI, leading to the 
possibility that a PK DDI could be classified, at the same time, as a PD DDI. Another 
example affects to roles; the same pharmacological entity can have several roles, including 
both ‘precipitant’ and ‘object’. Therefore, in some cases, we have not establishes disjoint 
classes. 
10. Analysis of consistency using a reasoner. 
DINTO is a large ontology with more than 25 thousand classes and 377 thousand axioms. 
Using a reasoner in such a large ontology leads to issues (see Section 9.2). Therefore, to 
check the consistency of the ontology we had to apply different strategies in order to reduce 
its size. This procedure has been proposed by other authors, such as Brank et al. (2005), who 
explains: «An ontology is a fairly complex structure and it is often more practical to focus on 
the evaluation of different levels of the ontology separately rather than trying to directly 
evaluate the ontology as a whole», or Holford et al. (2010), who had to reduce the complexity 
of its ontology in order to classify it using a reasoner. 
The first strategy is to reduce the number of classes and relationships between them. To do 
this we delete most pharmacological substances and proteins, obtaining a much shorter 
ontology,62 making possible to check the consistency of the whole conceptual model.  
                                                 
62 This version is named DINTO 0.0.6 and is available under request to the authors. 
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Annex 11 
Inference results in IExp3 
DDI DINTO DrugBank 
TR Ag Ant ER ES EId EIn Tn TS TId TIn CR CS CId CIn Tg E T N 
1 
abciximab 
tirofiban 
 x              x    
2 
acenocoumarol 
fluoxetine 
    x  x     x     x   
3 
alfacalcidol 
calcipotriol 
  x             x    
4 
aluminium 
ciprofloxacin 
                  x 
5 
alvimopan 
dezocine 
 x x             x    
6 
alvimopan 
morphine 
  x             x    
7 
amiodarone 
cisapride 
x    x  x         x x   
8 
amiodarone 
phenytoin 
    x x x   x x      x x  
9 
amprenavir 
diazepam 
    x  x   x x      x x  
10 
atorvastatin 
eltrombopag 
    x  x    x      x x  
11 
attapulgite 
doxycycline 
                  x 
12 
bepridil 
astemizole 
    x            x x  
13 
bismuth subsalicylate 
minocycline                   x 
14 
bromazepam 
itraconazole 
    x  x          x   
15 
calcium    
enoxacin 
                  x 
16 
calcium 
ibandronate 
                  x 
17 
cerivastatin 
rifampicin 
    x x x  x x x      x x  
18 chlorpropamide 
acetylsalicylic acid     x x x    x      x x  
19 
cholecalciferol 
alfacalcidol 
 x          x    x    
20 
colchicine 
clotrimazole 
     x x   x x      x x  
21 
dabigatran etexilate 
verapamil         x x x       x  
22 
dabrafenib 
midazolam 
    x x x  x x x      x x  
23 
desipramine 
ziprasidone 
 x   x  x         x x   
24 
devenlafaxine 
fluoxetine 
x    x  x         x x   
25 
dextromethorphan 
desvenlafaxine 
x    x           x x   
26 diazoxide 
bendroflumethiazide x               x    
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Annex 11 (continuation 2) 
Inference results in IExp3 
DDI DINTO DrugBank 
TR Ag Ant ER ES EId EIn Tn TS TId TIn CR CS CId CIn Tg E T N 
27 
diclofenac 
cyclosporin a 
    x  x    x      x x  
28 
digoxin   
quinidine 
    x x x  x x x      x x  
29 
dihydroergotamine 
clarithromycin     x x x    x      x x  
30 
dofetilide 
clarithromycin 
    x x x          x   
31 
dolasetron 
artemether 
    x x           x   
32 
dolasetron 
ziprasidone 
 x   x  x         x x   
33 
donepezil 
chlorpomazine 
x    x  x         x x   
34 
doxepin 
cimetidine 
 x     x    x     x x x  
35 
doxepin 
phenylephrine 
x     x          x x   
36 
eltrombopag 
cimetidine 
      x          x   
37 
ergotamine 
acebutolol 
          x       x  
38 
ergotamine 
carvedilol 
 x   x  x         x x x  
39 
ergotamine 
propranolol 
x    x  x    x     x x x  
40 
erythromycin 
vinorelbine 
    x  x    x      x x  
41 
estropipate 
raloxifeno 
 x   x  x         x x   
42 
fesoterodine 
ketoconazole 
    x  x  x  x      x x  
43 
fluconazole 
phenytoin 
      x    x      x x  
44 
fosamprenavir 
cyclosporin a 
    x  x          x   
45 
gemfibrozil 
rosuvastatin 
    x x x    x      x x  
46 
glucosamine 
glyburide 
    x            x   
47 
grepafloxacin 
chlorpromazine 
    x    x  x      x x  
48 grepafloxacin   
iron dextran                   x 
49 
halofantrine 
trimipramine 
    x  x          x   
50 
ibuprofen 
carvedilol 
    x  x    x      x x  
51 
imipramine 
fluvoxamine 
x    x  x    x     x x x  
52 
imipramine 
ziprasidone 
 x   x  x         x x   
53 
indinavir 
dantrolene 
    x  x          x   
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Annex 11 (continuation 3) 
Inference results in IExp3 
DDI DINTO DrugBank 
TR Ag Ant ER ES EId EIn Tn TS TId TIn CR CS CId CIn Tg E T N 
54 
iron 
demeclocycline 
                  x 
55 
isoproterenol 
acebutolol 
x               x    
56 
itraconazole 
trazodone 
    x  x          x x  
57 ketoprofen 
acetylsalicylic acid x    x  x    x     x x x  
58 
labetalol   
fenoterol 
  x             x    
59 
lopinavir 
darunavir 
x    x  x         x x   
60 
magnesium 
temafloxacin 
            
 
 
     x 
61 
maprotiline 
ziprasidone 
 x   x  x         x x   
62 
mefloquine 
halofantrine 
 x   x  x         x x   
63 
midazolam 
clobazam 
x    x  x  x x x     x x x  
64 
midrodine 
dexamethasone 
                x   
65 
mirabegron 
desipramine 
    x  x             
66 
moclobemide 
selegiline 
x    x  x         x x   
67 
nelfinavir 
cyclosporin a 
    x x x  x x x      x x  
68 
nortriptyline 
cisapride 
  x  x  x         x x   
69 
ondansetron 
asenapine 
x    x  x         x x   
70 
paliperidone 
amantadine 
  x             x    
71 
pancuronium 
quinine 
        x  x       x  
72 
pimozide 
mesoridazine 
 x     x         x x   
73 
posaconazole 
vinorelbine 
    x  x          x x  
74 
probenecid 
cefixime 
                 x  
75 
promethazine 
benzphetamine 
x    x           x x   
76 
quetiapine 
donepezil 
x    x  x         x x   
77 
regorafenib 
irinotecan 
    x  x    x      x x  
78 
rifabutin 
bromazepam 
    x x           x   
79 
saquinavir 
diazepam 
    x  x  x x x      x x  
80 
sertraline 
phenytoin 
    x x x    x      x x  
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Annex 11 (continuation 4) 
Inference results in IExp3 
DDI DINTO DrugBank 
TR Ag Ant ER ES EId EIn Tn TS TId TIn CR CS CId CIn Tg E T N 
81 
sucralfate 
etidronic acid 
                  x 
82 
sulindac       
bumetanide 
x                 x  
83 
telaprevir    
ketoconazole 
    x  x  x  x      x x  
84 
timolol 
chlorpropamide 
    x      x      x x  
85 
toremifene 
chlorpromazine 
    x    x  x      x x  
86 
trazodone     
nefazodone 
 x x  x  x         x x x  
87 
trimipramine 
venlafaxine 
x    x  x    x     x x x  
88 
trospium    
dicyclomine 
 x              x    
89 valproic acid 
acetylsalicylic acid     x x x  x        x x  
90 
verapamile 
carbamezepine 
x    x x x  x x x     x x x  
91 
vincristine   
ketoconzale 
    x  x  x x x      x x  
92 
vismodegib     
ivacaftor 
    x  x    x  x    x x  
93 
zinc             
norfloxacin 
                  x 
 
 
 
 
 
 
 
 
 
 
 
 
TR:  Target-related mechanism 
Ag:  Agonistic mechanism 
Ant: Antagonistic mechanism 
 
ER:  Enzyme-related mechanism 
ES:  Enzymatic saturation mechanism 
EId: Enzyme induction mechanism 
EIn: Enzyme inhibition mechanism 
 
Tn:  Transporter-related mechanism 
TS:  Transporter saturation mechanism 
TId: Transporter induction mechanism 
TIn: Transporter inhibition mechanism 
 
CR:  Carrier-related mechanism 
CS:  Carrier saturation mechanism 
CId: Carrier induction mechanism 
CIn: Carrier inhibition mechanism 
 
Tg: Target-related mechanism in DrugBank 
E:   Enzyme-related mechanism in DrugBank 
T:  Transporter-related mechanism in DrugBank 
N:  Non-absorbable complex formation mechanism       
in DrugBank 
